with the traditional appellate process by issuing a Statement of the Case.

(g) This section applies to all claims in which a Notice of Disagreement is filed on or after June 1, 2001.

(Authority: 38 U.S.C. 5109A and 7105(d))

[66 FR 21874, May 2, 2001, as amended at 67 FR 46868, July 17, 2002; 74 FR 26959, June 5, 2009; 79 FR 57697, Sept. 25, 2014]

### PART 4—SCHEDULE FOR RATING **DISABILITIES**

#### Subpart A—General Policy in Rating

Sec.

- 4.1 Essentials of evaluative rating.
- Interpretation of examination reports.
- 4.3 Resolution of reasonable doubt.
- Evaluation of evidence.
- Higher of two evaluations. 4.7
- 4.9 Congenital or developmental defects.
- 4.10 Functional impairment.
- 4.13 Effect of change of diagnosis.
- 4.14 Avoidance of pyramiding.
- 4.15 Total disability ratings.
- 4.16 Total disability ratings for compensation based on unemployability of the individual.
- 4.17 Total disability ratings for pension based on unemployability and age of the individual.
- 4.17a Misconduct etiology.
- 4.18 Unemployability.
- Age in service-connected claims. 4.19
- Analogous ratings. 4.20
- 4.21 Application of rating schedule.
- 4.22 Rating of disabilities aggravated by active service.
- 4.23 Attitude of rating officers.
- 4.24 Correspondence.
- 4.25 Combined ratings table.
- Bilateral factor.
- Use of diagnostic code numbers.
- 4.28 Prestabilization rating from date of discharge from service.
- 4.29 Ratings for service-connected disabilities requiring hospital treatment or observation.
- 4.30 Convalescent ratings.
- 4.31 Zero percent evaluations.

#### Subpart B—Disability Ratings

THE MUSCULOSKELETAL SYSTEM

- 4.40 Functional loss.
- 4.41 History of injury.
- 4.42 Complete medical examination of iniury cases.
- 4.43 Osteomyelitis.
- 4.44 The bones.
- 4.45 The joints.
- 4.46 Accurate measurement.
- 4.47-4.54 [Reserved]

- 4.55 Principles of combined ratings for muscle injuries.
- 4.56 Evaluation of muscle disabilities
- 4.57 Static foot deformities.
- 4.58 Arthritis due to strain.
- Painful motion. 4.59
- 4.60 [Reserved] 4.61
- Examination. Circulatory disturbances. 4.62
- Loss of use of hand or foot. 4.63
- 4.64 Loss of use of both buttocks.
- 4.65 [Reserved]
- Sacroiliac joint.
- Pelvic bones.
- Amputation rule. 4.68
- Dominant hand.
- Inadequate examinations.
- 4.71 Measurement of ankylosis and joint motion.
- 4.71a Schedule of ratings—musculoskeletal system.
- 4.72 [Reserved]
- 4.73 Schedule of ratings—muscle injuries.

#### THE ORGANS OF SPECIAL SENSE

- 4.75 General considerations for evaluating visual impairment.
- 4.76 Visual acuity
- 4.76a Computation of average concentric contraction of visual fields.
- Visual fields. 4.78 Muscle function.
- 4.79 Schedule of ratings—eye.
- 4.80-4.84 [Reserved]

#### IMPAIRMENT OF AUDITORY ACUITY

- 4.85 Evaluation of hearing impairment.
- 4.86 Exceptional patterns of hearing impairment.
- 4.87 Schedule of ratings—ear.
- 4.87a Schedule of ratings-other sense or-

INFECTIOUS DISEASES, IMMUNE DISORDERS AND NUTRITIONAL DEFICIENCIES

- 4.88 [Reserved]
- 4.88a Chronic fatigue syndrome.
- 4.88b Schedule of ratings-infectious diseases, immune disorders and nutritional deficiencies.
- 4.88c Ratings for inactive nonpulmonary tuberculosis initially entitled after August 19, 1968.
- 4.89 Ratings for inactive nonpulmonary tuberculosis in effect on August 19, 1968.

#### THE RESPIRATORY SYSTEM

- 4.96 Special provisions regarding evaluation of respiratory conditions.
- 4.97 Schedule of ratings-respiratory system.

#### THE CARDIOVASCULAR SYSTEM

4.100 Application of the evaluation criteria for diagnostic codes 7000-7007, 7011, and 7015 - 7020.

4.101-4.103 [Reserved]

4.104 Schedule of ratings—cardiovascular system.

#### THE DIGESTIVE SYSTEM

4.110 Ulcers.

4.111 Postgastrectomy syndromes.

4.112 Weight loss.

4.113 Coexisting abdominal conditions.

4.114 Schedule of ratings—digestive system.

#### THE GENITOURINARY SYSTEM

4.115 Nephritis.

4.115a Ratings of the genitourinary system—dysfunctions.

4.115b Ratings of the genitourinary system—diagnoses.

GYNECOLOGICAL CONDITIONS AND DISORDERS OF THE BREAST

4.116 Schedule of ratings—gynecological conditions and disorders of the breast.

THE HEMIC AND LYMPHATIC SYSTEMS

4.117 Schedule of ratings—hemic and lymphatic systems.

#### THE SKIN

4.118 Schedule of ratings—skin.

#### THE ENDOCRINE SYSTEM

4.119 Schedule of ratings—endocrine system.

## NEUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS

4.120 Evaluations by comparison.

4.121 Identification of epilepsy.

4.122 Psychomotor epilepsy.

4.123 Neuritis, cranial or peripheral.

4.124 Neuralgia, cranial or peripheral.

4.124a Schedule of ratings—neurological conditions and convulsive disorders.

#### MENTAL DISORDERS

4.125 Diagnosis of mental disorders.

4.126 Evaluation of disability from mental disorders.

4.127 Intellectual disability (intellectual developmental disorder) and personality disorders.

4.128 Convalescence ratings following extended hospitalization.

4.129 Mental disorders due to traumatic stress.

4.130 Schedule of ratings-Mental disorders.

#### DENTAL AND ORAL CONDITIONS

4.149 [Reserved]

4.150 Schedule of ratings—dental and oral conditions.

APPENDIX A TO PART 4—TABLE OF AMEND-MENTS AND EFFECTIVE DATES SINCE 1946 APPENDIX B TO PART 4—NUMERICAL INDEX OF DISABILITIES APPENDIX C TO PART 4—ALPHABETICAL INDEX OF DISABILITIES

AUTHORITY: 38 U.S.C. 1155, unless otherwise

SOURCE: 29 FR 6718, May 22, 1964, unless otherwise noted.

## Subpart A—General Policy in Rating

#### § 4.1 Essentials of evaluative rating.

This rating schedule is primarily a guide in the evaluation of disability resulting from all types of diseases and injuries encountered as a result of or incident to military service. The percentage ratings represent as far as can practicably be determined the average impairment in earning capacity resulting from such diseases and injuries and their residual conditions in civil occupations. Generally, the degrees of disability specified are considered adequate to compensate for considerable loss of working time from exacerbations or illnesses proportionate to the severity of the several grades of disability. For the application of this schedule, accurate and fully descriptive medical examinations are required, with emphasis upon the limitation of activity imposed by the disabling condition. Over a period of many years, a veteran's disability claim may require reratings in accordance with changes in laws, medical knowledge and his or her physical or mental condition. It is thus essential, both in the examination and in the evaluation of disability, that each disability be viewed in relation to its history.

[41 FR 11292, Mar. 18, 1976]

## § 4.2 Interpretation of examination reports.

Different examiners, at different times, will not describe the same disability in the same language. Features of the disability which must have persisted unchanged may be overlooked or a change for the better or worse may not be accurately appreciated or described. It is the responsibility of the rating specialist to interpret reports of examination in the light of the whole recorded history, reconciling the various reports into a consistent picture

so that the current rating may accurately reflect the elements of disability present. Each disability must be considered from the point of view of the veteran working or seeking work. If a diagnosis is not supported by the findings on the examination report or if the report does not contain sufficient detail, it is incumbent upon the rating board to return the report as inadequate for evaluation purposes.

[41 FR 11292, Mar. 18, 1976]

#### § 4.3 Resolution of reasonable doubt.

It is the defined and consistently applied policy of the Department of Veterans Affairs to administer the law under a broad interpretation, consistent, however, with the facts shown in every case. When after careful consideration of all procurable and assembled data, a reasonable doubt arises regarding the degree of disability such doubt will be resolved in favor of the claimant. See §3.102 of this chapter.

[40 FR 42535, Sept. 15, 1975]

#### § 4.6 Evaluation of evidence.

The element of the weight to be accorded the character of the veteran's service is but one factor entering into the considerations of the rating boards in arriving at determinations of the evaluation of disability. Every element in any way affecting the probative value to be assigned to the evidence in each individual claim must be thoroughly and conscientiously studied by each member of the rating board in the light of the established policies of the Department of Veterans Affairs to the end that decisions will be equitable and just as contemplated by the requirements of the law.

#### §4.7 Higher of two evaluations.

Where there is a question as to which of two evaluations shall be applied, the higher evaluation will be assigned if the disability picture more nearly approximates the criteria required for that rating. Otherwise, the lower rating will be assigned.

## § 4.9 Congenital or developmental defects.

Mere congenital or developmental defects, absent, displaced or super-

numerary parts, refractive error of the eye, personality disorder and mental deficiency are not diseases or injuries in the meaning of applicable legislation for disability compensation purposes.

[41 FR 11292, Mar. 18, 1976]

#### §4.10 Functional impairment.

The basis of disability evaluations is the ability of the body as a whole, or of the psyche, or of a system or organ of the body to function under the ordinary conditions of daily life including employment. Whether the upper or lower extremities, the back or abdominal wall, the eyes or ears, or the cardiovascular, digestive, or other system. or psyche are affected, evaluations are based upon lack of usefulness, of these parts or systems, especially in self-support. This imposes upon the medical examiner the responsibility of furnishing, in addition to the etiological, anatomical, pathological, laboratory and prognostic data required for ordinary medical classification, full description of the effects of disability upon the person's ordinary activity. In this connection, it will be remembered that a person may be too disabled to engage in employment although he or she is up and about and fairly comfortable at home or upon limited activitv.

[41 FR 11292, Mar. 18, 1976]

#### § 4.13 Effect of change of diagnosis.

The repercussion upon a current rating of service connection when change is made of a previously assigned diagnosis or etiology must be kept in mind. The aim should be the reconciliation and continuance of the diagnosis or etiology upon which service connection for the disability had been granted. The relevant principle enunciated in §4.125, entitled "Diagnosis of mental disorders," should have careful attention in this connection. When any change in evaluation is to be made, the rating agency should assure itself that there has been an actual change in the conditions, for better or worse, and not merely a difference in thoroughness of the examination or in use of descriptive terms. This will not, of course, preclude the correction of erroneous

ratings, nor will it preclude assignment of a rating in conformity with §4.7.

[29 FR 6718, May 22, 1964, as amended at 61 FR 52700, Oct. 8, 1996]

#### §4.14 Avoidance of pyramiding.

The evaluation of the same disability under various diagnoses is to be avoided. Disability from injuries to the muscles, nerves, and joints of an extremity may overlap to a great extent, so that special rules are included in the appropriate bodily system for their evaluation. Dyspnea, tachycardia, nervousness, fatigability, etc., may result from many causes; some may be service connected, others, not. Both the use of manifestations not resulting from service-connected disease or injury in establishing the service-connected evaluation, and the evaluation of the same manifestation under different diagnoses are to be avoided.

#### § 4.15 Total disability ratings.

The ability to overcome the handicap of disability varies widely among individuals. The rating, however, is based primarily upon the average impairment in earning capacity, that is, upon the economic or industrial handicap which must be overcome and not from individual success in overcoming it. However, full consideration must be given to unusual physical or mental effects in individual cases, to peculiar effects of occupational activities, to defects in physical or mental endowment preventing the usual amount of success in overcoming the handicap of disability and to the effect of combinations of disability. Total disability will be considered to exist when there is present any impairment of mind or body which is sufficient to render it impossible for the average person to follow a substantially gainful occupation; Provided, That permanent total disability shall be taken to exist when the impairment is reasonably certain to continue throughout the life of the disabled person. The following will be considered to be permanent total disability: the permanent loss of the use of both hands, or of both feet, or of one hand and one foot, or of the sight of both eyes, or becoming permanently helpless or permanently bedridden. Other total disability ratings are

scheduled in the various bodily systems of this schedule.

# §4.16 Total disability ratings for compensation based on unemployability of the individual.

(a) Total disability ratings for compensation may be assigned, where the schedular rating is less than total, when the disabled person is, in the judgment of the rating agency, unable to secure or follow a substantially gainful occupation as a result of service-connected disabilities: Provided That, if there is only one such disability, this disability shall be ratable at 60 percent or more, and that, if there are two or more disabilities, there shall be at least one disability ratable at 40 percent or more, and sufficient additional disability to bring the combined rating to 70 percent or more. For the above purpose of one 60 percent disability, or one 40 percent disability in combination, the following will be considered as one disability: (1) Disabilities of one or both upper extremities, or of one or both lower extremities, including the bilateral factor, if applicable, (2) disabilities resulting from common etiology or a single accident, (3) disabilities affecting a single body system, e.g. orthopedic, digestive, rescardiovascular-renal, piratory. neuropsychiatric, (4) multiple injuries incurred in action, or (5) multiple disabilities incurred as a prisoner of war. It is provided further that the existence or degree of nonservice-connected previous disabilities orunemployability status will be disregarded where the percentages referred to in this paragraph for the service-connected disability or disabilities are met and in the judgment of the rating agency such service-connected disabilities render the veteran unemployable. Marginal employment shall not be considered substantially gainful employment. For purposes of this section, marginal employment generally shall be deemed to exist when a veteran's earned annual income does not exceed the amount established by the U.S. Department of Commerce, Bureau of the Census, as the poverty threshold for one person. Marginal employment may also be held to exist, on a facts found basis (includes but is not limited to

employment in a protected environment such as a family business or sheltered workshop), when earned annual income exceeds the poverty threshold. Consideration shall be given in all claims to the nature of the employment and the reason for termination.

(Authority: 38 U.S.C. 501)

(b) It is the established policy of the Department of Veterans Affairs that all veterans who are unable to secure and follow a substantially gainful occupation by reason of service-connected disabilities shall be rated totally disabled. Therefore, rating boards should submit to the Director, Compensation Service, for extra-schedular consideration all cases of veterans who are unemployable by reason of service-connected disabilities, but who fail to meet the percentage standards set forth in paragraph (a) of this section. The rating board will include a full statement as to the veteran's serviceconnected disabilities, employment history, educational and vocational attainment and all other factors having a bearing on the issue.

[40 FR 42535, Sept. 15, 1975, as amended at 54 FR 4281, Jan. 30, 1989; 55 FR 31580, Aug. 3, 1990; 58 FR 39664, July 26, 1993; 61 FR 52700, Oct. 8, 1996; 79 FR 2100, Jan. 13, 2014]

# § 4.17 Total disability ratings for pension based on unemployability and age of the individual.

All veterans who are basically eligible and who are unable to secure and follow a substantially gainful occupation by reason of disabilities which are likely to be permanent shall be rated as permanently and totally disabled. For the purpose of pension, the permanence of the percentage requirements of §4.16 is a requisite. When the percentage requirements are met, and the disabilities involved are of a permanent nature, a rating of permanent and total disability will be assigned if the veteran is found to be unable to secure and follow substantially gainful employment by reason of such disability. Prior employment or unemployment status is immaterial if in the judgment of the rating board the veteran's disabilities render him or her unemployable. In making such determinations, the following guidelines will be used:

- (a) Marginal employment, for example, as a self-employed farmer or other person, while employed in his or her own business, or at odd jobs or while employed at less than half the usual remuneration will not be considered incompatible with a determination of unemployability, if the restriction, as to securing or retaining better employment, is due to disability.
- (b) Claims of all veterans who fail to meet the percentage standards but who meet the basic entitlement criteria and are unemployable, will be referred by the rating board to the Veterans Service Center Manager or the Pension Management Center Manager under §3.321(b)(2) of this chapter.

(Authority: 38 U.S.C. 1155; 38 U.S.C. 3102)

[43 FR 45348, Oct. 2, 1978, as amended at 56 FR 57985, Nov. 15, 1991; 71 FR 28586, May 17, 2006; 74 FR 26959, June 5, 2009]

#### § 4.17a Misconduct etiology.

A permanent and total disability rating under the provisions of §§ 4.15, 4.16 and 4.17 will not be precluded by reason of the coexistence of misconduct disability when:

- (a) A veteran, regardless of employment status, also has innocently acquired 100 percent disability, or
- (b) Where unemployable, the veteran has other disabilities innocently acquired which meet the percentage requirements of §§ 4.16 and 4.17 and would render, in the judgment of the rating agency, the average person unable to secure or follow a substantially gainful occupation.

[40 FR 42536, Sept. 15, 1975, as amended at 43 FR 45349, Oct. 2, 1978]

#### §4.18 Unemployability.

A veteran may be considered as unemployable upon termination of employment which was provided on account of disability, or in which special consideration was given on account of the same, when it is satisfactorily shown that he or she is unable to secure further employment. With amputations, sequelae of fractures and other residuals of traumatism shown to be of static character, a showing of continuous unemployability from date of incurrence, or the date the condition

reached the stabilized level, is a general requirement in order to establish the fact that present unemployability is the result of the disability. However, consideration is to be given to the circumstances of employment in individual claims, and, if the employment was only occasional, intermittent, tryout or unsuccessful, or eventually terminated on account of the disability. present unemployability may be attributed to the static disability. Where unemployability for pension previously has been established on the basis of combined service-connected and nonservice-connected disabilities and the service-connected disability or disabilities have increased in severity, §4.16 is for consideration.

 $[40~{\rm FR}~42536,~{\rm Sept.}~15,~1975,~{\rm as~amended~at}~43~{\rm FR}~45349,~{\rm Oct.}~2,~1978]$ 

#### § 4.19 Age in service-connected claims.

Age may not be considered as a factor in evaluating service-connected disability; and unemployability, in service-connected claims, associated with advancing age or intercurrent disability, may not be used as a basis for a total disability rating. Age, as such, is a factor only in evaluations of disability not resulting from service, *i.e.*, for the purposes of pension.

 $[29~{\rm FR}~6718,~{\rm May}~22,~1964,~{\rm as}~{\rm amended}~{\rm at}~43~{\rm FR}~45349,~{\rm Oct.}~2,~1978]$ 

#### § 4.20 Analogous ratings.

When an unlisted condition is encountered it will be permissible to rate under a closely related disease or injury in which not only the functions affected, but the anatomical localization and symptomatology are closely analogous. Conjectural analogies will be avoided, as will the use of analogous ratings for conditions of doubtful diagnosis, or for those not fully supported by clinical and laboratory findings. Nor will ratings assigned to organic diseases and injuries be assigned by analogy to conditions of functional origin.

#### §4.21 Application of rating schedule.

In view of the number of atypical instances it is not expected, especially with the more fully described grades of disabilities, that all cases will show all the findings specified. Findings suffi-

ciently characteristic to identify the disease and the disability therefrom, and above all, coordination of rating with impairment of function will, however, be expected in all instances.

[41 FR 11293, Mar. 18, 1976]

## § 4.22 Rating of disabilities aggravated by active service.

In cases involving aggravation by active service, the rating will reflect only the degree of disability over and above the degree existing at the time of entrance into the active service, whether the particular condition was noted at the time of entrance into the active service, or it is determined upon the evidence of record to have existed at that time. It is necessary therefore, in all cases of this character to deduct from the present degree of disability the degree, if ascertainable, of the disability existing at the time of entrance into active service, in terms of the rating schedule, except that if the disability is total (100 percent) no deduction will be made. The resulting difference will be recorded on the rating sheet. If the degree of disability at the time of entrance into the service is not ascertainable in terms of the schedule. no deduction will be made.

#### § 4.23 Attitude of rating officers.

It is to be remembered that the majority of applicants are disabled persons who are seeking benefits of law to which they believe themselves entitled. In the exercise of his or her functions, rating officers must not allow their personal feelings to intrude; an antagonistic, critical, or even abusive attitude on the part of a claimant should not in any instance influence the officers in the handling of the case. Fairness and courtesy must at all times be shown to applicants by all employees whose duties bring them in contact, directly or indirectly, with the Department's claimants.

[41 FR 11292, Mar. 18, 1976]

#### § 4.24 Correspondence.

All correspondence relative to the interpretation of the schedule for rating disabilities, requests for advisory opinions, questions regarding lack of clarity or application to individual cases

involving unusual difficulties, will be addressed to the Director, Compensation Service. A clear statement will be made of the point or points upon which information is desired, and the complete case file will be simultaneously forwarded to Central Office. Rating agencies will assure themselves that the recent report of physical examination presents an adequate picture of the claimant's condition. Claims in regard to which the schedule evaluations are considered inadequate or excessive, and errors in the schedule will be similarly brought to attention.

[41 FR 11292, Mar. 18, 1976, as amended at 79 FR 2100, Jan. 13, 2014]

#### § 4.25 Combined ratings table.

Table I. Combined Ratings Table, results from the consideration of the efficiency of the individual as affected first by the most disabling condition, then by the less disabling condition, then by other less disabling conditions, if any, in the order of severity. Thus, a person having a 60 percent disability is considered 40 percent efficient. Proceeding from this 40 percent efficiency, the effect of a further 30 percent disability is to leave only 70 percent of the efficiency remaining after consideration of the first disability, or 28 percent efficiency altogether. The individual is thus 72 percent disabled, as shown in table I opposite 60 percent and under 30 percent.

(a) To use table I, the disabilities will first be arranged in the exact order of their severity, beginning with the greatest disability and then combined with use of table I as hereinafter indicated. For example, if there are two disabilities, the degree of one disability will be read in the left column and the degree of the other in the top row, whichever is appropriate. The figures appearing in the space where the column and row intersect will represent the combined value of the two. This combined value will then be converted to the nearest number divisible by 10, and combined values ending in 5 will be adjusted upward. Thus, with a 50 percent disability and a 30 percent disability, the combined value will be found to be 65 percent, but the 65 percent must be converted to 70 percent to represent the final degree of disability. Similarly, with a disability of 40 percent, and another disability of 20 percent, the combined value is found to be 52 percent, but the 52 percent must be converted to the nearest degree divisible by 10, which is 50 percent. If there are more than two disabilities, the disabilities will also be arranged in the exact order of their severity and the combined value for the first two will be found as previously described for two disabilities. The combined value, exactly as found in table I, will be combined with the degree of the third disability (in order of severity). The combined value for the three disabilities will be found in the space where the column and row intersect, and if there are only three disabilities will be converted to the nearest degree divisible by 10, adjusting final 5's upward. Thus, if there are three disabilities ratable at 60 percent, 40 percent, and 20 percent, respectively, the combined value for the first two will be found opposite 60 and under 40 and is 76 percent. This 76 will be combined with 20 and the combined value for the three is 81 percent. This combined value will be converted to the nearest degree divisible by 10 which is 80 percent. The same procedure will be employed when there are four or more disabilities. (See table I).

(b) Except as otherwise provided in this schedule, the disabilities arising from a single disease entity, e.g., arthritis, multiple sclerosis, cerebrovascular accident, etc., are to be rated separately as are all other disabiling conditions, if any. All disabilities are then to be combined as described in paragraph (a) of this section. The conversion to the nearest degree divisible by 10 will be done only once per rating decision, will follow the combining of all disabilities, and will be the last procedure in determining the combined degree of disability.

TABLE I—COMBINED RATINGS TABLE [10 combined with 10 is 19]

_	[10 combined with 10 is 19]									
		10	20	30	40	50	60	70	80	90
10		27	35	43	51	60	68	76	84	92
		28	36	44	52	60	68	76	84	92
		29	37	45	53	61	68	76	84	92
		30	38	45	53	61	69	77	84	92
		31	38	46	54	62	69	77	85	92
24 25		32 33	39 40	47 48	54 55	62 63	70 70	77 78	85 85	92 93
26		33	41	48	56	63	70	78	85	93
		34	42	49	56	64	71	78	85	93
28		35	42	50	57	64	71	78	86	93
29		36	43	50	57	65	72	79	86	93
30		37	44	51	58	65	72	79	86	93
31 32		38 39	45 46	52 52	59 59	66 66	72 73	79 80	86 86	93 93
		40	46	53	60	67	73	80	87	93
34		41	47	54	60	67	74	80	87	93
35		42	48	55	61	68	74	81	87	94
36		42	49	55	62	68	74	81	87	94
37		43	50	56	62	69	75	81	87	94 94
38 39		44 45	50 51	57 57	63 63	69 70	75 76	81 82	88 88	94 94
		46	52	58	64	70	76	82	88	94
41		47	53	59	65	71	76	82	88	94
42		48	54	59	65	71	77	83	88	94
		49	54	60	66	72	77	83	89	94
		50 51	55 56	61 62	66 67	72 73	78 78	83 84	89 89	94 95
46		51	57	62	68	73	78	84	89	95
		52	58	63	68	74	79	84	89	95
48		53	58	64	69	74	79	84	90	95
49		54	59	64	69	75	80	85	90	95
50 51		55 56	60 61	65 66	70 71	75 76	80 80	85 85	90 90	95 95
		57	62	66	71	76	81	86	90	95
		58	62	67	72	77	81	86	91	95
54		59	63	68	72	77	82	86	91	95
55		60	64	69	73	78	82	87	91	96
56 57		60 61	65 66	69 70	74 74	78 79	82 83	87 87	91 91	96 96
58		62	66	71	75	79	83	87	92	96
59		63	67	71	75	80	84	88	92	96
		64	68	72	76	80	84	88	92	96
		65	69	73 73	77	81 81	84 85	88	92 92	96 96
63		66 67	70 70	73 74	77 78	82	85 85	89 89	92	96 96
64		68	71	75	78	82	86	89	93	96
		69	72	76	79	83	86	90	93	97
66		69	73	76	80	83	86	90	93	97
		70	74	77	80	84	87	90	93	97
68 69		71 72	74 75	78 78	81 81	84 85	87 88	90 91	94 94	97 97
70		72	75 76	78 79	82	85 85	88	91	94	97 97
		74	77	80	83	86	88	91	94	97
72		75	78	80	83	86	89	92	94	97
73		76	78	81	84	87	89	92	95	97
74 75		77 78	79	82	84	87 88	90 90	92 93	95	97
76		78	80 81	83 83	85 86	88	90	93	95 95	98 98
77		79	82	84	86	89	91	93	95	98
78		80	82	85	87	89	91	93	96	98
79		81	83	85	87	90	92	94	96	98
80		82	84	86	88	90	92	94	96	98
		83 84	85 86	87 87	89 89	91 91	92 93	94 95	96 96	98 98
83		85 85	86	88	90	91	93	95 95	96 97	98
84		86	87	89	90	92	94	95	97	98
85		87	88	90	91	93	94	96	97	99
86		87	89	90	92	93	94	96	97	99
87		88	90	91	92	94	95	96	97	99
88		89 90	90 91	92 92	93 93	94 95	95 96	96 87	98 38	99 99
09		901	91	92	931	90 1	90	0/	38	99

TABLE I—COMBINED RATINGS TABLE—Continued
[10 combined with 10 is 19]

	10	20	30	40	50	60	70	80	90
90 91 92 93 94	91 92 93 94 95	92 93 94 94 95	93 94 94 95 96	94 95 95 96 96	95 96 96 97 97	96 96 97 97 98	97 97 98 98 98	98 98 98 99	99 99 99 99

(Authority: 38 U.S.C. 1155)

[41 FR 11293, Mar. 18, 1976, as amended at 54 FR 27161, June 28, 1989; 54 FR 36029, Aug. 31, 1989]

### §4.26 Bilateral factor.

When a partial disability results from disease or injury of both arms, or of both legs, or of paired skeletal muscles, the ratings for the disabilities of the right and left sides will be combined as usual, and 10 percent of this value will be added (i.e., not combined) before proceeding with further combinations, or converting to degree of disability. The bilateral factor will be applied to such bilateral disabilities before other combinations are carried out and the rating for such disabilities including the bilateral factor in this section will be treated as 1 disability for the purpose of arranging in order of severity and for all further combinations. For example, with disabilities evaluated at 60 percent, 20 percent, 10 percent and 10 percent (the two 10's representing bilateral disabilities), the order of severity would be 60, 21 and 20. The 60 and 21 combine to 68 percent and the 68 and 20 to 74 percent, converted to 70 percent as the final degree of disability.

(a) The use of the terms "arms" and "legs" is not intended to distinguish between the arm, forearm and hand, or the thigh, leg, and foot, but relates to the upper extremities and lower extremities as a whole. Thus with a compensable disability of the right thigh, for example, amputation, and one of the left foot, for example, pes planus, the bilateral factor applies, and similarly whenever there are compensable disabilities affecting use of paired extremities regardless of location or specified type of impairment.

(b) The correct procedure when applying the bilateral factor to disabilities affecting both upper extremities and both lower extremities is to com-

bine the ratings of the disabilities affecting the 4 extremities in the order of their individual severity and apply the bilateral factor by adding, not combining, 10 percent of the combined value thus attained.

(c) The bilateral factor is not applicable unless there is partial disability of compensable degree in each of 2 paired extremities, or paired skeletal muscles.

#### § 4.27 Use of diagnostic code numbers.

The diagnostic code numbers appearing opposite the listed ratable disabilities are arbitrary numbers for the purpose of showing the basis of the evaluation assigned and for statistical analysis in the Department of Veterans Affairs, and as will be observed, extend from 5000 to a possible 9999. Great care will be exercised in the selection of the applicable code number and in its citation on the rating sheet. No other numbers than these listed or hereafter furnished are to be employed for rating purposes, with an exception as described in this section, as to unlisted conditions. When an unlisted disease, injury, or residual condition is encountered, requiring rating by analogy, the diagnostic code number will be "builtup" as follows: The first 2 digits will be selected from that part of the schedule most closely identifying the part, or system, of the body involved; the last 2 digits will be "99" for all unlisted conditions. This procedure will facilitate a close check of new and unlisted conditions, rated by analogy. In the selection of code numbers, injuries will generally be represented by the number assigned to the residual condition on the basis of which the rating is determined. With diseases, preference is to be given

to the number assigned to the disease itself; if the rating is determined on the basis of residual conditions, the number appropriate to the residual condition will be added, preceded by a hyphen. Thus, rheumatoid (atrophic) arthritis rated as ankylosis of the lumbar spine should be coded "5002-5240." In this way, the exact source of each rating can be easily identified. In the citation of disabilities on rating sheets, the diagnostic terminology will be that of the medical examiner, with no attempt to translate the terms into schedule nomenclature. Residuals of diseases or therapeutic procedures will not be cited without reference to the basic disease.

[41 FR 11293, Mar. 18, 1976, as amended at 70 FR 75399, Dec. 20, 2005]

## § 4.28 Prestabilization rating from date of discharge from service.

The following ratings may be assigned, in lieu of ratings prescribed elsewhere, under the conditions stated for disability from any disease or injury. The prestabilization rating is not to be assigned in any case in which a total rating is immediately assignable under the regular provisions of the schedule or on the basis of individual unemployability. The prestabilization 50-percent rating is not to be used in any case in which a rating of 50 percent or more is immediately assignable under the regular provisions.

	Rating
Unstabilized condition with severe disability— Substantially gainful employment is not feasible or advisable Unhealed or incompletely healed wounds or injuries—	100
Material impairment of employability likely	50

Note (1): Department of Veterans Affairs examination is not required prior to assignment of prestabilization ratings; however, the fact that examination was accomplished will not preclude assignment of these benefits. Prestabilization ratings are for assignment in the immediate postdischarge period. They will continue for a 12-month period following discharge from service. However, prestabilization ratings may be changed to a regular schedular total rating or one authorizing a greater benefit at any time. In each prestabilization rating an examination will be requested to be accomplished not earlier than 6 months nor more than 12 months following discharge. In those prestabilization ratings in which following examination reduction in evaluation is found to be warranted, the higher evaluation will be continued to the end of the 12th month following discharge or to the end of the period provided under §3.105(e) of this chapter, whichever is later. Special monthly compensation should be assigned concurrently in these cases whenever records are adequate to establish entitlement.

NOTE (2): Diagnosis of disease, injury, or residuals will be cited, with diagnostic code number assigned from this rating schedule for conditions listed therein.

[35 FR 11906, July 24, 1970]

# § 4.29 Ratings for service-connected disabilities requiring hospital treatment or observation.

A total disability rating (100 percent) will be assigned without regard to other provisions of the rating schedule when it is established that a service-connected disability has required hospital treatment in a Department of Veterans Affairs or an approved hospital for a period in excess of 21 days or hospital observation at Department of Veterans Affairs expense for a service-connected disability for a period in excess of 21 days.

(a) Subject to the provisions of paragraphs (d), (e), and (f) of this section this increased rating will be effective the first day of continuous hospitalization and will be terminated effective the last day of the month of hospital discharge (regular discharge or release to non-bed care) or effective the last day of the month of termination of treatment or observation for the service-connected disability. A temporary release which is approved by an attending Department of Veterans Affairs physician as part of the treatment plan will not be considered an absence.

(1) An authorized absence in excess of 4 days which begins during the first 21 days of hospitalization will be regarded as the equivalent of hospital discharge effective the first day of such authorized absence. An authorized absence of 4 days or less which results in a total of more than 8 days of authorized absence during the first 21 days of hospitalization will be regarded as the equivalent of hospital discharge effective the ninth day of authorized absence.

(2) Following a period of hospitalization in excess of 21 days, an authorized absence in excess of 14 days or a third

consecutive authorized absence of 14 days will be regarded as the equivalent of hospital discharge and will interrupt hospitalization effective on the last day of the month in which either the authorized absence in excess of 14 days or the third 14 day period begins, except where there is a finding that convalescence is required as provided by paragraph (e) or (f) of this section. The termination of these total ratings will not be subject to §3.105(e) of this chapter.

(b) Notwithstanding that hospital admission was for disability not connected with service, if during such hospitalization, hospital treatment for a service-connected disability is instituted and continued for a period in excess of 21 days, the increase to a total rating will be granted from the first day of such treatment. If service connection for the disability under treatment is granted after hospital admission, the rating will be from the first day of hospitalization if otherwise in order.

- (c) The assignment of a total disability rating on the basis of hospital treatment or observation will not preclude the assignment of a total disability rating otherwise in order under other provisions of the rating schedule, and consideration will be given to the propriety of such a rating in all instances and to the propriety of its continuance after discharge. Particular attention, with a view to proper rating under the rating schedule, is to be given to the claims of veterans discharged from hospital, regardless of length of hospitalization, with indications on the final summary of expected confinement to bed or house, or to inability to work with requirement of frequent care of physician or nurse at home.
- (d) On these total ratings Department of Veterans Affairs regulations governing effective dates for increased benefits will control.
- (e) The total hospital rating if convalescence is required may be continued for periods of 1, 2, or 3 months in addition to the period provided in paragraph (a) of this section.
- (f) Extension of periods of 1, 2 or 3 months beyond the initial 3 months

may be made upon approval of the Veterans Service Center Manager.

(g) Meritorious claims of veterans who are discharged from the hospital with less than the required number of days but need post-hospital care and a prolonged period of convalescence will be referred to the Director, Compensation Service, under §3.321(b)(1) of this chapter.

[29 FR 6718, May 22, 1964, as amended at 41 FR 11294, Mar. 18, 1976; 41 FR 34256, Aug. 13, 1976; 54 FR 4281, Jan. 30, 1989; 54 FR 34981, Aug. 23, 1989; 71 FR 28586, May 17, 2006; 79 FR 2100, Jan. 13, 2014]

#### § 4.30 Convalescent ratings.

A total disability rating (100 percent) will be assigned without regard to other provisions of the rating schedule when it is established by report at hospital discharge (regular discharge or release to non-bed care) or outpatient release that entitlement is warranted under paragraph (a) (1), (2) or (3) of this section effective the date of hospital admission or outpatient treatment and continuing for a period of 1, 2, or 3 months from the first day of the month following such hospital discharge or outpatient release. The termination of these total ratings will not be subject to §3.105(e) of this chapter. Such total rating will be followed by appropriate schedular evaluations. When the evidence is inadequate to assign a schedular evaluation, a physical examination will be scheduled and considered prior to the termination of a total rating under this section.

- (a) Total ratings will be assigned under this section if treatment of a service-connected disability resulted in:
- (1) Surgery necessitating at least one month of convalescence (Effective as to outpatient surgery March 1, 1989.)
- (2) Surgery with severe postoperative residuals such as incompletely healed surgical wounds, stumps of recent amputations, therapeutic immobilization of one major joint or more, application of a body cast, or the necessity for house confinement, or the necessity for continued use of a wheelchair or crutches (regular weight-bearing prohibited). (Effective as to outpatient surgery March 1, 1989.)

(3) Immobilization by cast, without surgery, of one major joint or more. (Effective as to outpatient treatment March 10, 1976.)

A reduction in the total rating will not be subject to §3.105(e) of this chapter. The total rating will be followed by an open rating reflecting the appropriate schedular evaluation; where the evidence is inadequate to assign the schedular evaluation, a physcial examination will be scheduled prior to the end of the total rating period.

- (b) A total rating under this section will require full justification on the rating sheet and may be extended as follows:
- (1) Extensions of 1, 2 or 3 months beyond the initial 3 months may be made under paragraph (a) (1), (2) or (3) of this section
- (2) Extensions of 1 or more months up to 6 months beyond the initial 6 months period may be made under paragraph (a) (2) or (3) of this section upon approval of the Veterans Service Center Manager.

[41 FR 34256, Aug. 13, 1976, as amended at 54 FR 4281, Jan. 30, 1989; 71 FR 28586, May 17, 2006]

#### § 4.31 Zero percent evaluations.

In every instance where the schedule does not provide a zero percent evaluation for a diagnostic code, a zero percent evaluation shall be assigned when the requirements for a compensable evaluation are not met.

[58 FR 52018, Oct. 6, 1993]

#### Subpart B—Disability Ratings

THE MUSCULOSKELETAL SYSTEM

#### § 4.40 Functional loss.

Disability of the musculoskeletal system is primarily the inability, due to damage or infection in parts of the system, to perform the normal working movements of the body with normal excursion, strength, speed, coordination and endurance. It is essential that the examination on which ratings are based adequately portray the anatomical damage, and the functional loss, with respect to all these elements. The functional loss may be due to absence of part, or all, of the necessary bones,

joints and muscles, or associated structures, or to deformity, adhesions, defective innervation, or other pathology, or it may be due to pain, supported by adequate pathology and evidenced by the visible behavior of the claimant undertaking the motion. Weakness is as important as limitation of motion, and a part which becomes painful on use must be regarded as seriously disabled. A little used part of the musculoskeletal system may be expected to show evidence of disuse, either through atrophy, the condition of the skin, absence of normal callosity or the like.

#### § 4.41 History of injury.

In considering the residuals of injury. it is essential to trace the medical-industrial history of the disabled person from the original injury, considering the nature of the injury and the attendant circumstances, and the requirements for, and the effect of, treatment over past periods, and the course of the recovery to date. The duration of the initial, and any subsequent, period of total incapacity, especially periods reflecting delayed union, inflammation, swelling, drainage, or operative intervention, should be given close attention. This consideration, or the absence of clear cut evidence of injury. may result in classifying the disability as not of traumatic origin, either reflecting congenital or developmental etiology, or the effects of healed disease.

## § 4.42 Complete medical examination of injury cases.

The importance of complete medical examination of injury cases at the time of first medical examination by the Department of Veterans Affairs cannot be overemphasized. When possible, this should include complete neurological and psychiatric examination, and other special examinations indicated by the physical condition, in addition to the required general and orthopedic or surgical examinations. When complete examinations are not conducted covering all systems of the body affected by disease or injury, it is impossible to visualize the nature and extent of the service connected disability. Incomplete examination is a common cause

of incorrect diagnosis, especially in the neurological and psychiatric fields, and frequently leaves the Department of Veterans Affairs in doubt as to the presence or absence of disabling conditions at the time of the examination.

#### § 4.43 Osteomyelitis.

Chronic, or recurring, suppurative osteomyelitis, once clinically identified, including chronic inflammation of bone marrow, cortex, or periosteum, should be considered as a continuously disabling process, whether or not an actively discharging sinus or other obvious evidence of infection is manifest from time to time, and unless the focus is entirely removed by amputation will entitle to a permanent rating to be combined with other ratings for residual conditions, however, not exceeding amputation ratings at the site of election.

#### § 4.44 The bones.

The osseous abnormalities incident to trauma or disease, such as malunion with deformity throwing abnormal stress upon, and causing malalignment of joint surfaces, should be depicted from study and observation of all available data, beginning with inception of injury or disease, its nature, degree of prostration, treatment and duration of convalescence, and progress of recovery with development of permanent residuals. With shortening of a long bone, some degree of angulation is to be expected; the extent and direction should be brought out by X-ray and observation. The direction of angulation and extent of deformity should be carefully related to strain on the neighboring joints, especially those connected with weight-bearing.

### § 4.45 The joints.

As regards the joints the factors of disability reside in reductions of their normal excursion of movements in different planes. Inquiry will be directed to these considerations:

- (a) Less movement than normal (due to ankylosis, limitation or blocking, adhesions, tendon-tie-up, contracted scars, etc.).
- (b) More movement than normal (from flail joint, resections, nonunion

- of fracture, relaxation of ligaments, etc.).
- (c) Weakened movement (due to muscle injury, disease or injury of peripheral nerves, divided or lengthened tendons, etc.).
  - (d) Excess fatigability.
- (e) Incoordination, impaired ability to execute skilled movements smoothly.
- (f) Pain on movement, swelling, deformity or atrophy of disuse. Instability of station, disturbance of locomotion, interference with sitting, standing and weight-bearing are related considerations. For the purpose of rating disability from arthritis, the shoulder, elbow, wrist, hip, knee, and ankle are considered major joints; multiple involvements of the interphalangeal, metacarpal and carpal joints of the upper extremities, the interphalangeal, metatarsal and tarsal joints of the lower extremities, the cervical vertebrae, the dorsal vertebrae, and the lumbar vertebrae, are considered groups of minor joints, ratable on a with major joints. parity lumbosacral articulation and both sacroiliac joints are considered to be a group of minor joints, ratable on disturbance of lumbar spine functions.

#### § 4.46 Accurate measurement.

Accurate measurement of the length of stumps, excursion of joints, dimensions and location of scars with respect to landmarks, should be insisted on. The use of a goniometer in the measurement of limitation of motion is indispensable in examinations conducted within the Department of Veterans Affairs. Muscle atrophy must also be accurately measured and reported.

[41 FR 11294, Mar. 18, 1976]

### §§4.47-4.54 [Reserved]

## § 4.55 Principles of combined ratings for muscle injuries.

- (a) A muscle injury rating will not be combined with a peripheral nerve paralysis rating of the same body part, unless the injuries affect entirely different functions.
- (b) For rating purposes, the skeletal muscles of the body are divided into 23 muscle groups in 5 anatomical regions: 6 muscle groups for the shoulder girdle

and arm (diagnostic codes 5301 through 5306); 3 muscle groups for the forearm and hand (diagnostic codes 5307 through 5309); 3 muscle groups for the foot and leg (diagnostic codes 5310 through 5312); 6 muscle groups for the pelvic girdle and thigh (diagnostic codes 5313 through 5318); and 5 muscle groups for the torso and neck (diagnostic codes 5319 through 5323).

- (c) There will be no rating assigned for muscle groups which act upon an ankylosed joint, with the following exceptions:
- (1) In the case of an ankylosed knee, if muscle group XIII is disabled, it will be rated, but at the next lower level than that which would otherwise be assigned.
- (2) In the case of an ankylosed shoulder, if muscle groups I and II are severely disabled, the evaluation of the shoulder joint under diagnostic code 5200 will be elevated to the level for unfavorable ankylosis, if not already assigned, but the muscle groups themselves will not be rated.
- (d) The combined evaluation of muscle groups acting upon a single unankylosed joint must be lower than the evaluation for unfavorable ankylosis of that joint, except in the case of muscle groups I and II acting upon the shoulder.
- (e) For compensable muscle group injuries which are in the same anatomical region but do not act on the same joint, the evaluation for the most severely injured muscle group will be increased by one level and used as the combined evaluation for the affected muscle groups.
- (f) For muscle group injuries in different anatomical regions which do not act upon ankylosed joints, each muscle group injury shall be separately rated and the ratings combined under the provisions of §4.25.

(Authority: 38 U.S.C. 1155) [62 FR 30237, June 3, 1997]

## § 4.56 Evaluation of muscle disabilities.

(a) An open comminuted fracture with muscle or tendon damage will be rated as a severe injury of the muscle group involved unless, for locations such as in the wrist or over the tibia,

evidence establishes that the muscle damage is minimal.

- (b) A through-and-through injury with muscle damage shall be evaluated as no less than a moderate injury for each group of muscles damaged.
- (c) For VA rating purposes, the cardinal signs and symptoms of muscle disability are loss of power, weakness, lowered threshold of fatigue, fatigue-pain, impairment of coordination and uncertainty of movement.
- (d) Under diagnostic codes 5301 through 5323, disabilities resulting from muscle injuries shall be classified as slight, moderate, moderately severe or severe as follows:
- (1) Slight disability of muscles—(i) Type of injury. Simple wound of muscle without debridement or infection.
- (ii) History and complaint. Service department record of superficial wound with brief treatment and return to duty. Healing with good functional results. No cardinal signs or symptoms of muscle disability as defined in paragraph (c) of this section.
- (iii) Objective findings. Minimal scar. No evidence of fascial defect, atrophy, or impaired tonus. No impairment of function or metallic fragments retained in muscle tissue.
- (2) Moderate disability of muscles—(i) Type of injury. Through and through or deep penetrating wound of short track from a single bullet, small shell or shrapnel fragment, without explosive effect of high velocity missile, residuals of debridement, or prolonged infection.
- (ii) History and complaint. Service department record or other evidence of in-service treatment for the wound. Record of consistent complaint of one or more of the cardinal signs and symptoms of muscle disability as defined in paragraph (c) of this section, particularly lowered threshold of fatigue after average use, affecting the particular functions controlled by the injured muscles.
- (iii) Objective findings. Entrance and (if present) exit scars, small or linear, indicating short track of missile through muscle tissue. Some loss of deep fascia or muscle substance or impairment of muscle tonus and loss of power or lowered threshold of fatigue when compared to the sound side.

- (3) Moderately severe disability of muscles—(i) Type of injury. Through and through or deep penetrating wound by small high velocity missile or large low-velocity missile, with debridement, prolonged infection, or sloughing of soft parts, and intermuscular scarring.
- (ii) History and complaint. Service department record or other evidence showing hospitalization for a prolonged period for treatment of wound. Record of consistent complaint of cardinal signs and symptoms of muscle disability as defined in paragraph (c) of this section and, if present, evidence of inability to keep up with work requirements.
- (iii) Objective findings. Entrance and (if present) exit scars indicating track of missile through one or more muscle groups. Indications on palpation of loss of deep fascia, muscle substance, or normal firm resistance of muscles compared with sound side. Tests of strength and endurance compared with sound side demonstrate positive evidence of impairment.
- (4) Severe disability of muscles—(i) Type of injury. Through and through or deep penetrating wound due to high-velocity missile, or large or multiple low velocity missiles, or with shattering bone fracture or open comminuted fracture with extensive debridement, prolonged infection, or sloughing of soft parts, intermuscular binding and scarring.
- (ii) History and complaint. Service department record or other evidence showing hospitalization for a prolonged period for treatment of wound. Record of consistent complaint of cardinal signs and symptoms of muscle disability as defined in paragraph (c) of this section, worse than those shown for moderately severe muscle injuries, and, if present, evidence of inability to keep up with work requirements.
- (iii) Objective findings. Ragged, depressed and adherent scars indicating wide damage to muscle groups in missile track. Palpation shows loss of deep fascia or muscle substance, or soft flabby muscles in wound area. Muscles swell and harden abnormally in contraction. Tests of strength, endurance, or coordinated movements compared with the corresponding muscles of the uninjured side indicate severe impairment of function. If present, the fol-

- lowing are also signs of severe muscle disability:
- (A) X-ray evidence of minute multiple scattered foreign bodies indicating intermuscular trauma and explosive effect of the missile.
- (B) Adhesion of scar to one of the long bones, scapula, pelvic bones, sacrum or vertebrae, with epithelial sealing over the bone rather than true skin covering in an area where bone is normally protected by muscle.
- (C) Diminished muscle excitability to pulsed electrical current in electrodiagnostic tests.
  - (D) Visible or measurable atrophy.
- (E) Adaptive contraction of an opposing group of muscles.
- (F) Atrophy of muscle groups not in the track of the missile, particularly of the trapezius and serratus in wounds of the shoulder girdle.
- (G) Induration or atrophy of an entire muscle following simple piercing by a projectile.

(Authority: 38 U.S.C. 1155 [62 FR 30238, June 3, 1997]

#### § 4.57 Static foot deformities.

It is essential to make an initial distinction between bilateral flatfoot as a congenital or as an acquired condition. The congenital condition, with depression of the arch, but no evidence of abnormal callosities, areas of pressure, strain or demonstrable tenderness, is a congenital abnormality which is not compensable or pensionable. In the acquired condition, it is to be remembered that depression of the longitudinal arch, or the degree of depression, is not the essential feature. The attention should be given to anatomical changes, as compared to normal, in the relationship of the foot and leg, particularly to the inward rotation of the superior portion of the os calcis, medial deviation of the insertion of the Achilles tendon, the medial tilting of the upper border of the astragalus. This is an unfavorable mechanical relationship of the parts. A plumb line dropped from the middle of the patella falls inside of the normal point. The forepart of the foot is abducted, and the foot everted. The plantar surface of the foot is painful and shows demonstrable tenderness, and manipulation

of the foot produces spasm of the Achilles tendon, peroneal spasm due to adhesion about the peroneal sheaths. and other evidence of pain and limited motion. The symptoms should be apparent without regard to exercise. In severe cases there is gaping of bones on the inner border of the foot, and rigid valgus position with loss of the power of inversion and adduction. Exercise with undeveloped or unbalanced musculature, producing chronic irritation, can be an aggravating factor. In the absence of trauma or other definite evidence of aggravation, service connection is not in order for pes cavus which is a typically congenital or juvenile disease.

#### § 4.58 Arthritis due to strain.

With service incurred lower extremity amputation or shortening, a disabling arthritis, developing in the same extremity, or in both lower extremities, with indications of earlier, or more severe, arthritis in the injured extremity, including also arthritis of the lumbosacral joints and lumbar spine, if associated with the leg amputation or shortening, will be considered as service incurred, provided, however, that arthritis affecting joints not directly subject to strain as a result of the service incurred amputation will not be granted service connection. This will generally require separate evaluation of the arthritis in the joints directly subject to strain. Amputation, or injury to an upper extremity, is not considered as a causative factor with subsequently developing arthritis, except in joints subject to direct strain or actually injured.

#### § 4.59 Painful motion.

With any form of arthritis, painful motion is an important factor of disability, the facial expression, wincing, etc., on pressure or manipulation, should be carefully noted and definitely related to affected joints. Muscle spasm will greatly assist the identification. Sciatic neuritis is not uncommonly caused by arthritis of the spine. The intent of the schedule is to recognize painful motion with joint or periarticular pathology as productive of disability. It is the intention to recognize actually painful, unstable, or

malaligned joints, due to healed injury, as entitled to at least the minimum compensable rating for the joint. Crepitation either in the soft tissues such as the tendons or ligaments, or crepitation within the joint structures should be noted carefully as points of contact which are diseased. Flexion elicits such manifestations. The joints involved should be tested for pain on both active and passive motion, in weight-bearing and nonweight-bearing and, if possible, with the range of the opposite undamaged joint.

#### §4.60 [Reserved]

#### §4.61 Examination.

With any form of arthritis (except traumatic arthritis) it is essential that the examination for rating purposes cover all major joints, with especial reference to Heberden's or Haygarth's nodes.

#### §4.62 Circulatory disturbances.

The circulatory disturbances, especially of the lower extremity following injury in the popliteal space, must not be overlooked, and require rating generally as phlebitis.

#### § 4.63 Loss of use of hand or foot.

Loss of use of a hand or a foot, for the purpose of special monthly compensation, will be held to exist when no effective function remains other than that which would be equally well served by an amputation stump at the site of election below elbow or knee with use of a suitable prosthetic appliance. The determination will be made on the basis of the actual remaining function of the hand or foot, whether the acts of grasping, manipulation, etc., in the case of the hand, or of balance and propulsion, etc., in the case of the foot, could be accomplished equally well by an amputation stump with prosthesis.

- (a) Extremely unfavorable complete ankylosis of the knee, or complete ankylosis of 2 major joints of an extremity, or shortening of the lower extremity of 3½ inches (8.9 cms.) or more, will be taken as loss of use of the hand or foot involved.
- (b) Complete paralysis of the external popliteal nerve (common peroneal)

#### **Department of Veterans Affairs**

and consequent, footdrop, accompanied by characteristic organic changes including trophic and circulatory disturbances and other concomitants confirmatory of complete paralysis of this nerve, will be taken as loss of use of

[29 FR 6718, May 22, 1964, as amended at 43 FR 45349, Oct. 2, 1978]

#### §4.64 Loss of use of both buttocks.

Loss of use of both buttocks shall be deemed to exist when there is severe damage to muscle Group XVII, bilateral (diagnostic code number 5317) and additional disability rendering it impossible for the disabled person, without assistance, to rise from a seated position and from a stooped position (fingers to toes position) and to maintain postural stability (the pelvis upon head of femur). The assistance may be rendered by the person's own hands or arms, and, in the matter of postural stability, by a special appliance.

#### §4.65 [Reserved]

#### §4.66 Sacroiliac joint.

The common cause of disability in this region is arthritis, to be identified in the usual manner. The lumbosacral and sacroiliac joints should be considered as one anatomical segment for rating purposes. X-ray changes from arthritis in this location are decrease or obliteration of the joint space, with the appearance of increased bone density of the sacrum and ilium and sharpening of the margins of the joint. Disability is manifest from erector spinae spasm (not accounted for by other pathology), tenderness on deep palpation and percussion over these joints, loss of normal quickness of motion and resiliency, and postural defects often accompanied by limitation of flexion and extension of the hip. Traumatism is a rare cause of disability in this connection, except when superimposed upon congenital defect or upon an existent arthritis; to permit assumption of pure traumatic origin, objective evidence of damage to the joint, and history of trauma sufficiently severe to injure this extremely strong and practically immovable joint is required. There should be careful consideration of lumbosacral sprain, and the various

symptoms of pain and paralysis attributable to disease affecting the lumbar vertebrae and the intervertebral disc.

#### § 4.67 Pelvic bones.

The variability of residuals following these fractures necessitates rating on specific residuals, faulty posture, limitation of motion, muscle injury, painful motion of the lumbar spine, manifest by muscle spasm, mild to moderate sciatic neuritis, peripheral nerve injury, or limitation of hip motion.

#### § 4.68 Amputation rule.

The combined rating for disabilities of an extremity shall not exceed the rating for the amputation at the elective level, were amputation to be performed. For example, the combined evaluations for disabilities below the knee shall not exceed the 40 percent evaluation, diagnostic code 5165. This 40 percent rating may be further combined with evaluation for disabilities above the knee but not to exceed the above the knee amputation elective level. Painful neuroma of a stump after amputation shall be assigned the evaluation for the elective site of reamputation.

#### § 4.69 Dominant hand.

Handedness for the purpose of a dominant rating will be determined by the evidence of record, or by testing on VA examination. Only one hand shall be considered dominant. The injured hand, or the most severely injured hand, of an ambidextrous individual will be considered the dominant hand for rating purposes.

(Authority: 38 U.S.C. 1155) [62 FR 30239, June 3, 1997]

#### §4.70 Inadequate examinations.

If the report of examination is inadequate as a basis for the required consideration of service connection and evaluation, the rating agency may request a supplementary report from the examiner giving further details as to the limitations of the disabled person's ordinary activity imposed by the disease, injury, or residual condition, the prognosis for return to, or continuance of, useful work. When the best interests of the service will be advanced by

personal conference with the examiner, such conference may be arranged through channels.

## §4.71 Measurement of ankylosis and joint motion.

Plates I and II provide a standardized description of ankylosis and joint motion measurement. The anatomical position is considered as  $0^{\circ}$ , with two major exceptions: (a) Shoulder rotation—arm abducted to  $90^{\circ}$ , elbow flexed to  $90^{\circ}$  with the position of the forearm reflecting the midpoint  $0^{\circ}$  between in-

ternal and external rotation of the shoulder; and (b) supination and pronation—the arm next to the body, elbow flexed to 90°, and the forearm in midposition 0° between supination and pronation. Motion of the thumb and fingers should be described by appropriate reference to the joints (See Plate III) whose movement is limited, with a statement as to how near, in centimeters, the tip of the thumb can approximate the fingers, or how near the tips of the fingers can approximate the proximal transverse crease of palm.




PLATE I




PLATE II

 $[29 \ FR \ 6718, May \ 22, \ 1964, as amended at 43 \ FR \ 45349, Oct. \ 2, \ 1978; \ 67 \ FR \ 48785, July \ 26, \ 2002]$ 

## $\$\,4.71a$ Schedule of ratings—musculo-skeletal system.

ACUTE, SUBACUTE, OR CHRONIC DISEASES

	Rat- ing
5000 Osteomyelitis, acute, subacute, or chronic:	
Of the pelvis, vertebrae, or extending into major joints, or with multiple localization or with long	
history of intractability and debility, anemia, amyloid liver changes, or other continuous	
constitutional symptoms	100
Frequent episodes, with constitutional symptoms	60
With definite involucrum or sequestrum, with or without discharging sinus	30
With discharging sinus or other evidence of ac-	- 00
tive infection within the past 5 years	20
Inactive, following repeated episodes, without	
evidence of active infection in past 5 years	10

## ACUTE, SUBACUTE, OR CHRONIC DISEASES—Continued

Rat-

NOTE (1): A rating of 10 percent, as an exception to the amputation rule, is to be assigned in any case of active osteomyelitis where the amputation rating for the affected part is no percent. This 10 percent rating and the other partial ratings of 30 percent roless are to be combined with ratings for ankylosis, limited motion, nonunion or malunion, shortening, etc., subject, of course, to the amputation rule. The 60 percent rating, as it is based on constitutional symptoms, is not subject to the amputation rule. A rating for osteomyelitis will not be applied following cure by removal or radical resection of the affected bone.

#### **Department of Veterans Affairs**

§4.71a

## ACUTE, SUBACUTE, OR CHRONIC DISEASES-

Continued	:5—
	Rat- ing
NOTE (2): The 20 percent rating on the basis of activity within the past 5 years is not assignable following the initial infection of active osteomyelitis with no subsequent reactivation. The prerequisite for this historical rating is an established recurrent osteomyelitis. To qualify for the 10 percent rating, 2 or more episodes following the initial infection are required. This 20 percent rating or the 10 percent rating, when applicable, will be assigned once only to cover disability at all sites of previously active infection with a future ending date in the case of the 20 percent rating.  5001 Bones and joints, tuberculosis of, active or inactive:	
Active	100
process: With constitutional manifestations associated with active joint involvement, totally incapaci-	
tating  Less than criteria for 100% but with weight loss and anemia productive of severe impairment of health or severely incapacitating exacerbations occurring 4 or more times a year or a	100
lesser number over prolonged periods	60
bations occurring 3 or more times a year  One or two exacerbations a year in a well-estab-	40
lished diagnosis.  For chronic residuals: For residuals such as limitation of motion or ankylosis, favorable or unfavorable, rate under the appropriate diagnostic codes for the specific joints involved. Where, however, the limitation of motion of the specific joint or joints involved is noncompensable under the codes a rating of 10 percent is for application for each such major joint or group of minor joints affected by limitation of motion, to be combined, not added under diagnostic code 5002. Limitation of motion must be objectively confirmed by findings such as swelling, muscle spasm, or satisfactory evidence of painful motion.	20

NOTE: The ratings for the active process will not be combined with the residual ratings for limitation of motion or ankylosis. Assign the higher evaluation.
5003 Arthritis, degenerative (hypertrophic or osteo-

arthritis):

Degenerative arthritis established by X-ray find-ings will be rated on the basis of limitation of motion under the appropriate diagnostic codes for the specific joint or joints involved (DC 5200 etc.). When however, the limitation of motion of the specific joint or joints involved is motion of the specific joint or joints involved is noncompensable under the appropriate diagnostic codes, a rating of 10 pct is for application for each such major joint or group of minor joints affected by limitation of motion, to be combined, not added under diagnostic code 5003. Limitation of motion must be objectively confirmed by findings such as swelling, muscle spasm, or satisfactory evidence of painful motion. In the absence of limitation of motion, rate as below: motion, rate as below:

#### ACUTE, SUBACUTE, OR CHRONIC DISEASES-Continued

	Rat- ing
With X-ray evidence of involvement of 2 or	
more major joints or 2 or more minor joint groups, with occasional incapacitating ex-	
acerbations	20
groups	10
on X-ray findings, above, will not be combined with ratings based on limitation of motion.  NOTE (2): The 20 pct and 10 pct ratings based	
on X-ray findings, above, will not be utilized in rating conditions listed under diagnostic codes 5013 to 5024, inclusive.	
5004 Arthritis, gonorrheal. 5005 Arthritis, pneumococcic.	
5006 Arthritis, typhoid. 5007 Arthritis, syphilitic.	
5008 Arthritis, streptococcic.	
With the types of arthritis, diagnostic codes 5004 through 5009, rate the disability as rheumatoid	
arthritis. 5010 Arthritis, due to trauma, substantiated by X-ray findings: Rate as arthritis, degenerative.	
5011 Bones, caisson disease of: Rate as arthritis, cord involvement, or deafness, depending on the	
severity of disabling manifestations.  5012 Bones, new growths of, malignant	100
Note: The 100 percent rating will be continued for 1 year following the cessation of surgical,	
X-ray, antineoplastic chemotherapy or other therapeutic procedure. At this point, if there has been no local recurrence or metastases, the rating will be made on residuals.	
5013 Osteoporosis, with joint manifestations.	
5014 Osteomalacia. 5015 Bones, new growths of, benign.	
5016 Osteitis deformans. 5017 Gout.	
5018 Hydrarthrosis, intermittent.	
5019 Bursitis. 5020 Synovitis.	
5021 Myositis.	
5022 Periostitis.	
5023 Myositis ossificans.	
5024 Tenosynovitis.  The diseases under diagnostic codes 5013	
through 5024 will be rated on limitation of mo- tion of affected parts, as arthritis, degenera- tive, except gout which will be rated under di-	
agnostic code 5002. 5025 Fibromyalgia (fibrositis, primary fibromyalgia	
syndrome) With widespread musculoskeletal pain and ten-	
der points, with or without associated fatigue, sleep disturbance, stiffness, paresthesias, headache, irritable bowel symptoms, depres-	
sion, anxiety, or Raynaud's-like symptoms: That are constant, or nearly so, and refrac-	
tory to therapy	40
That are episodic, with exacerbations often precipitated by environmental or emo- tional stress or by overexertion, but that	
are present more than one-third of the time	20

## 38 CFR Ch. I (7-1-16 Edition)

## §4.71a

## ACUTE, SUBACUTE, OR CHRONIC DISEASES—Continued

	Rat- ing
Note: Widespread pain means pain in both the left and right sides of the body, that is both above and below the waist, and that affects both the axial skeleton (i.e., cervical spine, anterior chest, thoracic spine, or low back) and the extremities.	

### PROSTHETIC IMPLANTS

	Rati	ing
	Major	Minor
5051 Shoulder replacement (prosthesis).  Prosthetic replacement of the shoulder joint:		
For 1 year following implantation of prosthesis	100	100
severe, painful motion or weak- ness in the affected extremity With intermediate degrees of resid- ual weakness, pain or limitation of motion, rate by analogy to di-	60	50
agnostic codes 5200 and 5203.  Minimum rating	30	20
joint:  For 1 year following implantation of prosthesis	100	100
severe painful motion or weak- ness in the affected extremity With intermediate degrees of resid- ual weakness, pain or limitation of motion rate by analogy to di- agnostic codes 5205 through 5208.	50	40
Minimum evaluation	30	20
prosthesis	100	100
ness in the affected extremity With intermediate degrees of residual weakness, pain or limitation of motion, rate by analogy to diagnostic code 5214.	40	30
Minimum rating	20	20
For 1 year following implantation of prosthesis		100
crutches		1 90

### PROSTHETIC IMPLANTS—Continued

	Rat	ing
	Major	Minor
Markedly severe residual weak-		
ness, pain or limitation of motion		
following implantation of pros-		70
thesis  Moderately severe residuals of		70
Moderately severe residuals of weakness, pain or limitation of		
motion		50
Minimum rating		30
5055 Knee replacement (prosthesis).		"
Prosthetic replacement of knee joint:		
For 1 year following implantation of		
prosthesis		100
With chronic residuals consisting of		
severe painful motion or weak-		
ness in the affected extremity		60
With intermediate degrees of resid-		
ual weakness, pain or limitation		
of motion rate by analogy to diagnostic codes 5256, 5261, or		
5262.		
Minimum rating		30
5056 Ankle replacement (prosthesis).		"
Prosthetic replacement of ankle joint:		
For 1 year following implantation of		İ
prosthesis		100
With chronic residuals consisting of		
severe painful motion or weak-		
ness		40
With intermediate degrees of resid-		
ual weakness, pain or limitation		
of motion rate by analogy to 5270 or 5271.		
Minimum rating		20
NOTE (1): The 100 pct rating for 1 year		20
following implantation of prosthesis		
will commence after initial grant of the		
1-month total rating assigned under		
§ 4.30 following hospital discharge.		
NOTE (2): Special monthly compensa-		
tion is assignable during the 100 pct		
rating period the earliest date perma-		
nent use of crutches is established.		
COMBINATIONS OF DISABILITIES		
5104 Anatomical loss of one hand and loss		
of use of one foot		1100
5105 Anatomical loss of one foot and loss		
of use of one hand		1100
5106 Anatomical loss of both hands		1100
5107 Anatomical loss of both feet		1100
5108 Anatomical loss of one hand and one		
foot		1100
5109 Loss of use of both hands		1100
5110 Loss of use of both feet		1100
5111 Loss of use of one hand and one		1100
foot	1	1100

Note: The term "prosthetic replacement" in diagnostic codes 5051 through 5056 means a total replacement of the named joint. However, in DC 5054, "prosthetic replacement" means a total replacement of the head of the femur or of the acetabulum.

<sup>&</sup>lt;sup>1</sup> Also entitled to special monthly compensation.

TABLE II—RATINGS FOR MULTIPLE LOSSES OF EXTREMITIES WITH DICTATOR'S RATING CODE AND 38 CFR CITATION

		`	or it on anon			
			Impairment of o	other extremity		
Impairment of one extremity	Anatomical loss or loss of use below elbow	Anatomical loss or loss of use below knee	Anatomical loss or loss of use above elbow (preventing use of prosthesis)	Anatomical loss or loss of use above knee (preventing use of prosthesis)	Anatomical loss near shoulder (preventing use of prosthesis)	Anatomical loss near hip (pre- venting use of prosthesis)
Anatomical loss or loss of use below elbow.	M Codes M-1 a, b, or c, 38 CFR 3.350 (c)(1)(i).	L Codes L-1 d, e, f, or g, 38 CFR 3.350(b).	M½ Code M-5, 38 CFR 3.350 (f)(1)(x).	L½ Code L-2 c, 38 CFR 3.350 (f)(1)(vi).	N Code N-3, 38 CFR 3.350 (f)(1)(xi).	M Code M-3 c, 38 CFR 3.350 (f)(1)(viii)
Anatomical loss or loss of use below knee.		L Codes L-1 a, b, or c, 38 CFR 3.350(b).	L½ Code L–2 b, 38 CFR 3.350	L½ Code L–2 a, 38 CFR 3.350 (f)(1)(i).	M Code M–3 b, 38 CFR 3.350	M Code M-3 a, 38 CFR 3.350 (f)(1)(ii)
Anatomical loss or loss of use above elbow			(f)(1)(iii). N Code N-1, 38 CFR 3.350 (d)(1).	M Code M–2 a, 38 CFR 3.350	(f)(1)(iv). N½ Code N–4, 38 CFR 3.350	M½ Code M-4 c, 38 CFR 3.350
(preventing use of prosthesis). Anatomical loss or loss of use above knee (preventing use				(c)(1)(iii).  M Code M–2 a, 38 CFR 3.350 (c)(1)(ii).	(f)(1)(ix). M½ Code M-4 b, 38 CFR 3.350 (f)(1)(vii).	(f)(1)(xi) M½ Code M-4 a, 38 CFR 3.350 (f)(1)(v)
of prosthesis). Anatomical loss near shoulder (preventing use					O Code O-1, 38 CFR 3.350 (e)(1)(i).	N Code N-2 b, 38 CFR 3.350 (d)(3)
of prosthesis).  Anatomical loss near hip (preventing use of prosthesis).						N Code N-2 a, 38 CFR 3.350 (d)(2)

Note.—Need for aid attendance or permanently bedridden qualifies for subpar. L. Code L-1 h, i (38 CFR 3.350(b)). Paraplegia with loss of use of both lower extremities and loss of anal and bladder sphincter control qualifies for subpar. O. Code O-2 (38 CFR 3.350(e)(2)). Where there are additional disabilities rated 50% or 100%, or anatomical or loss of use of a third extremity see 38 CFR 3.350(f) (3), (4) or (5).

(Authority: 38 U.S.C. 1115)

### AMPUTATIONS: UPPER EXTREMITY—Continued

	AMPUTATIONS: UPPER EXTREMITY					
		Rating				
		Major	Minor			
A	rm, amputation of:					
5120	Disarticulation	1 90	1 90			
5121	Above insertion of deltoid	1 90	180			
5122	Below insertion of deltoid	180	1 70			
F	orearm, amputation of:					
5123	Above insertion of pronator teres	<sup>1</sup> 80	<sup>1</sup> 70			
5124	Below insertion of pronator teres	1 70	1 60			
5125	Hand, loss of use of	170	<sup>1</sup> 60			
	MULTIPLE FINGER AMPUTATIONS					
5126 of	Five digits of one hand, amputation	1 70	¹ 60			
	our digits of one hand, amputation of:	. 70	. 60			
5127	Thumb, index, long and ring	1 70	160			
5128	Thumb, index, long and little	170	<sup>1</sup> 60			
5129	Thumb, index, ring and little	170	1 60			
5130	Thumb, long, ring and little	170	<sup>1</sup> 60			
5131	Index, long, ring and little	60	50			
T	hree digits of one hand, amputation of:					
5132	Thumb, index and long	60	50			
5133	Thumb, index and ring	60	50			
5134	Thumb, index and little	60	50			
5135	Thumb, long and ring	60	50			
5136	Thumb, long and little	60	50			

		Rati	ng
		Major	Minor
5137	Thumb, ring and little	60	50
5138	Index, long and ring	50	40
5139	Index, long and little	50	40
5140	Index, ring and little	50	40
5141	Long, ring and little	40	30
T	wo digits of one hand, amputation of:		
5142	Thumb and index	50	40
5143	Thumb and long	50	40
5144	Thumb and ring	50	40
5145	Thumb and little	50	40
5146	Index and long	40	30
5147	Index and ring	40	30
5148	Index and little	40	30
5149	Long and ring	30	20
5150	Long and little	30	20
5151	Ring and little	30	20
·	a) The ratings for multiple finger amputations apply to amputations at the proximal interphalangeal joints or through proximal phalanges. b) Amputation through middle phalanges will be rated as prescribed for unfavorable ankylosis of the fingers		

§4.71a

38 CFR Ch. I (7-1-16 Edition)

AMPUTATIONS: UPPER EXTREMITY—Continued

	Rati	ing
	Major	Minor
(c) Amputations at distal joints, or through distal phalanges, other than negligible losses, will be rated as prescribed for favorable ankylosis of the fingers.  (d) Amputation or resection of metacarpal bones (more than one-half the bone lost) in multiple fingers injuries will require a rating of 10 percent added to (not combined with) the ratings, multiple finger amputations, subject to the amputation rule applied to the forearm.  (e) Combinations of finger amputations at various levels, or finger amputations with ankylosis or limitation of motion of the fingers will be rated on the basis of the grade of disability, i.e., amputation, unfavorable ankylosis, most representative of the levels or combinations. With an even number of fingers involved, and adjacent grades of disability, select the higher of the two grades.  (f) Loss of use of the hand will be held to exist when no effective function remains other than that which would be equally well served by an amputation stump with a suitable prosthetic applicance.		

5152 Thumb, amputation of:

AMPUTATIONS: UPPER EXTREMITY—Continued

	Rati	Rating	
	Major	Mino	
With metacarpal resection At metacarpophalangeal joint or through	40	31	
proximal phalanx	30	20	
At distal joint or through distal phalanx 5153 Index finger, amputation of	20	21	
With metacarpal resection (more than one-half the bone lost)	30	20	
thereto	20	20	
Through middle phalanx or at distal joint 5154 Long finger, amputation of:	10	10	
With metacarpal resection (more than one-half the bone lost)	20	20	
mal interphalangeal joint or proximal thereto	10	10	
With metacarpal resection (more than one-half the bone lost)	20	2	
mal interphalangeal joint or proximal thereto	10	10	
With metacarpal resection (more than one-half the bone lost)	20	20	
Without metacarpal resection, at proxi- mal interphalangeal joint or proximal thereto	10	10	
NOTE: The single finger amputation rat- ings are the only applicable ratings for amputations of whole or part of single fingers.			

<sup>&</sup>lt;sup>1</sup> Entitled to special monthly compensation.

#### SINGLE FINGER AMPUTATIONS




PLATE III

## §4.71a

## 38 CFR Ch. I (7-1-16 Edition)

## AMPUTATIONS: LOWER EXTREMITY

	Rat- ing
Thigh, amputation of:	
5160 Disarticulation, with loss of extrinsic pelvic gir-	
dle muscles	2 90
5161 Upper third, one-third of the distance from	
perineum to knee joint measured from perineum	280
5162 Middle or lower thirds	<sup>2</sup> 60
Leg, amputation of:	
5163 With defective stump, thigh amputation rec-	
ommended	<sup>2</sup> 60
5164 Amputation not improvable by prosthesis con-	
trolled by natural knee action	<sup>2</sup> 60
5165 At a lower level, permitting prosthesis	<sup>2</sup> 40
5166 Forefoot, amputation proximal to metatarsal	
bones (more than one-half of metatarsal loss)	<sup>2</sup> 40
5167 Foot, loss of use of	2 40

## AMPUTATIONS: LOWER EXTREMITY—Continued

	Rat- ing
5170 Toes, all, amputation of, without metatarsal	
loss	30
5171 Toe, great, amputation of:	
With removal of metatarsal head	30
Without metatarsal involvement	10
5172 Toes, other than great, amputation of, with re-	
moval of metatarsal head:	
One or two	20
Without metatarsal involvement	0
5173 Toes, three or four, amputation of, without	
metatarsal involvement:	
Including great toe	20
Not including great toe	10

<sup>&</sup>lt;sup>2</sup> Also entitled to special monthly compensation.

#### AMPUTATIONS: LOWER EXTREMITY




PLATE IV

## 38 CFR Ch. I (7-1-16 Edition)

## §4.71a

## THE SHOULDER AND ARM

## THE ELBOW AND FOREARM—Continued

	Rating	
	Major	Minor
5200 Scapulohumeral articulation, anky-		
losis of:		
NOTE: The scapula and humerus move		
as one piece.		
Unfavorable, abduction limited to 25°		
from side	50	40
Intermediate between favorable and un-	4.0	
favorable	40	30
Favorable, abduction to 60°, can reach mouth and head	30	00
5201 Arm. limitation of motion of:	30	20
To 25° from side	40	30
Midway between side and shoulder	40	30
level	30	20
At shoulder level	20	20
5202 Humerus, other impairment of:	20	20
Loss of head of (flail shoulder)	80	70
Nonunion of (false flail joint)	60	50
Fibrous union of	50	40
Recurrent dislocation of at		
scapulohumeral joint.		
With frequent episodes and quard-		
ing of all arm movements	30	20
With infrequent episodes, and	"	
guarding of movement only at		
shoulder level	20	20
Malunion of:		
Marked deformity	30	20
Moderate deformity	20	20
5203 Clavicle or scapula, impairment of:		
Dislocation of	20	20
Nonunion of:		
With loose movement	20	20
Without loose movement	10	10
Malunion of	10	10
Or rate on impairment of function of		
contiguous joint.		

## THE ELBOW AND FOREARM

	Rati	ing
	Major	Minor
5205 Elbow, ankylosis of:		
Unfavorable, at an angle of less than		
50° or with complete loss of		
supination or pronation	60	50
Intermediate, at an angle of more than		
90°, or between 70° and 50°	50	40
Favorable, at an angle between 90° and		
70°	40	30
5206 Forearm, limitation of flexion of:		
Flexion limited to 45°	50	40
Flexion limited to 55°	40	30
Flexion limited to 70°	30	20
Flexion limited to 90°	20	20
Flexion limited to 100°	10	10
Flexion limited to 110°	0	0
5207 Forearm, limitation of extension of:		
Extension limited to 110°	50	40
Extension limited to 100°	40	30
Extension limited to 90°	30	20
Extension limited to 75°	20	20
Extension limited to 60°	10	10
Extension limited to 45°	10	10
5208 Forearm, flexion limited to 100° and	00	
extension to 45°	20	20
5209 Elbow, other impairment of Flail joint	60	50

	Rati	ng
	Major	Minor
Joint fracture, with marked cubitus		
varus or cubitus valgus deformity or		
with ununited fracture of head of ra-		
dius	20	20
5210 Radius and ulna, nonunion of, with		40
flail false joint	50	40
5211 Ulna, impairment of:		
Nonunion in upper half, with false		
movement:		
With loss of bone substance (1 inch		
(2.5 cms.) or more) and marked		
deformity	40	30
Without loss of bone substance or		
deformity	30	20
Nonunion in lower half	20	20
Malunion of, with bad alignment	10	10
5212 Radius, impairment of:		
Nonunion in lower half, with false move-		
ment:		
With loss of bone substance (1 inch		
(2.5 cms.) or more) and marked		
deformity	40	30
Without loss of bone substance or		
deformity	30	20
Nonunion in upper half	20	20
Malunion of, with bad alignment	10	10
5213 Supination and pronation, impairment		
of:		
Loss of (bone fusion):		
The hand fixed in supination or		
hyperpronation	40	30
The hand fixed in full pronation	30	20
The hand fixed near the middle of		
the arc or moderate pronation	20	20
Limitation of pronation:		
Motion lost beyond middle of arc	30	20
Motion lost beyond last quarter of		
arc, the hand does not approach		
full pronation	20	20
Limitation of supination:		
To 30° or less	10	10
NOTE: In all the forearm and wrist inju-		
ries, codes 5205 through 5213, mul-		
tiple impaired finger movements due		
to tendon tie-up, muscle or nerve in-		
jury, are to be separately rated and		
combined not to exceed rating for		
loss of use of hand.		

### THE WRIST

	Rating	
	Major	Minor
5214 Wrist, ankylosis of:     Unfavorable, in any degree of palmar flexion, or with ulnar or radial deviation Any other position, except favorable Favorable in 20° to 30° dorsiflexion NOTE: Extremely unfavorable ankylosis will be rated as loss of use of hands under diagnostic code 5125.	50 40 30	40 30 20
5215 Wrist, limitation of motion of:  Dorsiflexion less than 15°	10	10
arm	10	10

EVALUATION OF ANKYLOSIS OR LIMITATION OF MOTION OF SINGLE OR MULTIPLE DIGITS OF THE HAND

EVALUATION OF ANKYLOSIS OR LIMITATION OF MOTION OF SINGLE OR MULTIPLE DIGITS OF THE HAND—Continued

THE TIAND	_		THE TIAND CONTINUES		
	Rat	_		Rat	
	Major	Minor		Major	Mino
1) For the index, long, ring, and little fingers			(iv) If only the metacarpophalangeal		
(digits II, III, IV, and V), zero degrees of			or proximal interphalangeal joint		
flexion represents the fingers fully ex-			is ankylosed, and there is a gap		
tended, making a straight line with the rest			of two inches (5.1 cm.) or less		
of the hand. The position of function of the			between the fingertip(s) and the		
hand is with the wrist dorsiflexed 20 to 30			proximal transverse crease of the palm, with the finger(s) flexed to		
degrees, the metacarpophalangeal and			the extent possible, evaluate as		
proximal interphalangeal joints flexed to			favorable ankylosis		
30 degrees, and the thumb (digit I) abducted and rotated so that the thumb pad			(4) Evaluation of ankylosis of the thumb:		
faces the finger pads. Only joints in these			(i) If both the carpometacarpal and		
positions are considered to be in favorable			interphalangeal joints are		
position. For digits II through V, the			ankylosed, and either is in exten-		
metacarpophalangeal joint has a range of			sion or full flexion, or there is ro-		
zero to 90 degrees of flexion, the proximal			tation or angulation of a bone,		
interphalangeal joint has a range of zero			evaluate as amputation at		
to 100 degrees of flexion, and the distal			metacarpophalangeal joint or		
(terminal) interphalangeal joint has a			through proximal phalanx(ii) If both the carpometacarpal and		
range of zero to 70 or 80 degrees of flex-			interphalangeal joints are		
ion			ankylosed, evaluate as unfavor-		
2) When two or more digits of the same			able ankylosis, even if each joint		
hand are affected by any combination of			is individually fixed in a favorable		
amputation, ankylosis, or limitation of mo- tion that is not otherwise specified in the			position		
rating schedule, the evaluation level as-			(iii) If only the carpometacarpal or		
signed will be that which best represents			interphalangeal joint is		
the overall disability (i.e., amputation, un-			ankylosed, and there is a gap of		
favorable or favorable ankylosis, or limita-			more than two inches (5.1 cm.)		
tion of motion), assigning the higher level			between the thumb pad and the		
of evaluation when the level of disability is			fingers, with the thumb attempt-		
equally balanced between one level and			ing to oppose the fingers, evalu- ate as unfavorable ankylosis		
the next higher level			(iv) If only the carpometacarpal or		
3) Evaluation of ankylosis of the index,			interphalangeal joint is		
long, ring, and little fingers:			ankylosed, and there is a gap of		
(i) If both the metacarpophalangeal			two inches (5.1 cm.) or less be-		
and proximal interphalangeal			tween the thumb pad and the fin-		
joints of a digit are ankylosed,			gers, with the thumb attempting		
and either is in extension or full			to oppose the fingers, evaluate		
flexion, or there is rotation or an-			as favorable ankylosis		
gulation of a bone, evaluate as amputation without metacarpal			(5) If there is limitation of motion of two or		
resection, at proximal inter-			more digits, evaluate each digit separately		
phalangeal joint or proximal			and combine the evaluations		
thereto	l		I. Multiple Digits: Unfavorable Ank	cylosis	
(ii) If both the metacarpophalangeal				,	
and proximal interphalangeal			5216 Five digits of one hand, unfavorable		
joints of a digit are ankylosed,			ankylosis of	60	5
evaluate as unfavorable anky-			Note: Also consider whether evaluation as		
losis, even if each joint is individ-			amputation is warranted.		
ually fixed in a favorable position.			5217 Four digits of one hand, unfavorable		
(iii) If only the metacarpophalangeal			ankylosis of: Thumb and any three fingers	60	
or proximal interphalangeal joint			Index, long, ring, and little fingers	50	2
is ankylosed, and there is a gap			Note: Also consider whether evaluation as		
of more than two inches (5.1			amputation is warranted.		
cm.) between the fingertip(s) and			5218 Three digits of one hand, unfavorable		
the proximal transverse crease of the palm, with the finger(s) flexed			ankylosis of:		
to the extent possible, evaluate			Thumb and any two fingers	50	4
as unfavorable ankylosis			Index, long, and ring; index, long,		
ao amavorabio amyioolo		,	and little; or index, ring, and little		
			fingers	40	3
			Long, ring, and little fingers	30	2
			Note: Also consider whether evaluation as		
			amputation is warranted.		
			5219 Two digits of one hand, unfavorable ankylosis of:		
			Thumb and any finger	40	3
			mumb and any imger	. 40	

## 38 CFR Ch. I (7-1-16 Edition)

## §4.71a

EVALUATION OF ANKYLOSIS OR LIMITATION OF MOTION OF SINGLE OR MULTIPLE DIGITS OF THE HAND—Continued

	Rati	ing
	Major	Minor
Index and long; index and ring; or index and little fingers	30 20	20 20
amputation is warranted.		
II. Multiple Digits: Favorable Anky	/losis	
5220 Five digits of one hand, favorable ankylosis of	50	40
Thumb and any three fingers	50	40
Index, long, ring, and little fingers 5222 Three digits of one hand, favorable ankylosis of:	40	30
Thumb and any two fingers Index, long, and ring; index, long, and little; or index, ring, and little	40	30
fingers	30	20
Long, ring and little fingers5223 Two digits of one hand, favorable ankylosis of:	20	20
Thumb and any finger	30	20
Index and long; index and ring; or index and little fingers	20	20
Long and ring; long and little; or ring and little fingers	10	10
III. Ankylosis of Individual Dig	its	
5224 Thumb, ankylosis of:		
Unfavorable	20	20
Favorable  Note: Also consider whether evaluation as amputation is warranted and whether an additional evaluation is warranted for resulting limitation of motion of other digits or interference with overall function of the hand.	10	10
5225 Index finger, ankylosis of: Unfavorable or favorable	10	10
Note: Also consider whether evaluation as amputation is warranted and whether an additional evaluation is warranted for re- sulting limitation of motion of other digits or interference with overall function of the hand.		
5226 Long finger, ankylosis of:     Unfavorable or favorable  Note: Also consider whether evaluation as amputation is warranted and whether an additional evaluation is warranted for resulting limitation of motion of other digits or interference with overall function of the	10	10
hand. 5227 Ring or little finger, ankylosis of: Unfavorable or favorable	0	0

EVALUATION OF ANKYLOSIS OR LIMITATION OF MOTION OF SINGLE OR MULTIPLE DIGITS OF THE HAND—Continued

	Rati	ing
	Major	Mino
Note: Also consider whether evaluation as amputation is warranted and whether an additional evaluation is warranted for re- sulting limitation of motion of other digits or interference with overall function of the hand.		
IV. Limitation of Motion of Individua	al Digits	
5228 Thumb, limitation of motion:		
With a gap of more than two inches (5.1 cm.) between the thumb pad and the fingers, with the thumb attempting to oppose the fingers With a gap of one to two inches (2.5 to 5.1 cm.) between the	20	20
thumb pad and the fingers, with the thumb attempting to oppose the fingers	10	10
(2.5 cm.) between the thumb pad and the fingers, with the thumb attempting to oppose the fingers 5229 Index or long finger, limitation of mo-	0	(
tion: With a gap of one inch (2.5 cm.) or		
more between the fingertip and the proximal transverse crease of the palm, with the finger flexed to the extent possible, or; with ex- tension limited by more than 30		
degrees	10	10
and; extension is limited by no more than 30 degrees	0	(
tion:  Any limitation of motion	0	
THE SPINE		
THE OF INC		D-4
		Rat- ing
General Rating Formula for Diseases and of the Spine	Injuries	
(For diagnostic codes 5235 to 5243 unless evaluated under the Formula for Intervertebral Disc Syndrome Based on It tating Episodes):  With or without symptoms such (whther or not it radiates), stiff aching in the area of the spine affe	Rating ncapaci- as pain ness, or	
residuals of injury or disease Unfavorable ankylosis of th spine Unfavorable ankylosis of th		100

THE SPINE—Continued

## THE SPINE—Continued

	Rat- ing		Rat-
Unfavorable ankylosis of the entire cervical spine; or, forward flexion of the thoracolumbar spine 30 degrees or less; or, favorable ankylosis of the entire thoracolumbar spine		Note (2): (See also Plate V.) For VA compensation purposes, normal forward flexion of the cervical spine is zero to 45 degrees, extension is zero to 45 degrees, elft and right lateral flexion are zero to 45 degrees, and left and right lateral rotation are zero to 80 degrees. Normal forward flexion of the thoracolumbar spine is zero to 90 degrees, extension is zero to 30 degrees, left and right lateral flexion are zero to 30 degrees, left and right lateral flexion are zero to 30 degrees, and left and right lateral flexion, are zero to 30 degrees. The combined range of motion refers to the sum of the range of forward flexion, extension, left and right lateral flexion, and left and right rotation. The normal combined range of motion of the cervical spine is 340 degrees and of the thoracolumbar spine is 240 degrees. The normal ranges of motion for each component of spinal motion provided in this note are the maximum that can be used for calculation of the combined range of motion.  Note (3): In exceptional cases, an examiner may state that because of age, body habitus, neurologic disease, or other factors not the result of disease or injury of the spine, the range of motion of the spine in a particular individual, even though it does not conform to the normal range of motion stated in Note (2). Provided that the examiner supplies an explanation, the examiner's assessment that the range of motion is normal for that individual will be accepted.  Note (4): Round each range of motion measurement to the nearest five degrees.  Note (5): For VA compensation purposes, unfavorable ankylosis is a condition in which the entire cervical spine, the entire thoracolumbar spine, or the entire spine is fixed in flexion or extension, and the ankylosis results in one or more of the following: difficulty walking because of a limited line of vision; restricted opening of the mouth and chewing; breathing limited to diaphragmatic respiration; gastrointestinal symptoms due to nerve root stretching. Fixation of a spinal segment in neutral	
		diagnostic code 5003)	

### §4.71a


## 38 CFR Ch. I (7-1-16 Edition)

### THE SPINE—Continued

## 

### THE SPINE—Continued

	Hat- ing
Note (1): For purposes of evaluations under diagnostic code 5243, an incapacitating episode is a period of acute signs and symptoms due to intervertebral disc syndrome that requires bed rest prescribed by a physician and treatment by a physician.	
Note (2): If intervertebral disc syndrome is present in more than one spinal segment, provided that the effects in each spinal segment are clearly distinct, evaluate each segment on the basis of incapacitating episodes or under the General Rating Formula for Diseases and Injuries of the Spine, whichever method results in a higher evaluation for that segment.	






PLATE V
RANGE OF MOTION OF CERVICAL AND THORACOLUMBAR SPINE

## §4.71a

## 38 CFR Ch. I (7-1-16 Edition)

## THE HIP AND THIGH

	Rat- ing
5250 Hip, ankylosis of:	
Unfavorable, extremely unfavorable ankylosis, the foot not reaching ground, crutches neces-	
sitated	з 90
Intermediate	70
Favorable, in flexion at an angle between 20°	
and 40°, and slight adduction or abduction	60
5251 Thigh, limitation of extension of:	
Extension limited to 5°	10
5252 Thigh, limitation of flexion of:	
Flexion limited to 10°	40
Flexion limited to 20°	30
Flexion limited to 30°	20
Flexion limited to 45°	10
5253 Thigh, impairment of:	
Limitation of abduction of, motion lost beyond	
10°	20
Limitation of adduction of, cannot cross legs	10
Limitation of rotation of, cannot toe-out more	
than 15°, affected leg	10
5254 Hip, flail joint	80
5255 Femur, impairment of: Fracture of shaft or anatomical neck of:	
With nonunion, with loose motion (spiral or oblique fracture)	80
With nonunion, without loose motion,	80
weightbearing preserved with aid of brace	60
Fracture of surgical neck of, with false joint	60
Malunion of:	60
With marked knee or hip disability	30
With moderate knee or hip disability	20
With slight knee or hip disability	10

<sup>&</sup>lt;sup>3</sup>Entitled to special monthly compensation.

### THE KNEE AND LEG

	Rat- ing
5256 Knee, ankylosis of:	
Extremely unfavorable, in flexion at an angle of	
45° or more	60
In flexion between 20° and 45°	50
In flexion between 10° and 20°	40
Favorable angle in full extension, or in slight	
flexion between 0° and 10°	30
5257 Knee, other impairment of:	
Recurrent subluxation or lateral instability:	
Severe	30
Moderate	20
Slight	10
5258 Cartilage, semilunar, dislocated, with frequent	
episodes of "locking," pain, and effusion into the joint	20
5259 Cartilage, semilunar, removal of, symptomatic	10
5260 Leg, limitation of flexion of:	10
Flexion limited to 15°	30
Flexion limited to 13	20
Flexion limited to 45°	10
Flexion limited to 43	0
5261 Leg, limitation of extension of:	U
Extension limited to 45°	50
Extension limited to 40	40
Extension limited to 20°	30
Extension limited to 15°	20
Extension limited to 10°	10
Extension limited to 10	0
5262 Tibia and fibula, impairment of:	Ū
Nonunion of, with loose motion, requiring brace Malunion of:	40
With marked knee or ankle disability	30

## THE KNEE AND LEG—Continued

	Rat- ing
With moderate knee or ankle disability	20
With slight knee or ankle disability	10
tively demonstrated)	10

### THE ANKLE

	Rat- ing
5270 Ankle, ankylosis of:	
In plantar flexion at more than 40°, or in	
dorsiflexion at more than 10° or with abduc-	
tion, adduction, inversion or eversion deformity	40
In plantar flexion, between 30° and 40°, or in	
dorsiflexion, between 0° and 10°	30
In plantar flexion, less than 30°	20
5271 Ankle, limited motion of:	
Marked	20
Moderate	10
5272 Subastragalar or tarsal joint, ankylosis of:	
In poor weight-bearing position	20
In good weight-bearing position	10
5273 Os calcis or astragalus, malunion of:	
Marked deformity	20
Moderate deformity	10
5274 Astragalectomy	20

### SHORTENING OF THE LOWER EXTREMITY

	Rat- ing
5275 Bones, of the lower extremity, shortening of: Over 4 inches (10.2 cms.) 3½ to 4 inches (8.9 cms. to 10.2 cms.) 3 to 3½ inches (7.6 cms. to 8.9 cms.) 2½ to 3 inches (6.4 cms. to 7.6 cms.) 2 to 2½ inches (5.1 cms. to 6.4 cms.) 1¼ to 2 inches (3.2 cms. to 5.1 cms.) NOTE: Measure both lower extremities from anterior superior spine of the ilium to the internal malleolus of the tibia. Not to be combined with other ratings for fracture or faulty union in the same extremity.	<sup>3</sup> 60 <sup>3</sup> 50 40 30 20 10

<sup>&</sup>lt;sup>3</sup> Also entitled to special monthly compensation.

#### THE FOOT

	Hat- ing
5276 Flatfoot, acquired: Pronounced; marked pronation, extreme tenderness of plantar surfaces of the feet, marked inward displacement and severe spasm of the tendo achillis on manipulation, not improved	
by orthopedic shoes or appliances. Bilateral	50
11.9.11	30
Severe; objective evidence of marked deformity	30
(pronation, abduction, etc.), pain on manipulation and use accentuated, indication of swelling on use, characteristic callosities:	
Bilateral	30
Unilateral	20

#### **Department of Veterans Affairs**

### THE FOOT—Continued

	Rat- ing
Moderate; weight-bearing line over or medial to great toe, inward bowing of the tendo achillis, pain on manipulation and use of the feet, bilateral or unilateral	10 0
constitutional conditions, characterized by at- rophy of the musculature, disturbed circulation, and weakness:  Rate the underlying condition, minimum rat- ing	10
5278 Claw foot (pes cavus), acquired: Marked contraction of plantar fascia with dropped forefoot, all toes hammer toes, very painful callosities, marked varus deformity:	
Bilateral Unilateral All toes tending to dorsiflexion, limitation of dorsiflexion at ankle to right angle, shortened plantar fascia, and marked tenderness under metatarsal heads:	50 30
Bilateral	30 20
Bilateral	10 10 0
unilateral, or bilateral5280 Hallux valgus, unilateral:	10
Operated with resection of metatarsal head Severe, if equivalent to amputation of great toe 5281 Hallux rigidus, unilateral, severe: Rate as hallux valgus, severe. Note: Not to be combined with claw foot ratings.	10 10
5282 Hammer toe: All toes, unilateral without claw foot	10 0
Severe	30 20 10
5284 Foot injuries, other: Severe Moderately severe Moderate NOTE: With actual loss of use of the foot, rate 40 percent.	30 20 10

#### THE SKULL

	Rat- ing
5296 Skull, loss of part of, both inner and outer ta-	
bles:	
With brain hernia	80
Without brain hernia:	
Area larger than size of a 50-cent piece or	
1.140 in <sup>2</sup> (7.355 cm <sup>2</sup> )	50
Area intermediate	30
Area smaller than the size of a 25-cent	"
piece or 0.716 in 2 (4.619 cm <sup>2</sup> )	10

#### THE SKULL—Continued

	Rat- ing
NOTE: Rate separately for intracranial complications.	

#### THE RIBS

	Rat- ing
5297 Ribs, removal of:	
More than six	50
Five or six	40
Three or four	30
Two	20
One or resection of two or more ribs without regeneration	10

#### THE COCCYX

	Rat- ing
5298 Coccyx, removal of: Partial or complete, with painful residuals Without painful residuals	10 0

(Authority: 38 U.S.C. 1155)

[29 FR 6718, May 22, 1964, as amended at 34 FR 5062, Mar. 11, 1969; 40 FR 42536, Sept. 15, 1975; 41 FR 11294, Mar. 18, 1976; 43 FR 45350, Oct. 2, 1978; 51 FR 6411, Feb. 24, 1986; 61 FR 20439, May 7, 1996; 67 FR 48785, July 26, 2002; 67 FR 54349, Aug. 22, 2002; 68 FR 51456, Aug. 27, 2003; 69 FR 32450, June 10, 2004; 80 FR 42041, July 16, 2015]

### §4.72 [Reserved]

## §4.73 Schedule of ratings—muscle injuries.

NOTE: When evaluating any claim involving muscle injuries resulting in loss of use of any extremity or loss of use of both buttocks (diagnostic code 5317, Muscle Group XVII), refer to §3.350 of this chapter to determine whether the veteran may be entitled to special monthly compensation.

#### 38 CFR Ch. I (7-1-16 Edition)

THE FOREARM AND HAND

#### THE SHOULDER GIRDLE AND ARM

Rating

5307

5308

5309

	Rating	
	Domi- nant	Non- domi- nant
307 Group VII. Function: Flexion of wrist and fingers. Muscles arising from internal condyle of humerus: Flexors of the carpus and long flexors of fingers and thumb; pronator.		
Severe	40	30
Moderately Severe	30	20
Moderate	10	10
Slight	0	0
308 Group VIII. Function: Extension of wrist, fingers, and thumb; abduction of thumb. Muscles arising mainly from external condyle of humerus: Extensors of carpus, fingers, and thumb; supinator.		
Severe	30	20
Moderately Severe	20	20
Moderate	10	10
Slight	0	0
309 Group IX. Function: The forearm muscles act in strong grasping movements and are supplemented by the intrinsic muscles in delicate manipulative movements. Intrinsic muscles of hand:		

#### lumbricales; 4 dorsal and 3 palmar interossei. NOTE: The hand is so compact a structure 40 30 that isolated muscle injuries are rare, being nearly always complicated with iniu-30 20 ries of bones, joints, tendons, etc. Rate on 20 20 limitation of motion, minimum 10 percent.

### THE FOOT AND LEG

Rat-

Thenar eminence; short flexor, opponens,

abductor and adductor of thumb; hypothenar eminence; short flexor, opponens and abductor of little finger; 4

5310 Group X. Function: Movements of forefoot and toes; propulsion thrust in walking. Intrinsic muscles of the foot: Plantar: (1) Flexor digitorum brevis; (2) abductor hallucis; (3) abductor digiti minimi; (4) quadratus plantae; (5) lumbricales; (6) flexor hallucis brevis; (7) adductor hallucis; (8) flexor digiti minimi brevis; (9) dorsal and plantar interossei. Other important plantar structures: Plantar aponeurosis, long plantar and calcaneonavicular ligament, tendons of posterior tibial, peroneus longus, and long flexors of great and little toes.	
Severe	30
Moderately Severe	20
Moderate	10
Slight	0
Dorsal: (1) Extensor hallucis brevis; (2) extensor digitorum brevis. Other important dorsal structures: cruciate, crural, deltoid, and other ligaments; tendons of long extensors of toes and peronei muscles.	
Severe	20
Moderately Severe	10
Moderate	10
Slight	0

#### Non-Domidominant nant 5301 Group I. Function: Upward rotation of scapula; elevation of arm above shoulder level. Extrinsic muscles of shoulder girdle: (1) Trapezius; (2) levator scapulae; (3) serratus magnus. Severe .. 40 30 Moderately Severe ..... 30 20 Moderate .... 10 10 Slight . 0 0 5302 Group II. Function: Depression of arm from vertical overhead to hanging at side (1, 2); downward rotation of scapula (3, 4); 1 and 2 act with Group III in forward and backward swing of arm. Extrinsic muscles of shoulder girdle: (1) Pectoralis major II (costosternal); (2) latissimus dorsi and teres major (teres major, although technically an intrinsic muscle, is included with latissimus dorsi); (3) pectoralis minor; (4) rhomboid. Severe ... 40 30 Moderately Severe ..... 30 20 Moderate ..... 20 20 Slight 0 0 5303 Group III. Function: Elevation and abduction of arm to level of shoulder; act with 1 and 2 of Group II in forward and backward swing of arm. Intrinsic muscles of shoulder girdle: (1) Pectoralis major I (clavicular); (2) deltoid. Severe ... Moderately Severe ..... Moderate ..... Slight .... 0 5304 Group IV. Function: Stabilization of shoulder against injury in strong move-ments, holding head of humerus in socket; abduction; outward rotation and inward rotation of arm. Intrinsic muscles of shoulder girdle: (1) Supraspinatus; (2) infraspinatus and teres minor; (3) subscapularis; (4) coracobrachialis. Severe ... 20 Moderately Severe ..... 20 20 Moderate .... 10 10 Slight .. 0 0 5305 Group V. Function: Elbow supination (1) (long head of biceps is stabilizer of shoulder joint); flexion of elbow (1, 2, 3). Flexor muscles of elbow: (1) Biceps; (2) brachialis; (3) brachioradialis. Severe . 40 30 Moderately Severe ..... 30 20 Moderate ..... 10 10 Slight ... 0 0 5306 Group VI. Function: Extension of elbow (long head of triceps is stabilizer of shoulder joint). Extensor muscles of the elbow: (1) Triceps; (2) anconeus... Severe . 40 30 Moderately Severe ..... 30 20 Moderate ..... 10 10 Slight ..... 0

#### THE FOOT AND LEG—Continued

	Rat- ing
NOTE: Minimum rating for through-and-through wounds of the foot—10.	
5311 Group XI. Function: Propulsion, plantar flexion of foot (1); stabilization of arch (2, 3); flexion of toes (4, 5); Flexion of knee (6). Posterior and lateral crural muscles, and muscles of the calf: (1) Triceps surae (gastrocnemius and soleus); (2) tibialis posterior; (3) peroneus longus; (4) peroneus brevis; (5) flexor hallucis longus; (6) flexor digitorum longus; (7) popliteus; (8) plantaris.  Severe	30 20 10 0
Severe Moderately Severe Moderate Slight	30 20 10 0

#### THE PELVIC GIRDLE AND THIGH

	Rat- ing
5313 Group XIII. Function: Extension of hip and flexion of knee; outward and inward rotation of flexed knee; acting with rectus femoris and sartorius (see XIV, 1, 2) synchronizing simultaneous flexion of hip and knee and extension of hip and knee by belt-over-pulley action at knee joint. Posterior thigh group, Hamstring complex of 2-joint muscles:  (1) Biceps femoris; (2) semimembranosus; (3) semitendinosus.  Severe  Moderately Severe	40 30
Moderate	10 0
Severe Moderately Severe	40 30 10 0
brevis; (3) adductor magnus; (4) gracilis.  Severe	30 20 10 0
pectineus. Severe Moderately Severe Moderate Slight	40 30 10 0

#### THE PELVIC GIRDLE AND THIGH—Continued

	Rat- ing
5317 Group XVII. Function: Extension of hip (1); abduction of thigh; elevation of opposite side of pelvis (2, 3); tension of fascia lata and iliotibial (Maissiat's) band, acting with XIV (6) in postural support of body steadying pelvis upon head of femur and condyles of femur on tibia (1). Pelvic girdle group 2: (1) Gluteus maximus; (2) gluteus medius; (3) gluteus minimus.  Severe  Moderately Severe  Moderately Severe  Moderate  Slight  5318 Group XVIII. Function: Outward rotation of thigh and stabilization of hip joint. Pelvic girdle group 3: (1) Pyriformis; (2) gemellus (superior or inferior); (3) obturator (external or internal); (4) quadratus femoris.	*50 40 20 0
Severe	30
Moderately Severe	20
Moderate	10
Slight	0

\*If bilateral, see §3.350(a)(3) of this chapter to determine whether the veteran may be entitled to special monthly compensation.

#### THE TORSO AND NECK

THE TORSO AND NECK	
	Rat- ing
5319 Group XIX. Function: Support and compression of abdominal wall and lower thorax; flexion and lateral motions of spine; synergists in strong downward movements of arm (1). Muscles of the abdominal wall: (1) Rectus abdominis; (2) external oblique; (3) internal oblique; (4) transversalis; (5) quadratus lumborum.	
Severe Moderately Severe Moderate Slight	50 30 10 0
5320 Group XX. Function: Postural support of body; extension and lateral movements of spine. Spinal muscles: Sacrospinalis (erector spinae and its pro- longations in thoracic and cervical regions). Cervical and thoracic region:.	
Severe Moderately Severe Moderate Slight Lumbar region:	40 20 10 0
Severe	60 40 20 0
respiration: Thoracic muscle group. Severe or Moderately Severe Moderate	20 10 0
5322 Group XXII. Function: Rotary and forward movements of the head; respiration; deglutition. Muscles of the front of the neck: (Lateral, supra, and infrahyoid group.) (1) Trapezius I (clavicular insertion); (2) sternocleidomastoid; (3) the "hyoid" muscles: (4) sternothyroid; (5) digastric.	
Severe	30 20 10 0

#### THE TORSO AND NECK-Continued

	Rat- ing
5323 Group XXIII. Function: Movements of the head; fixation of shoulder movements. Muscles of the side and back of the neck: Suboccipital; lateral vertebral and anterior vertebral muscles.	
Severe	30
Moderately Severe	20
Moderate	10
Slight	0

#### **MISCELLANEOUS**

	Rat- ing

5324 Diaphragm, rupture of, with herniation. Rate under diagnostic code 7346.

5325 Muscle injury, facial muscles. Evaluate functional impairment as seventh (facial) cranial nerve neuropathy (diagnostic code 8207), disfiguring scar (diagnostic code 7800), etc. Minimum, if interfering to any extent with mastication—10.

5326 Muscle hernia, extensive. Without other injury to the muscle—10.

5327 Muscle, neoplasm of, malignant (excluding soft tissue sarcoma)—100.

NOTE: A rating of 100 percent shall continue beyond the cessation of any surgery, radiation treatment, antineoplastic chemotherapy or other therapeutic procedures. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residual impairment of function.

5328 Muscle, neoplasm of, benign, postoperative. Rate on impairment of function, i.e., limitation of motion, or scars, diagnostic code 7805, etc.

5329 Sarcoma, soft tissue (of muscle, fat, or fibrous connective tissue)—100.

NOTE: A rating of 100 percent shall continue beyond the cessation of any surgery, radiation treatment, antineoplastic chemotherapy or other therapeutic procedures. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residual impairment of function.

(Authority: 38 U.S.C. 1155) [62 FR 30239, June 3, 1997]

THE ORGANS OF SPECIAL SENSE

## § 4.75 General considerations for evaluating visual impairment.

(a) Visual impairment. The evaluation of visual impairment is based on impairment of visual acuity (excluding developmental errors of refraction), visual field, and muscle function.

- (b) Examination for visual impairment. The examination must be conducted by a licensed optometrist or by a licensed ophthalmologist. The examiner must identify the disease, injury, or other pathologic process responsible for any visual impairment found. Examinations of visual fields or muscle function will be conducted only when there is a medical indication of disease or injury that may be associated with visual field defect or impaired muscle function. Unless medically contraindicated, the fundus must be examined with the claimant's pupils dilated.
- (c) Service-connected visual impairment of only one eye. Subject to the provisions of 38 CFR 3.383(a), if visual impairment of only one eye is service-connected, the visual acuity of the other eye will be considered to be 20/40 for purposes of evaluating the service-connected visual impairment.
- (d) Maximum evaluation for visual impairment of one eye. The evaluation for visual impairment of one eye must not exceed 30 percent unless there is anatomical loss of the eye. Combine the evaluation for visual impairment of one eye with evaluations for other disabilities of the same eye that are not based on visual impairment (e.g., disfigurement under diagnostic code 7800).
- (e) Anatomical loss of one eye with inability to wear a prosthesis. When the claimant has anatomical loss of one eye and is unable to wear a prosthesis, increase the evaluation for visual acuity under diagnostic code 6063 by 10 percent, but the maximum evaluation for visual impairment of both eyes must not exceed 100 percent. A 10-percent increase under this paragraph precludes an evaluation under diagnostic code 7800 based on gross distortion or asymmetry of the eye but not an evaluation under diagnostic code 7800 based on other characteristics of disfigurement.
- (f) Special monthly compensation. When evaluating visual impairment, refer to 38 CFR 3.350 to determine whether the claimant may be entitled to special monthly compensation. Footnotes in the schedule indicate levels of visual impairment that potentially establish entitlement to special monthly compensation; however, other levels of visual impairment combined

with disabilities of other body systems may also establish entitlement.

(Authority: 38 U.S.C. 1114 and 1155) [73 FR 66549, Nov. 10, 2008]

#### §4.76 Visual acuity.

- (a) Examination of visual acuity. Examination of visual acuity must include the central uncorrected and corrected visual acuity for distance and near vision using Snellen's test type or its equivalent.
- (b) Evaluation of visual acuity. (1) Evaluate central visual acuity on the basis of corrected distance vision with central fixation, even if a central scotoma is present. However, when the lens required to correct distance vision in the poorer eye differs by more than three diopters from the lens required to correct distance vision in the better eye (and the difference is not due to congenital or developmental refractive error), and either the poorer eye or both eyes are service connected, evaluate the visual acuity of the poorer eye using either its uncorrected or corrected visual acuity, whichever results in better combined visual acuity.
- (2) Provided that he or she customarily wears contact lenses, evaluate the visual acuity of any individual affected by a corneal disorder that results in severe irregular astigmatism that can be improved more by contact lenses than by eyeglass lenses, as corrected by contact lenses.


- (3) In any case where the examiner reports that there is a difference equal to two or more scheduled steps between near and distance corrected vision, with the near vision being worse, the examination report must include at least two recordings of near and distance corrected vision and an explanation of the reason for the difference. In these cases, evaluate based on corrected distance vision adjusted to one step poorer than measured.
- (4) To evaluate the impairment of visual acuity where a claimant has a reported visual acuity that is between two sequentially listed visual acuities, use the visual acuity which permits the higher evaluation.

(Authority: 38 U.S.C. 1155) [73 FR 66549, Nov. 10, 2008]

## § 4.76a Computation of average concentric contraction of visual fields.

TABLE III—NORMAL VISUAL FIELD EXTENT AT 8
PRINCIPAL MERIDIANS

Meridian	Normal de- grees
Temporally	85
Down temporally	85
Down	65
Down nasally	50
Nasally	60
Up nasally	55
Up	45
Up temporally	55
Total	500



TS-19

Example of computation of concen-

tric contraction under the schedule with abnormal findings taken from Figure 1.

Loss	Degrees
Temporally	55
Down temporally	55
Down	45

52a

422

Loss	Degrees
Down nasally Nasally Up nasally Up top Up temporally	30 40 35 25 35
Total loss	320

Remaining field 500° minus 320° = 180°.  $180^{\circ} \div 8 = 22\frac{1}{2}^{\circ}$ 

(Authority: 38 U.S.C. 1155)

[43 FR 45352, Oct. 2, 1978, as amended at 73 FR 66549, Nov. 10, 2008]

#### § 4.77 Visual fields.

(a) Examination of visual fields. Examiners must use either Goldmann kinetic perimetry or automated perimetry using Humphrey Model 750, Octopus Model 101, or later versions of these perimetric devices with simulated kinetic Goldmann testing capability. For phakic (normal) individuals, as well as for pseudophakic or aphakic individuals who are well adapted to intraocular lens implant or contact lens correction, visual field examinations must be conducted using a standard target size and luminance, which is Goldmann's equivalent III/4e. For aphakic individuals not well adapted to correction contact lens Or pseudophakic individuals not adapted to intraocular lens implant. visual field examinations must be conducted using Goldmann's equivalent IV/4e. In all cases, the results must be recorded on a standard Goldmann chart

(see Figure 2), and the Goldmann chart must be included with the examination report. The examiner must chart at least 16 meridians 22½ degrees apart for each eye and indicate the Goldmann equivalent used. See Table III for the normal extent (in degrees) of the visual fields at the 8 principal meridians (45 degrees apart). When the examiner indicates that additional testing is necessary to evaluate visual fields, the additional testing must be conducted using either a tangent screen or a 30-degree threshold visual field with the Goldmann III stimulus size. The examination report must then include the tracing of either the tangent screen or of the 30-degree threshold visual field with the Goldmann III stimulus size.

- (b) Evaluation of visual fields. Determine the average concentric contraction of the visual field of each eye by measuring the remaining visual field (in degrees) at each of eight principal meridians 45 degrees apart, adding them, and dividing the sum by eight.
- (c) Combination of visual field defect and decreased visual acuity. To determine the evaluation for visual impairment when both decreased visual acuity and visual field defect are present in one or both eyes and are service connected, separately evaluate the visual acuity and visual field defect (expressed as a level of visual acuity), and combine them under the provisions of § 4.25.




Figure 2. Goldmann Perimeter Chart

52c

(Authority: 38 U.S.C. 1155)

 $[53~\mathrm{FR}~30262,~\mathrm{Aug}.~11,~1988,~\mathrm{as}~\mathrm{amended}~\mathrm{at}~73~\mathrm{FR}~66549,~\mathrm{Nov}.~10,~2008;~74~\mathrm{FR}~7648,~\mathrm{Feb}.~19,~2009]$ 

#### § 4.78 Muscle function.

(a) Examination of muscle function. The examiner must use a Goldmann perimeter chart that identifies the four major quadrants (upward, downward, left and right lateral) and the central field (20 degrees or less) (see Figure 2). The examiner must chart the areas of diplopia and include the plotted chart with the examination report.

(b) Evaluation of muscle function. (1) An evaluation for diplopia will be assigned to only one eye. When a claimant has both diplopia and decreased visual acuity or visual field defect, assign a level of corrected visual acuity

for the poorer eye (or the affected eye, if disability of only one eye is serviceconnected) that is: one step poorer than it would otherwise warrant if the evaluation for diplopia under diagnostic code 6090 is 20/70 or 20/100; two steps poorer if the evaluation under diagnostic code 6090 is 20/200 or 15/200; or three steps poorer if the evaluation under diagnostic code 6090 is 5/200. This adjusted level of corrected visual acuity, however, must not exceed a level of 5/200. Use the adjusted visual acuity for the poorer eye (or the affected eye, if disability of only one eye is serviceconnected), and the corrected visual

acuity for the better eye (or visual acuity of 20/40 for the other eye, if only one eye is service-connected) to determine the percentage evaluation for visual impairment under diagnostic codes 6065 through 6066.

(2) When diplopia extends beyond more than one quadrant or range of degrees, evaluate diplopia based on the quadrant and degree range that provides the highest evaluation.

(3) When diplopia exists in two separate areas of the same eye, increase the equivalent visual acuity under diagnostic code 6090 to the next poorer level of visual acuity, not to exceed 5/200

(Authority: 38 U.S.C. 1155) [73 FR 66550, Nov. 10, 2008]

#### § 4.79 Schedule of ratings—eye.

#### DISEASES OF THE EYE

	BIGEROES OF THE ETE	
		Rating
	Choroidopathy, including uveitis, iritis, cyclitis, and choroiditis.	
	Keratopathy.	
	Scleritis.	
	Retinopathy or maculopathy. Intraocular hemorrhage.	
	Detachment of retina.	
	Unhealed eye injury.	
	General Rating Formula for Diagnostic Codes 6000 through 6009	
	Evaluate on the basis of either visual impairment due to the particular condition or on incapacitating episodes, whichever results in a higher evaluation.	
	With incapacitating episodes having a total duration of at least 6 weeks during the past 12 months	60
	past 12 months	40
	past 12 months	20
	past 12 months	10
	For VA purposes, an incapacitating episode is a period of acute symptoms severe enough to require pre- bed bed rest and treatment by a physician or other healthcare provider.	
6010	Tuberculosis of eye:	
	Active	100
6011	Inactive: Evaluate under § 4.88c or § 4.89 of this part, whichever is appropriate.  Retinal scars, atrophy, or irregularities:	
3011	Localized scars, atrophy, or irregularities of the retina, unilateral or bilateral, that are centrally located and that result in an irregular, duplicated, enlarged, or diminished image	10
	Alternatively, evaluate based on visual impairment due to retinal scars, atrophy, or irregularities, if this	
	would result in a higher evaluation.	
6012	Angle-closure glaucoma:	
	Evaluate on the basis of either visual impairment due to angle-closure glaucoma or incapacitating episodes, whichever results in a higher evaluation.	
	With incapacitating episodes having a total duration of at least 6 weeks during the past 12 months	60
	past 12 months	40
	With incapacitating episodes having a total duration of at least 2 weeks, but less than 4 weeks, during the past 12 months	20
	Minimum evaluation if continuous medication is required	10
	For VA purposes, an incapacitating episode is a period of acute symptoms severe enough to require pre-	
	bed bed rest and treatment by a physician or other healthcare provider.	
6013	Open-angle glaucoma: Evaluate based on visual impairment due to open-angle glaucoma.	
	Minimum evaluation if continuous medication is required	10
6014	Malignant neoplasms (eyeball only):	
	Malignant neoplasm of the eyeball that requires therapy that is comparable to that used for systemic malig-	
	nancies, i.e., systemic chemotherapy, X-ray therapy more extensive than to the area of the eye, or surgery more extensive than enucleation	100
Note:	Continue the 100-percent rating beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or	
will	er therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent mination will be subject to the provisions of §3.105(e) of this chapter. If there has been no local recurrence or	
	astasis, evaluate based on residuals.	
	Malignant neoplasm of the eyeball that does not require therapy comparable to that for systemic malignancies:	
0045	Separately evaluate visual impairment and nonvisual impairment, e.g., disfigurement (diagnostic code 7800), and combine the evaluations.	
0015	Benign neoplasms (of eyeball and adnexa):	

### 38 CFR Ch. I (7-1-16 Edition)

### DISEASES OF THE EYE—Continued

		Rating
	Separately evaluate visual impairment and nonvisual impairment, e.g., disfigurement (diagnostic code 7800), and combine the evaluations.	
6016		10
6017	Trachomatous conjunctivitis: Active: Evaluate based on visual impairment, minimum	30
6018	Inactive: Evaluate based on residuals, such as visual impairment and disfigurement (diagnostic code 7800). Chronic conjunctivitis (nontrachomatous):	
0040	Active (with objective findings, such as red, thick conjunctivae, mucous secretion, etc.)	10
6019	Ptosis, unilateral or bilateral:  Evaluate based on visual impairment or, in the absence of visual impairment, on disfigurement (diagnostic code 7800).	
6020	Ectropion:	
	Bilateral	20
ഗോദ	Unilateral Entropion:	10
5021	Bilateral	20
	Unilateral	10
6022	Lagophthalmos:	
	Bilateral	20
6000	Unilateral Loss of eyebrows, complete, unilateral or bilateral	10 10
	Loss of eyelashes, complete, unilateral or bilateral	10
	Disorders of the lacrimal apparatus (epiphora, dacryocystitis, etc.):	
	Bilateral	20
	Unilateral	10
6026	Optic neuropathy:	
6007	Evaluate based on visual impairment.	
	Cataract of any type: operative:	
110	Evaluate based on visual impairment.	
Pos	toperative:	
	If a replacement lens is present (pseudophakia), evaluate based on visual impairment. If there is no re-	
	placement lens, evaluate based on aphakia.	
6029	Aphakia or dislocation of crystalline lens:	
	Evaluate based on visual impairment, and elevate the resulting level of visual impairment one step.  Minimum (unilateral or bilateral)	30
6030		20
	Loss of eyelids, partial or complete:	
	Separately evaluate both visual impairment due to eyelid loss and nonvisual impairment, e.g., disfigurement	
	(diagnostic code 7800), and combine the evaluations.	
6034	Pterygium:	
	Evaluate based on visual impairment, disfigurement (diagnostic code 7800), conjunctivitis (diagnostic code 6018), etc., depending on the particular findings.	
6035	Keratoconus:	
0000	Evaluate based on impairment of visual acuity.	
6036	Status post corneal transplant:	
	Evaluate based on visual impairment.	
0007	Minimum, if there is pain, photophobia, and glare sensitivity	10
6037	Pinguecula:  Evaluate based on disfigurement (diagnostic code 7800).	
	Evaluate based on distiguiement (diagnostic code 7000).	
	Impairment of Central Visual Acuity	
6061	Anatomical loss of both eyes 1	100
6062	No more than light perception in both eyes <sup>1</sup>	100
6063	Anatomical loss of one eye: 1	400
	In the other eye 5/200 (1.5/60)	100
	In the other eye 10/200 (3/60)	90 80
	In the other eye 20/200 (4/3/00)	70
	In the other eye 20/100 (6/30)	60
	In the other eye 20/70 (6/21)	60
	In the other eye 20/50 (6/15)	50
6064	In the other eye 20/40 (6/12)	40
6064	No more than light perception in one eye: 1	100
	In the other eye 5/200 (1.5/60)	90
	In the other eye 15/200 (4.5/60)	80
	In the other eye 20/200 (6/60)	70
	In the other eye 20/100 (6/30)	60 50

#### DISEASES OF THE EYE-Continued

		Rating
	In the other eye 20/50 (6/15)	4
	In the other eye 20/40 (6/12)	3
3065	Vision in one eye 5/200 (1.5/60):	Ū
	In the other eye 5/200 (1.5/60)	<sup>1</sup> 10
	In the other eye 10/200 (3/60)	9
	In the other eye 15/200 (4.5/60)	8
	In the other eye 20/200 (6/60)	7
	In the other eye 20/100 (6/30)	6
	In the other eye 20/70 (6/21)	5
	In the other eye 20/50 (6/15)	4
	In the other eye 20/40 (6/12)	3
3066	Visual acuity in one eye 10/200 (3/60) or better:	
	n in one eye 10/200 (3/60):	
	In the other eye 10/200 (3/60)	9
	In the other eye 15/200 (4.5/60)	8
	In the other eye 20/200 (6/60)	7
	In the other eye 20/100 (6/30)	6
	In the other eye 20/70 (6/21)	5
	In the other eye 20/50 (6/15)	4
	In the other eye 20/40 (6/12)	3
/ieior	n one eye 15/200 (4.5/60):	
v iSiOi	In the other eye 15/200 (4.5/60)	8
	In the other eye 13/200 (4:3/00)	7
	In the other eye 20/100 (6/30)	6
	In the other eye 20/70 (6/21)	4
	In the other eye 20/70 (6/21) In the other eye 20/50 (6/15)	3
	In the other eye 20/40 (6/12)	2
/:a:a=	ni one eye 20/200 (6/60):	2
/15101	In the other eye 20/200 (6/60)	7
		6
	In the other eye 20/100 (6/30)	
	In the other eye 20/70 (6/21)	4
	In the other eye 20/50 (6/15)	3
/:a:a=	In the other eye 20/40 (6/12)	
/ISIO	n in one eye 20/100 (6/30):	
	In the other eye 20/100 (6/30)	5
	In the other eye 20/70 (6/21)	3
	In the other eye 20/50 (6/15)	2
	In the other eye 20/40 (6/12)	1
/isior	n in one eye 20/70 (6/21):	
	In the other eye 20/70 (6/21)	3
	In the other eye 20/50 (6/15)	2
	In the other eye 20/40 (6/12)	1
/isior	n in one eye 20/50 (6/15):	
	In the other eye 20/50 (6/15)	1
	In the other eye 20/40 (6/12)	1
/isior	n in one eye 20/40 (6/12):	
	In the other eye 20/40 (6/12)	

 $<sup>^{\</sup>rm 1}\,\mbox{Review}$  for entitlement to special monthly compensation under 38 CFR 3.350.

#### RATINGS FOR IMPAIRMENT OF VISUAL FIELDS

	Rating
6080 Visual field defects:	
Homonymous hemianopsia	30
Loss of temporal half of visual field:	I
Bilateral	30
Unilateral	10
Or evaluate each affected eye as 20/70 (6/21).	I
Loss of nasal half of visual field:	1
Bilateral	10
Unilateral	10
Or evaluate each affected eye as 20/50 (6/15).	
Loss of inferior half of visual field:	
Bilateral	30
Unilateral	10
Or evaluate each affected eye as 20/70 (6/21).	
Loss of superior half of visual field:	
Bilateral	10
Unilateral	10
Or evaluate each affected eye as 20/50 (6/15).	i

#### §§ 4.80-4.84

#### RATINGS FOR IMPAIRMENT OF VISUAL FIELDS—Continued

	Rating
Concentric contraction of visual field:	
With remaining field of 5 degrees: 1	
Bilateral	100
Unilateral	30
Or evaluate each affected eye as 5/200 (1.5/60).	
With remaining field of 6 to 15 degrees:	
Bilateral	70
Unilateral	20
Or evaluate each affected eye as 20/200 (6/60).	
With remaining field of 16 to 30 degrees:	
Bilateral	50
Unilateral	10
Or evaluate each affected eye as 20/100 (6/30).	
With remaining field of 31 to 45 degrees:	
Bilateral	30
Unilateral	10
Or evaluate each affected eye as 20/70 (6/21).	
With remaining field of 46 to 60 degrees:	
Bilateral	10
Unilateral	10
Or evaluate each affected eye as 20/50 (6/15).	
6081 Scotoma, unilateral:	
Minimum, with scotoma affecting at least one-quarter of the visual field (quadrantanopsia) or with centrally	
located scotoma of any size	10
Alternatively, evaluate based on visual impairment due to scotoma, if that would result in a higher evaluation.	

<sup>&</sup>lt;sup>1</sup> Review for entitlement to special monthly compensation under 38 CFR 3.350.

#### RATINGS FOR IMPAIRMENT OF MUSCLE FUNCTION

Degree of diplopia					
6090 Diplopia (double vision): (a) Central 20 degrees (b) 21 degrees to 30 degrees (1) Down (2) Lateral (3) Up (c) 31 degrees to 40 degrees (1) Down (2) Lateral (3) Up (2) Lateral (3) Up (3) Up (5) Lateral (6) Up (1) Down (1) Lateral (2) Lateral (3) Up (3) Up (4) Lateral (5) Lateral (6) Up (7) Lateral (8) Up (9) Lateral (10) Lateral (11) Lateral (12) Lateral (13) Up (14) Lateral (15) Lateral (16) Lateral (17) Lateral (18) Lateral (19) Lateral (19) Lateral (19) Lateral (19) Lateral (20) Lateral (30) Lateral	5/200 (1.5/60) 15/200 (4.5/60) 20/100 (6/30) 20/70 (6/21) 20/200 (6/60) 20/70 (6/21) 20/40 (6/12)				

(Authority: 38 U.S.C. 1155) [73 FR 66550, Nov. 10, 2008]

#### $\S\S4.80-4.84$ [Reserved]

IMPAIRMENT OF AUDITORY ACUITY

## §4.85 Evaluation of hearing impairment.

(a) An examination for hearing impairment for VA purposes must be conducted by a state-licensed audiologist and must include a controlled speech discrimination test (Maryland CNC) and a puretone audiometry test. Ex-

aminations will be conducted without the use of hearing aids.

(b) Table VI, "Numeric Designation of Hearing Impairment Based on Puretone Threshold Average and Speech Discrimination," is used to determine a Roman numeral designation (I through XI) for hearing impairment based on a combination of the percent of speech discrimination (horizontal

rows) and the puretone threshold average (vertical columns). The Roman numeral designation is located at the point where the percentage of speech discrimination and puretone threshold average intersect.

- (c) Table VIa, "Numeric Designation of Hearing Impairment Based Only on Puretone Threshold Average," is used to determine a Roman numeral designation (I through XI) for hearing impairment based only on the puretone threshold average. Table VIa will be used when the examiner certifies that use of the speech discrimination test is not appropriate because of language difficulties, inconsistent speech discrimination scores, etc., or when indicated under the provisions of §4.86.
- (d) "Puretone threshold average," as used in Tables VI and VIa, is the sum of the puretone thresholds at 1000, 2000, 3000 and 4000 Hertz, divided by four. This average is used in all cases (including those in §4.86) to determine the Roman numeral designation for hearing impairment from Table VI or VIa.
- (e) Table VII, "Percentage Evaluations for Hearing Impairment," is used to determine the percentage evaluation by combining the Roman numeral designations for hearing impairment of each ear. The horizontal rows represent the ear having the better hearing and the vertical columns the ear having the poorer hearing. The percentage evaluation is located at the point where the row and column intersect.
- (f) If impaired hearing is service-connected in only one ear, in order to determine the percentage evaluation from Table VII, the non-service-connected ear will be assigned a Roman Numeral designation for hearing impairment of I, subject to the provisions of § 3.383 of this chapter.
- (g) When evaluating any claim for impaired hearing, refer to §3.350 of this chapter to determine whether the veteran may be entitled to special monthly compensation due either to deafness, or to deafness in combination with other specified disabilities.
  - (h) Numeric tables VI, VIA\*, and VII.

#### TABLE VI

## NUMERIC DESIGNATION OF HEARING IMPAIRMENT BASED ON PURETONE THRESHOLD AVERAGE AND SPEECH DISCRIMINATION

#### **Puretone Threshold Average**

% of discrim-ination	0-41	42-49	50-57	58-65	66-73	74-81	82-89	90-97	98+
92-100	Ι	I	I	II	II	II	III	III	IV
84-90	II	II	II	III	III	III	IV	IV	IV
76-82	III	III	IV	IV	IV	V	V	V	V
68-74	IV	IV	V	V	VI	VI	VII	VII	VII
60-66	v	V	VI	VI	VII	VII	VIII	VIII	VIII
52-58	VI	VI	VII	VII	VIII	VIII	VIII	VIII	IX
44-50	VII	VII	VIII	VIII	VIII	IX	IX	IX	X
36-42	VIII	VIII	VIII	IX	IX	IX	X	X	X
0-34	IX	X	XI						

#### TABLE VIA\*

## NUMERIC DESIGNATION OF HEARING IMPAIRMENT BASED ONLY ON PURETONE THRESHOLD AVERAGE

#### **Puretone Threshold Average**

0-41	42-48	49-55	56-62	63-69	70-76	77-83	84-90	91-97	98-104	105+
I	II	III	IV	V	VI	VII	VIII	IX	X	XI

<sup>\*</sup> This table is for use only as specified in §§ 4.85 and 4.86.

TABLE VII

## PERCENTAGE EVALUATION FOR HEARING IMPAIRMENT (DIAGNOSTIC CODE 6100)

#### Poorer Ear

	XI	100*										
	X	90	80									
	IX	80	70	60				MA II				
	VIII	70	60	50	50							
ar	VII	60	60	50	40	40						
Better Ear	VI	50	50	40	40	30	30	Procedural and an analysis of the second				
B	V	40	40	40	30	30	20	20				
	IV	30	30	30	20	20	20	10	10	-		
	III	20	20	20	20	20	10	10	10	0		
	II	10	10	10	10	10	10	10	0 -	0	0	
	I	10	10	0	0	0	0	0	0	. 0	0	0
	Reconstruction of the second	XI	X	IX	VIII	VII	VI	v	IV	III	II	I

<sup>\*</sup> Review for entitlement to special monthly compensation under §3.350 of this chapter.

 $[64~{\rm FR}~25206,~{\rm May}~11,~1999]$ 

## § 4.86 Exceptional patterns of hearing impairment.

(a) When the puretone threshold at each of the four specified frequencies (1000, 2000, 3000, and 4000 Hertz) is 55 decibels or more, the rating specialist will determine the Roman numeral designation for hearing impairment from either Table VI or Table VIa, whichever results in the higher nu-

meral. Each ear will be evaluated separately.

(b) When the puretone threshold is 30 decibels or less at 1000 Hertz, and 70 decibels or more at 2000 Hertz, the rating specialist will determine the Roman numeral designation for hearing impairment from either Table VI or Table VIa, whichever results in the higher numeral. That numeral will then be elevated to the next higher

Roman numeral. Each ear will be evaluated separately.

(Authority: 38 U.S.C. 1155) [64 FR 25209, May 11, 1999]

#### §4.87 Schedule of ratings—ear.

#### DISEASES OF THE EAR

Rating

10

100

60 30

10

6200 Chronic suppurative otitis media, mastoiditis, or cholesteatoma (or any combination):  During suppuration, or with aural polyps
NOTE: Evaluate hearing impairment, and complications such as labyrinthitis, tinnitus, facial nerve paralysis, or bone loss of skull, separately.
6201 Chronic nonsuppurative otitis media with effusion (serous otitis media): Rate hearing impairment
6202 Otosclerosis:
Rate hearing impairment 6204 Peripheral vestibular disorders:
Dizziness and occasional staggering
Occasional dizziness
NOTE: Objective findings supporting the diag- nosis of vestibular disequilibrium are required before a compensable evaluation can be as- signed under this code. Hearing impairment or suppuration shall be separately rated and
combined.
6205 Meniere's syndrome (endolymphatic hydrops): Hearing impairment with attacks of vertigo and
cerebellar gait occurring more than once
weekly, with or without tinnitus Hearing impairment with attacks of vertigo and
cerebellar gait occurring from one to four
times a month, with or without tinnitus
month, with or without tinnitus
NOTE: Evaluate Meniere's syndrome either under these criteria or by separately evaluating
vertigo (as a peripheral vestibular disorder), hearing impairment, and tinnitus, whichever method results in a higher overall evaluation.
But do not combine an evaluation for hearing impairment, tinnitus, or vertigo with an evalua-
tion under diagnostic code 6205. 6207 Loss of auricle:
Complete loss of both
Complete loss of one
Deformity of one, with loss of one-third or more of the substance
6208 Malignant neoplasm of the ear (other than skin only)
Note: A rating of 100 percent shall continue be-
yond the cessation of any surgical, radiation treatment, antineoplastic chemotherapy or
other therapeutic procedure. Six months after discontinuance of such treatment, the appro-
priate disability rating shall be determined by
mandatory VA examination. Any change in evaluation based on that or any subsequent
evaluation based on that or any subsequent examination shall be subject to the provisions
of §3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on re-
siduals.
6209 Benign neoplasms of the ear (other than skin only):
Rate on impairment of function.

6210 Chronic otitis externa:

#### 38 CFR Ch. I (7-1-16 Edition)

#### DISEASES OF THE EAR—Continued

	Rat- ing
Swelling, dry and scaly or serous discharge, and itching requiring frequent and prolonged treatment  Secondary of the seconda	10 0 10

(Authority: 38 U.S.C. 1155)

[64 FR 25210, May 11, 1999, as amended at 68 FR 25823, May 14, 2003]

## § 4.87a Schedule of ratings—other sense organs.

	Rat- ing
6275 Sense of smell, complete loss	10 10

(Authority: 38 U.S.C. 1155)

 $[64 \; \mathrm{FR} \; 25210, \; \mathrm{May} \; 11, \; 1999]$ 

INFECTIOUS DISEASES, IMMUNE DIS-ORDERS AND NUTRITIONAL DEFI-CIENCIES

#### § 4.88 [Reserved]

#### §4.88a Chronic fatigue syndrome.

- (a) For VA purposes, the diagnosis of chronic fatigue syndrome requires:
- (1) new onset of debilitating fatigue severe enough to reduce daily activity to less than 50 percent of the usual level for at least six months; and
- (2) the exclusion, by history, physical examination, and laboratory tests, of all other clinical conditions that may produce similar symptoms; and
  - (3) six or more of the following:
  - (i) acute onset of the condition,
  - (ii) low grade fever,
  - (iii) nonexudative pharyngitis,

432

§4.88b

- (iv) palpable or tender cervical or axillary lymph nodes,
- (v) generalized muscle aches or weakness,
- (vi) fatigue lasting 24 hours or longer after exercise,
- (vii) headaches (of a type, severity, or pattern that is different from headaches in the pre-morbid state),
  - (viii) migratory joint pains,
  - (ix) neuropsychologic symptoms,
  - (x) sleep disturbance.
  - (b) [Reserved]

[59 FR 60902, Nov. 29, 1994]

## $\$\,4.88b$ Schedule of ratings—infectious diseases, immune disorders and nutritional deficiencies.

	VIOIAL 46110101010	
		Rating
6300	Cholera, Asiatic: As active disease, and for 3 months convalescence  Thereafter rate residuals such as renal necrosis under the appropriate system	100
6301	Visceral Leishmaniasis:  During treatment for active disease	100
	NOTE: A 100 percent evaluation shall continue beyond the cessation of treatment for active disease. Six discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory V tion. Any change in evaluation based upon that or any subsequent examination shall be subject to the §3.105(e) of this chapter. Rate residuals such as liver damage or lymphadenopathy under the appropria	/A examina- provisions of
6302	Leprosy (Hansen's Disease): As active disease	100
	Note: A 100 percent evaluation shall continue beyond the date that an examining physician has determined become inactive. Six months after the date of inactivity, the appropriate disability rating shall be demandatory VA examination. Any change in evaluation based upon that or any subsequent examination eject to the provisions of §3.105(e) of this chapter. Rate residuals such as skin lesions or peripheral under the appropriate system.	etermined by shall be sub-
6304	Malaria: As active disease	100
	NOTE: The diagnosis of malaria depends on the identification of the malarial parasites in blood smears. If served in an endemic area and presents signs and symptoms compatible with malaria, the diagnosis m on clinical grounds alone. Relapses must be confirmed by the presence of malarial parasites in blood smalariar rate residuals such as liver or spleen damage under the appropriate system	ay be based
6305	Lymphatic Filariasis: As active disease Thereafter rate residuals such as epididymitis or lymphangitis under the appropriate system	100
6306	Bartonellosis: As active disease, and for 3 months convalescence	100
6307	Plague: As active disease	100
6308	Thereafter rate residuals such as lymphadenopathy under the appropriate system Relapsing Fever:	400
	As active disease  Thereafter rate residuals such as liver or spleen damage or central nervous system involvement under the system	100 appropriate
6309	Rheumatic fever: As active disease Thereafter rate residuals such as heart damage under the appropriate system	100
6310	Syphilis, and other treponemal infections: Rate the complications of nervous system, vascular system, eyes or ears. (See DC 7004, syphilitic heart 8013, cerebrospinal syphilis, DC 8014, meningovascular syphilis, DC 8015, tabes dorsalis, and DC 930 associated with central nervous system syphilis)	
6311	Tuberculosis, miliary: As active disease Inactive: See §§ 4.88c and 4.89.	100
6313	Avitaminosis:  Marked mental changes, moist dermatitis, inability to retain adequate nourishment, exhaustion, and cachexia	100
	With all of the symptoms listed below, plus mental symptoms and impaired bodily vigor	60
	With stomatitis, diarrhea, and symmetrical dermatitis	40 20
6314	Confirmed diagnosis with nonspecific symptoms such as: decreased appetite, weight loss, abdominal discomfort, weakness, inability to concentrate and irritability	10
0314	As active disease: With congestive heart failure, anasarca, or Wernicke-Korsakoff syndrome	100

		Rating
	With cardiomegaly, or; with peripheral neuropathy with footdrop or atrophy of thigh or calf muscles With peripheral neuropathy with absent knee or ankle jerks and loss of sensation, or; with symptoms such as weakness, fatigue, anorexia, dizziness, heaviness and stiffness of legs, headache or sleep	
	disturbance	
315	Pellagra:	
	Marked mental changes, moist dermatitis, inability to retain adequate nourishment, exhaustion, and cachexia	1
	With all of the symptoms listed below, plus mental symptoms and impaired bodily vigor	
	With stomatitis, diarrhea, and symmetrical dermatitis	
	With stomatitis, or achlorhydria, or diarrhea	
	Confirmed diagnosis with nonspecific symptoms such as: decreased appetite, weight loss, abdominal discomfort, weakness, inability to concentrate and irritability	
16	Brucellosis:	
	As active disease	1
17	Thereafter rate residuals such as liver or spleen damage or meningitis under the appropriate system Typhus, scrub:	
17	As active disease, and for 3 months convalescence	1
	Thereafter rate residuals such as spleen damage or skin conditions under the appropriate system	
18		
	As active disease	1
19	Thereafter rate residuals such as arthritis, lung lesions or meningitis under the appropriate system Lyme Disease:	
	As active disease	1
	Thereafter rate residuals such as arthritis under the appropriate system	
20		
	As active disease	1
50		
	Not to be combined with ratings under DC 7809 Acute, with frequent exacerbations, producing severe	
	impairment of health	1
	Exacerbations lasting a week or more, 2 or 3 times per year	
	NOTE: Evaluate this condition either by combining the evaluations for residuals under the appropriate sys	etom or h
	evaluating DC 6350, whichever method results in a higher evaluation.	otern, or i
51	HIV-Related Illness:	
٠.	AIDS with recurrent opportunistic infections or with secondary diseases afflicting multiple body systems; HIV-related illness with debility and progressive weight loss, without remission, or few or brief remis-	
	sions  Refractory constitutional symptoms, diarrhea, and pathological weight loss, or; minimum rating following	1
	development of AIDS-related opportunistic infection or neoplasm	
	rating with T4 cell count less than 200, or Hairy Cell Leukoplakia, or Oral Candidiasis	
	rating with T4 cell count less than 200, or Hairy Cell Leukoplakia, or Oral Candidiasis	
	rating with T4 cell count less than 200, or Hairy Cell Leukoplakia, or Oral Candidiasis	
	rating with T4 cell count less than 200, or Hairy Cell Leukoplakia, or Oral Candidiasis	ol at an a
	rating with T4 cell count less than 200, or Hairy Cell Leukoplakia, or Oral Candidiasis	ay be rate
54 :	rating with T4 cell count less than 200, or Hairy Cell Leukoplakia, or Oral Candidiasis.  Following development of definite medical symptoms, T4 cell of 200 or more and less than 500, and on approved medication(s), or, with evidence of depression or memory loss with employment limitations Asymptomatic, following initial diagnosis of HIV infection, with or without lymphadenopathy or decreased T4 cell count	ay be rate
54	rating with T4 cell count less than 200, or Hairy Cell Leukoplakia, or Oral Candidiasis	ay be rate entages ot
54	rating with T4 cell count less than 200, or Hairy Cell Leukoplakia, or Oral Candidiasis	ay be rate entages ot
54 -	rating with T4 cell count less than 200, or Hairy Cell Leukoplakia, or Oral Candidiasis  Following development of definite medical symptoms, T4 cell of 200 or more and less than 500, and on approved medication(s), or, with evidence of depression or memory loss with employment limitations  Asymptomatic, following initial diagnosis of HIV infection, with or without lymphadenopathy or decreased T4 cell count	ay be rate entages ot combination
54 -	rating with T4 cell count less than 200, or Hairy Cell Leukoplakia, or Oral Candidiasis  Following development of definite medical symptoms, T4 cell of 200 or more and less than 500, and on approved medication(s), or; with evidence of depression or memory loss with employment limitations  Asymptomatic, following initial diagnosis of HIV infection, with or without lymphadenopathy or decreased T4 cell count  NOTE (1): The term "approved medication(s)" includes medications prescribed as part of a research protoc credited medical institution.  NOTE (2): Psychiatric or central nervous system manifestations, opportunistic infections, and neoplasms meseparately under appropriate codes if higher overall evaluation results, but not in combination with perce erwise assignable above.  Chronic Fatigue Syndrome (CFS):  Debilitating fatigue, cognitive impairments (such as inability to concentrate, forgetfulness, confusion), or a confusion of other signs and symptoms:  Which are nearly constant and so severe as to restrict routine daily activities almost completely and which may occasionally preclude self-care	ay be rate entages of
54	rating with T4 cell count less than 200, or Hairy Cell Leukoplakia, or Oral Candidiasis  Following development of definite medical symptoms, T4 cell of 200 or more and less than 500, and on approved medication(s), or; with evidence of depression or memory loss with employment limitations  Asymptomatic, following initial diagnosis of HIV infection, with or without lymphadenopathy or decreased T4 cell count	ay be rate entages of
54	rating with T4 cell count less than 200, or Hairy Cell Leukoplakia, or Oral Candidiasis  Following development of definite medical symptoms, T4 cell of 200 or more and less than 500, and on approved medication(s), or; with evidence of depression or memory loss with employment limitations  Asymptomatic, following initial diagnosis of HIV infection, with or without lymphadenopathy or decreased T4 cell count  NOTE (1): The term "approved medication(s)" includes medications prescribed as part of a research protoc credited medical institution.  NOTE (2): Psychiatric or central nervous system manifestations, opportunistic infections, and neoplasms meseparately under appropriate codes if higher overall evaluation results, but not in combination with perce erwise assignable above.  Chronic Fatigue Syndrome (CFS):  Debilitating fatigue, cognitive impairments (such as inability to concentrate, forgetfulness, confusion), or of other signs and symptoms:  Which are nearly constant and so severe as to restrict routine daily activities almost completely and which may occasionally preclude self-care  Which are nearly constant and restrict routine daily activities to less than 50 percent of the pre-illness level, or; which wax and wane, resulting in periods of incapacitation of at least six weeks total duration per year	ay be rate entages otl
54	rating with T4 cell count less than 200, or Hairy Cell Leukoplakia, or Oral Candidiasis  Following development of definite medical symptoms, T4 cell of 200 or more and less than 500, and on approved medication(s), or; with evidence of depression or memory loss with employment limitations  Asymptomatic, following initial diagnosis of HIV infection, with or without lymphadenopathy or decreased T4 cell count	ay be rate entages of
54 '	rating with T4 cell count less than 200, or Hairy Cell Leukoplakia, or Oral Candidiasis  Following development of definite medical symptoms, T4 cell of 200 or more and less than 500, and on approved medication(s), or; with evidence of depression or memory loss with employment limitations  Asymptomatic, following initial diagnosis of HIV infection, with or without lymphadenopathy or decreased T4 cell count  NOTE (1): The term "approved medication(s)" includes medications prescribed as part of a research protoc credited medical institution.  NOTE (2): Psychiatric or central nervous system manifestations, opportunistic infections, and neoplasms meseparately under appropriate codes if higher overall evaluation results, but not in combination with perce erwise assignable above.  Chronic Fatigue Syndrome (CFS):  Debilitating fatigue, cognitive impairments (such as inability to concentrate, forgetfulness, confusion), or a confort of other signs and symptoms:  Which are nearly constant and so severe as to restrict routine daily activities almost completely and which may occasionally preclude self-care.  Which are nearly constant and restrict routine daily activities to less than 50 percent of the pre-illness level, or; which wax and wane, resulting in periods of incapacitation of at least six weeks total duration per year.  Which are nearly constant and restrict routine daily activities to 50 to 75 percent of the pre-illness level, or; which wax and wane, resulting in periods of incapacitation of at least four but less than six weeks total duration per year.	ay be rate entages of
54	rating with T4 cell count less than 200, or Hairy Cell Leukoplakia, or Oral Candidiasis	ay be rate entages of
54 '	rating with T4 cell count less than 200, or Hairy Cell Leukoplakia, or Oral Candidiasis  Following development of definite medical symptoms, T4 cell of 200 or more and less than 500, and on approved medication(s), or; with evidence of depression or memory loss with employment limitations  Asymptomatic, following initial diagnosis of HIV infection, with or without lymphadenopathy or decreased T4 cell count  NOTE (1): The term "approved medication(s)" includes medications prescribed as part of a research protococredited medical institution.  NOTE (2): Psychiatric or central nervous system manifestations, opportunistic infections, and neoplasms meseparately under appropriate codes if higher overall evaluation results, but not in combination with percevine easignable above.  Chronic Fatigue Syndrome (CFS):  Debilitating fatigue, cognitive impairments (such as inability to concentrate, forgetfulness, confusion), or a confusion of other signs and symptoms:  Which are nearly constant and so severe as to restrict routine daily activities almost completely and which may occasionally preclude self-care  Which are nearly constant and restrict routine daily activities to less than 50 percent of the pre-illness level, or; which wax and wane, resulting in periods of incapacitation of at least six weeks total duration per year  Which are nearly constant and restrict routine daily activities to 50 to 75 percent of the pre-illness level, or; which wax and wane, resulting in periods of incapacitation of at least four but less than six weeks total duration per year  Which are nearly constant and restrict routine daily activities by less than 25 percent of the pre-illness level, or; which wax and wane, resulting in periods of incapacitation of at least two but less than four	ay be rate entages ot combination
54 :	rating with T4 cell count less than 200, or Hairy Cell Leukoplakia, or Oral Candidiasis  Following development of definite medical symptoms, T4 cell of 200 or more and less than 500, and on approved medication(s), or; with evidence of depression or memory loss with employment limitations  Asymptomatic, following initial diagnosis of HIV infection, with or without lymphadenopathy or decreased T4 cell count  NOTE (1): The term "approved medication(s)" includes medications prescribed as part of a research protoc credited medical institution.  NOTE (2): Psychiatric or central nervous system manifestations, opportunistic infections, and neoplasms me separately under appropriate codes if higher overall evaluation results, but not in combination with perce erwise assignable above.  Chronic Fatigue Syndrome (CFS):  Debilitating fatigue, cognitive impairments (such as inability to concentrate, forgetfulness, confusion), or a confort of other signs and symptoms:  Which are nearly constant and so severe as to restrict routine daily activities almost completely and which may occasionally preclude self-care.  Which are nearly constant and restrict routine daily activities to less than 50 percent of the pre-illness level, or; which wax and wane, resulting in periods of incapacitation of at least six weeks total duration per year.  Which are nearly constant and restrict routine daily activities to 50 to 75 percent of the pre-illness level, or; which wax and wane, resulting in periods of incapacitation of at least four but less than six weeks total duration per year.  Which are nearly constant and restrict routine daily activities by less than 25 percent of the pre-illness level, or; which wax and wane, resulting in periods of incapacitation of at least two but less than four weeks total duration per year.	ay be rate entages of
54 '	rating with T4 cell count less than 200, or Hairy Cell Leukoplakia, or Oral Candidiasis  Following development of definite medical symptoms, T4 cell of 200 or more and less than 500, and on approved medication(s), or; with evidence of depression or memory loss with employment limitations  Asymptomatic, following initial diagnosis of HIV infection, with or without lymphadenopathy or decreased T4 cell count  NOTE (1): The term "approved medication(s)" includes medications prescribed as part of a research protococredited medical institution.  NOTE (2): Psychiatric or central nervous system manifestations, opportunistic infections, and neoplasms meseparately under appropriate codes if higher overall evaluation results, but not in combination with percevine easignable above.  Chronic Fatigue Syndrome (CFS):  Debilitating fatigue, cognitive impairments (such as inability to concentrate, forgetfulness, confusion), or a confusion of other signs and symptoms:  Which are nearly constant and so severe as to restrict routine daily activities almost completely and which may occasionally preclude self-care  Which are nearly constant and restrict routine daily activities to less than 50 percent of the pre-illness level, or; which wax and wane, resulting in periods of incapacitation of at least six weeks total duration per year  Which are nearly constant and restrict routine daily activities to 50 to 75 percent of the pre-illness level, or; which wax and wane, resulting in periods of incapacitation of at least four but less than six weeks total duration per year  Which are nearly constant and restrict routine daily activities by less than 25 percent of the pre-illness level, or; which wax and wane, resulting in periods of incapacitation of at least two but less than four	ay be rate entages of combinatio

#### §4.88c Ratings for inactive nonpulmonary tuberculosis initially entitled after August 19, 1968.

	Rat- ing
For 1 year after date of inactivity, following active tu- berculosis	100
Thereafter: Rate residuals under the specific body	

Following the total rating for the 1 year period after date of inactivity, the schedular evaluation for residuals of nonpulmonary tuberculosis, i.e., ankylosis, surgical removal of a part, etc., will be assigned under the appropriate diagnostic code for the residual preceded by the diagnostic code for tuberculosis of the body part affected. For example, tuberculosis of the hip joint with residual ankylosis would be coded 5001–5250. Where there are existing residuals of pulmonary and nonpulmonary conditions, the evaluations for residual separate functional impairment may be combined.

Where there are existing pulmonary and nonpulmonary conditions, the total rating for the 1 year, after attainment of inactivity, may not be applied to both conditions during the same period. However, the total rating during the 1-year period for the pulmonary or for the nonpulmonary condition will be utilized, combined with evaluation for residuals of the condition not covered by the 1-year total evaluation, so as to allow any additional benefit provided during such period.

[34 FR 5062, Mar. 11, 1969. Redesignated at 59 FR 60902, Nov. 29, 1994]

#### § 4.89 Ratings for inactive nonpulmonary tuberculosis in effect on August 19, 1968.

Public Law 90-493 repealed section 356 of title 38, United States Code which provided graduated ratings for inactive tuberculosis. The repealed section, however, still applies to the case of any veteran who on August 19, 1968, was receiving or entitled to receive compensation for tuberculosis. The use of the protective provisions of Pub. L. 90-493 should be mentioned in the discussion portion of all ratings in which these provisions are applied. For use in rating cases in which the protective provisions of Pub. L. 90-493 apply, the former evaluations are retained in this section.

	Rat- ing
For 2 years after date of inactivity, following active tuberculosis, which was clinically identified during	
service or subsequently	100
Thereafter, for 4 years, or in any event, to 6 years after date of inactivity	50
Thereafter, for 5 years, or to 11 years after date of inactivity	30
Thereafter, in the absence of a schedular compen-	
sable permanent residual	0

Following the total rating for the 2-year period after date of inactivity, the schedular evaluation for residuals of nonpulmonary tuberculosis, *i.e.*, ankylosis, surgical removal of a part, etc., if in excess of 50 percent or 30 percent will be assigned under the appropriate diagnostic code for the specific residual preceded by the diagnostic code for tuberculosis of the body part affected. For example, tuberculosis of the hipjoint with residual ankylosis would be coded 5001–5250.

The graduated ratings for nonpulmonary tuberculosis will not be combined with residuals of nonpulmonary tuberculosis unless the graduated rating and the rating for residual disability cover separate functional losses, e.g., graduated ratings for tuberculosis of the kidney and residuals of tuberculosis of the spine. Where there are existing pulmonary and nonpulmonary conditions, the graduated evaluation for the pulmonary, or for the nonpulmonary, condition will be utilized, combined with evaluations for residuals of the condition not covered by the graduated evaluation utilized, so as to provide the higher evaluation over such period.

The ending dates of all graduated ratings of nonpulmonary tuberculosis will be controlled by the date of attainment of inactivity.

These ratings are applicable only to veterans with nonpulmonary tuberculosis active on or after October 10, 1949.

[29 FR 6718, May 22, 1964, as amended at 34 FR 5062, Mar. 11, 1969; 43 FR 45361, Oct. 2, 1978]

#### THE RESPIRATORY SYSTEM

## § 4.96 Special provisions regarding evaluation of respiratory conditions.

(a) Rating coexisting respiratory conditions. Ratings under diagnostic codes 6600 through 6817 and 6822 through 6847 will not be combined with each other. Where there is lung or pleural involvement, ratings under diagnostic codes 6819 and 6820 will not be combined with each other or with diagnostic codes 6600 through 6817 or 6822 through 6847. A single rating will be assigned under the diagnostic code which reflects the predominant disability with elevation to the next higher evaluation where the severity of the overall disability warrants such elevation. However, in cases protected by the provisions of Pub. L. 90-493, the graduated ratings of 50 and 30 percent for inactive tuberculosis will not be elevated.

(b) Rating "protected" tuberculosis cases. Public Law 90-493 repealed section 356 of title 38, United States Code which had provided graduated ratings for inactive tuberculosis. The repealed

section, however, still applies to the case of any veteran who on August 19, 1968, was receiving or entitled to receive compensation for tuberculosis. The use of the protective provisions of Pub. L. 90–493 should be mentioned in the discussion portion of all ratings in which these provisions are applied. For application in rating cases in which the protective provisions of Pub. L. 90–493 apply the former evaluations pertaining to pulmonary tuberculosis are retained in §4.97.

- (c) Special monthly compensation. When evaluating any claim involving complete organic aphonia, refer to §3.350 of this chapter to determine whether the veteran may be entitled to special monthly compensation. Footnotes in the schedule indicate conditions which potentially establish entitlement to special monthly compensation; however, there are other conditions in this section which under certain circumstances also establish entitlement to special monthly compensation;
- (d) Special provisions for the application of evaluation criteria for diagnostic codes 6600, 6603, 6604, 6825–6833, and 6840–6845. (1) Pulmonary function tests (PFT's) are required to evaluate these conditions except:
- (i) When the results of a maximum exercise capacity test are of record and are 20 ml/kg/min or less. If a maximum exercise capacity test is not of record, evaluate based on alternative criteria.
- (ii) When pulmonary hypertension (documented by an echocardiogram or cardiac catheterization), cor pulmonale, or right ventricular hypertrophy has been diagnosed.
- (iii) When there have been one or more episodes of acute respiratory failure.
- (iv) When outpatient oxygen therapy is required.

- (2) If the DLCO (SB) (Diffusion Capacity of the Lung for Carbon Monoxide by the Single Breath Method) test is not of record, evaluate based on alternative criteria as long as the examiner states why the test would not be useful or valid in a particular case.
- (3) When the PFT's are not consistent with clinical findings, evaluate based on the PFT's unless the examiner states why they are not a valid indication of respiratory functional impairment in a particular case.
- (4) Post-bronchodilator studies are required when PFT's are done for disability evaluation purposes except when the results of pre-bronchodilator pulmonary function tests are normal or when the examiner determines that post-bronchodilator studies should not be done and states why.
- (5) When evaluating based on PFT's, use post-bronchodilator results in applying the evaluation criteria in the rating schedule unless the post-bronchodilator results were poorer than the pre-bronchodilator results. In those cases, use the pre-bronchodilator values for rating purposes.
- (6) When there is a disparity between the results of different PFT's (FEV-1 (Forced Expiratory Volume in one second), FVC (Forced Vital Capacity), etc.), so that the level of evaluation would differ depending on which test result is used, use the test result that the examiner states most accurately reflects the level of disability.
- (7) If the FEV-1 and the FVC are both greater than 100 percent, do not assign a compensable evaluation based on a decreased FEV-1/FVC ratio.

(Authority: 38 U.S.C. 1155)

[34 FR 5062, Mar. 11, 1969, as amended at 61 FR 46727, Sept. 5, 1996; 71 FR 52459, Sept. 6, 2006]

#### $\S 4.97$ Schedule of ratings—respiratory system.

		Rating
	DISEASES OF THE NOSE AND THROAT	
6502	Septum, nasal, deviation of: Traumatic only,	
	With 50-percent obstruction of the nasal passage on both sides or complete obstruction on one side	10
6504	Nose, loss of part of, or scars:	
	Exposing both nasal passages	30
	Loss of part of one ala, or other obvious disfigurement	10

		Rating
Note:	Or evaluate as DC 7800, scars, disfiguring, head, face, or neck.	
6511 6512	Sinusitis, frontal, chronic. Sinusitis, maxillary, chronic. Sinusitis, sphenoid, chronic. General Rating Formula for Sinusitis (DC's 6510 through 6514): Following radical surgery with chronic osteomyelitis, or; near constant sinusitis characterized by headaches, pain and tenderness of affected sinus, and purulent discharge or crusting after repeated surgeries  Three or more incapacitating episodes per year of sinusitis requiring prolonged (lasting four to six weeks) antibiotic treatment, or; more than six non-incapacitating episodes per year of sinusitis characterized by headaches, pain, and purulent discharge or crusting  One or two incapacitating episodes per year of sinusitis requiring prolonged (lasting four to six weeks) antibiotic treatment, or; three to six non-incapacitating episodes per year of sinusitis requiring prolonged (lasting four to six weeks) antibiotic treatment, or; three to six non-incapacitating episodes per year of sinusitis characterized by headaches, pain, and purulent discharge or crusting	50
	Detected by X-ray only	0
6515	Note: An incapacitating episode of sinusitis means one that requires bed rest and treatment by a physician.  Laryngitis, tuberculous, active or inactive.  Rate under §§ 4.88c or 4.89, whichever is appropriate.	
6516	Laryngitis, chronic: Hoarseness, with thickening or nodules of cords, polyps, submucous infiltration, or pre-malignant changes on biopsy	30
6518	Hoarseness, with inflammation of cords or mucous membrane	10 1100
	Rate the residuals of partial laryngectomy as laryngitis (DC 6516), aphonia (DC 6519), or stenosis of larynx (DC 6520).	
6519	Aphonia, complete organic: Constant inability to communicate by speech Constant inability to speak above a whisper	¹ 100 60
	Note: Evaluate incomplete aphonia as laryngitis, chronic (DC 6516).	
6520	Larynx, stenosis of, including residuals of laryngeal trauma (unilateral or bilateral):  Forced expiratory volume in one second (FEV-1) less than 40 percent of predicted value, with Flow-Volume Loop compatible with upper airway obstruction, or; permanent tracheostomy	100 60 30 10
6521	Pharynx, injuries to:	
	Stricture or obstruction of pharynx or nasopharynx, or; absence of soft palate secondary to trauma, chemical burn, or granulomatous disease, or; paralysis of soft palate with swallowing difficulty (nasal regurgitation) and speech impairment	50
6522	Allergic or vasomotor rhinitis:  With polyps Without polyps, but with greater than 50-percent obstruction of nasal passage on both sides or complete ob-	30
6523	struction on one side  Bacterial rhinitis:	10
	Rhinoscleroma With permanent hypertrophy of turbinates and with greater than 50-percent obstruction of nasal passage on both sides or complete obstruction on one side	50 10
6524	Granulomatous rhinitis: Wegener's granulomatosis, lethal midline granuloma	100
	Other types of granulomatous infection	20
	DISEASES OF THE TRACHEA AND BRONCHI	
6600	Bronchitis, chronic: FEV-1 less than 40 percent of predicted value, or; the ratio of Forced Expiratory Volume in one second to Forced Vital Capacity (FEV-1/FVC) less than 40 percent, or; Diffusion Capacity of the Lung for Carbon Monoxide by the Single Breath Method (DLCO (SB)) less than 40-percent predicted, or; maximum exercise capacity less than 15 ml/kg/min oxygen consumption (with cardiac or respiratory limitation), or; cor pulmonale (right heart failure), or; right ventricular hypertrophy, or; pulmonary hypertension (shown by Echo or cardiac catheterization), or; episode(s) of acute respiratory failure, or; requires outpatient oxygen therapy FEV-1 of 40 to 55-percent predicted, or; FEV-1/FVC of 40 to 55 percent, or; DLCO (SB) of 40- to 55-percent predicted, or; maximum oxygen consumption of 15 to 20 ml/kg/min (with cardiorespiratory limit)	100 60 30
6601	predicted  Bronchiectasis:	10
	With incapacitating episodes of infection of at least six weeks total duration per year	100

		Ra
	With incapacitating episodes of infection of four to six weeks total duration per year, or; near constant findings of cough with purulent sputum associated with anorexia, weight loss, and frank hemoptysis and requiring antibiotic usage almost continuously	
	With incapacitating episodes of infection of two to four weeks total duration per year, or; daily productive cough with sputum that is at times purulent or blood-tinged and that requires prolonged (lasting four to six weeks) antibiotic usage more than twice a year	
	Intermittent productive cough with acute infection requiring a course of antibiotics at least twice a year  Or rate according to pulmonary impairment as for chronic bronchitis (DC 6600).	
	Note: An incapacitating episode is one that requires bedrest and treatment by a physician.	
602	Asthma, bronchial:	
002	FEV-1 less than 40-percent predicted, or; FEV-1/FVC less than 40 percent, or; more than one attack per week with episodes of respiratory failure, or; requires daily use of systemic (oral or parenteral) high dose corticosteroids or immuno-suppressive medications	
	FEV-1 of 40- to 55-percent predicted, or; FEV-1/FVC of 40 to 55 percent, or; at least monthly visits to a physician for required care of exacerbations, or; intermittent (at least three per year) courses of systemic (oral or parenteral) corticosteroids	
	FEV-1 of 56- to 70-percent predicted, or; FEV-1/FVC of 56 to 70 percent, or; daily inhalational or oral bronchodilator therapy, or; inhalational anti-inflammatory medication	
	FEV-1 of 71- to 80-percent predicted, or; FEV-1/FVC of 71 to 80 percent, or; intermittent inhalational or oral bronchodilator therapy	
	Note: In the absence of clinical findings of asthma at time of examination, a verified history of asthmatic attacks must be of record.	
6603	Emphysema, pulmonary:  FEV-1 less than 40 percent of predicted value, or; the ratio of Forced Expiratory Volume in one second to Forced Vital Capacity (FEV-1/FVC) less than 40 percent, or; Diffusion Capacity of the Lung for Carbon Monoxide by the Single Breath Method (DLCO (SB)) less than 40-percent predicted, or; maximum exercise capacity less than 15 ml/kg/min oxygen consumption (with cardiac or respiratory limitation), or; cor pulmonale (right heart failure), or; right ventricular hypertrophy, or; pulmonary hypertension (shown by Echo or cardiac catheterization), or; episode(s) of acute respiratory failure, or; requires outpatient oxygen therapy.  FEV-1 of 40- to 55-percent predicted, or; FEV-1/FVC of 40 to 55 percent, or; DLCO (SB) of 40- to 55-percent predicted, or; or; FEV-1/FVC of 56 to 70 percent, or; DLCO (SB) 56- to 65-percent	
604	predicted	
	FEV-1 less than 40 percent of predicted value, or; the ratio of Forced Expiratory Volume in one second to Forced Vital Capacity (FEV-1/FVC) less than 40 percent, or; Diffusion Capacity of the Lung for Carbon Monoxide by the Single Breath Method (DLCO (SB)) less than 40-percent predicted, or; maximum exercise capacity less than 15 ml/kg/min oxygen consumption (with cardiac or respiratory limitation), or; cor pulmonale (right heart failure), or; right ventricular hypertrophy, or; pulmonary hypertension (shown by Echo or cardiac catheterization), or; episode(s) of acute respiratory failure, or; requires outpatient oxygen therapy. FEV-1 of 40- to 55-percent predicted, or; FEV-1/FVC of 40 to 55 percent, or; DLCO (SB) of 40- to 55-percent predicted, or; maximum oxygen consumption of 15 to 20 ml/kg/min (with cardiorespiratory limit)	
	DISEASES OF THE LUNGS AND PLEURA—TUBERCULOSIS	
704	Ratings for Pulmonary Tuberculosis Entitled on August 19, 1968	
	Tuberculosis, pulmonary, chronic, far advanced, active	
	Tuberculosis, pulmonary, chronic, minimal, active	
	Tuberculosis, pulmonary, chronic, active, advancement unspecified	
721	Tuberculosis, pulmonary, chronic, far advanced, inactive.	
22	Tuberculosis, pulmonary, chronic, moderately advanced, inactive.	
23	Tuberculosis, pulmonary, chronic, minimal, inactive.	
724	Tuberculosis, pulmonary, chronic, inactive, advancement unspecified.  General Rating Formula for Inactive Pulmonary Tuberculosis: For two years after date of inactivity, following	
	General Rating Formula for Inactive Pulmonary Tuberculosis: For two years after date of inactivity, following active tuberculosis, which was clinically identified during service or subsequently	
	Thereafter for four years, or in any event, to six years after date of inactivity	
	Thereafter, for five years, or to eleven years after date of inactivity	
	Following far advanced lesions diagnosed at any time while the disease process was active, minimum Following moderately advanced lesions, provided there is continued disability, emphysema, dyspnea on exertion, impairment of health, etc	

		Rating
treat repo bero 1 to Vete Note ( inac thor	(1): The 100-percent rating under codes 6701 through 6724 is not subject to a requirement of precedent hospital trent. It will be reduced to 50 percent for failure to submit to examination or to follow prescribed treatment upon ont to that effect from the medical authorities. When a veteran is placed on the 100-percent rating for inactive tuculosis, the medical authorities will be appropriately notified of the fact, and of the necessity, as given in footnote 38 U.S.C. 1156 (and formerly in 38 U.S.C. 356, which has been repealed by Public Law 90–493), to notify the errans Service Center in the event of failure to submit to examination or to follow treatment.  (2): The graduated 50-percent and 30-percent ratings and the permanent 30 percent and 20 percent ratings for titve pulmonary tuberculosis are not to be combined with ratings for other respiratory disabilities. Following acoplasty the rating will be for removal of ribs combined with the rating for collapsed lung. Resection of the ribs dent to thoracoplasty will be rated as removal.	
	Ratings for Pulmonary Tuberculosis Initially Evaluated After August 19, 1968	
6730	Tuberculosis, pulmonary, chronic, active	100
6731	findings of a stationary or retrogressive lesion.  Tuberculosis, pulmonary, chronic, inactive:  Depending on the specific findings, rate residuals as interstitial lung disease, restrictive lung disease, or, when obstructive lung disease is the major residual, as chronic bronchitis (DC 6600). Rate thoracoplasty as removal of ribs under DC 5297.  Note: A mandatory examination will be requested immediately following notification that active tuberculosis	
6732	evaluated under DC 6730 has become inactive. Any change in evaluation will be carried out under the provisions of § 3.105(e).  Pleurisy, tuberculous, active or inactive: Rate under §§ 4.88c or 4.89, whichever is appropriate.	
	NONTUBERCULOUS DISEASES	
6817	Pulmonary Vascular Disease:  Primary pulmonary hypertension, or; chronic pulmonary thromboembolism with evidence of pulmonary hypertension, right ventricular hypertrophy, or cor pulmonale, or; pulmonary hypertension secondary to other obstructive disease of pulmonary arteries or veins with evidence of right ventricular hypertrophy or cor pulmonale	100
	Chronic pulmonary thromboembolism requiring anticoagulant therapy, or; following inferior vena cava surgery without evidence of pulmonary hypertension or right ventricular dysfunction  Symptomatic, following resolution of acute pulmonary embolism  Asymptomatic, following resolution of pulmonary thromboembolism	60 30 0
	Note: Evaluate other residuals following pulmonary embolism under the most appropriate diagnostic code, such as chronic bronchitis (DC 6600) or chronic pleural effusion or fibrosis (DC 6844), but do not combine that evaluation with any of the above evaluations.	
	Note: A rating of 100 percent shall continue beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals.	100
6820	Neoplasms, benign, any specified part of respiratory system. Evaluate using an appropriate respiratory analogy.	
	Bacterial Infections of the Lung	
	Actinomycosis.  Nocardiosis.  Chronic lung abscess.  General Rating Formula for Bacterial Infections of the Lung (diagnostic codes 6822 through 6824):  Active infection with systemic symptoms such as fever, night sweats, weight loss, or hemoptysis  Depending on the specific findings, rate residuals as interstitial lung disease, restrictive lung disease, or, when obstructive lung disease is the major residual, as chronic bronchitis (DC 6600).	100
	Interstitial Lung Disease	
6825 6826 6827 6828	Desquamative interstitial pneumonitis. Pulmonary alveolar proteinosis.	

		Rating
6830 6831 6832	Drug-induced pulmonary pneumonitis and fibrosis. Radiation-induced pulmonary pneumonitis and fibrosis. Hypersensitivity pneumonitis (extrinsic allergic alveolitis). Pneumoconiosis (silicosis, anthracosis, etc.). Asbestosis.  General Rating Formula for Interstitial Lung Disease (diagnostic codes 6825 through 6833): Forced Vital Capacity (FVC) less than 50-percent predicted, or; Diffusion Capacity of the Lung for Carbon Monoxide by the Single Breath Method (DLCO (SB)) less than 40-percent predicted, or; maximum exercise capacity less than 15 ml/kg/min oxygen consumption with cardiorespiratory limitation, or; cor pulmonale or pulmonary hypertension, or; requires outpatient oxygen therapy	100 60 30 10
	Mycotic Lung Disease	
6835	Aspergillosis.	100 50 30 0
	Restrictive Lung Disease	
6840 6841 6842 6843 6844 6845	Diaphragm paralysis or paresis. Spinal cord injury with respiratory insufficiency. Kyphoscoliosis, pectus excavatum, pectus carinatum. Traumatic chest wall defect, pneumothorax, hernia, etc. Post-surgical residual (lobectomy, pneumonectomy, etc.).	100 60 30 10

		Rating
	Cor pulmonale, or; cardiac involvement with congestive heart failure, or; progressive pulmonary disease with fever, night sweats, and weight loss despite treatment	100
	Pulmonary involvement requiring systemic high dose (therapeutic) corticosteroids for control	60
	Pulmonary involvement with persistent symptoms requiring chronic low dose (maintenance) or intermittent corticosteroids	30
	Chronic hilar adenopathy or stable lung infiltrates without symptoms or physiologic impairment	0
	Or rate active disease or residuals as chronic bronchitis (DC 6600) and extra-pulmonary involvement under specific body system involved.	
6847	Sleep Apnea Syndromes (Obstructive, Central, Mixed):	
	Chronic respiratory failure with carbon dioxide retention or cor pulmonale, or; requires tracheostomy	100
	Requires use of breathing assistance device such as continuous airway pressure (CPAP) machine	50
	Persistent day-time hypersomnolence	30
	Asymptomatic but with documented sleep disorder breathing	0

[61 FR 46728, Sept. 5, 1996, as amended at 71 FR 28586, May 17, 2006]

#### THE CARDIOVASCULAR SYSTEM

#### §4.100 Application of the evaluation criteria for diagnostic codes 7000-7007, 7011, and 7015–7020.

- (a) Whether or not cardiac hypertrophy or dilatation (documented by electrocardiogram, echocardiogram, or X-ray) is present and whether or not there is a need for continuous medication must be ascertained in all cases.
- (b) Even if the requirement for a 10% (based on the need for continuous medication) or 30% (based on the presence of cardiac hypertrophy or dilatation) evaluation is met, METs testing is required in all cases except:
- (1) When there is a medical contraindication.
- (2) When the left ventricular ejection fraction has been measured and is 50%
- (3) When chronic congestive heart failure is present or there has been more than one episode of congestive heart failure within the past year.
- (4) When a 100% evaluation can be assigned on another basis.
- (c) If left ventricular ejection fraction (LVEF) testing is not of record, evaluate based on the alternative criteria unless the examiner states that the LVEF test is needed in a particular case because the available medical information does not sufficiently reflect the severity of the veteran's cardiovascular disability.

[71 FR 52460, Sept. 6, 2006]

#### §§ 4.101-4.103 [Reserved]

#### §4.104 Schedule of ratings—cardiovascular system.

#### DISEASES OF THE HEART

Rat- ing
100
100

<sup>&</sup>lt;sup>1</sup> Review for entitlement to special monthly compensation under § 3.350 of this chapter.

### 38 CFR Ch. I (7-1-16 Edition)

#### DISEASES OF THE HEART—Continued

		Rat- ing		Rat- ing
	Workload of greater than 5 METs but not greater than 7 METs results in dyspnea,	9	Chronic congestive heart failure, or; work-	
	fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilata- tion on electro-cardiogram, echocardio-		load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of less than 30 percent	100
\	gram, or X-ray  Workload of greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or;	30	More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue,	
	continuous medication requiredndocarditis: For three months following cessation of	10	angina, dizziness, or syncope, or; left ven- tricular dysfunction with an ejection frac- tion of 30 to 50 percent	60
7	therapy for active infection with cardiac in- volvement Thereafter, with endocarditis (documented by findings on physical examination and	100	Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilata-	
,	either echocardiogram, Doppler echo- cardiogram, or cardiac catheterization) re- sulting in:		tion on electro-cardiogram, echocardiogram, or X-ray	30
(	Chronic congestive heart failure, or; work- load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection		greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication required	10
ı	fraction of less than 30 percent	100	Chronic congestive heart failure, or; work- load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection	
	than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection frac-	60	fraction of less than 30 percent	100
١	tion of 30 to 50 percent	60	of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ven- tricular dysfunction with an ejection frac-	
١	evidence of cardiac hypertrophy or dilata- tion on electrocardiogram, echocardio- gram, or X-ray	30	tion of 30 to 50 percent	60
7002 Pa	greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication required	10	evidence of cardiac hypertrophy or dilata- tion on electrocardiogram, echocardio- gram, or X-ray	30
	For three months following cessation of therapy for active infection with cardiac involvement	100	Workload of greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication required	10
	Thereafter, with documented pericarditis resulting in: Chronic congestive heart failure, or; work-		NOTE: Evaluate syphilitic aortic aneurysms under DC 7110 (aortic aneurysm).	
	load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or, left ventricular dysfunction with an ejection fraction of less than 30 percent.	100	7005 Arteriosclerotic heart disease (Coronary artery disease):  With documented coronary artery disease resulting in:	
ľ	More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue,	100	Chronic congestive heart failure, or; work- load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection	
,	angina, dizziness, or syncope, or; left ven- tricular dysfunction with an ejection frac- tion of 30 to 50 percent	60	fraction of less than 30 percent More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater	100
	greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilata- tion on electro-cardiogram, echocardio-		than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of 30 to 50 percent	60
١	gram, or X-ray	30	Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or;	60
7003 Pe	fatigue, angina, dizziness, or syncope, or; continuous medication requiredericardial adhesions:	10	evidence of cardiac hypertrophy or dilata- tion on electrocardiogram, echocardio- gram, or X-ray	30

#### §4.104

DISEASES OF THE HEART—Continued

greater than 10 METs results in dyspnea,

fatigue, angina, dizziness, or syncope, or; continuous medication required NOTE: If nonservice-connected arteriosclerotic heart disease is superimposed on service-connected valvular or other non-arteriosclerotic heart disease, request a medical opinion as to which condition is

causing the current signs and symptoms.

#### 7006 Myocardial infarction:

During and for three months following myocardial infarction, documented by labora-

#### Thereafter:

With history of documented myocardial infarction, resulting in:
Chronic congestive heart failure, or; work-

load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection 

heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of 30 to 50 percent

Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilatation on electrocardiogram, echocardiogram, or X-ray .....

Workload of greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication required 7007 Hypertensive heart disease:

Chronic congestive heart failure, or; workload of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of less than 30 percent ...... More than one episode of acute congestive

heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of 30 to 50 percent

Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilatation on electrocardiogram, echocardiogram, or X-ray

Workload of greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication required

#### 7008 Hyperthyroid heart disease:

Include as part of the overall evaluation for hyperthyroidism under DC 7900. How-ever, when atrial fibrillation is present, hyperthyroidism may be evaluated either under DC 7900 or under DC 7010 (supraventricular arrhythmia), whichever results in a higher evaluation.

7010 Supraventricular arrhythmias:

Rat- ing		Rat- ing
10	Paroxysmal atrial fibrillation or other supraventricular tachycardia, with more than four episodes per year documented by ECG or Holter monitor	30
100	praventricular tachycardia documented by ECG or Holter monitor	10
100	(AICD) in place	100
60	More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection frac-	100
30	tion of 30 to 50 percent	60
10	gram, or X-ray  Workload of greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or;	30
100	continuous medication required	10
60	7015 Atrioventricular block:  Chronic congestive heart failure, or; workload of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection	
30 10	fraction of less than 30 percent	100
	angina, dizziness, or syncope, or; left ven- tricular dysfunction with an ejection frac- tion of 30 to 50 percent	60
	tion on electrocardiogram, echocardio- gram, or X-ray	30

### 38 CFR Ch. I (7-1-16 Edition)

#### DISEASES OF THE HEART—Continued

	Rat- ing		Rat- ing
Workload of greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication or a pacemaker required	10	Workload greater than 7 METs but not greater than 10 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; continuous medication required	10
ventricular block associated with a supraventricular arrhythmia or pathological bradycardia should be submitted to the Director, Compensation Service. Simple delayed P-R conduction time, in the absence of other evidence of cardiac disease, is not a disability.		for implantation or reimplantation	100
7016 Heart valve replacement (prosthesis):  For indefinite period following date of hospital admission for valve replacement	100	NOTE: Evaluate implantable Cardioverter-Defibrillators (AICD's) under DC 7011.  7019 Cardiac transplantation:	
Thereafter: Chronic congestive heart failure, or; workload of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or;		For an indefinite period from date of hospital admission for cardiac transplantation Thereafter: Chronic congestive heart failure, or; work-	100
left ventricular dysfunction with an ejection fraction of less than 30 percent	100	load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of less than 30 percent	100
of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of 30 to 50 percent	60	More than one episode of acute congestive heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ven- tricular dysfunction with an ejection frac-	
Workload of greater than 5 METs but not greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilata-		tion of 30 to 50 percent	60 30
tion on electrocardiogram, echocardio- gram, or X-ray	30	the date of hospital admission for cardiac trans- plantation. One year following discharge, the ap- propriate disability rating shall be determined by mandatory VA examination. Any change in evalua-	
fatigue, angina, dizziness, or syncope, or; continuous medication required	10	tion based upon that or any subsequent examina- tion shall be subject to the provisions of §3.105(e) of this chapter.	
the date of hospital admission for valve replace- ment. Six months following discharge, the appro- priate disability rating shall be determined by man- datory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter.		7020 Cardiomyopathy: Chronic congestive heart failure, or; work- load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of less than 30 percent More than one episode of acute congestive	100
7017 Coronary bypass surgery:  For three months following hospital admission for surgery  Thereafter:	100	heart failure in the past year, or; workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ven- tricular dysfunction with an ejection frac-	
Chronic congestive heart failure, or; work- load of 3 METs or less results in dyspnea, fatigue, angina, dizziness, or syncope, or; left ventricular dysfunction with an ejection fraction of less than 30 percent	100	tion of 30 to 50 percent	60
More than one episode of acute congestive heart failure in the past year, or, workload of greater than 3 METs but not greater than 5 METs results in dyspnea, fatigue,		tion on electrocardiogram, echocardio- gram, or X-ray	30
angina, dizziness, or syncope, or; left ven- tricular dysfunction with an ejection frac- tion of 30 to 50 percent	60	fatigue, angina, dizziness, or syncope, or; continuous medication required	10
greater than 7 METs results in dyspnea, fatigue, angina, dizziness, or syncope, or; evidence of cardiac hypertrophy or dilata-		and isolated systolic hypertension):  Diastolic pressure predominantly 130 or more	60
tion on electrocardiogram, echocardiogram, or X-ray	30	Diastolic pressure predominantly 120 or more	40

### §4.104

#### DISEASES OF THE HEART—Continued

	Rat- ing		Rat- ing
Diastolic pressure predominantly 110 or more, or; systolic pressure predominantly 200 or more	20	NOTE (2): These evaluations are for involvement of a single extremity. If more than one extremity is affected, evaluate each extremity separately and combine (under § 4.25), using the bilateral factor, if applicable.  NOTE (3): A rating of 100 percent shall be assigned as of the date of hospital admission for surgical correction. Six months following discharge, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter.  7112 Aneurysm, any small artery:	<u> </u>
means that the diastolic blood pressure is predominantly 90mm. or greater, and isolated systolic hypertension means that the systolic blood pressure is predominantly 160mm. or greater with a diastolic blood pressure of less than 90mm.		Asymptomatic	0
NOTE (2): Evaluate hypertension due to aortic insuffi- ciency or hyperthyroidism, which is usually the iso- lated systolic type, as part of the condition causing it rather than by a separate evaluation. NOTE (3): Evaluate hypertension separately from hy- pertensive heart disease and other types of heart disease.		7113 Arteriovenous fistula, traumatic: With high output heart failure Without heart failure but with enlarged heart, wide pulse pressure, and tachycardia Without cardiac involvement but with edema, stasis dermatitis, and either ulcer-	100 60
7110 Aortic aneurysm:  If five centimeters or larger in diameter, or; if symptomatic, or; for indefinite period from date of hospital admission for surgical		ation or cellulitis:  Lower extremity	50 40 30
correction (including any type of graft insertion)  Precluding exertion  Evaluate residuals of surgical correction according to organ systems affected.	100 60	Upper extremity	100
NOTE: A rating of 100 percent shall be assigned as of the date of admission for surgical correction. Six months following discharge, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter.		Claudication on walking less than 25 yards on a level grade at 2 miles per hour, and; either persistent coldness of the extremity or ankle/brachial index of 0.5 or less	60
7111 Aneurysm, any large artery:  If symptomatic, or; for indefinite period from date of hospital admission for surgical correction	100	sence of hair, dystrophic nails) or ankle/ brachial index of 0.7 or less	40 20
Following surgery: Ischemic limb pain at rest, and; either deep ischemic ulcers or ankle/brachial index of 0.4 or less	100	NOTE (1): The ankle/brachial index is the ratio of the systolic blood pressure at the ankle (determined by Doppler study) divided by the simultaneous brachial artery systolic blood pressure. The normal index is 1.0 or greater.  NOTE (2): Evaluate residuals of aortic and large arterial bypass surgery or arterial graft as arterio-	20
brachial index of 0.5 or less	60	sclerosis obliterans.  NOTE (3): These evaluations are for involvement of a single extremity. If more than one extremity is affected, evaluate each extremity separately and combine (under § 4.25), using the bilateral factor (§ 4.26), if applicable.	
brachial index of 0.7 or less	40	7115 Thrombo-angiitis obliterans (Buerger's Disease):  Ischemic limb pain at rest, and; either deep	
NOTE (1): The ankle/brachial index is the ratio of the systolic blood pressure at the ankle (determined by Doppler study) divided by the simultaneous brachial artery systolic blood pressure. The normal index is 1.0 or greater.		ischemic ulcers or ankle/brachial index of 0.4 or less	100

### 38 CFR Ch. I (7-1-16 Edition)

#### DISEASES OF THE HEART—Continued

#### DISEASES OF THE HEART—Continued

	Rat- ing		Rat- ing
Claudication on walking between 25 and 100 yards on a level grade at 2 miles per hour, and; trophic changes (thin skin, absence of hair, dystrophic nails) or ankle/ brachial index of 0.7 or less	40	Note: For purposes of this section, a characteristic attack of erythromelalgia consists of burning pain in the hands, feet, or both, usually bilateral and symmetrical, with increased skin temperature and redness, occurring at warm ambient temperatures. These evaluations are for the disease as a whole, regardless of the number of extremities involved.  7120 Varicose veins:  With the following findings attributed to the effects of varicose veins: Massive board-like edema with constant pain at rest  Persistent edema or subcutaneous induration, stasis pigmentation or eczema, and persistent ulceration  Persistent edema and stasis pigmentation or eczema, with or without intermittent ulcer-	100
combine (under § 4.25), using the bilateral factor (§ 4.26), if applicable.		ation  Persistent edema, incompletely relieved by	40
7117 Raynaud's syndrome:  With two or more digital ulcers plus autoamputation of one or more digits and history of characteristic attacks	100	elevation of extremity, with or without be- ginning stasis pigmentation or eczema Intermittent edema of extremity or aching and fatique in leg after prolonged standing	20
With two or more digital ulcers and history of characteristic attacks	60	or walking, with symptoms relieved by elevation of extremity or compression ho-	10
Characteristic attacks occurring at least daily	40	siery Asymptomatic palpable or visible varicose veins	0
times a week	10	Note: These evaluations are for involvement of a single extremity. If more than one extremity is involved, evaluate each extremity separately and combine (under §4.25), using the bilateral factor (§4.26), if applicable.  7121 Post-phlebitic syndrome of any etiology: With the following findings attributed to venous disease:  Massive board-like edema with constant pain at rest	100
Attacks without laryngeal involvement last- ing one to seven days or longer and oc- curring more than eight times a year, or; attacks with laryngeal involvement of any		eczema, and persistent ulcera- tion Persistent edema and stasis pig-	60
duration occurring more than twice a year Attacks without laryngeal involvement last- ing one to seven days and occurring five to eight times a year, or; attacks with la-	40	mentation or eczema, with or without intermittent ulceration Persistent edema, incompletely re- lieved by elevation of extremity, with or without beginning stasis	40
ryngeal involvement of any duration oc- curring once or twice a year	20	pigmentation or eczema	20
7119 Erythromelalgia: Characteristic attacks that occur more than once a day, last an average of more than two hours each, respond poorly to treatment, and that restrict most routine daily		vation of extremity or compression hosiery  Asymptomatic palpable or visible varicose veins	10 0
activities	100	NOTE: These evaluations are for involvement of a single extremity. If more than one extremity is involved, evaluate each extremity separately and combine (under §4.25), using the bilateral factor (§4.26), if applicable.	
routine daily activities	60	7122 Cold injury residuals:	
Characteristic attacks that occur daily or more often but that respond to treatment Characteristic attacks that occur less than daily but at least three times a week and	30		
daily but at least three times a week and that respond to treatment	10		

DISEASES OF THE HEART—Continued

DISEASES OF THE HEART—CONTINUED	ı
	Rat- ing
With the following in affected parts:  Arthralgia or other pain, numbness, or cold sensitivity plus two or more of the following: tissue loss, nail abnormalities, color changes, locally impaired sensation, hyperhidrosis, X-ray abnormalities (osteoporosis, subarticular punched out lesions, or osteoarthritis)	30

Arthraigia or other pain, numbness, or cold sensitivity plus tissue loss, nail abnormalities, color changes, locally impaired sensation, hyperhidrosis, or X-ray abnormalities (osteoporosis, subarticular punched out lesions, or osteoarthritis)

Arthralgia or other pain, numbness, or cold sensitivity .....

NOTE (1): Separately evaluate amputations of fingers or toes, and complications such as squamous cell carcinoma at the site of a cold injury scar or peripheral neuropathy, under other diagnostic codes. Separately evaluate other disabilities that have been diagnosed as the residual effects of cold injury, such as Raynaud's phenomenon, muscle atrophy, etc., unless they are used to support an evaluation under diagnostic code 7122.

NOTE (2): Evaluate each affected part (e.g., hand, foot, ear, nose) separately and combine the ratings in accordance with §§ 4.25 and 4.26.

7123 Soft tissue sarcoma (of vascular origin) ......

NOTE: A rating of 100 percent shall continue beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals.

(Authority: 38 U.S.C. 1155)

[62 FR 65219, Dec. 11, 1997, as amended at 63 FR 37779, July 14, 1998; 71 FR 52460, Sept. 6, 2006; 79 FR 2100, Jan. 13, 2014]

#### THE DIGESTIVE SYSTEM

#### § 4.110 Ulcers.

Experience has shown that the term "peptic ulcer" is not sufficiently specific for rating purposes. Manifest differences in ulcers of the stomach or duodenum in comparison with those at an anastomotic stoma are sufficiently recognized as to warrant two separate graduated descriptions. In evaluating the ulcer, care should be taken that the findings adequately identify the particular location.

#### § 4.111 Postgastrectomy syndromes.

There are various postgastrectomy symptoms which may occur following anastomotic operations of the stomach. When present, those occurring during or immediately after eating and known as the "dumping syndrome" are characterized by gastrointestinal complaints and generalized symptoms simulating hypoglycemia; those occurring from 1 to 3 hours after eating usually present definite manifestations of hypoglycemia.

#### § 4.112 Weight loss.

For purposes of evaluating conditions in §4.114, the term "substantial weight loss" means a loss of greater than 20 percent of the individual's baseline weight, sustained for three months or longer; and the term "minor weight loss" means a weight loss of 10 to 20 percent of the individual's baseline weight, sustained for three months or longer. The term "inability to gain weight" means that there has been substantial weight loss with inability to regain it despite appropriate therapy. "Baseline weight" means the average weight for the two-year-period preceding onset of the disease.

(Authority: 38 U.S.C. 1155) [66 FR 29488, May 31, 2001]

### § 4.113 Coexisting abdominal conditions.

There are diseases of the digestive system, particularly within the abdomen, which, while differing in the site of pathology, produce a common disability picture characterized in the main by varying degrees of abdominal distress or pain, anemia and disturbances in nutrition. Consequently, certain coexisting diseases in this area, as indicated in the instruction under the title "Diseases of the Digestive System," do not lend themselves to distinct and separate disability evaluations without violating the fundarelating mental principle pyramiding as outlined in §4.14.

## §4.114 Schedule of ratings—digestive system.

Ratings under diagnostic codes 7301 to 7329, inclusive, 7331, 7342, and 7345 to 7348 inclusive will not be combined

with each other. A single evaluation will be assigned under the diagnostic code which reflects the predominant disability picture, with elevation to the next higher evaluation where the severity of the overall disability warrants such elevation.

Rat-ing

100 30

> 80 50 30

> > 50

30

10

60

40

20

10

7200 Mouth, injuries of.
Rate as for disfigurement and impairment of function of mastication.
7201 Lips, injuries of.
Rate as for disfigurement of face.
7202 Tongue, loss of whole or part:
With inability to communicate by speech
One-half or more
With marked speech impairment
Permitting passage of liquids only, with marked impairment of general health
Severe, permitting liquids only
Moderate
7204 Esophagus, spasm of (cardiospasm).
If not amenable to dilation, rate as for the de- gree of obstruction (stricture).
7205 Esophagus, diverticulum of, acquired.
Rate as for obstruction (stricture). 7301 Peritoneum, adhesions of:
7301 Peritoneum, adhesions of: Severe; definite partial obstruction shown by X-
ray, with frequent and prolonged episodes of
severe colic distension, nausea or vomiting,
following severe peritonitis, ruptured appendix,
perforated ulcer, or operation with drainage
Moderately severe; partial obstruction mani-
fested by delayed motility of barium meal and less frequent and less prolonged episodes of
pain  Moderate; pulling pain on attempting work or ag-
gravated by movements of the body, or occasional episodes of colic pain, nausea, constipation (perhaps alternating with diarrhea) or
abdominal distension
Mild
NOTE: Ratings for adhesions will be considered
when there is history of operative or other
traumatic or infectious (intraabdominal) proc- ess, and at least two of the following: disturb- ance of motility, actual partial obstruction, re-
flex disturbances, presence of pain.
7304 Ulcer, gastric.
7305 Ulcer, duodenal:
Severe; pain only partially relieved by standard ulcer therapy, periodic vomiting, recurrent
hematemesis or melena, with manifestations
of anemia and weight loss productive of defi- nite impairment of health
Moderately severe; less than severe but with im-
pairment of health manifested by anemia and weight loss; or recurrent incapacitating epi-
sodes averaging 10 days or more in duration at least four or more times a year
Moderate; recurring episodes of severe symp-
toms two or three times a year averaging 10 days in duration; or with continuous moderate
manifestations
Mild; with recurring symptoms once or twice yearly
7306 Ulcer, marginal (gastrojejunal):

00 OIR OII. 1 (7 1 10 Ed.	
	Rat- ing
Pronounced; periodic or continuous pain unrelieved by standard ulcer therapy with periodic vomiting, recurring melena or hematemesis, and weight loss. Totally inca-	
pacitating	100
nounced and less continuous symptoms with definite impairment of health	60
dominal pain at least once a month partially or completely relieved by ulcer therapy, mild and	40
transient episodes of vomiting or melena  Moderate; with episodes of recurring symptoms	40
several times a year	20
once or twice yearly	10
Chronic; with severe hemorrhages, or large ulcerated or eroded areas	60
Chronic; with multiple small eroded or ulcerated areas, and symptoms	30
Chronic; with small nodular lesions, and symptoms	10
A complication of a number of diseases, including pernicious anemia.	
Rate the underlying condition.	
7308 Postgastrectomy syndromes: Severe; associated with nausea, sweating, cir-	
culatory disturbance after meals, diarrhea, hypoglycemic symptoms, and weight loss with	
malnutrition and anemia	60
disorders with characteristic mild circulatory symptoms after meals but with diarrhea and	40
weight loss  Mild; infrequent episodes of epigastric distress with characteristic mild circulatory symptoms	40
or continuous mild manifestations	20
7309 Stomach, stenosis of. Rate as for gastric ulcer.	
7310 Stomach, injury of, residuals.	
Rate as peritoneal adhesions. 7311 Residuals of injury of the liver:	
Depending on the specific residuals, separately	
evaluate as adhesions of peritoneum (diag- nostic code 7301), cirrhosis of liver (diagnostic code 7312), and chronic liver disease without	
cirrhosis (diagnostic code 7345).	
7312 Cirrhosis of the liver, primary biliary cirrhosis, or cirrhotic phase of sclerosing cholangitis:	
Generalized weakness, substantial weight loss, and persistent jaundice, or; with one of the fol-	
lowing refractory to treatment: ascites, hepatic	
encephalopathy, hemorrhage from varices or portal gastropathy (erosive gastritis)	100
History of two or more episodes of ascites, he-	
patic encephalopathy, or hemorrhage from varices or portal gastropathy (erosive gas- tritis), but with periods of remission between	
attacks	70
encephalopathy, or hemorrhage from varices or portal gastropathy (erosive gastritis)	50
Portal hypertension and splenomegaly, with	30
weakness, anorexia, abdominal pain, malaise, and at least minor weight loss	30
Symptoms such as weakness, anorexia, abdominal pain, and malaise	10

	Rat-		Rat-
	ing		ing
NOTE: For evaluation under diagnostic code		Symptomatic with diarrhea, anemia and inability	2
7312, documentation of cirrhosis (by biopsy or imaging) and abnormal liver function tests		to gain weight	2
must be present.		predominant disability, rate under diagnostic	
7314 Cholecystitis, chronic:		code 7301.	
Severe; frequent attacks of gall bladder colic	30	7329 Intestine, large, resection of:	
Moderate; gall bladder dyspepsia, confirmed by X-ray technique, and with infrequent attacks		With severe symptoms, objectively supported by	4
(not over two or three a year) of gall bladder		examination findings With moderate symptoms	4
colic, with or without jaundice	10	With slight symptoms	1
Mild	0	Note: Where residual adhesions constitute the	•
7315 Cholelithiasis, chronic.		predominant disability, rate under diagnostic	
Rate as for chronic cholecystitis.  7316 Cholangitis, chronic.		code 7301.	
Rate as for chronic cholecystitis.		7330 Intestine, fistula of, persistent, or after attempt	
7317 Gall bladder, injury of.		at operative closure:	10
Rate as for peritoneal adhesions.		Copious and frequent, fecal discharge  Constant or frequent, fecal discharge	10 6
7318 Gall bladder, removal of:	30	Slight infrequent, fecal discharge	3
With severe symptoms	10	Healed; rate for peritoneal adhesions.	Ŭ
Nonsymptomatic	0	7331 Peritonitis, tuberculous, active or inactive:	
Spleen, disease or injury of.		Active	10
See Hemic and Lymphatic Systems.		Inactive: See §§ 4.88b and 4.89.	
7319 Irritable colon syndrome (spastic colitis, mucous colitis, etc.):		7332 Rectum and anus, impairment of sphincter	
Severe; diarrhea, or alternating diarrhea and		control:  Complete loss of sphincter control	10
constipation, with more or less constant ab-		Extensive leakage and fairly frequent involuntary	10
dominal distress	30	bowel movements	6
Moderate; frequent episodes of bowel disturb-		Occasional involuntary bowel movements, ne-	
ance with abdominal distress	10	cessitating wearing of pad	3
Mild; disturbances of bowel function with occasional episodes of abdominal distress	0	Constant slight, or occasional moderate leakage	1
7321 Amebiasis:	U	Healed or slight, without leakage	1
Mild gastrointestinal disturbances, lower abdom-		7333 Rectum and anus, stricture of:	10
inal cramps, nausea, gaseous distention,		Requiring colostomy  Great reduction of lumen, or extensive leakage	5
chronic constipation interrupted by diarrhea	10	Moderate reduction of lumen, or moderate con-	0
Asymptomatic	0	stant leakage	3
parallel in symptomatology with ulcerative coli-		7334 Rectum, prolapse of:	
tis and should be rated on the scale provided		Severe (or complete), persistent	5
for the latter. Similarly, lung abscess due to		Moderate, persistent or frequently recurring	3
amebiasis will be rated under the respiratory		Mild with constant slight or occasional moderate	1
system schedule, diagnostic code 6809.  322 Dysentery, bacillary.		leakage7335 Ano, fistula in.	'
Rate as for ulcerative colitis		Rate as for impairment of sphincter control.	
7323 Colitis, ulcerative:		7336 Hemorrhoids, external or internal:	
Pronounced; resulting in marked malnutrition,		With persistent bleeding and with secondary	
anemia, and general debility, or with serious	100	anemia, or with fissures	2
complication as liver abscess	100	Large or thrombotic, irreducible, with excessive	
nutrition, the health only fair during remissions	60	redundant tissue, evidencing frequent recurrences	1
Moderately severe; with frequent exacerbations	30	Mild or moderate	
Moderate; with infrequent exacerbations	10	7337 Pruritus ani.	
7324 Distomiasis, intestinal or hepatic: Severe symptoms	30	Rate for the underlying condition.	
Moderate symptoms	10	7338 Hernia, inguinal:	
Mild or no symptoms	0	Large, postoperative, recurrent, not well sup-	
7325 Enteritis, chronic.		ported under ordinary conditions and not read- ily reducible, when considered inoperable	6
Rate as for irritable colon syndrome.		Small, postoperative recurrent, or unoperated ir-	U
'326 Enterocolitis, chronic.  Rate as for irritable colon syndrome.		remediable, not well supported by truss, or not	
327 Diverticulitis.		readily reducible	3
Rate as for irritable colon syndrome, peritoneal		Postoperative recurrent, readily reducible and	
adhesions, or colitis, ulcerative, depending		well supported by truss or belt	1
upon the predominant disability picture.		Not operated, but remediable	
'328 Intestine, small, resection of: With marked interference with absorption and		sion	
nutrition, manifested by severe impairment of		Note: Add 10 percent for bilateral involvement,	
health objectively supported by examination		provided the second hernia is compensable.	
findings including material weight loss	60	This means that the more severely disabling	
With definite interference with absorption and		hernia is to be evaluated, and 10 percent,	
nutrition, manifested by impairment of health		only, added for the second hernia, if the latter is of compensable degree.	
objectively supported by examination findings			

	Rat- ing		Rat- ing
Massive, persistent, severe diastasis of recti muscles or extensive diffuse destruction or weakening of muscular and fascial support of abdominal wall so as to be inoperable	100	Intermittent fatigue, malaise, and anorexia, or; incapacitating episodes (with symptoms such as fatigue, malaise, nausea, vomiting, anorexia, arthralgia, and right upper quadrant pain) having a total duration of at least one week, but less than two weeks, during the	
conditions	40	past 12-month period	10
wall and indication for a supporting belt Wounds, postoperative, healed, no disability, belt not indicated	20 0	malignancy of the liver, under an appropriate diagnostic code, but do not use the same signs and symptoms as the basis for evalua-	
7340 Hernia, femoral. Rate as for inguinal hernia.		tion under DC 7354 and under a diagnostic code for sequelae. (See § 4.14.).  Note (2): For purposes of evaluating conditions	
7342 Visceroptosis, symptomatic, marked	100	under diagnostic code 7345, "incapacitating episode" means a period of acute signs and	
NOTE: A rating of 100 percent shall continue be- yond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other thera- peutic procedure. Six months after discontinu-		symptoms severe enough to require bed rest and treatment by a physician.  Note (3): Hepatitis B infection must be confirmed by serologic testing in order to evaluate it under diagnostic code 7345.	
ance of such treatment, the appropriate dis- ability rating shall be determined by mandatory VA examination. Any change in evaluation		7346 Hernia hiatal: Symptoms of pain, vomiting, material weight loss	
based upon that or any subsequent examina- tion shall be subject to the provisions of §3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residu-		and hematemesis or melena with moderate anemia; or other symptom combinations pro- ductive of severe impairment of health Persistently recurrent epigastric distress with	60
als. 7344 Benign neoplasms, exclusive of skin growths: Evaluate under an appropriate diagnostic code,		dysphagia, pyrosis, and regurgitation, accom- panied by substernal or arm or shoulder pain, productive of considerable impairment of	
depending on the predominant disability or the specific residuals after treatment.		With two or more of the symptoms for the 30 percent evaluation of less severity	10
7345 Chronic liver disease without cirrhosis (including hepatitis B, chronic active hepatitis, autoimmune hepatitis, hemochromatosis, drug-induced hepatitis, etc., but excluding bile duct disorders and hepatitis C):		7347 Pancreatitis: With frequently recurrent disabling attacks of abdominal pain with few pain free intermissions and with steatorrhea, malabsorption, diarrhea	40.
Near-constant debilitating symptoms (such as fa- tigue, malaise, nausea, vomiting, anorexia, arthralgia, and right upper quadrant pain)	100	and severe malnutrition	100
Daily fatigue, malaise, and anorexia, with sub- stantial weight loss (or other indication of mal- nutrition), and hepatomegaly, or; incapacitating		ing continuing pancreatic insufficiency be- tween acute attacks	60
episodes (with symptoms such as fatigue, malaise, nausea, vomiting, anorexia, arthralgia, and right upper quadrant pain) hav-		tacks of abdominal pain per year with good remission between attacks	30
ing a total duration of at least six weeks during the past 12-month period, but not occurring constantly	60	vere abdominal pain in the past year NOTE 1: Abdominal pain in this condition must be confirmed as resulting from pancreatitis by	10
Daily fatigue, malaise, and anorexia, with minor weight loss and hepatomegaly, or; incapacitating episodes (with symptoms such as fatigue, malaise, pauses, promiting, approximation).		appropriate laboratory and clinical studies. NOTE 2: Following total or partial pancreatectomy, rate under above, symptoms, minimum rating 30 percent.	
tigue, malaise, nausea, vomiting, anorexia, arthralgia, and right upper quadrant pain) hav- ing a total duration of at least four weeks, but less than six weeks, during the past 12-month		7348 Vagotomy with pyloroplasty or gastro- enterostomy: Followed by demonstrably confirmative post-	
period  Daily fatigue, malaise, and anorexia (without weight loss or hepatomegaly), requiring dietary	40	operative complications of stricture or con- tinuing gastric retention	41
restriction or continuous medication, or, inca- pacitating episodes (with symptoms such as fatigue, malaise, nausea, vomiting, anorexia, arthralgia, and right upper quadrant pain) hav-		rhea  Recurrent ulcer with incomplete vagotomy  NOTE: Rate recurrent ulcer following complete	30 20
ing a total duration of at least two weeks, but less than four weeks, during the past 12-month period	20	vagotomy under diagnostic code 7305, min- imum rating 20 percent; and rate dumping syndrome under diagnostic code 7308. 7351 Liver transplant:	
		For an indefinite period from the date of hospital admission for transplant surgery	100

Rating

NOTE: A rating of 100 percent shall be assigned as of the date of hospital admission for transplant surgery and shall continue. One year following discharge, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter.

7354 Hepatitis C (or non-A, non-B hepatitis):

With serologic evidence of hepatitis C infection and the following signs and symptoms due to hepatitis C infection:

Near-constant debilitating symptoms (such as fatigue, malaise, nausea, vomiting, anorexia, arthralgia, and right upper quadrant pain) .......

Daily fatigue, malaise, and anorexia, with substantial weight loss (or other indication of malnutrition), and hepatomegaly, or; incapacitating episodes (with symptoms such as fatigue, malaise, nausea, vomiting, anorexia, arthralgia, and right upper quadrant pain) having a total duration of at least six weeks during the past 12-month period, but not occurring constantly

Daily fatigue, malaise, and anorexia, with minor weight loss and hepatomegaly, or; incapacitating episodes (with symptoms such as fatigue, malaise, nausea, vomiting, anorexia, arthralgia, and right upper quadrant pain) having a total duration of at least four weeks, but less than six weeks, during the past 12-month period

Intermittent fatigue, malaise, and anorexia, or; incapacitating episodes (with symptoms such as fatigue, malaise, nausea, vomiting, anorexia, arthralgia, and right upper quadrant pain) having a total duration of at least one week, but less than two weeks, during the past 12-month period......

Nonsymptomatic ...

Note (1): Evaluate sequelae, such as cirrhosis or malignancy of the liver, under an appropriate diagnostic code, but do not use the same signs and symptoms as the basis for evaluation under DC 7354 and under a diagnostic code for sequelae. (See § 4.14.).

Note (2): For purposes of evaluating conditions under diagnostic code 7354, "incapacitating episode" means a period of acute signs and symptoms severe enough to require bed rest and treatment by a physician.

(Authority: 38 U.S.C. 1155)

[29 FR 6718, May 22, 1964, as amended at 34 FR 5063, Mar. 11, 1969; 40 FR 42540, Sept. 15, 1975; 41 FR 11301, Mar. 18, 1976; 66 FR 29488, May 31, 2001]

THE GENITOURINARY SYSTEM

#### §4.115 Nephritis.

Albuminuria alone is not nephritis, nor will the presence of transient albumin and casts following acute febrile illness be taken as nephritis. The glomerular type of nephritis is usually preceded by or associated with severe infectious disease: the onset is sudden. and the course marked by red blood cells, salt retention, and edema; it may clear up entirely or progress to a chronic condition. The nephrosclerotic type, originating in hypertension or arteriosclerosis, develops slowly, with minimum laboratory findings, and is associated with natural progress. Separate ratings are not to be assigned for disability from disease of the heart and any form of nephritis, on account of the close interrelationships of cardiovascular disabilities. If, however, absence of a kidney is the sole renal disability, even if removal was required because of nephritis, the absent kidney and any hypertension or heart disease will be separately rated. Also, in the event that chronic renal disease has progressed to the point where regular dialysis is required, any coexisting hypertension or heart disease will be separately rated.

[41 FR 34258, Aug. 13, 1976, as amended at 59 FR 2527, Jan. 18, 1994]

## §4.115a Ratings of the genitourinary system—dysfunctions.

Diseases of the genitourinary system generally result in disabilities related to renal or voiding dysfunctions, infections, or a combination of these. The following section provides descriptions of various levels of disability in each of these symptom areas. Where diagnostic codes refer the decisionmaker to these specific areas dysfunction, only the predominant area of dysfunction shall be considered for rating purposes. Since the areas of dysfunction described below do not cover all symptoms resulting from genitourinary diseases, specific diagnoses may include a description of symptoms assigned to that diagnosis.

10

### §4.115b

	Rat-			Rat-
	ing	-		ing
Renal dysfunction: Requiring regular dialysis, or precluding more		L	ong-term drug therapy, 1-2 hospitalizations per year and/or requiring intermittent intensive	
than sedentary activity from one of the fol- lowing: persistent edema and albuminuria; or,			management	10
BUN more than 80mg%; or, creatinine more than 8mg%; or, markedly decreased function of kidney or other organ systems, estpecially		[59 F 1994]	<sup>P</sup> R 2527, Jan. 18, 1994; 59 FR 10676, M	[ar. 7,
cardiovascular	100		15b Ratings of the genitouri	now.
to 80mg%; or, creatinine 4 to 8mg%; or, generalized poor health characterized by lethargy, weakness, anorexia, weight loss, or limitation			system—diagnoses.	пагу
of exertion	80			Rat- ing
Constant albuminuria with some edema; or, defi- nite decrease in kidney function; or, hyper- tension at least 40 percent disabling under di-		-	Note: When evaluating any claim in-	
agnostic code 7101	60		volving loss or loss of use of one or more creative organs, refer to § 3.350	
Albumin constant or recurring with hyaline and granular casts or red blood cells; or, transient			of this chapter to determine whether the veteran may be entitled to special	
or slight edema or hypertension at least 10 percent disabling under diagnostic code 7101	30		monthly compensation. Footnotes in the schedule indicate conditions	
Albumin and casts with history of acute nephritis; or, hypertension non-compensable under diag-			which potentially establish entitlement to special monthly compensation;	
nostic code 7101	0		however, there are other conditions in	
Voiding dysfunction:  Rate particular condition as urine leakage, fre-			this section which under certain cir- cumstances also establish entitlement	
quency, or obstructed voiding Continual Urine Leakage, Post Surgical Urinary		7500	to special monthly compensation.	
Diversion, Urinary Incontinence, or Stress Incontinence:		7500	Kidney, removal of one:  Minimum evaluation	30
Requiring the use of an appliance or the wearing of absorbent materials which must be changed			Or rate as renal dysfunction if there is nephritis, infection, or pathology of	
more than 4 times per day	60	7501	the other. Kidney, abscess of:	
Requiring the wearing of absorbent materials which must be changed 2 to 4 times per day	40	7500	Rate as urinary tract infection	
Requiring the wearing of absorbent materials which must be changed less than 2 times per		7502	Rate as renal dysfunction.	
day	20	7504	Pyelonephritis, chronic:  Rate as renal dysfunction or urinary	
Daytime voiding interval less than one hour, or; awakening to void five or more times per night	40		tract infection, whichever is predominant.	
Daytime voiding interval between one and two	40	7505	**	
hours, or; awakening to void three to four times per night	20		Rate in accordance with §§ 4.88b or 4.89, whichever is appropriate.	
Daytime voiding interval between two and three hours, or; awakening to void two times per		7507	Nephrosclerosis, arteriolar:  Rate according to predominant symp-	
night	10		toms as renal dysfunction, hyper-	
Obstructed voiding:  Urinary retention requiring intermittent or contin-			tension or heart disease. If rated under the cardiovascular schedule,	
uous catheterization	30		however, the percentage rating which would otherwise be assigned will be	
slow or weak stream, decreased force of			elevated to the next higher evalua- tion.	
stream) with any one or combination of the fol- lowing:		7508	Nephrolithiasis:	
<ol> <li>Post void residuals greater than 150 cc.</li> <li>Uroflowmetry; markedly diminished peak</li> </ol>			Rate as hydronephrosis, except for re- current stone formation requiring one or more of the following:	
flow rate (less than 10 cc/sec).  3. Recurrent urinary tract infections sec-			1. diet therapy	
ondary to obstruction. 4. Stricture disease requiring periodic dilata-			drug therapy     invasive or non-invasive proce-	
tion every 2 to 3 months	10	7500	dures more than two times/year	30
Obstructive symptomatology with or without stric- ture disease requiring dilatation 1 to 2 times		7509	Severe; Rate as renal dysfunction.	
per year	0		Frequent attacks of colic with infection (pyonephrosis), kidney function impaired	30
Poor renal function: Rate as renal dysfunction.			Frequent attacks of colic, requiring catheter	
Recurrent symptomatic infection requiring drain- age/frequent hospitalization (greater than two			drainage Only an occasional attack of colic, not in-	20
times/year), and/or requiring continuous intensive management	30		fected and not requiring catheter drainage	10

§4	.1	15	b
----	----	----	---

		Rat- ing		Rat- ing
	Ureterolithiasis: Rate as hydronephrosis, except for recurrent stone formation requiring one or more of the following:  1. diet therapy 2. drug therapy 3. invasive or non-invasive procedures more than two times/year Ureter, stricture of: Rate as hydronephrosis, except for recurrent stone formation requiring one or more of the following: 1. diet therapy 2. drug therapy 3. invasive or non-invasive procedures more than two times/year	30	Note—Following the cessation of surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure, the rating of 100 percent shall continue with a mandatory VA examination at the expiration of six months. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. If there has been no local reocurrence or metastasis, rate on residuals as voiding dysfunction or renal dysfunction, whichever is predominant.	3
etio 7515	Cystitis, chronic, includes interstitial and all logies, infectious and non-infectious: Rate as voiding dysfunction. Bladder, calculus in, with symptoms intergraphy with function:		tem:  Rate as voiding dysfunction or renal dysfunction, whichever is predominant.  7530 Chronic renal disease requiring regular dialy-	
	Rate as voiding dysfunction Bladder, fistula of: Rate as voiding dysfunction or urinary tract infection, whichever is predominant. Postoperative, suprapubic cystotomy	100	sis:  Rate as renal dysfunction.  7531 Kidney transplant: Following transplant surgery Thereafter: Rate on residuals as renal dysfunction, minimum rating	10
	Bladder, injury of: Rate as voiding dysfunction.		Note—The 100 percent evaluation shall be assigned as of the date of hospital admission for transplant surgery and	
	Urethra, stricture of: Rate as voiding dysfunction.		shall continue with a mandatory VA examination one year following hos-	
	Urethra, fistual of: Rate as voiding dysfunction. Multiple urethroperineal fistulae Penis, removal of half or more	100 30	pital discharge. Any change in eval- uation based upon that or any subse- quent examination shall be subject to the provisions of §3.105(e) of this	
7521	Or rate as voiding dysfunction.  Penis removal of glans  Or rate as voiding dysfunction.	20	chapter.  7532 Renal tubular disorders (such as renal glycosurias, aminoacidurias, renal tubular acidosis,	
201	Penis, deformity, with loss of erectile power-		Fanconi's syndrome, Bartter's syndrome, related disorders of Henle's loop and proximal or distal	
7323	Both—20 <sup>1</sup> One—0 <sup>1</sup>		nephron function, etc.):  Minimum rating for symptomatic condition	2
7524	Testis, removal:.  Both—30 ¹  One—0 ¹			
	Note: In cases of the removal of one testis as the result of a service-incurred injury or disease, other than an undescended or congenitally undeveloped testis, with the absence or nonfunctioning of the other testis unrelated to service, an evaluation of 30 percent will be assigned for the service-connected testicular loss. Testis, underscended, or congenitally undeveloped is not a ratable disability.			
7525	Epididymo-orchitis, chronic only: Rate as urinary tract infection. For tubercular infections: Rate in accordance with §§ 4.88b or 4.89, whichever is appropriate.			
	Prostate gland injuries, infections, hyper- hy, postoperative residuals:			
пор	Rate as voiding dysfunction or urinary tract infection, whichever is predomi-			
	nant.  Malignant neoplasms of the genitourinary sys-	100		
tern		100		

#### 38 CFR Ch. I (7-1-16 Edition)

Rat-ing Or rate as renal dysfunction. 7533 Cystic diseases of the kidneys (polycystic disease, uremic medullary cystic disease, Medullary sponge kidney, and similar conditions): Rate as renal dysfunction.

7534 Atherosclerotic renal disease (renal artery stenosis or atheroembolic renal disease): Rate as renal dysfunction. 7535 Toxic nephropathy (antibotics, radiocontrast agents, nonsteroidal anti-inflammatory agents, heavy metals, and similar agents): Rate as renal dysfunction. 7536 Glomerulonephritis: Rate as renal dysfunction. 7537 Interstitial nephritis: Rate as renal dysfunction. 7538 Papillary necrosis: Rate as renal dysfunction. 7539 Renal amyloid disease: Rate as renal dysfunction. 7540 Disseminated intravascular coagulation with renal cortical necrosis: Rate as renal dysfunction. 7541 Renal involvement in diabetes mellitus, sickle cell anemia, systemic lupus erythematosus, vasculitis, or other systemic disease processes. Rate as renal dysfunction. 7542 Neurogenic bladder: Rate as voiding dysfunction.

<sup>1</sup> Review for entitlement to special monthly compensation under § 3.350 of this chapter.

[59 FR 2527, Jan. 18, 1994; 59 FR 14567, Mar. 29, 1994, as amended at 59 FR 46339, Sept. 8, 1994]

GYNECOLOGICAL CONDITIONS AND DISORDERS OF THE BREAST

# § 4.116 Schedule of ratings—gynecological conditions and disorders of the breast.

Note 1: Natural menopause, primary amenorrhea, and pregnancy and child-birth are not disabilities for rating purposes. Chronic residuals of medical or surgical complications of pregnancy may be disabilities for rating purposes.  Note 2: When evaluating any claim involving loss or loss of use of one or more creative organs or anatomical loss of one or both breasts, refer to § 3.350 of this chapter to determine whether the veteran may be entitled to special monthly compensation. Footnotes in the schedule indicate conditions which potentially establish entitlement to special monthly compensation; however, almost any condition in this section might, under certain circumstances, establish entitlement to special monthly compensation.  7610 Vulva, disease or injury of (including vulvovaginitis).  7611 Vagina, disease or injury of.	
surgical complications of pregnancy may be disabilities for rating purposes.  Note 2: When evaluating any claim involving loss or loss of use of one or more creative organs or anatomical loss of one or both breasts, refer to § 3.350 of this chapter to determine whether the veteran may be entitled to special monthly compensation. Footnotes in the schedule indicate conditions which potentially establish entitlement to special monthly compensation; however, almost any condition in this section might, under certain circumstances, establish entitlement to special monthly compensation.  7610 Vulva, disease or injury of (including vulvovaginitis).  7611 Vagina, disease or injury of.	
surgical complications of pregnancy may be disabilities for rating purposes.  Note 2: When evaluating any claim involving loss or loss of use of one or more creative organs or anatomical loss of one or both breasts, refer to § 3.350 of this chapter to determine whether the veteran may be entitled to special monthly compensation. Footnotes in the schedule indicate conditions which potentially establish entitlement to special monthly compensation; however, almost any condition in this section might, under certain circumstances, establish entitlement to special monthly compensation.  7610 Vulva, disease or injury of (including vulvovaginitis).  7611 Vagina, disease or injury of.	
surgical complications of pregnancy may be disabilities for rating purposes.  Note 2: When evaluating any claim involving loss or loss of use of one or more creative organs or anatomical loss of one or both breasts, refer to §3.350 of this chapter to determine whether the veteran may be entitled to special monthly compensation. Footnotes in the schedule indicate conditions which potentially establish entitlement to special monthly compensation; however, almost any condition in this section might, under certain circumstances, establish entitlement to special monthly compensation.  7610 Vulva, disease or injury of (including vulvovaginitis).  7611 Vagina, disease or injury of.	
be disabilities for rating purposes.  Note 2: When evaluating any claim involving loss or loss of use of one or more creative organs or anatomical loss of one or both breasts, refer to § 3.350 of this chapter to determine whether the veteran may be entitled to special monthly compensation. Footnotes in the schedule indicate conditions which potentially establish entitlement to special monthly compensation; however, almost any condition in this section might, under certain circumstances, establish entitlement to special monthly compensation.  7610 Vulva, disease or injury of (including vulvovaginitis).  7611 Vagina, disease or injury of.	
Note 2: When evaluating any claim involving loss or loss of use of one or more creative organs or anatomical loss of one or both breasts, refer to § 3.350 of this chapter to determine whether the veteran may be entitled to special monthly compensation. Footnotes in the schedule indicate conditions which potentially establish entitlement to special monthly compensation; however, almost any condition in this section might, under certain circumstances, establish entitlement to recreat in circumstances, establish entitlement to special monthly compensation. 7610 Vulva, disease or injury of (including vulvovaginitis). 7611 Vagina, disease or injury of.	
ing loss or loss of use of one or more creative organs or anatomical loss of one or both breasts, refer to §3.350 of this chapter to determine whether the veteran may be entitled to special monthly compensation. Footnotes in the schedule indicate conditions which potentially establish entitlement to special monthly compensation; however, almost any condition in this section might, under certain circumstances, establish entitlement to special monthly compensation.  7610 Vulva, disease or injury of (including vulvovaginitis).  7611 Vagina, disease or injury of.	
creative organs or anatomical loss of one or both breasts, refer to § 3.350 of this chapter to determine whether the veteran may be entitled to special monthly compensation. Footnotes in the schedule indicate conditions which potentially establish entitlement to special monthly compensation; however, almost any condition in this section might, under certain circumstances, establish entitlement to special monthly compensation.  7610 Vulva, disease or injury of (including vulvovaginitis).  7611 Vagina, disease or injury of.	
this chapter to determine whether the veteran may be entitled to special monthly compensation. Footnotes in the schedule indicate conditions which potentially establish entitlement to special monthly compensation; however, almost any condition in this section might, under certain circumstances, establish entitlement to special monthly compensation. Yollow, disease or injury of (including vulvovaginitis). Yollow, disease or injury of.	
veteran may be entitled to special monthly compensation. Footnotes in the schedule indicate conditions which potentially establish entitlement to special monthly compensation; however, almost any condition in this section might, under certain circumstances, establish entitlement to special monthly compensation.  7610 Vulva, disease or injury of (including vulvovaginitis).  7611 Vagina, disease or injury of.	
monthly compensation. Footnotes in the schedule indicate conditions which potentially establish entitlement to special monthly compensation; however, almost any condition in this section might, under certain circumstances, establish entitlement to special monthly compensation.  7610 Vulva, disease or injury of (including vulvovaginitis).  7611 Vagina, disease or injury of.	
schedule indicate conditions which potentially establish entitlement to special monthly compensation; however, almost any condition in this section might, under certain circumstances, establish entitlement to special monthly compensation.  7610 Vulva, disease or injury of (including vulvovaginitis).  7611 Vagina, disease or injury of.	
tentially establish entitlement to special monthly compensation; however, almost any condition in this section might, under certain circumstances, establish entitlement to special monthly compensation.  7610 Vulva, disease or injury of (including vulvovaginitis).  7611 Vagina, disease or injury of.  7612 Cervix, disease or injury of.	
monthly compensation; however, almost any condition in this section might, under certain circumstances, establish entitlement to special monthly compensation.  7610 Vulva, disease or injury of (including vulvovaginitis).  7611 Vagina, disease or injury of.  7612 Cervix, disease or injury of.	
any condition in this section might, under certain circumstances, establish entitlement to special monthly compensation.  7610 Vulva, disease or injury of (including vulvovaginitis).  7611 Vagina, disease or injury of.  7612 Cervix, disease or injury of.	
ment to special monthly compensation. 7610 Vulva, disease or injury of (including vulvovaginitis). 7611 Vagina, disease or injury of. 7612 Cervix, disease or injury of.	
7610 Vulva, disease or injury of (including vulvovaginitis). 7611 Vagina, disease or injury of. 7612 Cervix, disease or injury of.	
vulvovaginitis). 7611 Vagina, disease or injury of. 7612 Cervix, disease or injury of.	
7611 Vagina, disease or injury of. 7612 Cervix, disease or injury of.	
7612 Cervix, disease or injury of.	
7613 Uterus, disease, injury, or adhesions of.	
7614 Fallopian tube, disease, injury, or adhesions	
of (including pelvic inflammatory disease (PID)).	
7615 Ovary, disease, injury, or adhesions of.	
General Rating Formula for Disease, Injury, or Ad-	
hesions of Female Reproductive Organs (diag-	
nostic codes 7610 through 7615):  Symptoms not controlled by continuous	
treatment	30
Symptoms that require continuous treat-	
ment	10
Symptoms that do not require continuous	
treatment	(
plete:	
For three months after removal	1100
Thereafter	1 50
7618 Uterus, removal of, including corpus:	
For three months after removal	1 100
Thereafter	1 30
7619 Ovary, removal of:	1400
For three months after removal Thereafter:	1 100
Complete removal of both ovaries	1 30
Removal of one with or without	
partial removal of the other	1 (
7620 Ovaries, atrophy of both, complete	1 20
7621 Uterus, prolapse:	
Complete, through vagina and introitus	50
Incomplete	30
7622 Uterus, displacement of: With marked displacement and frequent or	
continuous menstrual disturbances	30
With adhesions and irregular menstruation	10
7623 Pregnancy, surgical complications of:	
With rectocele or cystocele	50
With relaxation of perineum	10
7624 Fistula, rectovaginal:	
Vaginal fecal leakage at least once a day	100
requiring wearing of pad	100
Vaginal fecal leakage four or more times per week, but less than daily, requiring	
wearing of pad	

Rating

<sup>1</sup>50

	Vaginal fecal leakage one to three times
	per week requiring wearing of pad
	Vaginal fecal leakage less than once a week
	Without leakage
7625	Fistula, urethrovaginal:
020	Multiple urethrovaginal fistulae
	Requiring the use of an appliance or the
	wearing of absorbent materials which must be changed more than four times
	per day
	Requiring the wearing of absorbent materials which must be changed two to four
	times per day
	rials which must be changed less than two times per day
7626	Breast, surgery of:
020	
	Following radical mastectomy:  Both
	One
	Following modified radical mastectomy:
	Both
	One
	Following simple mastectomy or wide loca
	excision with significant alteration of size or form:
	Both
	One
	Following wide local excision without sig- nificant alteration of size or form:
	Both or one
	Note: For VA purposes:
	(1) Radical mastectomy means
	removal of the entire breast, un- derlying pectoral muscles, and regional lymph nodes up to the
	coracoclavicular ligament
	(2) Modified radical mastectomy means removal of the entire
	breast and axillary lymph nodes (in continuity with the breast)
	Pectoral muscles are left intact. (3) Simple (or total) mastectomy
	means removal of all of the breast tissue, nipple, and a
	small portion of the overlying skin, but lymph nodes and mus
	cles are left intact
	(4) Wide local excision (including
	partial mastectomy lumpectomy, tylectomy
	segmentectomy, and quadrantectomy) means re-
	moval of a portion of the breastissue
7627	Malignant neoplasms of gynecological sys-

	Rating
Note: A rating of 100 percent shall continue beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals.  7628 Benign neoplasms of the gynecological system or breast. Rate according to impairment in	
function of the urinary or gynecological systems, or skin.	
7629 Endometriosis:	
Lesions involving bowel or bladder con- firmed by laparoscopy, pelvic pain or heavy or irregular bleeding not controlled by treatment, and bowel or bladder	
symptoms	50
Pelvic pain or heavy or irregular bleeding	
not controlled by treatment  Pelvic pain or heavy or irregular bleeding	30
requiring continuous treatment for control  Note: Diagnosis of endometriosis must be substantiated by laparoscopy.	10

 $<sup>^{\</sup>rm 1} \mbox{Review}$  for entitlement to special monthly compensation under  $\S\,3.350$  of this chapter.

[60 FR 19855, Apr. 21, 1995, as amended at 67 FR 6874, Feb. 14, 2002; 67 FR 37695, May 30, 2002]

#### THE HEMIC AND LYMPHATIC SYSTEMS

# $\$\,4.117\,$ Schedule of ratings—hemic and lymphatic systems.

		Rating
meg	Anemia, hypochromic-microcytic and paloblastic, such as iron-deficiency and per-	
	Hemoglobin 5gm/100ml or less, with find- ings such as high output congestive heart failure or dyspnea at rest	100
	Hemoglobin 7gm/100ml or less, with find- ings such as dyspnea on mild exertion, cardiomegaly, tachycardia (100 to 120 beats per minute) or syncope (three epi-	
	sodes in the last six months) Hemoglobin 8gm/100ml or less, with find- ings such as weakness, easy fatigability,	70
	headaches, lightheadedness, or short- ness of breath	30
	ings such as weakness, easy fatigability or headaches	10
	tomatic	0
	Evaluate complications of pernicious anemia, sentia or peripheral neuropathy, separately.	such as
7702	Agranulocytosis, acute: Requiring bone marrow transplant, or; requiring transfusion of platelets or red cells at least once every six weeks, or;	

7709 Hodgkin's disease:

With active disease or during a treatment

NOTE: The 100 percent rating shall continue beyond the cessation of any surgical, radiation, antineoplastic chemo-

therapy or other therapeutic procedures. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination.

Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of

§ 3.105(e) of this chapter. If there has been no local recur-

rence or metastasis, rate on residuals.

#### 38 CFR Ch. I (7-1-16 Edition)

	Rating		Rating
Requiring transfusion of platelets or red cells at least once every three months, or; infections recurring at least once every three months	60 30 10	<ul> <li>7710 Adenitis, tuberculous, active or inactive. Rate under §§ 4.88c or 4.89 of this part, whichever is appropriate.</li> <li>7714 Sickle cell anemia: With repeated painful crises, occurring in skin, joints, bones or any major organs caused by hemolysis and sickling of red blood cells, with anemia, thrombosis and infarction, with symptoms precluding even light manual labor</li> </ul>	100
NOTE: The 100 percent rating for bone marrow tra shall be assigned as of the date of hospital admiss shall continue with a mandatory VA examinat months following hospital discharge. Any change uation based upon that or any subsequent exar shall be subject to the provisions of §3.105(e) chapter.	ansplant sion and tion six in eval- mination	With painful crises several times a year or with symptoms precluding other than light manual labor	60
7703 Leukemia:  With active disease or during a treatment phase  Otherwise rate as anemia (code 7700) or aplastic anemia (code 7716), whichever would result in the greater benefit.	100	ment  Note: Sickle cell trait alone, without a history of dire tributable pathological findings, is not a ratable di Cases of symptomatic sickle cell trait will be forwa the Director, Compensation Service, for considured § 3.321(b)(1) of this chapter.	sability. Irded to
NoTE: The 100 percent rating shall continue beyond to sation of any surgical, radiation, antineoplastic therapy or other therapeutic procedures. Six mont discontinuance of such treatment, the appropriate of rating shall be determined by mandatory VA exame Any change in evaluation based upon that or any quent examination shall be subject to the provistic 3.105(e) of this chapter. If there has been no recturate on residuals.	chemo- ths after disability nination. subse- sions of	7715 Non-Hodgkin's lymphoma: With active disease or during a treatment phase NOTE: The 100 percent rating shall continue beyond t sation of any surgical, radiation, antineoplastic therapy or other therapeutic procedures. Six mont discontinuance of such treatment, the appropriate or rating shall be dtermined by mandatory VA exam Any change in evaluation based upon that or any	chemo- hs after isability ination. subse-
7704 Polycythemia vera:  During periods of treatment with myelosuppressants and for three months		quent examination shall be subject to the provis § 3.105(e) of this chapter. If there has been no loca rence or metastasis, rate on residuals.	
following cessation of myelosuppressant therapy	100 40 10 t, stroke	7716 Aplastic anemia: Requiring bone marrow transplant, or; requiring transfusion of platelets or red cells at least once every six weeks, or; infections recurring at least once every six weeks.	100
or thrombotic disease separately.  7705 Thrombocytopenia, primary, idiopathic or im-		Requiring transfusion of platelets or red cells at least once every three months, or; infections recurring at least once	
mune:  Platelet count of less than 20,000, with active bleeding, requiring treatment with medication and transfusions	100	every three months	60
Stable platelet count between 70,000 and 100,000, without bleeding	30	Requiring continuous medication for control  Note: The 100 percent rating for bone marrow tra	10
Stable platelet count of 100,000 or more, without bleeding	0 20	shall be assigned as of the date of hospital admiss shall continue with a mandatory VA examinat months following hospital discharge. Any change uation based upon that or any subsequent example be subject to the provisions of §3.105(e)	ion and ion six in eval- nination
7707 Spleen, injury of, healed. Rate for any residuals.		chapter. 7717 AL amyloidosis (primary amyloidosis)	100

 $[60~\mathrm{FR}~49227,~\mathrm{Sept.}~22,~1995,~\mathrm{as}~\mathrm{amended}~\mathrm{at}~77~\mathrm{FR}~6467,~\mathrm{Feb.}~8,~2012;~79~\mathrm{FR}~2100,~\mathrm{Jan.}~13,~2014]$ 

#### THE SKIN

#### $\S 4.118$ Schedule of ratings—skin.

A veteran whose scars were rated by VA under a prior version of diagnostic codes 7800, 7801, 7802, 7803, 7804, or 7805,

as in effect before October 23, 2008, may request review under diagnostic codes 7800, 7801, 7802, 7804, and 7805, irrespective of whether his or her disability has worsened since the last review. VA will review that veteran's disability rating to determine whether the veteran may be entitled to a higher disability rating under diagnostic codes 7800, 7801, 7802, 7804, and 7805. A request for review pursuant to this rulemaking will be treated as a claim for an increased rating for purposes of determining the effective date of an increased rating awarded as a result of such review; however, in no case will the award be effective before October 23, 2008

	Rat- ing
7800 Burn scar(s) of the head, face, or neck; scar(s) of the head, face, or neck due to other causes; or other disfigurement of the head, face, or neck:	
With visible or palpable tissue loss and either gross distortion or asymmetry of three or more features or paired sets of features (nose, chin, forehead, eyes (including eyelids), ears (auricles), cheeks, lips), or; with six or more characteristics of disfigurement	80
With visible or palpable tissue loss and either gross distortion or asymmetry of two features or paired sets of features (nose, chin, forehead, eyes (including eyelids), ears (auricles), cheeks, lips), or; with four or five characteristics of disfigurement	50
With visible or palpable tissue loss and ei- ther gross distortion or asymmetry of one feature or paired set of features (nose, chin, forehead, eyes (including eyelids), ears (auricles), cheeks, lips), or; with two or three characteristics of disfigurement	30
With one characteristic of disfigurement  Note (1):The 8 characteristics of disfigurement, for purposes of evaluation under § 4.118, are:	10
Scar 5 or more inches (13 or more cm.) in length.	
Scar at least one-quarter inch (0.6 cm.) wide at widest part.	
Surface contour of scar elevated or depressed on palpation.	
Scar adherent to underlying tissue.  Skin hypo-or hyper-pigmented in an area exceeding six square inches (39 sq. cm.).	
Skin texture abnormal (irregular, atrophic, shiny, scaly, etc.) in an area exceeding six square inches (39 sq. cm.).	
Underlying soft tissue missing in an area exceeding six square inches (39 sq. cm.).	
Skin indurated and inflexible in an area ex-	

ceeding six square inches (39 sq. cm.).

	Rat- ing
Note (2): Rate tissue loss of the auricle under DC 6207 (loss of auricle) and ana- tomical loss of the eye under DC 6061	
(anatomical loss of both eyes) or DC 6063 (anatomical loss of one eye), as appropriate.	
Note (3): Take into consideration unretouched color photographs when evaluating under these criteria.	
Note (4): Separately evaluate disabling effects other than disfigurement that are associated with individual scar(s) of the head, face, or neck, such as pain, instability, and residuals of associated muscle or nerve injury, under the appropriate diagnostic code(s) and apply § 4.25 to com-	
bine the evaluation(s) with the evaluation assigned under this diagnostic code.	
Note (5): The characteristic(s) of disfigure- ment may be caused by one scar or by multiple scars; the characteristic(s) re- quired to assign a particular evaluation need not be caused by a single scar in order to assign that evaluation.	
7801 Burn scar(s) or scar(s) due to other causes, not of the head, face, or neck, that are deep and nonlinear:	
Area or areas of 144 square inches (929 sq. cm.) or greater Area or areas of at least 72 square inches	40
(465 sq. cm.) but less than 144 square inches (929 sq. cm.)	30
(77 sq. cm.) but less than 72 square inches (465 sq. cm.)	20
Area or areas of at least 6 square inches (39 sq. cm.) but less than 12 square inches (77 sq. cm.)	10
Note (1): A deep scar is one associated with underlying soft tissue damage.	
Note (2): If multiple qualifying scars are present, or if a single qualifying scar affects more than one extremity, or a single qualifying scar affects one or more extremities and either the anterior portion or posterior portion of the trunk, or both, or a single qualifying scar affects both the anterior portion and the posterior portion of the trunk, assign a separate evaluation for each affected extremity based on the total area of the qualifying scars that affect that extremity, assign a separate evaluation based on the total area of the qualifying scars that affect the anterior portion of the trunk, and assign a separate evaluation based on the total area of the qualifying scars that affect the posterior portion of the trunk. The midaxillary line on each side separates the anterior and posterior portions of the trunk. Combine the separate evaluations under §4.25. Qualifying scars are scars that are nonlinear, deep, and are not located on the head, face, or neck.	

not of the head, face, or neck, that are superficial

Area or areas of 144 square inches (929 sq. cm.) or greater .....

10

and nonlinear:

	Rat- ing		Rat- ing
Note (1): A superficial scar is one not asso-		Less than 5 percent of the entire body or	
ciated with underlying soft tissue damage		less than 5 percent of exposed areas af-	
Note (2): If multiple qualifying scars are		fected, and; no more than topical therapy	
present, or if a single qualifying scar af-		required during the past 12-month period	
fects more than one extremity, or a single		Or rate as disfigurement of the head, face,	
qualifying scar affects one or more ex-		or neck (DC 7800) or scars (DC's 7801,	
tremities and either the anterior portion or		7802, 7803, 7804, or 7805), depending	
posterior portion of the trunk, or both, or a		upon the predominant disability.	
single qualifying scar affects both the an-			
terior portion and the posterior portion of		` ,	
the trunk, assign a separate evaluation for		(mucocutaneous, espundia):	
each affected extremity based on the total		Rate as disfigurement of the head, face, or	
area of the qualifying scars that affect that		neck (DC 7800), scars (DC's 7801, 7802,	
extremity, assign a separate evaluation		7803, 7804, or 7805), or dermatitis (DC	
based on the total area of the qualifying		7806), depending upon the predominant	
scars that affect the anterior portion of the		disability.	
trunk, and assign a separate evaluation		Note: Evaluate non-cutaneous (visceral)	
based on the total area of the qualifying		leishmaniasis under DC 6301 (visceral	
scars that affect the posterior portion of		leishmaniasis).	
the trunk. The midaxillary line on each		7808 Old World leishmaniasis (cutaneous, Oriental	
side separates the anterior and posterior		sore):	
portions of the trunk. Combine the sepa-		Rate as disfigurement of the head, face, or	
rate evaluations under §4.25. Qualifying		neck (DC 7800), scars (DC's, 7801, 7802,	
scars are scars that are nonlinear, super-		7803, 7804, or 7805), or dermatitis (DC	
ficial, and are not located on the head,		7806), depending upon the predominant	
face, or neck.		disabililty.	
04 Scar(s), unstable or painful:.		Note: Evaluate non-cutaneous (visceral)	
Five or more scars that are unstable or		leishmaniasis under DC 6301 (visceral	
painful	30	leishmaniasis).	
Three or four scars that are unstable or		7809 Discoid lupus erythematosus or subacute cu-	
painful	20	taneous lupus erythematosus:	
One or two scars that are unstable or pain-		Rate as disfigurement of the head, face, or	
ful	10	neck (DC 7800), scars (DC's 7801, 7802,	
Note (1): An unstable scar is one where, for		7803, 7804, or 7805), or dermatitis (DC	
any reason, there is frequent loss of cov-		7806), depending upon the predominant	
ering of skin over the scar.		disability. Do not combine with ratings	
Note (2): If one or more scars are both un-		under DC 6350.	
stable and painful, add 10 percent to the		7811 Tuberculosis luposa (lupus vulgaris), active or	
evaluation that is based on the total num-		inactive:	
ber of unstable or painful scars		Rate under §§ 4.88c or 4.89, whichever is	
Note (3): Scars evaluated under diagnostic		appropriate.	
codes 7800, 7801, 7802, or 7805 may		7813 Dermatophytosis (ringworm: of body, tinea	
also receive an evaluation under this di-		corporis; of head, tinea capitis; of feet, tinea pedis;	
agnostic code, when applicable		of beard area, tinea barbae; of nails, tinea	
05 Scars, other (including linear scars) and other		unguium; of inguinal area (jock itch), tinea cruris):	
effects of scars evaluated under diagnostic codes		Rate as disfigurement of the head, face, or	
7800, 7801, 7802, and 7804:		neck (DC 7800), scars (DC's 7801, 7802,	
Evaluate any disabling effect(s) not consid-		7803, 7804, or 7805), or dermatitis (DC	
ered in a rating provided under diagnostic		7806), depending upon the predominant	
codes 7800-04 under an appropriate di-		disability.	
agnostic code		7815 Bullous disorders (including pemphigus	
Dermatitis or eczema.  More than 40 percent of the entire body or		vulgaris, pemphigus foliaceous, bullous	
more than 40 percent of the entire body or		pemphigoid, dermatitis herpetiformis, epidermolysis	
affected, or; constant or near-constant		bullosa acquisita, benign chronic familial	
systemic therapy such as corticosteroids		pemphigus (Hailey-Hailey), and porphyria cutanea	
or other immunosuppressive drugs re-		tarda):	
quired during the past 12-month period	60	More than 40 percent of the entire body or	
20 to 40 percent of the entire body or 20 to	00	more than 40 percent of exposed areas	
40 percent of exposed areas affected, or;		affected, or; constant or near-constant	
systemic therapy such as corticosteroids		systemic therapy such as corticosteroids	
or other immunosuppressive drugs re-		or other immunosuppressive drugs re-	
guired for a total duration of six weeks or		quired during the past 12-month period	(
more, but not constantly, during the past		20 to 40 percent of the entire body or 20 to	
12-month period	30	40 percent of the entire body of 20 to	
At least 5 percent, but less than 20 percent,		systemic therapy such as corticosteroids	
of the entire body, or at least 5 percent,		or other immunosuppressive drugs re-	
but less than 20 percent, of exposed		quired for a total duration of six weeks or	
areas affected, or; intermittent systemic		more, but not constantly, during the past	
therapy such as corticosteroids or other		12-month period	3
immunosuppressive drugs required for a			,
total duration of less than six weeks dur-			
	10		

		Rat- ing		Rat- ing
	At least 5 percent, but less than 20 percent,	9	Any extent of involvement of the skin, and;	"'Y
	of the entire body, or at least 5 percent,		systemic therapy such as therapeutic	
	but less than 20 percent, of exposed		doses of corticosteroids, immuno-	
	areas affected, or; intermittent systemic		suppressive retinoids, PUVA (psoralen	
	therapy such as corticosteroids or other		with long-wave ultraviolet-A light) or UVB	
	immunosuppressive drugs required for a		(ultraviolet-B light) treatments, or electron	
	total duration of less than six weeks dur-		beam therapy required for a total duration	
	ing the past 12-month period	10	of six weeks or more, but not constantly,	
	Less than 5 percent of the entire body or		during the past 12-month period	30
	exposed areas affected, and; no more		Any extent of involvement of the skin, and;	-
	than topical therapy required during the		systemic therapy such as therapeutic	
	past 12-month period	0	doses of corticosteroids, immuno-	
	Or rate as disfigurement of the head, face,	U	suppressive retinoids, PUVA (psoralen	
			with long-wave ultraviolet-A light) or UVB	
	or neck (DC 7800) or scars (DC's 7801,		(ultraviolet-B light) treatments, or electron	
	7802, 7803, 7804, or 7805), depending		beam therapy required for a total duration	
	upon the predominant disability.		of less than six weeks during the past 12-	
816	Psoriasis:			10
	More than 40 percent of the entire body or		month period	10
	more than 40 percent of exposed areas		Any extent of involvement of the skin, and;	
	affected, or; constant or near-constant		no more than topical therapy required dur-	
	systemic therapy such as corticosteroids		ing the past 12-month period	(
	or other immunosuppressive drugs re-		7818 Malignant skin neoplasms (other than malig-	
	quired during the past 12-month period	60	nant melanoma):	
	20 to 40 percent of the entire body or 20 to		Rate as disfigurement of the head, face, or	
	40 percent of exposed areas affected, or;		neck (DC 7800), scars (DC's 7801, 7802,	
	systemic therapy such as corticosteroids		7803, 7804, or 7805), or impairment of	
	or other immunosuppressive drugs re-		function.	
	quired for a total duration of six weeks or		Note: If a skin malignancy requires therapy	
	more, but not constantly, during the past		that is comparable to that used for sys-	
	12-month period	30	temic malignancies, i.e., systemic chemo-	
	At least 5 percent, but less than 20 percent,		therapy, X-ray therapy more extensive	
	of the entire body, or at least 5 percent,		than to the skin, or surgery more exten-	
	but less than 20 percent, of exposed		sive than wide local excision, a 100-per-	
	areas affected, or; intermittent systemic		cent evaluation will be assigned from the	
	therapy such as corticosteroids or other		date of onset of treatment, and will con-	
	immunosuppressive drugs required for a		tinue, with a mandatory VA examination	
	total duration of less than six weeks dur-		six months following the completion of	
	ing the past 12-month period	10	such antineoplastic treatment, and any	
	Less than 5 percent of the entire body or		change in evaluation based upon that or	
	exposed areas affected, and; no more		any subsequent examination will be sub-	
	than topical therapy required during the		ject to the provisions of §3.105(e) of this	
	past 12-month period	0	chapter. If there has been no local recur-	
	Or rate as disfigurement of the head, face,	U	rence or metastasis, evaluation will then	
	or neck (DC 7800) or scars (DC's 7801,		be made on residuals. If treatment is con-	
	7802, 7803, 7804, or 7805), depending		fined to the skin, the provisions for a 100-	
			percent evaluation do not apply.	
017	upon the predominant disability.		7819 Benign skin neoplasms:	
817	Exfoliative dermatitis (erythroderma):		Rate as disfigurement of the head, face, or	
	Generalized involvement of the skin, plus		neck (DC 7800), scars (DC's 7801, 7802,	
	systemic manifestations (such as fever,		7803, 7804, or 7805), or impairment of	
	weight loss, and hypoproteinemia), and;		function.	
	constant or near-constant systemic ther-		7820 Infections of the skin not listed elsewhere (in-	
	apy such as therapeutic doses of		cluding bacterial, fungal, viral, treponemal and	
	corticosteroids, immunosuppressive		parasitic diseases):	
	retinoids, PUVA (psoralen with long-wave		• /	
	ultraviolet-A light) or UVB (ultraviolet-B		Rate as disfigurement of the head, face, or	
	light) treatments, or electron beam ther-		neck (DC 7800), scars (DC's 7801, 7802,	
	apy required during the past 12-month pe-		7803, 7804, or 7805), or dermatitis (DC	
	riod	100	7806), depending upon the predominant	
	Generalized involvement of the skin without		disability.	
	systemic manifestations, and; constant or		7821 Cutaneous manifestations of collagen-vas-	
	near-constant systemic therapy such as		cular diseases not listed elsewhere (including	
	therapeutic doses of corticosteroids, im-		scleroderma, calcinosis cutis, and dermato-	
	munosuppressive retinoids, PUVA		myositis):	
	(psoralen with long-wave ultraviolet-A		More than 40 percent of the entire body or	
	light) or UVB (ultraviolet-B light) treat-		more than 40 percent of exposed areas	
	ments, or electron beam therapy required		affected, or; constant or near-constant	
	during the past 12-month period	60	systemic therapy such as corticosteroids	
			or other immunosuppressive drugs re-	
			guired during the past 12-month period	6

	Det		Det
	Rat- ing		Rat- ing
20 to 40 percent of the entire body or 20 to 40 percent of exposed areas affected, or; systemic therapy such as corticosteroids or other immunosuppressive drugs required for a total duration of six weeks or more, but not constantly, during the past		With localized or episodic cutaneous in- volvement and intermittent systemic medi- cation, such as immunosuppressive retinoids, required for a total duration of less than six weeks during the past 12- month period	10
12-month period	30	No more than topical therapy required during the past 12-month period	10
of the entire body, or at least 5 percent, but less than 20 percent, of exposed areas affected, or; intermittent systemic		7825 Urticaria:  Recurrent debilitating episodes occurring at least four times during the past 12-month	Ū
therapy such as corticosteroids or other immunosuppressive drugs required for a total duration of less than six weeks dur- ing the past 12-month period	10	period despite continuous immuno- suppressive therapy Recurrent debilitating episodes occurring at	60
Less than 5 percent of the entire body or exposed areas affected, and; no more than topical therapy required during the	10	least four times during the past 12-month period, and; requiring intermittent sys- temic immunosuppressive therapy for	00
past 12-month period Or rate as disfigurement of the head, face, or neck (DC 7800) or scars (DC's 7801,	0	control  Recurrent episodes occurring at least four times during the past 12-month period, and; responding to treatment with antihis-	30
7802, 7803, 7804, or 7805), depending upon the predominant disability. 7822 Papulosquamous disorders not listed elsewhere (including lichen planus, large or small		tamines or sympathomimetics	10
plaque parapsoriasis, pityriasis lichenoides et varioliformis acuta (PLEVA), lymphomatoid papulosus, and pityriasis rubra pilaris (PRP)):		least four times during the past 12-month period despite continuous immunosuppressive therapy	60
More than 40 percent of the entire body or more than 40 percent of exposed areas affected, and; constant or near-constant systemic medications or intensive light		Recurrent debilitating episodes occurring at least four times during the past 12-month period, and; requiring intermittent systemic immunosuppressive therapy for	
therapy required during the past 12-month period	60	control	30
40 percent of exposed areas affected, or; systemic therapy or intensive light therapy required for a total duration of six weeks or more, but not constantly, during the		and; requiring intermittent systemic im- munosuppressive therapy for control Or rate as disfigurement of the head, face, or neck (DC 7800) or scars (DC's 7801,	10
past 12-month period	30	7802, 7803, 7804, or 7805), depending upon the predominant disability. 7827 Erythema multiforme; Toxic epidermal	
areas affected, or, systemic therapy or in- tensive light therapy required for a total duration of less than six weeks during the		necrolysis:  Recurrent debilitating episodes occurring at least four times during the past 12-month period despite ongoing immuno-	
past 12-month period Less than 5 percent of the entire body or exposed areas affected, and; no more than topical therapy required during the	10	suppressive therapy  Recurrent episodes occurring at least four times during the past 12-month period,	60
past 12-month period	0	and; requiring intermittent systemic im- munosuppressive therapy	30
7802, 7803, 7804, or 7805), depending upon the predominant disability.  7823 Vitiligo:		past 12-month period that respond to treatment with antihistamines or sympathomimetics, or; one to three epi- sodes occurring during the past 12-month	
With exposed areas affected	10	period requiring intermittent systemic im- munosuppressive therapy Or rate as disfigurement of the head, face, or neck (DC 7800) or scars (DC's 7801,	10
ment or systemic manifestations, and; constant or near-constant systemic medi- cation, such as immunosuppressive retinoids, required during the past 12-		7802, 7803, 7804, or 7805), depending upon the predominant disability.  7828 Acne: Deep acne (deep inflamed nodules and pus-	
month period	60	filled cysts) affecting 40 percent or more of the face and neck  Deep acne (deep inflamed nodules and pus-	30
intermittent systemic medication, such as immunosuppressive retinoids, required for a total duration of six weeks or more, but		filled cysts) affecting less than 40 percent of the face and neck, or; deep acne other than on the face and neck	10
not constantly, during the past 12-month period	30	Superficial acne (comedones, papules, pustules, superficial cysts) of any extent	0

				_
		Rat- ing		Ra in
	Or rate as disfigurement of the head, face, or neck (DC 7800) or scars (DC's 7801, 7802, 7803, 7804, or 7805), depending		Thyroid enlargement, tachycardia (more than 100 beats per minute), eye involvement, muscular weakness, loss of weight, and sympathetic	
	upon the predominant disability.		nervous system, cardiovascular, or	
7829	Chloracne:		astrointestinal symptoms	1
	Deep acne (deep inflamed nodules and pus-		Emotional instability, tachycardia, fatigability, and	
	filled cysts) affecting 40 percent or more		increased pulse pressure or blood pressure	
	of the face and neck	30	Tachycardia, tremor, and increased pulse pres-	
	Deep acne (deep inflamed nodules and pus-		sure or blood pressure	
	filled cysts) affecting less than 40 percent		Tachycardia, which may be intermittent, and trem-	
	of the face and neck, or; deep acne other		or, or; continuous medication required for con-	
	than on the face and neck	10	trol	
	Superficial acne (comedones, papules,		Note (1): If disease of the heart is the predominant	
	pustules, superficial cysts) of any extent	0	finding, evaluate as hyperthyroid heart disease	
	Or rate as disfigurement of the head, face,		(DC 7008) if doing so would result in a higher	
	or neck (DC 7800) or scars (DC's 7801,		evaluation than using the criteria above.  Note (2): If ophthalmopathy is the sole finding,	
	7802, 7803, 7804, or 7805), depending upon the predominant disability.		evaluate as field vision, impairment of (DC	
7830	Scarring alopecia:		6080); diplopia (DC 6090); or impairment of	
7000	Affecting more than 40 percent of the scalp	20	central visual acuity (DC 6061-6079).	
	Affecting 20 to 40 percent of the scalp	10	7901 Thyroid gland, toxic adenoma of	
	Affecting less than 20 percent of the scalp	0	Thyroid enlargement, tachycardia (more than 100	
7831		•	beats per minute), eye involvement, muscular	
	With loss of all body hair	10	weakness, loss of weight, and sympathetic	
	With loss of hair limited to scalp and face	0	nervous system, cardiovascular, or gastro-	
7832	Hyperhidrosis:		intestinal symptoms	1
	Unable to handle paper or tools because of		Emotional instability, tachycardia, fatigability, and increased pulse pressure or blood pressure	
	moisture, and unresponsive to therapy	30	Tachycardia, tremor, and increased pulse pres-	
	Able to handle paper or tools after therapy	0	sure or blood pressure	
7833	Malignant melanoma:		Tachycardia, which may be intermittent, and trem-	İ
	Rate as scars (DC's 7801, 7802, 7803,		or, or; continuous medication required for con-	
	7804, or 7805), disfigurement of the head,		trol	
	face, or neck (DC 7800), or impairment of		Note (1): If disease of the heart is the predominant	
	function (under the appropriate body sys-		finding, evaluate as hyperthyroid heart disease	
	tem).  Note: If a skin malignancy requires therapy		(DC 7008) if doing so would result in a higher	
	that is comparable to that used for sys-		evaluation than using the criteria above.	
	temic malignancies, <i>i.e.</i> , systemic chemo-		Note (2): If ophthalmopathy is the sole finding,	
	therapy, X-ray therapy more extensive		evaluate as field vision, impairment of (DC 6080); diplopia (DC 6090); or impairment of	
	than to the skin, or surgery more exten-		central visual acuity (DC 6061–6079).	
	sive than wide local excision, a 100-per-		7902 Thyroid gland, nontoxic adenoma of	İ
	cent evaluation will be assigned from the		With disfigurement of the head or neck	
	date of onset of treatment, and will con-		Without disfigurement of the head or neck	
	tinue, with a mandatory VA examination		NOTE: If there are symptoms due to pressure on	
	six months following the completion of		adjacent organs such as the trachea, larynx, or	
	such antineoplastic treatment, and any change in evaluation based upon that or		esophagus, evaluate under the diagnostic code	
	any subsequent examination will be sub-		for disability of that organ, if doing so would re-	
	ject to the provisions of § 3.105(e). If there		sult in a higher evaluation than using this diag-	
	has been no local recurrence or metas-		nostic code.	
	tasis, evaluation will then be made on re-		7903 Hypothyroidism Cold intolerance, muscular weakness, cardio-	
	siduals. If treatment is confined to the		vascular involvement, mental disturbance (de-	
	skin, the provisions for a 100-percent		mentia, slowing of thought, depression),	
	evaluation do not apply.		bradycardia (less than 60 beats per minute),	
			and sleepiness	1
(Ant	hority: 38 U.S.C. 1155)		Muscular weakness, mental disturbance, and	
			_ weight gain	
[67 F	'R 49596, July 31, 2002; 67 FR 58448,	58449,	Fatigability, constipation, and mental sluggishness	
	. 16, 2002; 73 FR 54710, Oct. 23, 2008;	$77~\mathrm{FR}$	Fatigability, or; continuous medication required for	
2910,	Jan. 20, 2012]		control	
			7904 Hyperparathyroidism  Generalized decalcification of bones, kidney	
	THE ENDOCRINE SYSTEM		stones, gastrointestinal symptoms (nausea,	
			vomiting, anorexia, constipation, weight loss, or	
§ 4.1	19 Schedule of ratings-endo	crine	peptic ulcer), and weakness	1
	system.		Gastrointestinal symptoms and weakness	
	-,		Continuous medication required for control	
		Rat-	Note: Following surgery or treatment, evaluate as	

Rat-ing

7900 Hyperthyroidism

NOTE: Following surgery or treatment, evaluate as digestive, skeletal, renal, or cardiovascular residuals or as endocrine dysfunction.

7905 Hypoparathyroidism

	Rat-		Rat-
	ing		ing
Marked neuromuscular excitability (such as convulsions, muscular spasms (tetany), or laryngeal stridor) plus either cataract or evidence of increased intracranial pressure (such as papilledema)  Marked neuromuscular excitability, or; paresthesias (of arms, legs, or circumoral area) plus either cataract or evidence of increased intracranial pressure  Continuous medication required for control  7907 Cushing's syndrome  As active, progressive disease including loss of muscle strength, areas of osteoporosis, hypertension, weakness, and enlargement of pituitary or adrenal gland  Loss of muscle strength and enlargement of pituitary or adrenal gland  With striae, obesity, moon face, glucose intolerance, and vascular fragility  NOTE: With recovery or control, evaluate as residuals of adrenal insufficiency or cardiovascular, psychiatric, skin, or skeletal complications under ampropriate diagnostic code	100 60 10 100 60 30	Note (1): An Addisonian "crisis" consists of the rapid onset of peripheral vascular collapse (with acute hypotension and shock), with findings that may include: anorexia; nausea; vomiting; dehydration; profound weakness; pain in abdomen, legs, and back; fever; apathy, and depressed mentation with possible progression to coma, renal shutdown, and death.  Note (2): An Addisonian "episode," for VA purposes, is a less acute and less severe event than an Addisonian crisis and may consist of anorexia, nausea, vomiting, diarrhea, dehydration, weakness, malaise, orthostatic hypotension, or hypoglycemia, but no peripheral vascular collapse.  Note (3): Tuberculous Addison's disease will be evaluated as active or inactive tuberculosis. If inactive, these evaluations are not to be combined with the graduated ratings of 50 percent or 30 percent for non-pulmonary tuberculosis specified under § 4.88b. Assign the higher rating.	ing
tions under appropriate diagnostic code. 7908 Acromegaly		Evaluate according to major manifestations. 7913 Diabetes mellitus	
Evidence of increased intracranial pressure (such as visual field defect), arthropathy, glucose intolerance, and either hypertension or cardio-		Requiring more than one daily injection of insulin, restricted diet, and regulation of activities (avoidance of strenuous occupational and rec-	
megalyintelegrance and human	100	reational activities) with episodes of ketoacidosis or hypoglycemic reactions requir-	
Arthropathy, glucose intolerance, and hyper- tension	60	ing at least three hospitalizations per year or	
Enlargement of acral parts or overgrowth of long bones, and enlarged sella turcica	20	weekly visits to a diabetic care provider, plus ei- ther progressive loss of weight and strength or	
7909 Diabetes insipidus	30	complications that would be compensable if separately evaluated	100
Polyuria with near-continuous thirst, and more than two documented episodes of dehydration		Requiring insulin, restricted diet, and regulation of	
requiring parenteral hydration in the past year Polyuria with near-continuous thirst, and one or	100	activities with episodes of ketoacidosis or hypo- glycemic reactions requiring one or two hos- pitalizations per year or twice a month visits to	
two documented episodes of dehydration re- quiring parenteral hydration in the past year Polyuria with near-continuous thirst, and one or	60	a diabetic care provider, plus complications that would not be compensable if separately evaluated	60
more episodes of dehydration in the past year not requiring parenteral hydration	40	Requiring insulin, restricted diet, and regulation of	40
Polyuria with near-continuous thirst	20	activities Requiring insulin and restricted diet, or; oral hypo-	40
7911 Addison's disease (Adrenal Cortical Hypofunction)		glycemic agent and restricted diet	20 10
Four or more crises during the past year	60	Note (1): Evaluate compensable complications of diabetes separately unless they are part of the	
Three crises during the past year, or; five or more episodes during the past year	40	criteria used to support a 100 percent evalua-	
One or two crises during the past year, or; two to		tion. Noncompensable complications are con- sidered part of the diabetic process under diag-	
four episodes during the past year, or; weak- ness and fatigability, or; corticosteroid therapy		nostic code 7913.	
required for control	20	Note (2): When diabetes mellitus has been conclu- sively diagnosed, do not request a glucose tol-	
		erance test solely for rating purposes. 7914 Neoplasm, malignant, any specified part of the	
		endocrine system	100
		NOTE: A rating of 100 percent shall continue be- yond the cessation of any surgical, X-ray,	
		antineoplastic chemotherapy or other thera-	
		peutic procedure. Six months after discontinu- ance of such treatment, the appropriate dis-	
		ability rating shall be determined by mandatory	
		VA examination. Any change in evaluation based upon that or any subsequent examina-	
		tion shall be subject to the provisions of	
		§3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residu-	
		als.	
		7915 Neoplasm, benign, any specified part of the en- docrine system rate as residuals of endocrine dys- function.	
		tunction.	I

	Ra
7916 Hyperpituitarism (prolactin secreting pituitary dysfunction) 7917 Hyperaldosteronism (benign or malignant) 7918 Pheochromocytoma (benign or malignant) NOTE: Evaluate diagnostic codes 7916, 7917, and 7918 as malignant or benign neoplasm as appropriate. 7919 C-cell hyperplasia of the thyroid NOTE: A rating of 100 percent shall continue beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. Six months after discontinuance of such treatment, the appropriate disability rating shall be determined by mandatory VA examination. Any change in evaluation based upon that or any subsequent examination shall be subject to the provisions of § 3.105(e) of this chapter. If there has been no local recurrence or metastasis, rate on residuals.	1
	1

[61 FR 20446, May 7, 1996]

NEUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS

#### § 4.120 Evaluations by comparison.

Disability in this field is ordinarily to be rated in proportion to the impairment of motor, sensory or mental function. Consider especially psychotic manifestations, complete or partial loss of use of one or more extremities, speech disturbances, impairment of vision, disturbances of gait, tremors, visceral manifestations, injury to the skull, etc. In rating disability from the conditions in the preceding sentence refer to the appropriate schedule. In rating peripheral nerve injuries and their residuals, attention should be given to the site and character of the injury, the relative impairment in motor function, trophic changes, or sensory disturbances.

#### § 4.121 Identification of epilepsy.

When there is doubt as to the true nature of epileptiform attacks, neurological observation in a hospital adequate to make such a study is necessary. To warrant a rating for epilepsy, the seizures must be witnessed or verified at some time by a physician. As to frequency, competent, consistent lay testimony emphasizing convulsive and immediate post-convulsive characteristics may be accepted. The frequency of seizures should be ascertained under the ordinary conditions of life (while not hospitalized).

#### § 4.122 Psychomotor epilepsy.

The term psychomotor epilepsy refers to a condition that is characterized by seizures and not uncommonly by a chronic psychiatric disturbance as well.

(a) Psychomotor seizures consist of episodic alterations in conscious control that may be associated with automatic states, generalized convulsions, random motor movements (chewing, lip smacking, fumbling), hallucinatory phenomena (involving taste, smell, sound, vision), perceptual illusions (deja vu, feelings of loneliness, strangeness, macropsia, micropsia, dreamy states), alterations in thinking (not open to reason), alterations in memory, abnormalities of mood or affect (fear, alarm, terror, anger, dread, wellbeing), and autonomic disturbances (sweating, pallor, flushing of the face, visceral phenomena such as nausea, vomiting, defecation, a rising feeling of warmth in the abdomen). Automatic states or automatisms are characterized by episodes of irrational, irrelevant. disjointed. unconventional. asocial, purposeless though seemingly coordinated and purposeful, confused or inappropriate activity of one to several minutes (or, infrequently, hours) duration with subsequent amnesia for the seizure. Examples: A person of high social standing remained seated, muttered angrily, and rubbed the arms of his chair while the National Anthem was being played; an apparently normal person suddenly disrobed in public; a man traded an expensive automobile for an antiquated automobile in poor mechanical condition and after regaining conscious control, discovered that he had signed an agreement to pay an additional sum of money in the trade. The seizure manifestations of psychomotor epilepsy vary from patient to patient and in the same patient from seizure to seizure.

(b) A chronic mental disorder is not uncommon as an interseizure manifestation of psychomotor epilepsy and may include psychiatric disturbances extending from minimal anxiety to severe personality disorder (as distinguished from developmental) or almost complete personality disintegration (psychosis). The manifestations of a chronic mental disorder associated

with psychomotor epilepsy, like those of the seizures, are protean in character.

#### §4.123 Neuritis, cranial or peripheral.

Neuritis, cranial or peripheral, characterized by loss of reflexes, muscle atrophy, sensory disturbances, and constant pain, at times excruciating, is to be rated on the scale provided for injury of the nerve involved, with a maximum equal to severe, incomplete, paralysis. See nerve involved for diagnostic code number and rating. The maximum rating which may be assigned for neuritis not characterized by organic changes referred to in this section will be that for moderate, or with sciatic nerve involvement, for moderately severe, incomplete paralysis.

# § 4.124 Neuralgia, cranial or peripheral.

Neuralgia, cranial or peripheral, characterized usually by a dull and intermittent pain, of typical distribution so as to identify the nerve, is to be rated on the same scale, with a maximum equal to moderate incomplete paralysis. See nerve involved for diagnostic code number and rating. Tic douloureux, or trifacial neuralgia, may be rated up to complete paralysis of the affected nerve.

#### §4.124a Schedule of ratings—neurological conditions and convulsive disorders.

[With the exceptions noted, disability from the following diseases and their residuals may be rated from 10 percent to 100 percent in proportion to the impairment of motor, sensory, or mental function. Consider especially psychotic manifestations, complete or partial loss of use of one or more extremities, speech disturbances, impairment of vision, disturbances of gait, tremors, visceral manifestations, etc., referring to the appropriate bodily system of the schedule. With partial loss of use of one or more extremities from neurological lesions, rate by comparison with the mild, moderate, severe, or complete paralysis of peripheral nerves]

# ORGANIC DISEASES OF THE CENTRAL NERVOUS SYSTEM

	Rat- ing
8000 Encephalitis, epidemic, chronic: As active febrile disease	100

### ORGANIC DISEASES OF THE CENTRAL NERVOUS SYSTEM—Continued

	Rat- ing
Rate residuals, minimum	10
Brain, new growth of:	
8002 Malignant	100
NOTE: The rating in code 8002 will be continued	
for 2 years following cessation of surgical, chemotherapeutic or other treatment modality.	
At this point, if the residuals have stabilized,	
the rating will be made on neurological residu-	
als according to symptomatology.	
Minimum rating	30
8003 Benign, minimum	60
Rate residuals, minimum	10
8004 Paralysis agitans:	
Minimum rating	30
8005 Bulbar palsy	100
. ,	
8008 Brain, vessels, thrombosis of. 8009 Brain, vessels, hemorrhage from:	
Rate the vascular conditions under Codes 8007	
through 8009, for 6 months	100
Rate residuals, thereafter, minimum	10
B010 Myelitis:	
Minimum rating	10
8011 Poliomyelitis, anterior:	
As active febrile disease	100
Rate residuals, minimum	10
B012 Hematomyelia:	
For 6 months	100
Rate residuals, minimum	10
8013 Syphilis, cerebrospinal.	
8014 Syphilis, meningovascular.	
8015 Tabes dorsalis.	
NOTE: Rate upon the severity of convulsions, pa- ralysis, visual impairment or psychotic involve-	
ment, etc.	
8017 Amyotrophic lateral sclerosis	100
NOTE: Consider the need for special monthly	
compensation.	
·	
Minimum rating	30
Minimum rating	
Minimum rating 8019 Meningitis, cerebrospinal, epidemic: As active febrile disease	100
Minimum rating	100
Minimum rating  8019 Meningitis, cerebrospinal, epidemic: As active febrile disease  Rate residuals, minimum  8020 Brain, abscess of:	100
Minimum rating  8019 Meningitis, cerebrospinal, epidemic: As active febrile disease  Rate residuals, minimum  8020 Brain, abscess of: As active disease	100
Minimum rating	100
Minimum rating	100 10 100 100
Minimum rating 8019 Meningitis, cerebrospinal, epidemic: As active febrile disease Rate residuals, minimum 8020 Brain, abscess of: As active disease Rate residuals, minimum Spinal cord, new growths of: 8021 Malignant	100 10 100 100
Minimum rating  8019 Meningitis, cerebrospinal, epidemic: As active febrile disease Rate residuals, minimum  8020 Brain, abscess of: As active disease Rate residuals, minimum  Spinal cord, new growths of:  8021 Malignant  NOTE: The rating in code 8021 will be continued for 2 years following cessation of surgical.	100 10 100 100
Minimum rating 8019 Meningitis, cerebrospinal, epidemic: As active febrile disease Rate residuals, minimum 8020 Brain, abscess of: As active disease Rate residuals, minimum Spinal cord, new growths of: 8021 Malignant NOTE: The rating in code 8021 will be continued for 2 years following cessation of surgical, chemotherapeutic or other treatment modality.	100 10 100 100
Minimum rating  8019 Meningitis, cerebrospinal, epidemic: As active febrile disease Rate residuals, minimum  8020 Brain, abscess of: As active disease Rate residuals, minimum Spinal cord, new growths of:  8021 Malignant NOTE: The rating in code 8021 will be continued for 2 years following cessation of surgical, chemotherapeutic or other treatment modality. At this point, if the residuals have stabilized,	100 10 100 100
Minimum rating	100 10 100 100
Minimum rating 8019 Meningitis, cerebrospinal, epidemic: As active febrile disease Rate residuals, minimum 8020 Brain, abscess of: As active disease Rate residuals, minimum Spinal cord, new growths of: 8021 Malignant NOTE: The rating in code 8021 will be continued for 2 years following cessation of surgical, chemotherapeutic or other treatment modality. At this point, if the residuals have stabilized, the rating will be made on neurological residuals according to symptomatology.	100 100 100 100
Minimum rating 8019 Meningitis, cerebrospinal, epidemic: As active febrile disease Rate residuals, minimum 8020 Brain, abscess of: As active disease Rate residuals, minimum Spinal cord, new growths of: 8021 Malignant NOTE: The rating in code 8021 will be continued for 2 years following cessation of surgical, chemotherapeutic or other treatment modality. At this point, if the residuals have stabilized, the rating will be made on neurological residuals according to symptomatology. Minimum rating	100 100 100 100
Minimum rating  8019 Meningitis, cerebrospinal, epidemic: As active febrile disease Rate residuals, minimum  8020 Brain, abscess of: As active disease Rate residuals, minimum Spinal cord, new growths of:  8021 Malignant  NOTE: The rating in code 8021 will be continued for 2 years following cessation of surgical, chemotherapeutic or other treatment modality. At this point, if the residuals have stabilized, the rating will be made on neurological residuals according to symptomatology.  Minimum rating  8022 Benign, minimum rating	100 10 100 100 100 30 60
Minimum rating  8019 Meningitis, cerebrospinal, epidemic: As active febrile disease Rate residuals, minimum  8020 Brain, abscess of: As active disease Rate residuals, minimum  Spinal cord, new growths of:  8021 Malignant  NOTE: The rating in code 8021 will be continued for 2 years following cessation of surgical, chemotherapeutic or other treatment modality. At this point, if the residuals have stabilized, the rating will be made on neurological residuals according to symptomatology.  Minimum rating  8022 Benign, minimum rating Rate residuals, minimum	100 10 100 100 100 30 60
Minimum rating 8019 Meningitis, cerebrospinal, epidemic: As active febrile disease Rate residuals, minimum 8020 Brain, abscess of: As active disease Rate residuals, minimum Spinal cord, new growths of: 8021 Malignant NOTE: The rating in code 8021 will be continued for 2 years following cessation of surgical, chemotherapeutic or other treatment modality. At this point, if the residuals have stabilized, the rating will be made on neurological residuals according to symptomatology. Minimum rating 8022 Benign, minimum rating Rate residuals, minimum 8023 Progressive muscular atrophy:	100 100 100 100 100 100
Minimum rating 8019 Meningitis, cerebrospinal, epidemic: As active febrile disease Rate residuals, minimum 8020 Brain, abscess of: As active disease Rate residuals, minimum Spinal cord, new growths of: 8021 Malignant NOTE: The rating in code 8021 will be continued for 2 years following cessation of surgical, chemotherapeutic or other treatment modality. At this point, if the residuals have stabilized, the rating will be made on neurological residuals according to symptomatology. Minimum rating 8022 Benign, minimum rating Rate residuals, minimum 8023 Progressive muscular atrophy: Minimum rating Minimum rating Minimum rating Minimum rating Minimum rating Minimum rating Minimum rating Minimum rating	100 100 100 100 100 100
Minimum rating  8019 Meningitis, cerebrospinal, epidemic: As active febrile disease Rate residuals, minimum  8020 Brain, abscess of: As active disease Rate residuals, minimum Spinal cord, new growths of:.  8021 Malignant  NOTE: The rating in code 8021 will be continued for 2 years following cessation of surgical, chemotherapeutic or other treatment modality. At this point, if the residuals have stabilized, the rating will be made on neurological residuals according to symptomatology.  Minimum rating  8022 Benign, minimum rating Rate residuals, minimum  8023 Progressive muscular atrophy: Minimum rating Minimum rating Minimum rating Minimum rating S024 Syringomyelia:	100 100 100 100 100 300 600 100
Minimum rating 8019 Meningitis, cerebrospinal, epidemic: As active febrile disease Rate residuals, minimum 8020 Brain, abscess of: As active disease Rate residuals, minimum Spinal cord, new growths of: 8021 Malignant NOTE: The rating in code 8021 will be continued for 2 years following cessation of surgical, chemotherapeutic or other treatment modality. At this point, if the residuals have stabilized, the rating will be made on neurological residuals according to symptomatology. Minimum rating 8022 Benign, minimum rating Rate residuals, minimum 8023 Progressive muscular atrophy: Minimum rating Minimum rating Minimum rating Minimum rating Minimum rating Minimum rating Minimum rating Minimum rating	300 1000 1000 1000 1000 300 300 300 300

§4.124a

### ORGANIC DISEASES OF THE CENTRAL NERVOUS SYSTEM—Continued

ing

# ORGANIC DISEASES OF THE CENTRAL NERVOUS SYSTEM—Continued

NOTE: It is required for the minimum ratings for residuals under diagnostic codes 8000–8025, that there be ascertainable residuals. Determinations as to the presence of residuals not capable of objective verification, *i.e.*, headaches, dizziness, fatigability, must be approached on the basis of the diagnosis recorded; subjective residuals will be accepted

proached on the basis of the diagnosis recorded; subjective residuals will be accepted when consistent with the disease and not more likely attributable to other disease or no disease. It is of exceptional importance that when ratings in excess of the prescribed minimum ratings are assigned, the diagnostic codes utilized as bases of evaluation be cited, in addition to the codes identifying the diag-

8045 Residuals of traumatic brain injury (TBI):

There are three main areas of dysfunction that may result from TBI and have profound effects on functioning: cognitive (which is common in varying degrees after TBI), emotional/behavioral, and physical. Each of these areas of dysfunction may require evaluation.

Cognitive impairment is defined as decreased memory, concentration, attention, and executive functions of the brain. Executive functions are goal setting, speed of information processing, planning, organizing, prioritizing, self-monitoring, problem solving, judgment, decision making, spontaneity, and flexibility in changing actions when they are not productive. Not all of these brain functions may be affected in a given individual with cognitive impairment, and some functions may be affected more severely than others. In a given individual, symptoms may fluctuate in severity from day to day. Evaluate cognitive impairment under the table titled "Evaluation of Cognitive Impairment and Other Residuals of TBI Not Otherwise Classified."

Subjective symptoms may be the only residual of TBI or may be associated with cognitive impairment or other areas of dysfunction. Evaluate subjective symptoms that are residuals of TBI, whether or not they are part of cognitive impairment, under the subjective symptoms facet in the table titled "Evaluation of Cognitive Impairment and Other Residuals of TBI Not Otherwise Classified." However, separately evaluate any residual with a distinct diagnosis that may be evaluated under another diagnostic code, such as migraine headache or Meniere's disease, even if that diagnosis is based on subjective symptoms, rather than under the "Evaluation of Cognitive Impairment and Other Residuals of TBI Not Otherwise Classified" table.

Evaluate emotional/behavioral dysfunction under § 4.130 (Schedule of ratings—mental disorders) when there is a diagnosis of a mental disorder. When there is no diagnosis of a mental disorder, evaluate emotional/behavioral symptoms under the criteria in the table titled "Evaluation of Cognitive Impairment and Other Residuals of TBI Not Otherwise Classified.".

Evaluate physical (including neurological) dysfunction based on the following list, under an appropriate diagnostic code: Motor and sensory dysfunction, including pain, of the extremities and face; visual impairment; hearing loss and tinnitus; loss of sense of smell and taste; seizures; gait, coordination, and balance problems; speech and other communication difficulties, including aphasia and related disorders, and dysarthria; neurogenic bladder; neurogenic bowel; cranial nerve dysfunctions; autonomic nerve dysfunctions; and endocrine dysfunctions.

The preceding list of types of physical dysfunction does not encompass all possible residuals of TBI. For residuals not listed here that are reported on an examination, evaluate under the most appropriate diagnostic code. Evaluate each condition separately, as long as the same signs and symptoms are not used to support more than one evaluation, and combine under \$4.25 the evaluations for each separately rated condition. The evaluation assigned based on the "Evaluation of Cognitive Impairment and Other Residuals of TBI Not Otherwise Classified" table will be considered the evaluation for a single condition for purposes of combining with other disability evaluations.

Consider the need for special monthly compensation for such problems as loss of use of an extremity, certain sensory impairments, erectile dysfunction, the need for aid and attendance (including for protection from hazards or dangers incident to the daily environment due to cognitive impairment), being housebound, etc.

#### 38 CFR Ch. I (7-1-16 Edition)

ing

#### §4.124a

# ORGANIC DISEASES OF THE CENTRAL NERVOUS SYSTEM—Continued

	Rat- ing
Evaluation of Cognitive Impairment and Subjective Symptoms	

The table titled "Evaluation of Cognitive Impairment and Other Residuals of TBI Not Otherwise Classified" contains 10 important facets of TBI related to cognitive impairment and subjective symptoms. It provides criteria for levels of impairment for each facet, as appropriate, ranging from 0 to 3, and a 5th level, the highest level of impairment, labeled "total." However, not every facet has every level of severity. The Consciousness facet, for example, does not provide for an impairment level other than "total," since any level of impaired consciousness would be totally disabling. Assign a 100-percent evaluation if "total" is the level of evaluation for one or more facets. If no facet is evaluated as "total," assign the overall percentage evaluation based on the level of the highest facet as follows: 0 = 0 percent; 1 = 10 percent; 2 = 40 percent; and 3 = 70 percent. For example, assign a 70 percent evaluation if 3 is the highest level of evaluation for any facet.

Note (1): There may be an overlap of manifestations of conditions evaluated under the table titled "Evaluation Of Cognitive Impairment And Other Residuals Of TBI Not Otherwise Classified" with manifestations of a comorbid mental or neurologic or other physical disorder that can be separately evaluated under another diagnostic code. In such cases, do not assign more than one evaluation based on the same manifestations. If the manifestations of two or more conditions cannot be clearly separated, assign a single evaluation under whichever set of diagnostic criteria allows the better assessment of overall impaired functioning due to both conditions. However, if the manifestations are clearly separatele, assign a separate evaluation for each condition.

Note (2): Symptoms listed as examples at certain evaluation levels in the table are only examples and are not symptoms that must be present in order to assign a particular evaluation.

Note (3): "Instrumental activities of daily living" refers to activities other than self-care that are needed for independent living, such as meal preparation, doing housework and other chores, shopping, traveling, doing laundry, being responsible for one's own medications, and using a telephone. These activities are distinguished from "Activities of daily living," which refers to basic self-care and includes bathing or showering, dressing, eating, getting in or out of bed or a chair, and using the toilet.

Note (4): The terms "mild," "moderate," and "severe" TBI, which may appear in medical records, refer to a classification of TBI made at, or close to, the time of injury rather than to the current level of functioning. This classification does not affect the rating assigned under diagnostic code

# ORGANIC DISEASES OF THE CENTRAL NERVOUS SYSTEM—Continued

Note (5): A veteran whose residuals of TBI are rated under a version of §4.124a, diagnostic code 8045, in effect before Octoagricult code 50-5, in short school 50-5 ber 23, 2008 may request review under diagnostic code 8045, irrespective of whether his or her disability has worsened since the last review. VA will review that veteran's disability rating to determine whether the veteran may be entitled to a higher disability rating under diagnostic code 8045. A request for review pursuant to this note will be treated as a claim for an increased rating for purposes of determining the effective date of an increased rating awarded as a result of such review however, in no case will the award be effective before October 23, 2008. For the purposes of determining the effective date of an increased rating awarded as a result of such review, VA will apply 38 CFR 3.114, if applicable..

#### 8046 Cerebral arteriosclerosis:

Purely neurological disabilities, such as hemiplegia, cranial nerve paralysis, etc., due to cerebral arteriosclerosis will be rated under the diagnostic codes dealing with such specific disabilities, with citation of a hyphenated diagnostic code (e.g., 8046–8207).

Purely subjective complaints such as headache, dizziness, tinnitus, insomnia and irritability, recognized as symptomatic of a properly diagnosed cerebral arteriosclerosis, will be rated 10 percent and no more under diagnostic code 9305. This 10 percent rating will not be combined with any other rating for a disability due to cerebral or generalized arteriosclerosis. Ratings in excess of 10 percent for cerebral arteriosclerosis under diagnostic code 9305 are not assignable in the absence of a diagnosis of multi-infarct dementia with cerebral arteriosclerosis.

NOTE: The ratings under code 8046 apply only when the diagnosis of cerebral arteriosclerosis is substantiated by the entire clinical picture and not solely on findings of retinal arteriosclerosis.

# EVALUATION OF COGNITIVE IMPAIRMENT AND OTHER RESIDUALS OF TBI NOT OTHERWISE CLASSIFIED

Facets of cognitive impairment and other residuals of TBI not otherwise classified	Level of im- pair- ment	Criteria
Memory, attention, con- centration, executive functions.	0	No complaints of impairment of memory, attention, concentration, or executive functions.

§4.124a

EVALUATION OF COGNITIVE IMPAIRMENT AND OTHER RESIDUALS OF TBI NOT OTHERWISE CLASSIFIED—Continued

EVALUATION OF COGNITIVE IMPAIRMENT AND OTHER RESIDUALS OF TBI NOT OTHERWISE CLASSIFIED—Continued

Facets of cognitive impairment and other residuals of TBI not otherwise classified	Level of im- pair- ment	Criteria	Facets of cognitive impairment and other residuals of TBI not otherwise classified	Level of im- pair- ment	Criteria
	2	A complaint of mild loss of memory (such as having difficulty following a conversation, recalling recent conversations, remembering names of new acquaintances, or finding words, or often misplacing items), attention, concentration, or executive functions, but without objective evidence on testing. Objective evidence on testing of mild impairment of memory, attention, concentration, or executive functions resulting in mild functional impairment. Objective evidence on testing of moderate impairment of memory, attention, concentration, or executive functions resulting in moderate functional impairment.	Social interaction	Total	Moderately severely impaired judgment. For even routine and familiar decisions, occasionally unable to identify, understand, and weigh the alternatives, understand the consequences of choices, and make a reasonable decision.  Severely impaired judgment. For even routine and familiar decisions, usually unable to identify, understand, and weigh the alternatives, understand the consequences of choices, and make a reasonable decision. For example, unable to determine appropriate clothing for current weather conditions or judge when to avoid dangerous situations or activities.
	Total	Objective evidence on testing of severe im-		1	tinely appropriate. Social interaction is oc-
		pairment of memory, attention, concentra- tion, or executive func-		2	casionally inappro- priate. Social interaction is fre-
		tions resulting in se- vere functional impair- ment.		3	quently inappropriate. Social interaction is inappropriate most or all of
Judgment	0	Normal.			the time.
·	2	Mildly impaired judgment. For complex or unfamiliar decisions, occasionally unable to identify, understand, and weigh the alternatives, understand the consequences of choices, and make a reasonable decision. Moderately impaired judgment. For complex or unfamiliar decisions,	Orientation	0 1 2	Always oriented to person, time, place, and situation.  Occasionally disoriented to one of the four aspects (person, time, place, situation) of orientation.  Occasionally disoriented to two of the four aspects (person, time, place, situation) of orientation or often dis-
		usually unable to iden- tify, understand, and weigh the alternatives, understand the con- sequences of choices, and make a reason- able decision, although has little difficulty with simple decisions.		3 Total	oriented to one aspect of orientation.  Often disoriented to two or more of the four aspects (person, time, place, situation) of orientation.  Consistently disoriented to two or more of the four aspects (person, time, place, situation) of orientation.

#### 38 CFR Ch. I (7-1-16 Edition)

#### §4.124a

EVALUATION OF COGNITIVE IMPAIRMENT AND OTHER RESIDUALS OF TBI NOT OTHERWISE CLASSIFIED—Continued

Level of im-pair-ment Facets of cognitive impairment and other residuals of TBI not otherwise classified Criteria Motor activity (with intact Motor activity normal. motor and sensory sys-Motor activity normal most of the time, but mildly slowed at times due to apraxia (inability to perform pre-viously learned motor activities, despite normal motor function). Motor activity mildly decreased or with moderate slowing due to apraxia. 3 Motor activity moderately decreased due to apraxia. Motor activity severely Total decreased due to apraxia. Visual spatial orientation 0 Normal. Mildly impaired. Occa-sionally gets lost in un-familiar surroundings, has difficulty reading maps or following directions. Is able to use assistive devices such as GPS (global positioning system). Moderately impaired. Usually gets lost in unfamiliar surroundings, has difficulty reading maps, following directions, and judging distance. Has difficulty using assistive devices such as GPS (global positioning system). Moderately severely impaired. Gets lost even in familiar sur-roundings, unable to use assistive devices such as GPS (global positioning system).
Severely impaired. May be unable to touch or Total name own body parts when asked by the ex-aminer, identify the rel-ative position in space of two different objects, or find the way from one room to another in a familiar enviEVALUATION OF COGNITIVE IMPAIRMENT AND OTHER RESIDUALS OF TBI NOT OTHERWISE CLASSIFIED—Continued

Facets of cognitive impairment and other residuals of TBI not otherwise classified	Level of im- pair- ment	Criteria
Subjective symptoms	0	Subjective symptoms that do not interfere with work; instrumental activities of daily living; or work, family, or other close relationships. Examples are: mild or occasional headaches, mild anxiety.
	1	Three or more subjective symptoms that mildly interfere with work; instrumental activities of daily living; or work, family, or other close relationships. Examples of findings that might be seen at this level of impairment are: intermittent dizziness, daily mild to moderate headaches, tinnitus, frequent insomnia, hypersensitivity to sound, hypersensitivity to light.
	2	Three or more subjective symptoms that moderately interfere with work; instrumental activities of daily living; or work, family, or other close relationships. Examples of findings that might be seen at this level of impairment are: marked fatigability, blurred or double vision, headaches requiring rest periods during most days.

§4.124a

Facets of cognitive impairment and other residuals of TBI not otherwise classified	Level of im- pair- ment	Criteria	Facets of cognitive impairment and other residuals of TBI not otherwise classified	Level of im- pair- ment	Criteria	
Neurobehavioral effects	1 2 2	One or more neurobehavioral effects that do not interfere with workplace interaction. Examples of neurobehavioral effects are: Irritability, impulsivity, unpredictability, lack of motivation, verbal aggression, belligerence, apathy, lack of empathy, lack of cooperation, inflexibility, and impaired awareness of disability. Any of these effects may range from slight to severe, although verbal and physical aggression are likely to have a more serious impact on workplace interaction and social interaction than some of the other effects.  One or more neurobehavioral effects that occasionally interfere with workplace interaction, or both but do not preclude them.  One or more neurobehavioral effects that frequently interfere with workplace interaction, social interaction, or both but do not preclude them.  One or more neurobehavioral effects that frequently interfere with workplace interaction, social interaction, or both but do not preclude them.  One or more neurobehavioral effects that interfere with workplace interaction, or both but do not preclude them.  One or more neurobehavioral effects that interfere with or preclude them.  One or more neurobehavioral effects that interfere with or preclude them.  One or more neurobehavioral effects that interfere with or preclude interaction, social interaction, social interaction, or both on most	Consciousness	2	either by spoken I guage, written lan guage, written lan guage, or both, m than occasionally less than half of the time, or to comprehend spoken Is guage, written lan guage, or both, m than occasionally less than half of the time. Can general communicate com ideas. Inability to communicate ither by spoken I guage, written lan guage, or both, at least half of the time to the tor to comprehend ken language, written land the tor to comprehend ken language, or both least half of the time than the time than the tor to comprehend the staff of the time than the time than the tor the time than the time that the time than the time than the time than the time than the time than the time that the time th	of
Communication	0	days or that occasion- ally require supervision for safety of self or others.  Able to communicate by spoken and written	MISCELLAI	VEOUS	such as vegetative state, minimally responsive state, co	e-
		language (expressive communication), and to comprehend spoken and written language.				Rat-

#### 38 CFR Ch. I (7-1-16 Edition)

#### §4.124a

#### MISCELLANEOUS DISEASES—Continued

#### DISEASES OF THE CRANIAL NERVES

	R:
Disability from lesions of peripheral portions of first, second, third, fourth, sixth, and eighth nerves will be rated under the Organs of Special Sense. The ratings for the cranial nerves are for unilateral involvement; when bilateral, combine but without the bilateral factor.  Fifth (trigeminal) cranial nerve  8205 Paralysis of:	
Complete	
Incomplete, severe	
Note: Dependent upon relative degree of sen-	
sory manifestation or motor loss.	
8305 Neuritis.	
8405 Neuralgia.	
NOTE: Tic douloureux may be rated in accord- ance with severity, up to complete paralysis. Seventh (facial) cranial nerve 8207 Paralysis of:	
Complete	
Incomplete, severe	
Incomplete, moderate	
8307 Neuritis.	
8407 Neuralgia. Ninth (glossopharyngeal) cranial nerve.	
8209 Paralysis of:	
Complete	
Incomplete, severe	
Incomplete, moderate	

#### DISEASES OF THE CRANIAL NERVES—Continued

		Rat- ing
N	OTE: Dependent upon relative loss of ordinary sensation in mucous membrane of the pharynx, fauces, and tonsils.	
8309	Neuritis.	
8409	Neuralgia.	
Т	enth (pneumogastric, vagus) cranial nerve.	
8210	Paralysis of:	
С	complete	50
In	ncomplete, severe	30
In	ncomplete, moderate	10
N	IOTE: Dependent upon extent of sensory and	
	motor loss to organs of voice, respiration,	
	pharynx, stomach and heart.	
8310	Neuritis.	
	Neuralgia.	
Е	leventh (spinal accessory, external branch) cra-	
	nial nerve.	
	Paralysis of:	
	complete	30
	ncomplete, severe	20
	ncomplete, moderate	10
N	OTE: Dependent upon loss of motor function of	
	sternomastoid and trapezius muscles.	
	Neuritis.	
	Neuralgia.	
	welfth (hypoglossal) cranial nerve.	
	Paralysis of:	
	complete	50
	ncomplete, severe	30
	ncomplete, moderate	10
N	IOTE: Dependent upon loss of motor function of	
0010	tongue.	
	Neuritis.	
0412	Neuralgia.	

#### DISEASES OF THE PERIPHERAL NERVES

	Rat	ina
Schedule of ratings	паі	iiig
	Major	Minor
The term "incomplete paralysis," with this and other peripheral nerve injuries, indicates a degree of lost or impaired function substantially less than the type picture for complete paralysis given with each nerve, whether due to varied level of the nerve lesion or to partial regeneration. When the involvement is wholly sensory, the rating should be for the mild, or at most, the moderate degree. The ratings for the peripheral nerves are for unilateral involvement; when bilateral, combine with application of the bilateral factor.  Upper radicular group (fifth and sixth cervicals)		
8510 Paralysis of: Complete; all shoulder and elbow movements lost or severely affected, hand and wrist movements not affected	70 50 40 20	60 40 30 20

30 20 10

#### DISEASES OF THE PERIPHERAL NERVES— Continued

# DISEASES OF THE PERIPHERAL NERVES—Continued

Schedule of ratings	Rating Ratings		Schedule of ratings	Rating	
Scriedule of ratings	Major	Minor	Scriedule of fattings	Major	Mino
8610 Neuritis. 8710 Neuralgia.			8614 Neuritis. 8714 Neuralgia.		
Middle radicular group			NOTE: Lesions involving only "dissocia	ation of e	xtenso
B511 Paralysis of:			communis digitorum" and "paralysis sor communis digitorum," will not e	below the	exten
Complete; adduction, abduction and			erate rating under code 8514.	xceeu iii	e mou
rotation of arm, flexion of elbow, and			•		
extension of wrist lost or severely af-			The median nerve		
fected	70	60	8515 Paralysis of:		
Incomplete:			Complete; the hand inclined to the ulnar side, the index and middle fin-		
Severe	50	40	gers more extended than normally,		
Moderate Mild	40 20	30 20	considerable atrophy of the muscles		
3611 Neuritis.	20	20	of the thenar eminence, the thumb		
3711 Neuralgia.			in the plane of the hand (ape hand);		
-			pronation incomplete and defective, absence of flexion of index finger		
Lower radicular group			and feeble flexion of middle finger,		
B512 Paralysis of:			cannot make a fist, index and mid-		
Complete; all intrinsic muscles of			dle fingers remain extended; cannot		
hand, and some or all of flexors of wrist and fingers, paralyzed (sub-			flex distal phalanx of thumb, defec- tive opposition and abduction of the		
stantial loss of use of hand)	70	60	thumb, at right angles to palm; flex-		
Incomplete:			ion of wrist weakened; pain with		
Severe	50	40	trophic disturbances	70	(
Moderate	40	30	Incomplete:		
Mild	20	20	Severe	50 30	4
3612 Neuritis.			ModerateMild	10	2
3712 Neuralgia.			8615 Neuritis.	10	·
All radicular groups			8715 Neuralgia.		
3513 Paralysis of:			The ulnar nerve		
Complete	90	80	8516 Paralysis of:		
Incomplete:			Complete; the "griffin claw" deformity,		
Severe	70	60	due to flexor contraction of ring and		
Moderate	40	30	little fingers, atrophy very marked in dorsal interspace and thenar and		
Mild	20	20	hypothenar eminences; loss of ex-		
3613 Neuritis. 3713 Neuralgia.			tension of ring and little fingers can-		
3713 Neuraigia.			not spread the fingers (or reverse),		
The musculospiral nerve (radial nerve)			cannot adduct the thumb; flexion of wrist weakened	60	5
3514 Paralysis of:			Incomplete:	60	
Complete; drop of hand and fingers,			Severe	40	3
wrist and fingers perpetually flexed, the thumb adducted falling within the			Moderate	30	2
line of the outer border of the index			Mild	10	1
finger; can not extend hand at wrist,			8616 Neuritis.		
extend proximal phalanges of fin-			8716 Neuralgia.		
gers, extend thumb, or make lateral			Musculocutaneous nerve		
movement of wrist; supination of hand, extension and flexion of elbow			8517 Paralysis of:		
weakened, the loss of synergic mo-			Complete; weakness but not loss of		
tion of extensors impairs the hand			flexion of elbow and supination of forearm	30	2
grip seriously; total paralysis of the			Incomplete:	30	-
triceps occurs only as the greatest	70	00	Severe	20	2
rarity Incomplete:	70	60	Moderate	10	-
Severe	50	40	Mild	0	
Moderate	30	20	8617 Neuritis.		
Mild	20	20	8717 Neuralgia.		
-		_,	Circumflex nerve		
			8518 Paralysis of:		
			Complete; abduction of arm is impos- sible, outward rotation is weakened;		
			muscles supplied are deltoid and		
			teres minor	50	_

#### §4.124a

# DISEASES OF THE PERIPHERAL NERVES—Continued

Schodula of ratings		Rating	
	Schedule of ratings	Major	Minor
In	complete:		
	Severe	30	20
	Moderate	10	10
	Mild	0	(
8618	Neuritis.		
8718	Neuralgia.		
	Long thoracic nerve		
8519	Paralysis of:		
C	omplete; inability to raise arm above		
	shoulder level, winged scapula de-		
	formity	30	2
ln	complete:		
	Severe	20	_
	Moderate	10	
	Mild	0	
N	OTE: Not to be combined with lost mot der level.	ion abov	e shoul-
8619	Neuritis.		
8719	Neuralgia.		
N	OTE: Combined nerve injuries should erence to the major involvement, or it tent, consider radicular group ratings.		

Sciatic nerve	
8520 Paralysis of:  Complete; the foot dangles and drops, no active movement possible of muscles below the knee, flexion of knee weakened or (very rarely) lost Incomplete:  Severe, with marked muscular atrophy  Moderately severe  Moderate  Mild  8620 Neuritis.	
8720 Neuralgia.	
External popliteal nerve (common peroneal)	
8521 Paralysis of:  Complete; foot drop and slight droop of first phalanges of all toes, cannot dorsiflex the foot, extension (dorsal flexion) of proximal phalanges of toes lost; abduction of foot lost, adduction weakened; anesthesia covers entire dorsum of foot and toes  Incomplete:  Severe  Moderate  Mild	

		Rating
8621	Neuritis.	
8721	Neuralgia.	
Mus	sculocutaneous nerve (superficial peroneal)	
8522	Paralysis of:	
	Complete; eversion of foot weakened incomplete:	30
	Severe	20
	Moderate Mild	10
8622	Neuritis.	
8722	Neuralgia.	
Ant	terior tibial nerve (deep peroneal)	
8523	Paralysis of:	
	complete; dorsal flexion of foot lost	30
Ir	ncomplete:	
	Severe Moderate	20 10
	Mild	(
8623	Neuritis.	
8723	Neuralgia.	
	Internal popliteal nerve (tibial)	
8524	Paralysis of:	
C	Complete; plantar flexion lost, frank adduction of foot impossible, flexion	
	and separation of toes abolished; no	
	muscle in sole can move; in lesions	
	of the nerve high in popliteal fossa, plantar flexion of foot is lost	40
Ir	ncomplete:	.,
	Severe	30
	Moderate	20
8624	Mild Neuritis.	10
8724		
	Posterior tibial nerve	
8525	Paralysis of:	
C	Complete; paralysis of all muscles of	
	sole of foot, frequently with painful paralysis of a causalgic nature; toes	
	cannot be flexed; adduction is weak-	
	ened; plantar flexion is impaired	30
Ir	ncomplete:	0/
	Severe Moderate	20 10
	Mild	10
8625	Neuritis.	
8725	Neuralgia.	
	Anterior crural nerve (femoral)	
8526	Paralysis of:	
C	Complete; paralysis of quadriceps extensor muscles	40
Ir	ncomplete:	
	Severe	30
	Moderate	20
	Mild	10

#### §4.124a

		Rating
8626	Neuritis.	
8726	Neuralgia.	
	Internal saphenous nerve	
8527	Paralysis of:	
S	evere to complete	10
M	lild to moderate	0
8627	Neuritis.	
8727	Neuralgia.	
	Obturator nerve	
8528	Paralysis of:	
S	evere to complete	10
M	lild or moderate	0
8628	Neuritis.	
8728	Neuralgia.	
Ex	ternal cutaneous nerve of thigh	
8529	Paralysis of:	
S	evere to complete	10
M	lild or moderate	0
8629	Neuritis.	
8729	Neuralgia.	
	Ilio-inguinal nerve	
8530	Paralysis of:	
S	evere to complete	10
M	lild or moderate	0
8630	Neuritis.	
	Neuralgia.	
	Soft-tissue sarcoma (of neurogenic	
orig	in)	100

NOTE: The 100 percent rating will be continued for 6 months following the cessation of surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. At this point, if there has been no local recurrence or metastases, the rating will be made on residuals.

#### THE EPILEPSIES

	Rat
A thorough study of all material in §§ 4.121 and 4.122 of the preface and under the ratings for epilepsy is necessary prior to any rating action.  8910 Epilepsy, grand mal.  Rate under the general rating formula for major seizures.  8911 Epilepsy, petit mal.	
-p.:-p-5,, p-:::	

	Rat- ing
Rate under the general rating formula for minor	
seizures.  NOTE (1): A major seizure is characterized by the generalized tonic-clonic convulsion with unconsciousness.	
NOTE (2): A minor seizure consists of a brief interruption in consciousness or conscious control associated with staring or rhythmic blinking of the eyes or nodding of the head ("pure" petit mal), or sudden jerking movements of the arms, trunk, or head (myoclonic type) or sudden loss of postural control (akinetic type).	
General Rating Formula for Major and Minor Epileptic Seizures:	
Averaging at least 1 major seizure per month over the last year Averaging at least 1 major seizure in 3	100
months over the last year; or more than 10 minor seizures weekly	80
months over the last year; or 9–10 minor seizures per week	60
or 2 in the last year; or averaging at least 5 to 8 minor seizures weekly	40
or at least 2 minor seizures in the last 6 months	20
A confirmed diagnosis of epilepsy with a history of seizures	10
necessary for the control of epilepsy, the min- imum evaluation will be 10 percent. This rating will not be combined with any other rating for epilepsy.	
NOTE (2): In the presence of major and minor seizures, rate the predominating type.  NOTE (3): There will be no distinction between	
diurnal and nocturnal major seizures. 8912 Epilepsy, Jacksonian and focal motor or sensory.	
8913 Epilepsy, diencephalic. Rate as minor seizures, except in the presence of major and minor seizures, rate the predomi- nating type.	
8914 Epilepsy, psychomotor.  Major seizures: Psychomotor seizures will be rated as major seizures under the general rating formula	
when characterized by automatic states and/or generalized convulsions with unconsciousness.	
Minor seizures:  Psychomotor seizures will be rated as minor seizures under the general rating formula when characterized by brief transient episodes of random motor movements, hallucinations, perceptual illusions, abnormalities of thinking, memory or mood, or auto-	

THE EPILEPSIES—Continued

Mental Disorders in Epilepsies: A nonpsychotic organic brain syndrome will be rated separately under the appropriate diagnostic code (e.g., 9304 or 9326). In the absence of a diagnosis of non-psychotic organic psychiatric disturbance (psychotic, psychoneurotic or personality disorder) if diagnosed and shown to be secondary to or directly associated with epilepsy will be rated separately. The psychotic or psychroneurotic disorder will be rated under the appropriate diagnostic code. The personality disorder will be rated as a dementia (e.g., diagnostic code 9304 or 9326).

Epilepsy and Unemployability: (1) Rating specialists must bear in mind that the epileptic, although his or her seizures are controlled, may find employment and rehabilitation difficult of attainment due to employer reluctance to the hiring of the

(2) Where a case is encountered with a definite history of unemployment, full and complete development should be un-dertaken to ascertain whether the epilepsy is the determining factor in his or her inability to obtain employment.

(3) The assent of the claimant should first be obtained for

(a) The assent of the calman should hist be obtained in open ission to conduct this economic and social survey. The purpose of this survey is to secure all the relevant facts and data necessary to permit of a true judgment as to the reason for his or her unemployment and should include information

Occupations prior and subsequent to service;

(b) Occupations prior and subsequent to service;
(c) Places of employment and reasons for termination;
(d) Wages received;
(e) Number of seizures.
(4) Upon completion of this survey and current examination, the case should have rating board consideration. Where in the judgment of the rating board the veteran's unemployability is due to epilepsy and jurisdiction is not vested in that body by reason of schedular evaluations, the case should be substituted to the Compensation Service or the Director. Pension mitted to the Compensation Service or the Director, Pension and Fiduciary Service.

(Authority: 38 U.S.C. 1155)

[29 FR 6718, May 22, 1964, as amended at 40 FR 42540, Sept. 15, 1975; 41 FR 11302, Mar. 18, 1976; 43 FR 45362, Oct. 2, 1978; 54 FR 4282, Jan. 30, 1989; 54 FR 49755, Dec. 1, 1989; 55 FR 154, Jan. 3, 1990; 56 FR 51653, Oct. 15, 1991; 57 FR 24364, June 9, 1992; 70 FR 75399, Dec. 20, 2005; 73 FR 54705, Sept. 23, 2008; 73 FR 69554, Nov. 19, 2008; 76 FR 78824, Dec. 20, 2011; 79 FR 2100, Jan. 13, 2014]

#### MENTAL DISORDERS

#### § 4.125 Diagnosis of mental disorders.

(a) If the diagnosis of a mental disorder does not conform to DSM-5 or is not supported by the findings on the examination report, the rating agency shall return the report to the examiner to substantiate the diagnosis. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association (2013), is incorporated by reference into this section with the approval of the Director of the Federal Register under 5 U.S.C. 552(a) and 1 CFR part 51. To enforce any edition other than that specified in this section, the Department of Veterans Affairs must publish notice of change in the FEDERAL REGISTER and the material must be available to the public. All approved material is available from the American Psychiatric Association, 1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901, 703-907-7300, http://www.dsm5.org. It is also available for inspection at the Office of Regulation Policy and Management, Department of Veterans Affairs, 810 Vermont Avenue NW., Room 1068,

Washington, DC 20420. It is also available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this information at NARA, call 202–741–6030 or go to http://www.archives.gov/federal register/ code of federal regulations/ ibr publications.html.

(b) If the diagnosis of a mental disorder is changed, the rating agency shall determine whether the new diagnosis represents progression of the prior diagnosis, correction of an error in the prior diagnosis, or development of a new and separate condition. If it is not clear from the available records what the change of diagnosis represents, the rating agency shall return the report to the examiner for a determination.

(Authority: 38 U.S.C. 1155)

[61 FR 52700, Oct. 8, 1996, as amended at 79 FR 45099, Aug. 4, 2014]

#### §4.126 Evaluation of disability from mental disorders.

- (a) When evaluating a mental disorder, the rating agency shall consider the frequency, severity, and duration of psychiatric symptoms, the length of remissions, and the veteran's capacity for adjustment during periods of remission. The rating agency shall assign an evaluation based on all the evidence of record that bears on occupational and social impairment rather than solely on the examiner's assessment of the level of disability at the moment of the examination.
- (b) When evaluating the level of disability from a mental disorder, the rating agency will consider the extent of social impairment, but shall not assign an evaluation solely on the basis of social impairment.
- (c) Neurocognitive disorders shall be evaluated under the general rating formula for mental disorders; neurologic deficits or other impairments stemming from the same etiology (e.g., a head injury) shall be evaluated separately and combined with the evaluation for neurocognitive disorders (see § 4.25).
- (d) When a single disability has been diagnosed both as a physical condition and as a mental disorder, the rating

agency shall evaluate it using a diagnostic code which represents the dominant (more disabling) aspect of the condition (see § 4.14).

(Authority: 38 U.S.C. 1155)

[61 FR 52700, Oct. 8, 1996, as amended at 79 FR 45099, Aug. 4, 2014]

#### §4.127 Intellectual disability (intellectual developmental disorder) and personality disorders.

Intellectual disability (intellectual developmental disorder) and personality disorders are not diseases or injuries for compensation purposes, and, except as provided in §3.310(a) of this chapter, disability resulting from them may not be service-connected. However, disability resulting from a mental disorder that is superimposed upon intellectual disability (intellectual developmental disorder) or a personality disorder may be service-connected.

(Authority: 38 U.S.C. 1155) [79 FR 45100, Aug. 4, 2014]

#### § 4.128 Convalescence ratings following extended hospitalization.

If a mental disorder has been assigned a total evaluation due to a continuous period of hospitalization lasting six months or more, the rating agency shall continue the total evaluation indefinitely and schedule a mandatory examination six months after the veteran is discharged or released to nonbed care. A change in evaluation based on that or any subsequent examination shall be subject to the provisions of §3.105(e) of this chapter.

(Authority: 38 U.S.C. 1155) [61 FR 52700, Oct. 8, 1996]

#### §4.129 Mental disorders due to traumatic stress.

When a mental disorder that develops in service as a result of a highly stressful event is severe enough to bring about the veteran's release from active military service, the rating agency shall assign an evaluation of not less than 50 percent and schedule an examination within the six month period following the veteran's discharge to determine whether a change in evaluation is warranted.

(Authority: 38 U.S.C. 1155) [61 FR 52700, Oct. 8, 1996]

#### §4.130 Schedule of ratings-Mental disorders.

The nomenclature employed in this portion of the rating schedule is based upon the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (see §4.125 for availability information). Rating agencies must be thoroughly familiar with this manual to properly implement the directives in §4.125 through §4.129 and to apply the general rating formula for mental disorders in §4.130. The schedule for rating for mental disorders is set forth as follows:

9201 Schizophrenia

9202 [Removed] 9203 [Removed]

[Removed]

[Removed]

Delusional disorder

Other specified and unspecified schizophrenia spectrum and other psychotic disorders

9211 Schizoaffective disorder

Delirium

9301 Major or mild neurocognitive disorder due to HIV or other infections

9304 Major or mild neurocognitive disorder due to traumatic brain injury

9305 Major or mild vascular neurocognitive disorder

9310 Unspecified neurocognitive disorder

9312 Major or mild neurocognitive disorder due to Alzheimer's disease

9326 Major or mild neurocognitive disorder due to another medical condition or substance/medication-induced major or mild neurocognitive disorder

9327 [Removed]

9400 Generalized anxiety disorder

9403 Specific phobia; social anxiety disorder (social phobia)

9404 Obsessive compulsive disorder

9410 Other specified anxiety disorder

9411 Posttraumatic stress disorder

Panic disorder and/or agoraphobia 9412

Unspecified anxiety disorder

identity disorder dissociative 9416 Dissociative

9417 Depersonalization/Derealization disorder

9421 Somatic symptom disorder

Other specified somatic symptom and related disorder

9423 Unspecified somatic symptom and related disorder

#### 38 CFR Ch. I (7-1-16 Edition)

9424 Conversion disorder (functional neuro- logical symptom disorder) 9425 Illness anxiety disorder 9431 Cyclothymic disorder	9433 Persistent depressive disorder (dysthymia) 9434 Major depressive disorder 9435 Unspecified depressive disorder
9432 Bipolar disorder	9440 Chronic adjustment disorder

#### GENERAL RATING FORMULA FOR MENTAL DISORDERS

	Rating
Total occupational and social impairment, due to such symptoms as: gross impairment in thought processes or communication; persistent delusions or hallucinations; grossly inappropriate behavior; persistent danger of hurting self or others; intermittent inability to perform activities of daily living (including maintenance of minimal personal hygiene); disorientation to time or place; memory loss for names of close relatives, own occupation, or own name.  Occupational and social impairment, with deficiencies in most areas, such as work, school, family relations, judg-	100
ment, thinking, or mood, due to such symptoms as: suicidal ideation; obsessional rituals which interfere with rou- tine activities; speech intermittently illogical, obscure, or irrelevant; near-continuous panic or depression affecting the ability to function independently, appropriately and effectively; impaired impulse control (such as unprovoked irritability with periods of violence); spatial disorientation; neglect of personal appearance and hygiene; difficulty in adapting to stressful circumstances (including work or a worklike setting); inability to establish and maintain effec-	
tive relationships.  Occupational and social impairment with reduced reliability and productivity due to such symptoms as: flattened affect; circumstantial, circumlocutory, or stereotyped speech; panic attacks more than once a week; difficulty in understanding complex commands; impairment of short- and long-term memory (e.g., retention of only highly	70
learned material, forgetting to complete tasks); impaired judgment; impaired abstract thinking; disturbances of motivation and mood; difficulty in establishing and maintaining effective work and social relationships.  Occupational and social impairment with occasional decrease in work efficiency and intermittent periods of inability to perform occupational tasks (although generally functioning satisfactorily, with routine behavior, self-care, and conversation normal), due to such symptoms as: depressed mood, anxiety, suspiciousness, panic attacks (weekly	50
or less often), chronic sleep impairment, mild memory loss (such as forgetting names, directions, recent events). Occupational and social impairment due to mild or transient symptoms which decrease work efficiency and ability to perform occupational tasks only during periods of significant stress, or symptoms controlled by continuous medi- cation.	30
A mental condition has been formally diagnosed, but symptoms are not severe enough either to interfere with occupational and social functioning or to require continuous medication.	0

9520 Anorexia nervosa 9521 Bulimia nervosa

#### RATING FORMULA FOR EATING DISORDERS

	Rating
Self-induced weight loss to less than 80 percent of expected minimum weight, with incapacitating episodes of at	
least six weeks total duration per year, and requiring hospitalization more than twice a year for parenteral nutrition or tube feeding.	100
Self-induced weight loss to less than 85 percent of expected minimum weight with incapacitating episodes of six or	100
more weeks total duration per year.	60
Self-induced weight loss to less than 85 percent of expected minimum weight with incapacitating episodes of more than two but less than six weeks total duration per year.	30
Binge eating followed by self-induced vomiting or other measures to prevent weight gain, or resistance to weight gain even when below expected minimum weight, with diagnosis of an eating disorder and incapacitating episodes of up to two weeks total duration per year.	10
Binge eating followed by self-induced vomiting or other measures to prevent weight gain, or resistance to weight	
gain even when below expected minimum weight, with diagnosis of an eating disorder but without incapacitating	
episodes.	0

Note 1: An incapacitating episode is a period during which bed rest and treatment by a physician are required.

Note 2: Ratings under diagnostic codes 9201 to 9440 will be evaluated using the General Rating Formula for Mental Disorders. Ratings under diagnostic codes 9520 and 9521 will be evaluated using the General Rating Formula for Eating Disorders.

20

30

#### **Department of Veterans Affairs**

(Authority: 38 U.S.C. 1155) [79 FR 45100, Aug. 4, 2014]

DENTAL AND ORAL CONDITIONS

#### §4.149 [Reserved]

DENTAL AND ORAL CONDITIONS		Unilateral	10
		9908 Condyloid process, loss of, one or both sides	30
§ 4.149 [Reserved]		9909 Coronoid process, loss of:	
		Bilateral	20
§ 4.150 Schedule of ratings-dental	and	Unilateral	10
oral conditions.	and	9911 Hard palate, loss of half or more:	
oral conditions.		Not replaceable by prosthesis	30
	Det	Replaceable by prosthesis	10
	Rat- ing	9912 Hard palate, loss of less than half of:	
	iiig	Not replaceable by prosthesis	20
9900 Maxilla or mandible, chronic osteomyelitis or		Replaceable by prostriesis	0
osteoradionecrosis of:			U
Rate as osteomyelitis, chronic under diag-		9913 Teeth, loss of, due to loss of substance of	
nostic code 5000.		body of maxilla or mandible without loss of con-	
9901 Mandible, loss of, complete, between angles	100	tinuity:	
9902 Mandible, loss of approximately one-half:		Where the lost masticatory surface cannot	
Involving temporomandibular articulation	50	be restored by suitable prosthesis:	
Not involving temporomandibular articulation	30	Loss of all teeth	40
9903 Mandible, nonunion of:		Loss of all upper teeth	30
Severe	30	Loss of all lower teeth	30
Moderate	10	All upper and lower posterior teeth	
Note—Dependent upon degree of motion		missing	20
and relative loss of masticatory function.		All upper and lower anterior teeth	
9904 Mandible, malunion of:		missing	20
Severe displacement	20	All upper anterior teeth missing	10
Moderate displacement	10	All lower anterior teeth missing	10
Slight displacement	0	All upper and lower teeth on one	
NOTE—Dependent upon degree of motion		side missing	10
and relative loss of masticatory function.		Where the loss of masticatory surface can	
9905 Temporomandibular articulation, limited mo-		be restored by suitable prosthesis	0
tion of:		NOTE—These ratings apply only to bone	-
Inter-incisal range:		loss through trauma or disease such as	
0 to 10 mm	40	osteomyelitis, and not to the loss of the	
11 to 20 mm	30	alveolar process as a result of periodontal	
21 to 30 mm	20	disease, since such loss is not considered	
31 to 40 mm	10	disabling.	
Range of lateral excursion:		9914 Maxilla, loss of more than half:	
0 to 4 mm	10	Not replaceable by prosthesis	100
Note—Ratings for limited inter-incisal move-		Replaceable by prosthesis	50
ment shall not be combined with ratings		9915 Maxilla, loss of half or less:	50
for limited lateral excursion.		Loss of 25 to 50 percent:	
9906 Ramus, loss of whole or part of:			40
Involving loss of temporomandibular articu-		Not replaceable by prosthesis	
lation		Replaceable by prosthesis	30
Bilateral	50	Loss of less than 25 percent:	00
Unilateral	30	Not replaceable by prosthesis	20
Not involving loss of temporomandibular ar-		Replaceable by prosthesis	0
ticulation Bilateral	30	9916 Maxilla, malunion or nonunion of:	
	20	Severe displacement	30
9907 Ramus, loss of less than one-half the sub-	20	Moderate displacement	10
stance of, not involving loss of continuity:		Slight displacement	0
stance of, not involving loss of continuity.			

Bilateral ...

Unilateral .....

[59 FR 2530, Jan. 18, 1994]

#### APPENDIX A TO PART 4—TABLE OF AMENDMENTS AND EFFECTIVE DATES SINCE 1946

Sec.	Diagnostic code No.	
4.71a	5000	Evaluation February 1, 1962.
	5001	Evaluation March 11, 1969.
	5002	Evaluation March 1, 1963.
	5003	Added July 6, 1950.
	5012	Criterion March 10, 1976.
	5024	Criterion March 1, 1963.
	5025	Added May 7, 1996.
	5051	Added September 22, 1978. Note July 16, 2015.
	5052	Added September 22, 1978. Note July 16, 2015.
	5053	Added September 22, 1978. Note July 16, 2015.

Sec.	Diagnostic code No.	
	5054	Added September 22, 1978. Note July 16, 2015.
	5055	Added September 22, 1978. Note July 16, 2015.
	5056	Added September 22, 1978. Note July 16, 2015.
	5100-5103	Removed March 10, 1976.
	5104 5105	Criterion March 10, 1976. Criterion March 10, 1976.
	5164	Evaluation June 9, 1952.
	5166	Criterion September 22, 1978.
	5172	Added July 6, 1950.
	5173	Added June 9, 1952.
	5174	Added September 9, 1975; removed September 22, 1978.
	5211 5212	Criterion September 22, 1978. Criterion September 22, 1978.
	5214	Criterion September 22, 1978.
	5216	Preceding paragraph criterion September 22, 1978.
	5217	Criterion August 26, 2002.
	5218	Criterion August 26, 2002.
	5219	Criterion September 22, 1978; criterion August 26, 2002.
	5220 5223	Preceding paragraph criterion September 22, 1978; criterion August 26, 2002. Criterion August 26, 2002.
	5224	Criterion August 26, 2002.
	5225	Criterion August 26, 2002.
	5226	Criterion August 26, 2002.
	5227	Criterion September 22, 1978; criterion August 26, 2002.
	5228	Added August 26, 2002.
	5229 5230	Added August 26, 2002.
	5235-5243	Added August 26, 2002.   Replaces 5285–5295 September 26, 2003.
	5243	Criterion September 26, 2003.
	5255	Criterion July 6, 1950.
	5257	Evaluation July 6, 1950.
	5264	Added September 9, 1975; removed September 22, 1978.
	5275 5285–5292	Criterion March 10, 1976; criterion September 22, 1978.
	5285-5292	Revised to 5235–5243 September 26, 2003.  Criterion March 10, 1976; criterion September 23, 2002; revised and moved to
	5294	5235–5243 September 26, 2003. Evaluation March 10, 1976; revised and moved to 5235–5243 September 26
	5295	2003. Evaluation March 10, 1976; revised and moved to 5235–5243 September 26
		2003.
	5296 5297	Criterion March 10, 1976. Criterion August 23, 1948; criterion February 1, 1962.
	5298	Added August 23, 1948.
1.73	0200	Introduction NOTE criterion July 3, 1997.
	5317	Criterion September 22, 1978.
	5324	Added February 1, 1962.
	5325	Criterion July 3, 1997.
	5327	Added March 10, 1976; criterion October 15, 1991; criterion July 3, 1997.
	5328 5329	Added NOTE March 10, 1976. Added NOTE July 3, 1997.
4.84a		Table V criterion July 1, 1994.
	6010	Criterion March 11, 1969.
	6019	Criterion September 22, 1978.
	6029	NOTE August 23, 1948; criterion September 22, 1978.
	6035	Added September 9, 1975.
	6050–6062 6061	Removed March 10, 1976.
	6062	Added March 10, 1976. Added March 10, 1976.
	6063–6079	Criterion September 22, 1978.
	6064	Criterion March 10, 1976.
	6071	Criterion March 10, 1976.
	6076	Evaluation August 23, 1948.
	6080	Criterion September 22, 1978.
	6081	Criterion March 10, 1976.  Criterion September 22, 1978; criterion September 12, 1988.
I.84b	6090 6260	Added October 1, 1961; criterion October 1, 1961; evaluation March 10, 1976
1.87		removed December 18, 1987; re-designated § 4.87a December 18, 1987. Tables VI and VII replaced by new Tables VI, VIA, and VII December 18, 1987 6200–6260 revised and re-designated § 4.87 June 10, 1999.
	6200–6260	6200-6200 revised and re-designated § 4.87 June 10, 1999.  Moved to § 4.87 June 10, 1999.
I.87a		
I.87a	6275–6276 6277–6297	Moved from §4.87b June 10, 1999.  March 23, 1956 removed, December 17, 1987; Table II revised Table V Marc

Sec.	Diagnostic code No.	
	6286	Removed December 17, 1987.
	6291	Criterion March 10, 1976; removed December 17, 1987.
1.071	6297	Criterion March 10, 1976; removed December 17, 1987.
		Removed June 10, 1999.    March 11, 1969; re-designated § 4.88b November 29, 1994; § 4.88a added to
1.00a		read "Chronic fatigue syndrome"; criterion November 29, 1994.
l.88b d88.l		Added March 11, 1969; re-designated §4.88c November 29, 1994; §4.88a re-
		designated to § 4.88b November 29, 1994.
	6300	Criterion August 30, 1996.
	6302	Criterion September 22, 1978; criterion August 30, 1996.
	6304 6305	Evaluation August 30, 1996. Criterion March 1, 1989; evaluation August 30, 1996.
	6306	Evaluation August 30, 1996.
	6307	Criterion August 30, 1996.
	6308	Criterion August 30, 1996.
	6309	Added March 1, 1963; criterion March 1, 1989; criterion August 30, 1996.
	6314	Evaluation March 1, 1989; evaluation August 30, 1996.
	6315	Criterion August 30, 1996.
	6316 6317	Evaluation March 1, 1989; evaluation August 30, 1996. Criterion August 30, 1996.
	6318	Added March 1, 1989; criterion August 30, 1996.
	6319	Added August 30, 1996.
	6320	Added August 30, 1996.
	6350	Evaluation March 1, 1963; evaluation March 10, 1976; evaluation August 30 1996.
	6351	Added March 1, 1989; evaluation March 24, 1992; criterion August 30, 1996.
	6352	Added March 1, 1989; removed March 24, 1992.
	6353	Added March 1, 1989; removed March 24, 1992.
00-	6354	Added November 29, 1994; criterion August 30, 1996.
		Re-designated from § 4.88b November 29, 1994. Ratings for nonpulmonary TB December 1, 1949; criterion March 11, 1969.
.97	6502	Criterion October 7, 1996.
	6504	Criterion October 7, 1996.
	6510-6514	Criterion October 7, 1996.
	6515	Criterion March 11, 1969.
	6516	Criterion October 7, 1996.
	6517	Removed October 7, 1996.
	6518	Criterion October 7, 1996.
	6519 6520	Criterion October 7, 1996. Criterion October 7, 1996.
	6521	Added October 7, 1996.
	6522	Added October 7, 1996.
	6523	Added October 7, 1996.
	6524	Added October 7, 1996.
	6600	Evaluation September 9, 1975; criterion October 7, 1996.
	6601	Criterion October 7, 1996.
	6602 6603	Criterion September 9, 1975; criterion October 7, 1996.  Added September 9, 1975; criterion October 7, 1996.
	6604	Added October 7, 1996.
	6701	Evaluation October 7, 1996.
	6702	Evaluation October 7, 1996.
	6703	Evaluation October 7, 1996.
	6704	Subparagraph (1) following December 1, 1949; criterion March 11, 1969; criterior
	0705	September 22, 1978.
	6705 6707–6710	Removed March 11, 1969.  Added March 11, 1969; removed September 22, 1978.
	6721	Criterion July 6, 1950; criterion September 22, 1978.
	6724	Second note following December 1, 1949; criterion March 11, 1969; evaluation
	*	October 7, 1996.
	6725-6728	Added March 11, 1969; removed September 22, 1978.
	6730	
	6731	Evaluation September 22, 1978; criterion October 7, 1996.
	6732	Criterion March 11, 1969. Criterion September 9, 1975; removed October 7, 1996.
	6800 6801	Removed October 7, 1996.
	6802	Criterion September 9, 1975; removed October 7, 1996.
		Removed October 7, 1996.
	6810-6813	
	6810–6813 6814	Criterion March 10, 1976; removed October 7, 1996.
		Criterion March 10, 1976; removed October 7, 1996. Removed October 7, 1996.
	6814 6815 6816	Criterion March 10, 1976; removed October 7, 1996. Removed October 7, 1996. Removed October 7, 1996.
	6814 6815	Criterion March 10, 1976; removed October 7, 1996. Removed October 7, 1996.

Sec.	Diagnostic code No.	
	6821	Evaluation August 23, 1948.
	6822–6847	Added October 7, 1996.
4.104	7000	Evaluation July 6, 1950; evaluation September 22, 1978; evaluation January 12 1998.
	7001	Evaluation January 12, 1998.
	7002	Evaluation January 12, 1998.
	7003	Evaluation January 12, 1998.
	7004	Criterion September 22, 1978; evaluation January 12, 1998.
	7005	Evaluation September 9, 1975; evaluation September 22, 1978; evaluation Janu
	7006	ary 12, 1998. Evaluation January 12, 1998.
	7007	Evaluation September 22, 1978; evaluation January 12, 1998.
	7008	Evaluation January 12, 1998.
	7010	Evaluation January 12, 1998.
	7011	Evaluation January 12, 1998.
	7013 7014	Removed January 12, 1998. Removed January 12, 1998.
	7015	Evaluation September 9, 1975; criterion January 12, 1998.
	7016	Added September 9, 1975; evaluation January 12, 1998.
	7017	Added September 22, 1978; evaluation January 12, 1998.
	7018	Added January 12, 1998.
	7019	Added January 12, 1998.
	7020 7100	Added January 12, 1998. Evaluation July 6, 1950.
	7101	Criterion September 1, 1960; criterion September 9, 1975; criterion January 12
		1998.
	7110	Evaluation September 9, 1975; evaluation January 12, 1998.
	7111	Criterion September 9, 1975; evaluation January 12, 1998.
	7112	Evaluation January 12, 1998.
	7113 7114	Evaluation January 12, 1998.
	7114	Added June 9, 1952; evaluation January 12, 1998.  Added June 9, 1952; evaluation January 12, 1998.
	7116	Added June 9, 1952; evaluation March 10, 1976; removed January 12, 1998.
	7117	Added June 9, 1952; evaluation January 12, 1998.
	7118	Criterion January 12, 1998.
	7119	Evaluation January 12, 1998.
	7120	Note following July 6, 1950; evaluation January 12, 1998.
	7121 7122	Criterion July 6, 1950; evaluation March 10, 1976; evaluation January 12, 1998. Last sentence of Note following July 6, 1950; evaluation January 12, 1998; cr
		terion August 13, 1998.
	7123	Added October 15, 1991; criterion January 12, 1998.
1.114		Introduction paragraph revised March 10, 1976.
	7304	Evaluation November 1, 1962.
	7305	Evaluation November 1, 1962.
	7308 7311	Evaluation April 8, 1959. Criterion July 2, 2001.
	7312	Evaluation March 10, 1976; evaluation July 2, 2001.
	7313	Evaluation March 10, 1976; removed July 2, 2001.
	7319	Evaluation November 1, 1962.
	7321	Evaluation July 6, 1950; criterion March 10, 1976.
	7328	Evaluation November 1, 1962.
	7329 7330	Evaluation November 1, 1962. Evaluation November 1, 1962.
	7331	Criterion March 11, 1969.
	7332	Evaluation November 1, 1962.
	7334	Evaluation July 6, 1950; evaluation November 1, 1962.
	7339	Criterion March 10, 1976.
	7341	Removed March 10, 1976.
	7343 7344	Criterion March 10, 1976; criterion July 2, 2001. Criterion July 2, 2001.
	7345	Evaluation August 23, 1948; evaluation February 17, 1955; evaluation July 2 2001.
	7346	Evaluation February 1, 1962.
	7347	Added September 9, 1975.
	7348	Added March 10, 1976.
	7351	Added July 2, 2001.
l.115a	7354	Added July 2, 2001.  Re-designated and revised as §4.115b; new §4.115a "Ratings of the genitor."
l.115b	7500	urinary system-dysfunctions" added February 17, 1994.  Note July 6, 1950; evaluation February 17, 1994, criterion September 8, 1994.
	7501	Evaluation February 17, 1994.
	7502	Evaluation February 17, 1994.
		Removed February 17, 1994.

Sec.	Diagnostic code No.	
	7504	Criterion February 17, 1994.
	7505	Criterion March 11, 1969; evaluation February 17, 1994.
	7507 7508	Criterion February 17, 1994.  Evaluation February 17, 1994.
	7509	Criterion February 17, 1994.
	7510	Evaluation February 17, 1994.
	7511	Evaluation February 17, 1994.
	7512 7513	Evaluation February 17, 1994.
	7514	Removed February 17, 1994. Criterion March 11, 1969; removed February 17, 1994.
	7515	Criterion February 17, 1994.
	7516	Criterion February 17, 1994.
	7517	Criterion February 17, 1994.
	7518 7519	Evaluation February 17, 1994.  Evaluation March 10, 1976; evaluation February 17, 1994.
	7520	Criterion February 17, 1994.
	7521	Criterion February 17, 1994.
	7522	Criterion September 8, 1994.
	7523	Criterion September 8, 1994.
	7524 7525	Note July 6, 1950; evaluation February 17, 1994; evaluation September 8, 1994. Criterion March 11, 1969; evaluation February 17, 1994.
	7526	Removed February 17, 1994.
	7527	Criterion February 17, 1994.
	7528	Criterion March 10, 1976; criterion February 17, 1994.
	7529 7520	Criterion February 17, 1994.
	7530 7531	Added September 9, 1975; evaluation February 17, 1994.  Added September 9, 1975; criterion February 17, 1994.
	7532–7542	Added February 17, 1994.
4.116		§4.116 removed and §4.116a re-designated §4.116 "Schedule of ratings-gyne
	=0.40	cological conditions and disorders of the breasts" May 22, 1995.
	7610	Criterion May 22, 1995.
	7611 7612	Criterion May 22, 1995.   Criterion May 22, 1995.
	7613	Criterion May 22, 1995.
	7614	Criterion May 22, 1995.
	7615	Criterion May 22, 1995.
	7617 7618	Criterion May 22, 1995.  Criterion May 22, 1995.
	7619	Criterion May 22, 1995.
	7620	Criterion May 22, 1995.
	7621	Criterion May 22, 1995.
	7622	Evaluation May 22, 1995.
	7623 7624	Evaluation May 22, 1995.  Criterion August 9, 1976; evaluation May 22, 1995.
	7625	Criterion August 9, 1976; evaluation May 22, 1995.
	7626	Criterion May 22, 1995; criterion March 18, 2002.
	7627	Criterion March 10, 1976; criterion May 22, 1995.
	7628	Added May 22, 1995.
4.117	7629 7700	Added May 22, 1995. Evaluation October 23, 1995.
	7701	Removed October 23, 1995.
	7702	Evaluation October 23, 1995.
	7703	Evaluation August 23, 1948; criterion October 23, 1995.
	7704	Evaluation October 23, 1995.
	7705 7706	Evaluation October 23, 1995. Evaluation October 23, 1995.
	7707	Criterion October 23, 1995.
	7709	Evaluation March 10, 1976; criterion October 23, 1995.
	7710	Criterion October 23, 1995.
	7711 7712	Criterion October 23, 1995.
	7712 7713	Criterion October 23, 1995. Removed October 23, 1995.
	7714	Added September 9, 1975; criterion October 23, 1995.
	7715	Added October 26, 1990.
	7716	Added October 23, 1995.
1 1 1 0	7717	Added March 9, 2012.
4.118	7800 7801	Evaluation August 30, 2002; criterion October 23, 2008.  Criterion July 6, 1950; criterion August 30, 2002; criterion October 23, 2008.
	7802	Criterion September 22, 1978; criterion August 30, 2002; criterion October 23, 2008.
	7803	Criterion August 30, 2002; removed October 23, 2008.
ı	7804	Criterion July 6, 1950; criterion September 22, 1978; criterion and evaluation Oc

Sec.	Diagnostic code No.	
	7805	Criterion October 23, 2008.
	7806	Criterion September 9, 1975; evaluation August 30, 2002.
	7807	Criterion August 30, 2002.
	7808	Criterion August 30, 2002.
	7809 7810	Criterion August 30, 2002. Removed August 30, 2002.
	7811	Criterion March 11, 1969; evaluation August 30, 2002.
	7812	Removed August 30, 2002.
	7813	Criterion August 30, 2002.
	7814	Removed August 30, 2002.
	7815	Evaluation August 30, 2002.
	7816 7817	Evaluation August 30, 2002. Evaluation August 30, 2002.
	7818	Criterion August 30, 2002.
	7819	Criterion August 30, 2002.
	7820–7833	Added August 30, 2002.
l.119	7900	Criterion August 13, 1981; evaluation June 9, 1996.
	7901	Criterion August 13, 1981; evaluation June 9, 1996.
	7902 7903	Evaluation August 13, 1981; criterion June 9, 1996.  Criterion August 13, 1981; evaluation June 9, 1996.
	7904	Criterion August 13, 1981; evaluation June 9, 1996.
	7905	Evaluation; August 13, 1981; evaluation June 9, 1996.
	7907	Evaluation August 13, 1981; evaluation June 9, 1996.
	7908	Criterion August 13, 1981; criterion June 9, 1996.
	7909	Evaluation August 13, 1981; criterion June 9, 1996.
	7910	Removed June 9, 1996.
	7911 7913	Evaluation March 11, 1969; evaluation August 13, 1981; criterion June 9, 1996. Criterion September 9, 1975; criterion August 13, 1981; criterion June 6, 1996.
	7914	Criterion March 10, 1976; criterion August 13, 1981; criterion June 9, 1996.
	7916	Added June 9, 1996.
	7917	Added June 9, 1996.
	7918	Added June 9, 1996.
	7919	Added June 9, 1996.
I.124a	8002	Criterion September 22, 1978.
	8021	Criterion September 22, 1978; criterion October 1, 1961; criterion March 10, 1976; criterion March 1, 1989.
	8045	Criterion and evaluation October 23, 2008.
	8046	Added October 1, 1961; criterion March 10, 1976; criterion March 1, 1989.
	8100	Evaluation June 9, 1953.
	8540	Added October 15, 1991.
	8910	Added October 1, 1961.
	8911	Added October 1, 1961; evaluation September 9, 1975.
	8912 8913	Added October 1, 1961.
	8914	Added October 1, 1961.  Added October 1, 1961; criterion September 9, 1975; criterion March 10, 1976.
	8910–8914	Evaluations September 9, 1975.
1.125—4.132		All Diagnostic Codes under Mental Disorders October 1, 1961; except as to eva
		uation for Diagnostic Codes 9500 through 9511 September 9, 1975.
l.130		Re-designated from §4.132 November 7, 1996.
	9200	Removed February 3, 1988.
	9201	Criterion February 3, 1988; Title August 4, 2014.
	9202 9203	Criterion February 3, 1988; removed August 4, 2014. Criterion February 3, 1988; removed August 4, 2014.
	9204	Criterion February 3, 1988; removed August 4, 2014.
	9205	Criterion February 3, 1988; criterion November 7, 1996; Removed August
		2014.
	9206	Criterion February 3, 1988; removed November 7, 1996.
	9207	Criterion February 3, 1988; removed November 7, 1996.
	9208 9209	Criterion February 3, 1988; removed November 7, 1996.  Criterion March 10, 1976; criterion February 3, 1988; removed November
	9209	1996.
	9210	Criterion March 10, 1976; criterion February 3, 1988; criterion November 7, 1990 Title August 4, 2014.
	9211	Added November 7, 1996.
	9300 9301	Criterion March 10, 1976; criterion February 3, 1988; criterion November 7, 1990 Criterion March 10, 1976; criterion February 3, 1988; criterion November 7, 1990
	9302	Title August 4, 2014.  Criterion March 10, 1976; criterion February 3, 1988; removed November 7
	9302	1996. Criterion March 10, 1976; criterion February 3, 1988; removed November 3
		1996.
	9304	Criterion March 10, 1976; criterion February 3, 1988; criterion November 7, 199 Title August 4, 2014.

Sec.	Diagnostic code No.	
	9305	Criterion March 10, 1976; criterion February 3, 1988; criterion November 7, 1996;
	9306	Title August 4, 2014. Criterion March 10, 1976; criterion February 3, 1988; removed November 7, 1996.
	9307	Criterion March 10, 1976; criterion February 3, 1988; removed November 7, 1996.
	9308	Criterion March 10, 1976; criterion February 3, 1988; removed November 7, 1996.
	9309	Criterion March 10, 1976; criterion February 3, 1988; removed November 7, 1996.
	9310	Criterion March 10, 1976; criterion February 3, 1988; criterion November 7, 1996; Title August 4, 2014.
	9311	Criterion March 10, 1976; criterion February 3, 1988; removed November 7, 1996.
	9312	Added March 10, 1976; criterion February 3, 1988; criterion November 7, 1996; Title August 4, 2014.
	9313 9314	Added March 10, 1976; removed February 3, 1988. Added March 10, 1976; removed February 3, 1988.
	9315	Added March 10, 1976, criterion February 3, 1988; removed November 7, 1996.
	9316–9321	Added March 10, 1976; removed February 3, 1988.
	9322	Added March 10, 1976; criterion February 3, 1988; removed November 7, 1996.
	9323 9324	Added March 10, 1976; removed February 3, 1988.  Added March 10, 1976; criterion February 3, 1988; removed November 7, 1996.
	9325	Added March 10, 1976; criterion February 3, 1988; removed November 7, 1996.
	9326	Added March 10, 1976; removed February 3, 1988; added November 7, 1996; Title August 4, 2014.
	9327	Added November 7, 1996; removed August 4, 2014.
	9400–9411 9400	Evaluations February 3, 1988. Criterion March 10, 1976; criterion February 3, 1988.
	9401	Criterion March 10, 1976; criterion February 3, 1988; removed November 7, 1996.
	9402	Criterion March 10, 1976; criterion February 3, 1988; removed November 7, 1996.
	9403	Criterion March 10, 1976; criterion February 3, 1988; criterion November 7, 1996; Title August 4, 2014.
	9410 9411	Added March 10, 1976; criterion February 3, 1988; Title August 4, 2014.
	9412	Added February 3, 1988. Added November 7, 1996.
	9413	Added November 7, 1996; Title August 4, 2014.
	9416	Added November 7, 1996; Title August 4, 2014.
	9417 9421	Added November 7, 1996; Title August 4, 2014. Added November 7, 1996; Title August 4, 2014.
	9422	Added November 7, 1996; Title August 4, 2014.
	9423	Added November 7, 1996; Title August 4, 2014.
	9424 9425	Added November 7, 1996; Title August 4, 2014. Added November 7, 1996; Title August 4, 2014.
	9431	Added November 7, 1996.
	9432	Added November 7, 1996.
	9433	Added November 7, 1996; Title August 4, 2014.
	9434 9435	Added November 7, 1996. Added November 7, 1996; Title August 4, 2014.
	9440	Added November 7, 1996.
	9500	Criterion March 10, 1976; criterion February 3, 1988.
	9501 9502	Criterion March 10, 1976; criterion February 3, 1988. Criterion March 10, 1976; criterion February 3, 1988.
	9503	Removed March 10, 1976.
	9504	Criterion September 9, 1975; removed March 10, 1976.
	9505 9506	Added March 10, 1976; criterion February 3, 1988.
	9507	Added March 10, 1976; criterion February 3, 1988.  Added March 10, 1976; criterion February 3, 1988.
	9508	Added March 10, 1976; criterion February 3, 1988.
	9509	Added March 10, 1976; criterion February 3, 1988.
	9510 9511	Added March 10, 1976; criterion February 3, 1988.  Added March 10, 1976; criterion February 3, 1988.
	9520 9521	Added November 7, 1996. Added November 7, 1996.
4.132	9321	Re-designated as § 4.130 November 7, 1996.
4.150	9900	Criterion September 22, 1978; criterion February 17, 1994.
	9901	Criterion February 17, 1994. Criterion February 17, 1994.
	9902 9903	Criterion February 17, 1994.  Criterion February 17, 1994.
	9905	Criterion September 22, 1978; evaluation February 17, 1994.
	9910	Removed February 17, 1994.

Sec.	Diagnostic code No.	
	9914 9915	Criterion February 17, 1994. Added February 17, 1994. Added February 17, 1994. Added February 17, 1994.

[72 FR 12983, Mar. 20, 2007; 72 FR 16728, Apr. 5, 2007, as amended at 73 FR 54708, 54711, Sept. 23, 2008; 73 FR 69554, Nov. 19, 2008; 77 FR 6467, Feb. 8, 2012; 79 FR 45101, Aug. 4, 2014; 80 FR 42042, July 16, 2015]

#### APPENDIX B TO PART 4—NUMERICAL INDEX OF DISABILITIES

Diagnostic Code No.	
	THE MUSCULOSKELETAL SYSTEM Acute, Subacute, or Chronic Diseases
5000	
5001	
5002	
003	
6004 6005	
006	
007	
008	
009	
010	
011	
012	Bones, new growths, malignant.
013	
014	Osteomalacia.
015	
016	
017	
018	7
019	
020	
021	
022	
023	
5024	
5025	Fibromyalgia.
	Prosthetic Implants
051	Shoulder replacement (prosthesis).
052	
053	
5054	
5055	
5056	Ankle replacement (prosthesis).
	Combination of Disabilities
i104	Anatomical loss of one hand and loss of use of one foot.
105	
106	Anatomical loss of both hands.
107	Anatomical loss of both feet.
108	Anatomical loss of one hand and one foot.
109	
5110	
5111	Loss of use of one hand and one foot.
	Amputations: Upper Extremity
Arm amputation of:	
i120	Disarticulation.
5121	
5122	
Forearm amputation of:	
	Above insertion of pronator teres.

Diagnostia Cada Na				
Diagnostic Code No.				
5124	Below insertion of pronator teres.			
5125	Hand, loss of use of.			
Multiple Finger Amputations				
5126	Five digits of one hand.			
Four digits of one hand:				
5127	Thumb, index, long and ring.			
5128	Thumb, index, long and little.			
5129	Thumb, index, ring and little.			
5130 5131	Thumb, long, ring and little. Index, long, ring and little.			
	index, long, mig and mile.			
Three digits of one hand:				
5132	Thumb, index and long.			
5133	Thumb, index and ring.			
5134	Thumb, index and little.			
5135	Thumb, long and ring.			
5136 5137	Thumb, long and little.  Thumb, ring and little.			
5138	Index, long and ring.			
5139	Index, long and little.			
5140	Index, ring and little.			
5141	Long, ring and little.			
Two digits of one bonds				
Two digits of one hand: 5142	Thumb and index.			
5143	Thumb and long.			
5144	Thumb and ring.			
5145	Thumb and little.			
5146	Index and long.			
5147	Index and ring.			
5148	Index and little.			
5149	Long and ring.			
5150	Long and little.			
5151	Ring and little.			
Single finger:				
5152	Thumb.			
5153	Index finger.			
5154	Long finger.			
5155	Ring finger.			
5156	Little finger.			
	Amputations: Lower Extremity			
Thigh amputation of:				
5160	Disarticulation.			
5161	Upper third.			
5162	Middle or lower thirds.			
Leg amputation of:				
5163	With defective stump.			
5164	Not improvable by prosthesis controlled by natural knee action.			
5165	At a lower level, permitting prosthesis.			
5166	Forefoot, proximal to metatarsal bones.			
5167	Foot, loss of use of.			
5170	Toes, all, without metatarsal loss.			
5171	Toe, great.			
5172 5173	Toes, other than great, with removal of metatarsal head.			
31/3	Toes, three or more, without metatarsal involvement.			
	Shoulder and Arm			
5200	Scapulohumeral articulation, ankylosis.			
5201	Arm, limitation of motion.			
5202	Humerus, other impairment.			
5203	Clavicle or scapula, impairment.			
	Elbow and Forearm			
5205	Elbow, ankylosis.			
5206 5207	Forearm, limitation of flexion.  Forearm, limitation of extension.			
J2U1	i i organii, illilitation of extension.			

#### 38 CFR Ch. I (7-1-16 Edition)

4, App. 5		00 01 K 011. 1 () 1 10 2011011)
Diagnostic Code No.		
5208	Forearm, flexion limited.	
5209	Elbow, other impairment.	
5210	Radius and ulna, nonunion.	
5211	Ulna, impairment.	
5212	Radius, impairment.	
5213	Supination and pronation, impairment.	
	Wrist	
5214	Wrist, ankylosis.	
5215	Wrist, limitation of motion.	
	Limitation of Motion	
Multiple Digits: Unfavorable Anky		
5216	Five digits of one hand.	
5217 5218	Four digits of one hand. Three digits of one hand.	
5219	Two digits of one hand.	
3219	Two digits of one fiand.	
Multiple Digits: Favorable Ankylosis:		
5220	Five digits of one hand.	
5221	Four digits of one hand.	
5222	Three digits of one hand.	
5223	Two digits of one hand.	
Ankylosis of Individual Digits:		
5224	Thumb.	
5225	Index finger.	
5226	Long finger.	
5227	Ring or little finger.	
Limitation of Motion of Individual	Digits:	
5228	Thumb.	
5229	Index or long finger.	
5230	Ring or little finger.	
	Spine	
5235	Vertebral fracture or dislocation.	
5236	Sacroiliac injury and weakness.	
5237	Lumbosacral or cervical strain.	
5238	Spinal stenosis.	
5239 5240	Spondylolisthesis or segmental instability.  Ankylosing spondylitis.	
5241	Spinal fusion.	
5242	Degenerative arthritis.	
5243	Intervertebral disc syndrome.	
-	Hip and Thigh	
5250	Hip, ankylosis.	
5251	Thigh, limitation of extension.	
5252	Thigh, limitation of flexion.	
5253	Thigh, impairment.	
5254	Hip, flail joint.	
5255	Femur, impairment.	
	Knee and Leg	
5256	Knee, ankylosis.	
5257	Knee, other impairment.	
5258	Cartilage, semilunar, dislocated.	
5259	Cartilage, semilunar, removal.	
5260	Leg, limitation of flexion.	
5261	Leg, limitation of extension.	
5262 5263	Tibia and fibula, impairment.  Genu recurvatum.	
>		
	Ankle	
5270 5271	Ankle, ankylosis. Ankle, limited motion.	
5272	Subastragalar or tarsal joint, ankylosis.	

Diagnostic Code No.			
·			
5273 5274	Os calcis or astragalus, malunion. Astragalectomy.		
	Shortening of the Lower Extremity		
5275	Bones, of the lower extremity		
	The Foot		
5276	Flatfoot, acquired.		
5277	Weak foot, bilateral.		
5278 5279	Claw foot (pes cavus), acquired.  Metatarsalgia, anterior (Morton's disease).		
5280	Hallux valgus.		
5281	Hallux rigidus.		
5282 5283	Hammer toe. Tarsal or metatarsal bones.		
5284	Foot injuries, other.		
	The Skull		
5296	Loss of part of.		
	The Ribs		
5297	Removal of.		
	The Coccyx		
5298	Removal of.		
	MUSCLE INJURIES		
	Shoulder Girdle and Arm		
5301	Group I Function: Upward rotation of scapula.		
5302	Group II Function: Depression of arm.		
5303 5304	Group III Function: Elevation and abduction of arm. Group IV Function: Stabilization of shoulder.		
5305	Group V Function: Stabilization of shoulder.		
5306	Group VI Function: Extension of elbow.		
	Forearm and Hand		
5307	Group VII Function: Flexion of wrist and fingers.		
5308	Group VIII Function: Extension of wrist, fingers, thumb.		
5309	Group IX Function: Forearm muscles.		
	Foot and Leg		
5310	Group X Function: Movement of forefoot and toes.		
5311 5312	Group XI Function: Propulsion of foot. Group XII Function: Dorsiflexion.		
	<u> </u>		
F212	Pelvic Girdle and Thigh		
5313 5314	Group XIII Function: Extension of hip and flexion of knee. Group XIV Function: Extension of knee.		
5315	Group XV Function: Adduction of hip.		
5316	Group XVI Function: Flexion of hip.		
5317 5318	Group XVII Function: Extension of hip. Group XVIII Function: Outward rotation of thigh.		
	<u> </u>		
	Torso and Neck		
5319 5320	Group XIX Function: Abdominal wall and lower thorax.  Group XX Function: Postural support of body.		
5321	Group XXI Function: Postural support of body.  Group XXI Function: Respiration.		
5322	Group XXII Function: Rotary and forward movements, head.		
5323	Group XXIII Function: Movements of head.		
	Miscellaneous		
5324	Diaphragm, rupture.		
5325 5326	Muscle injury, facial muscles.		
53∠6	Muscle hernia.		

Diagnostic Code No.			
5327	Muscle, neoplasm of, malignant.		
5328	Muscle, neoplasm of, benign.		
5329	Sarcoma, soft tissue.		
	THE EYE Diseases of the Eye		
6000	Uveitis.		
6001	Keratitis.		
6002 6003	Scleritis.		
6004	Cyclitis.		
6005	Choroiditis.		
6006 6007	Retinitis. Hemorrhage, intra-ocular, recent.		
6008	Retina, detachment.		
6009	Eye, injury of, unhealed.		
6010	Eye, tuberculosis.		
6011 6012	Retina, localized scars. Glaucoma, congestive or inflammatory.		
6013	Glaucoma, simple, primary, noncongestive.		
6014	New growths, malignant, eyeball.		
6015 6016	New growths, benign, eyeball and adnexa.		
6017	Nystagmus, central. Conjunctivitis, trachomatous, chronic.		
6018	Conjunctivitis, other, chronic.		
6019	Ptosis unilateral or bilateral.		
6020 6021	Ectropion. Entropion.		
6022	Lagophthalmos.		
6023	Eyebrows, loss.		
6024 6025	Eyelashes, loss. Epiphora.		
6026	Neuritis, optic.		
6027	Cataract, traumatic.		
6028	Cataract, senile, and others.		
6029 6030	Aphakia. Accommodation, paralysis.		
6031	Dacryocystitis.		
6032	Eyelids, loss of portion.		
6033 6034	Lens, crystalline, dislocation. Pterygium.		
6035	Keratoconus.		
	Impairment of Central Visual Acuity		
6061	Anatomical loss both eyes.		
6062	Blindness, both eyes, only light perception.		
Anatomical loss of 1 eye:			
6063	Other eye 5/200 (1.5/60).		
6064 6064	Other eye 10/200 (3/60). Other eye 15/200 (4.5/60).		
6064	Other eye 13/200 (4.3/60).  Other eye 20/200 (6/60).		
6065	Other eye 20/100 (6/30).		
6065	Other eye 20/70 (6/21).		
6065 6066	Other eye 20/50 (6/15). Other eye 20/40 (6/12).		
Blindness in 1 eye, only light per	contion		
6067	Other eye 5/200 (1.5/60).		
6068	Other eye 10/200 (3/60).		
6068	Other eye 15/200 (4.5/60).		
6068 6069	Other eye 20/200 (6/60). Other eye 20/100 (6/30).		
6069	Other eye 20/70 (6/21).		
6069	Other eye 20/50 (6/15).		
6070	Other eye 20/40 (6/12).		
Vision in 1 eye 5/200 (1.5/60):	Others and 5/000 (4.5/00)		
6071 6072	Other eye 5/200 (1.5/60). Other eye 10/200 (3/60).		
6072	Other eye 15/200 (3/60). Other eye 15/200 (4.5/60).		
6072	Other eye 20/200 (6/60).		

Diagnostic Code No.	
6073	Other eye 20/100 (6/30).
6073	Other eye 20/70 (6/21).
6073	Other eye 20/50 (6/15).
6074	Other eye 20/40 (6/12).
	, , ,
Vision in 1 eye 10/200 (3/60):	Leu caractera
6075	Other eye 10/200 (3/60).
6075	Other eye 15/200 (4.5/60).
6075 6076	Other eye 20/200 (6/60). Other eye 20/100 (6/30).
6076	Other eye 20/70 (6/21).
6076	Other eye 20/50 (6/15).
6077	Other eye 20/40 (6/12).
Vision in 1 eye 15/200 (4.5/60):	01/2
6075 6075	Other eye 15/200 (4.5/60).
6076	Other eye 20/200 (6/60). Other eye 20/100 (6/30).
6076	Other eye 20/70 (6/21).
6076	Other eye 20/50 (6/15).
6077	Other eye 20/40 (6/12).
	<u> </u>
Vision in 1 eye 20/200 (6/60):	Other ave 20/200 (6/60)
6075 6076	Other eye 20/200 (6/60). Other eye 20/100 (6/30).
6076	Other eye 20/70 (6/21).
6076	Other eye 20/50 (6/15).
6077	Other eye 20/40 (6/12).
	<u> </u>
Vision in 1 eye 20/100 (6/30):	01/200 000 000 (0/00)
6078 6078	Other eye 20/100 (6/30).
6078	Other eye 20/70 (6/21). Other eye 20/50 (6/15).
6079	Other eye 20/40 (6/12).
	0.1101. 030 207.10 (0.112).
Vision in 1 eye 20/70 (6/21):	
6078	Other eye 20/70 (6/21).
6078	Other eye 20/50 (6/15).
6079	Other eye 20/40 (6/12).
Vision in 1 eye 20/50 (6/15):	
6078	Other eye 20/50 (6/15).
6079	Other eye 20/40 (6/12).
Impairment of Field Vision:	
6080	Field vision, impairment.
6081	Scotoma.
Impairment of Muscle Function:	Distanta
6090	Diplopia.
6091 6092	Symblepharon.  Diplopia, limited muscle function.
	Sprapa, minou muono minonon.
	THE EAR
6200	Chronic suppurative otitis media.
6201	Chronic nonsuppurative otitis media.
6202	Otosclerosis.
6204	Peripheral vestibular disorders.
6205	Meniere's syndrome.
6207	Loss of auricle.
6208	Malignant neoplasm.
6209	Benign neoplasm.
6210	Chronic otitis externa.
6211 6260	Tympanic membrane.
<u></u>	Tinnitus, recurrent.
	OTHER SENSE ORGANS
6275	Small complete less
6276	Smell, complete loss.  Taste, complete loss.
	Table, complete 1000.
INFECTIOU	S DISEASES, IMMUNE DISORDERS AND NUTRITIONAL DEFICIENCIES
6300	Cholera, Asiatic.
	the state of the s

#### 38 CFR Ch. I (7-1-16 Edition)

	Diagnostic Code No.	
Leprosy (Hansen's Disease)		
Maiaria   Maiaria		
Bartonellosis		
Relegating fever		
Rheumatic fever.	6307	
Syphilis		
Tuberculosis, millary,   Santaminosis,   San		
Avitaminosis.   Berrberi.		
Beriber   Beri		
Pellagra   Pellagra   Brucellosis   Brucellosis   Brucellosis   Brucellosis   Brucellosis   Typhus, scrub.   Moliodosis   S11		
Bruceilosis		
Meliotodosis   Lyme disease		
6319 Lyme disease. 6320 Parasitic diseases. 6350 Lupus erythematosus. 6351 HIV-Related filness. 6354 Chronic Fatigue Syndrome (CFS).  THE RESPIRATORY SYSTEM Nose and Throat  Septum, nasal, deviation. 8004 Nose, loss of part of, or scars. 810 Sirusitis, pasnitusitis, chronic. 811 Sirusitis, pasnitusitis, chronic. 812 Sirusitis, submiculary chronic. 813 Sirusitis, submiculary chronic. 814 Sirusitis, submiculary chronic. 815 Laryngitis, tuberculous. 816 Laryngitis, chronic. 817 Laryngitis, chronic. 818 Laryngitis, chronic. 819 Aphonia, complete organic. 819 Aphonia, complete organic. 820 Larynx, stenosis of. 821 Pharynx, injuries to. 822 Allergic or vasomotor rhinitis. 823 Bacterial rhinitis. 824 Granulomatous rhinitis. 825 Traches and Bronchi  8600 Bronchitis, chronic. 8610 Bronchiectasis. 8621 Chronic Struchiectasis. 8622 Astima, pronchial. 8623 Bronchiectasis. 8624 Sirusitis and Bronchi  8601 Bronchiectasis. 8602 Astima, pronchial. 8603 Emphysema, pulmonary. 8604 Chronic Struche pulmonary disease.  8605 Lungs and Pleura Tuberculosis  8606 Active, moderately advanced. 8607 Active, ard advanced. 8607 Active, ard advanced. 8608 Inactive, in advanced. 8609 Inactive, in advanced. 8609 Inactive, in advanced. 8609 Inactive, in advanced. 8609 Inactive, in advanced. 8600 Inactive, in advanced. 8601 Inactive, in advanced. 8602 Inactive, in advanced. 8603 Inactive, in imimal. 8604 Chronic, active. 8605 Chronic, active. 8607 Chronic, active. 8607 Chronic, active. 8607 Pleurins, advancement unspecified. 8608 Chronic, active. 8609 Chronic, active. 8617 Pleurins, advancement unspecified. 8617 Pleurins, advancement unspecified. 8617 Pleurins, advancement unspecified. 8618 Neoplasms, malignant. 8620 Neoplasms, benign. 8620 Neoplasms, benign.	6317	Typhus, scrub.
Parasitic diseases		
Lupus erythematosus		
HIV-Related Illness.   Chronic Fatigue Syndrome (CFS).		
### Chronic Fatigue Syndrome (CFS).  ### THE RESPIRATORY SYSTEM Nose and Throat  ### Nose and Throat  ### Nose and Throat  ### Simushis, apasinushis, chronic.  ### Simushis, apasinushis, chronic.  ### Simushis, apasinushis, chronic.  ### Simushis, apasinushis, chronic.  ### Simushis, maxillary, chronic.  ### Simushis, maxillary, chronic.  ### Simushis, sphenoid, chronic.  ### Simushis, sphenoid, chronic.  ### Simushis, sphenoid, chronic.  ### Simushis, sphenoid, chronic.  ### Simushis, sphenoid, chronic.  ### Laryngitis, tuberculous.  ### Laryngitis, tuberculous.  ### Laryngitis, chronic.  ### Laryngitis, chronic.  ### Simushis, sphenoid, chronic.  ### Simushis, sphenoid, chronic.  ### Simushis, sphenoid, chronic.  ### Simushis, sphenoid, chronic.  ### Simushis, sphenoid, chronic.  ### Simushis, sphenoid, chronic.  ### Simushis, sphenoid, chronic.  ### Simushis, chronic.  ### Bronchitis, chronic.  #### Bronchitis, chronic.  #### Bronchitis, chronic.  #### Bronchitis, chronic.  #### Bronchitis, chronic.  ##### Bronchitis, chronic.  ###################################		
### TIPE RESPIRATORY SYSTEM Nose and Throat    Septum, nasal, deviation,		
Septum, nasal, deviation		<u> </u>
Solution		
Solution	6502	Septum, nasal, deviation.
Sinusitis, ethmoid, chronic.	6504	Nose, loss of part of, or scars.
Sinustiis, frontal, chronic.		
Sinusitis, maxillary, chronic.		
Sinustits, sphenoid, chronic   Sinustits, sphenoid, chronic   Laryngitis, tuberculous   Laryngitis, tuberculous   Laryngitis, tuberculous   Laryngitis, chronic   Laryngectomy, total.   Aphonia, complete organic.   Larynx, stenosis of.		
Laryngitis, tuberculous,   Laryngitis, chronic,		
Laryngitis, chronic   Laryngetcomy, total.		
Laryngectomy, total.   Aphonia, complete organic.   Larynx, stenosis of.		
Earlymx, stenosis of.   Pharymx, injuries to.	6518	
Pharynx, injuries to.   Allergic or vasomotor rhinitis.		Aphonia, complete organic.
Allergic or vasomotor rhinitis. Bacterial rhinitis.  Trachea and Bronchi  Frachea and Bronchi  Bronchitis, chronic. Bronchitis, chronic. Bronchiectasis. Asthma, bronchial. Bron		
Bacterial rhinitis.		
Granulomatous rhinitis.		
Bronchitis, chronic.   Bronchitis, chronic.   Bronchietasis.   Asthma, bronchial.   Bronchietasis.   Asthma, bronchial.   Emphysema, pulmonary.   Chronic obstructive pulmonary disease.   Eungs and Pleura Tuberculosis		
6601 Bronchiectasis. Asthma, bronchial. 6602 Emphysema, pulmonary. 6604 Chronic obstructive pulmonary disease.  Lungs and Pleura Tuberculosis  Ratings for Pulmonary Tuberculosis (Chronic) Entitled on August 19, 1968: 6701 Active, far advanced. 6702 Active, moderately advanced. 6703 Active, minimal. 6704 Active, at advancement unspecified. 6721 Inactive, far advanced. 6722 Inactive, minimal. 6723 Inactive, minimal. 6724 Inactive, advancement unspecified. 8819 Plumonary Tuberculosis Initially Evaluated After August 19, 1968:  Chronic, active.  Nontuberculous Diseases  Bacterial Infections of the Lung  Bacterial Infections of the Lung		
6601 Bronchiectasis. Asthma, bronchial. 6602 Emphysema, pulmonary. 6604 Chronic obstructive pulmonary disease.  Lungs and Pleura Tuberculosis  Ratings for Pulmonary Tuberculosis (Chronic) Entitled on August 19, 1968: 6701 Active, far advanced. 6702 Active, moderately advanced. 6703 Active, minimal. 6704 Active, at advancement unspecified. 6721 Inactive, far advanced. 6722 Inactive, minimal. 6723 Inactive, minimal. 6724 Inactive, advancement unspecified. 8819 Plumonary Tuberculosis Initially Evaluated After August 19, 1968:  Chronic, active.  Nontuberculous Diseases  Bacterial Infections of the Lung  Bacterial Infections of the Lung	0000	Prenchitic abrenia
Asthma, bronchial. Emphysema, pulmonary. 6604		
6603 Emphysema, pulmonary. Chronic obstructive pulmonary disease.  Lungs and Pleura Tuberculosis  Ratings for Pulmonary Tuberculosis (Chronic) Entitled on August 19, 1968: 6701 Active, far advanced. 6702 Active, moderately advanced. 6703 Active, minimal. 6704 Active, advancement unspecified. 6721 Inactive, far advanced. 6722 Inactive, moderately advanced. 6723 Inactive, minimal. 6724 Inactive, advancement unspecified. Ratings for Pulmonary Tuberculosis Initially Evaluated After August 19, 1968: 6730 Chronic, active. 6731 Chronic, inactive. 6732 Pleurisy, active or inactive.  Nontuberculous Diseases  6817 Pulmonary Vascular Disease. Neoplasms, malignant. Neoplasms, benign.  Bacterial Infections of the Lung		
Chronic obstructive pulmonary disease.  Lungs and Pleura Tuberculosis  Ratings for Pulmonary Tuberculosis (Chronic) Entitled on August 19, 1968: 6701		
Ratings for Pulmonary Tuberculosis (Chronic) Entitled on August 19, 1968: 6701	6604	
Ratings for Pulmonary Tuberculosis (Chronic) Entitled on August 19, 1968: 6701		Lungs and Plaura Tuberculosis
6701	<u>*</u>	
6702 Active, moderately advanced. 6703 Active, minimal. 6704 Active, advancement unspecified. 6721 Inactive, far advanced. 6722 Inactive, moderately advanced. 6723 Inactive, moderately advanced. 6724 Inactive, advancement unspecified.  Ratings for Pulmonary Tuberculosis Initially Evaluated After August 19, 1968: 6730 Chronic, active. 6731 Chronic, inactive. 6732 Pleurisy, active or inactive.  Nontuberculous Diseases  6817 Pulmonary Vascular Disease. 6820 Neoplasms, malignant. Neoplasms, benign.  Bacterial Infections of the Lung		
Active, minimal.   Active, minimal.   Active, advancement unspecified.		
6721         Inactive, far advanced.           6722         Inactive, moderately advanced.           6723         Inactive, minimal.           6724         Inactive, advancement unspecified.           Ratings for Pulmonary Tuberculosis Initially Evaluated After August 19, 1968:           6730         Chronic, active.           6731         Chronic, inactive.           6732         Pleurisy, active or inactive.           Nontuberculous Diseases           6817         Pulmonary Vascular Disease.           6819         Neoplasms, malignant.           Neoplasms, benign.    Bacterial Infections of the Lung		
6722		
6723		
6724		
Ratings for Pulmonary Tuberculosis Initially Evaluated After August 19, 1968:  6730		
6730 Chronic, active. 6731 Chronic, inactive. 6732 Pleurisy, active or inactive.  Nontuberculous Diseases  8817 Pulmonary Vascular Disease. 8819 Neoplasms, malignant. Neoplasms, benign.  Bacterial Infections of the Lung		
6731 Chronic, inactive. 6732 Pleurisy, active or inactive.  Nontuberculous Diseases  6817 Pulmonary Vascular Disease. 6819 Neoplasms, malignant. Neoplasms, benign.  Bacterial Infections of the Lung		
6732 Pleurisy, active or inactive.  Nontuberculous Diseases  6817 Pulmonary Vascular Disease. Neoplasms, malignant. Neoplasms, benign.  Bacterial Infections of the Lung		
Nontuberculous Diseases  6817 Pulmonary Vascular Disease. 6819 Neoplasms, malignant. Neoplasms, benign.  Bacterial Infections of the Lung		
6819	Nontuberculous Diseases	
6819	6817	Pulmonary Vascular Disease
6820		
6822 Actinomycosis.		Bacterial Infections of the Lung
	6822	Actinomycosis.

### **Department of Veterans Affairs**

Diagnostic Code No.	
6823	Nocardiosis.
6824	Chronic lung abscess.
	Interstitial Lung Disease
6825	Fibrosis of lung, diffuse interstitial.
6826	Desquamative interstitial pneumonitis.
6827	Pulmonary alveolar proteinosis.
6828 6829	Eosinophilic granuloma.  Drug-induced, pneumonitis & fibrosis.
6830	Radiation-induced, pneumonitis & fibrosis.
6831	Hypersensitivity pneumonitis.
6832 6833	Pneumoconiosis. Asbestosis.
	Mycotic Lung Disease
6834 6835	Histoplasmosis.
6836	Coccidioidomycosis.  Blastomycosis.
6837	Cryptococcosis.
6838	Aspergillosis.
6839	Mucormycosis.
	Restrictive Lung Disease
6840	Diaphragm paralysis or paresis.
6841	Spinal cord injury with respiratory insufficiency.
6842 6843	Kyphoscoliosis, pectus excavatum/carinatum.  Traumatic chest wall defect.
6844	Post-surgical residual.
6845	Pleural effusion or fibrosis.
6846	Sarcoidosis.
6847	Sleep Apnea Syndromes.
	THE CARDIOVASCULAR SYSTEM Diseases of the Heart
7000	Valvular heart disease.
7001 7002	Endocarditis. Pericarditis.
7003	Pericardial adhesions.
7004	Syphilitic heart disease.
7005	Arteriosclerotic heart disease.
7006 7007	Myocardial infarction.  Hypertensive heart disease.
7008	Hyperthyroid heart disease.
7010	Supraventricular arrhythmias.
7015	Ventricular arrhythmias.
7015 7016	Atrioventricular block. Heart valve replacement.
7017	Coronary bypass surgery.
7018	Implantable cardiac pacemakers.
7019 7020	Cardiac transplantation. Cardiomyopathy.
7020	
	Diseases of the Arteries and Veins
7101 7110	Hypertensive vascular disease. Aortic aneurysm.
7111	Aneurysm, large artery.
7112	Aneurysm, small artery.
7113	Arteriovenous fistula, traumatic.
7114 7115	Arteriosclerosis obliterans.  Thrombo-angiitis obliterans (Buerger's Disease).
7117	Raynaud's syndrome.
7118	Angioneurotic edema.
7119	Erythromelalgia. Varicose veins.
7120 7121	Post-phlebitic syndrome.
7122	Cold injury residuals.
7123	Soft tissue sarcoma.
	THE DIGESTIVE SYSTEM
7200	Mouth, injuries.

Diagnostic Code No.	
7201	. Lips, injuries.
7202	
7203	
7204	
7205	
7301	
7304	
7305	
7306	
7307	
7308	
7309	
7310	
7311	
7312	1 . , , , . ,
7314	
7314	
7316	
7317	1
7318	
7319	.  ,
7321	
7322	
7323	
7324	.
7325	.   Enteritis, chronic.
7326	.   Enterocolitis, chronic.
7327	. Diverticulitis.
7328	. Intestine, small, resection.
7329	. Intestine, large, resection.
7330	
7331	. Peritonitis.
7332	Rectum & anus, impairment.
7333	. Rectum & anus, stricture.
7334	. Rectum, prolapse.
7335	and the same of th
7336	
7337	
7338	
7339	3
7340	
7342	
7343	
7344	,
	3
7345	
7346	
7347	
7348	
7351	
7354	.   Hepatitis C.

#### THE GENITOURINARY SYSTEM

Kidney, removal.
Kidney, abscess.
Nephritis, chronic.
Pyelonephritis, chronic.
Kidney, tuberculosis.
Nephrosclerosis, arteriolar.
Nephrolithiasis.
Hydronephrosis.
Ureterolithiasis.
Ureter, stricture.
Cystitis, chronic.
Bladder, calculus.
Bladder, fistula.
Bladder, injury.
Urethra, stricture.
Urethra, fistula.
Penis, removal of half or more.
Penis, removal of glans.
Penis, deformity, with loss of erectile power.
Testis, atrophy, complete.
Testis, removal.

Diagnostic Code No.	
7525	Epididymo-orchitis, chronic only.
7527	Prostate gland.
7528	Malignant neoplasms.
7529	3 - 1
7530	
7531	
7532 7533	
7534	
7535	
7536	
7537	
7538	
7539	
7540 7541	
7542	Neurogenic bladder.
	NECOLOGICAL CONDITIONS AND DISORDERS OF THE BREAST
7610	Vulva, disease or injury.
7611 7612	Vagina, disease or injury.  Cervix, disease or injury.
7613	
7614	
7615	Ovary, disease or injury.
7617	
7618	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
7619 7620	
7621	
7622	
7623	Pregnancy, surgical complications.
7624	1
7625	1 · · · · · · · · · · · · · · · · · · ·
7626 7627	
7628	
7629	Endometriosis.
	THE HEMIC AND LYMPHATIC SYSTEMS
7700	Anemia.
7702	
7703	
7704	
7705	
7706 7707	
7709	
7710	
7714	Sickle cell anemia.
7715	
7716 7717	Aplastic anemia. AL amyloidosis (primary amyloidosis).
	THE SKIN
7800	Burn scar(s) of the head, face, or neck; scar(s) of the head, face, or neck due to other causes; or other disfigurement of the head, face, or neck.
7801	Burn scar(s) or scar(s) due to other causes, not of the head, face, or neck, that are deep and
	nonlinear.
7802	Burn scar(s) or scar(s) due to other causes, not of the head, face, or neck, that are superficial and nonlinear.
7804	
7805	Scars, other.
7806	
7807	
7808 7809	
7811	
7813	
7815	Bullous disorders.
7816	Psoriasis.

### 38 CFR Ch. I (7-1-16 Edition)

Diagnostic Code No.	
7817	Exfoliative dermatitis.
7818	Malignant skin neoplasms.
7819	Benign skin neoplasms.
7820	Infections of the skin.
7821	Cutaneous manifestations of collagen-vascular diseases.
7822	Papulosquamous disorders.
7823 7824	Vitiligo. Keratinization, diseases.
7825	Urticaria.
7826	Vasculitis, primary cutaneous.
7827	Erythema multiforme.
7828	Acne.
7829	Chloracne.
7830 7831	Scarring alopecia.
7832	Alopecia areata. Hyperhidrosis.
7833	Malignant melanoma.
	THE ENDOCRINE SYSTEM
7000	
7900 7901	Hyperthyroidism. Thyroid gland, toxic adenoma.
7902	Thyroid gland, nontoxic adenoma.
7903	Hypothyroidism.
7904	Hyperparathyroidism.
7905	Hypoparathyroidism.
7907	Cushing's syndrome.
7908	Acromegaly.
7909 7911	Diabetes insipidus. Addison's disease.
7912	Pluriglandular syndrome.
7913	Diabetes mellitus.
7914	Malignant neoplasm.
7915	Benign neoplasm.
7916	Hyperpituitarism.
7917	Hyperaldosteronism.
7918 7919	Pheochromocytoma.  C-cell hyperplasia thyroid
7919	C-cell hyperplasia, thyroid.
7919	
7919	C-cell hyperplasia, thyroid.  EUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS
7919N	C-cell hyperplasia, thyroid.  EUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS  Organic Diseases of the Central Nervous System
7919N	C-cell hyperplasia, thyroid.  EUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS Organic Diseases of the Central Nervous System  Encephalitis, epidemic, chronic.
7919	C-cell hyperplasia, thyroid.  EUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS Organic Diseases of the Central Nervous System  Encephalitis, epidemic, chronic.  Brain, New Growth of  Malignant. Benign.
7919	C-cell hyperplasia, thyroid.  EUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS Organic Diseases of the Central Nervous System  Encephalitis, epidemic, chronic.  Brain, New Growth of  Malignant. Benign. Parallysis agitans.
8000	C-cell hyperplasia, thyroid.  EUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS Organic Diseases of the Central Nervous System  Encephalitis, epidemic, chronic.  Brain, New Growth of  Malignant. Benign. Paralysis agitans. Bulbar palsy.
8002	C-cell hyperplasia, thyroid.  EUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS Organic Diseases of the Central Nervous System  Encephalitis, epidemic, chronic.  Brain, New Growth of  Malignant. Benign. Paralysis agitans. Bulbar palsy. Brain, vessels, embolism.
8000	C-cell hyperplasia, thyroid.  EUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS Organic Diseases of the Central Nervous System  Encephalitis, epidemic, chronic.  Brain, New Growth of  Malignant. Benign. Paralysis agitans. Bulbar palsy.
7919	C-cell hyperplasia, thyroid.  EUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS Organic Diseases of the Central Nervous System  Encephalitis, epidemic, chronic.  Brain, New Growth of  Malignant. Benign. Paralysis agitans. Bulbar palsy. Brain, vessels, embolism. Brain, vessels, thrombosis. Brain, vessels, hemorrhage. Myelitis.
7919	C-cell hyperplasia, thyroid.  EUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS Organic Diseases of the Central Nervous System  Encephalitis, epidemic, chronic.  Brain, New Growth of  Malignant. Benign. Paralysis agitans. Bulbar palsy. Brain, vessels, embolism. Brain, vessels, thrombosis. Brain, vessels, hemorrhage. Myelitis. Poliomyelitis, anterior.
7919	C-cell hyperplasia, thyroid.  EUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS Organic Diseases of the Central Nervous System  Encephalitis, epidemic, chronic.  Brain, New Growth of  Malignant. Benign. Paralysis agitans. Bulbar palsy. Brain, vessels, embolism. Brain, vessels, thrombosis. Brain, vessels, hemorrhage. Myelitis. Poliomyelitis, anterior. Hematomyelia.
7919	C-cell hyperplasia, thyroid.  EUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS Organic Diseases of the Central Nervous System  Encephalitis, epidemic, chronic.  Brain, New Growth of  Malignant. Benign. Paralysis agitans. Bulbar palsy. Brain, vessels, embolism. Brain, vessels, thrombosis. Brain, vessels, hemorrhage. Myelitis. Poliomyelitis, anterior. Hematomyelia. Syphilis, cerebrospinal.
7919	C-cell hyperplasia, thyroid.  EUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS Organic Diseases of the Central Nervous System  Encephalitis, epidemic, chronic.  Brain, New Growth of  Malignant. Benign. Paralysis agitans. Bulbar palsy. Brain, vessels, embolism. Brain, vessels, thrombosis. Brain, vessels, thrombosis. Brain, vessels, hemorrhage. Myelitis. Poliomyelitis, anterior. Hematomyelia. Syphilis, cerebrospinal. Syphilis, meningovascular.
7919	C-cell hyperplasia, thyroid.  EUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS Organic Diseases of the Central Nervous System  Encephalitis, epidemic, chronic.  Brain, New Growth of  Malignant. Benign. Parallysis agitans. Bulbar palsy. Brain, vessels, embolism. Brain, vessels, thrombosis. Brain, vessels, thrombosis. Brain, vessels, hemorrhage. Myelitis. Poliomyelitis, anterior. Hematomyelia. Syphilis, cerebrospinal. Syphilis, meningovascular. Tabes dorsalis.
7919	C-cell hyperplasia, thyroid.  EUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS Organic Diseases of the Central Nervous System  Encephalitis, epidemic, chronic.  Brain, New Growth of  Malignant. Benign. Paralysis agitans. Bulbar palsy. Brain, vessels, embolism. Brain, vessels, thrombosis. Brain, vessels, thrombosis. Brain, vessels, hemorrhage. Myelitis. Poliomyelitis, anterior. Hematomyelia. Syphilis, cerebrospinal. Syphilis, meningovascular.
7919	C-cell hyperplasia, thyroid.  EUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS Organic Diseases of the Central Nervous System  Encephalitis, epidemic, chronic.  Brain, New Growth of  Malignant. Benign. Paralysis agitans. Bulbar palsy. Brain, vessels, embolism. Brain, vessels, thrombosis. Brain, vessels, thrombosis. Brain, vessels, hemorrhage. Myelitis. Poliomyelitis, anterior. Hematomyelia. Syphilis, cerebrospinal. Syphilis, meningovascular. Tabes dorsalis. Amyotrophic lateral sclerosis. Multiple sclerosis. Multiple sclerosis. Meningilis, cerebrospinal, epidemic.
8000	C-cell hyperplasia, thyroid.  EUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS Organic Diseases of the Central Nervous System  Encephalitis, epidemic, chronic.  Brain, New Growth of  Malignant. Benign. Paralysis agitans. Bulbar palsy. Brain, vessels, embolism. Brain, vessels, thrombosis. Brain, vessels, hemorrhage. Myelitis. Poliomyelitis, anterior. Hematomyelia. Syphilis, cerebrospinal. Syphilis, meningovascular. Tabes dorsalis. Amyotrophic lateral sclerosis. Multiple sclerosis.
7919	C-cell hyperplasia, thyroid.  EUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS Organic Diseases of the Central Nervous System  Encephalitis, epidemic, chronic.  Brain, New Growth of  Malignant. Benign. Paralysis agitans. Bulbar palsy. Brain, vessels, embolism. Brain, vessels, thrombosis. Brain, vessels, thrombosis. Brain, vessels, hemorrhage. Myelitis. Poliomyelitis, anterior. Hematomyelia. Syphilis, cerebrospinal. Syphilis, meningovascular. Tabes dorsalis. Amyotrophic lateral sclerosis. Multiple sclerosis. Multiple sclerosis. Meningilis, cerebrospinal, epidemic.
7919	C-cell hyperplasia, thyroid.  EUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS Organic Diseases of the Central Nervous System  Encephalitis, epidemic, chronic.  Brain, New Growth of  Malignant. Benign. Paralysis agitans. Bulbar palsy. Brain, vessels, embolism. Brain, vessels, thrombosis. Brain, vessels, thrombosis. Brain, vessels, hemorrhage. Myelitis. Poliomyelitis, anterior. Hematomyelia. Syphilis, cerebrospinal. Syphilis, meningovascular. Tabes dorsalis. Amyotrophic lateral sclerosis. Multiple sclerosis. Multiple sclerosis. Meningitis, cerebrospinal, epidemic. Brain, abscess.
7919	C-cell hyperplasia, thyroid.  EUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS Organic Diseases of the Central Nervous System  Encephalitis, epidemic, chronic.  Brain, New Growth of  Malignant. Benign. Paralysis agitans. Bulbar palsy. Brain, vessels, embolism. Brain, vessels, thrombosis. Brain, vessels, thrombosis. Brain, vessels, hemorrhage. Myelitis. Poliomyelitis, anterior. Hematomyelia. Syphilis, cerebrospinal. Syphilis, cerebrospinal. Syphilis, meningovascular. Tabes dorsalis. Amyotrophic lateral sclerosis. Multiple sclerosis. Multiple sclerosis. Muningitis, cerebrospinal, epidemic. Brain, abscess.  Spinal Cord, New Growths  Malignant. Benign.
7919	C-cell hyperplasia, thyroid.  EUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS Organic Diseases of the Central Nervous System  Encephalitis, epidemic, chronic.  Brain, New Growth of  Malignant. Benign. Paralysis agitans. Bulbar palsy. Brain, vessels, embolism. Brain, vessels, thrombosis. Brain, vessels, thrombosis. Brain, vessels, hemorrhage. Myelitis. Poliomyelitis, anterior. Hematomyelia. Syphilis, cerebrospinal. Syphilis, reningovascular. Tabes dorsalis. Amyotrophic lateral sclerosis. Multiple sclerosis. Meningitis, cerebrospinal, epidemic. Brain, abscess.  Spinal Cord, New Growths  Malignant. Benign. Progressive muscular atrophy.
7919	C-cell hyperplasia, thyroid.  EUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS Organic Diseases of the Central Nervous System  Encephalitis, epidemic, chronic.  Brain, New Growth of  Malignant. Benign. Paralysis agitans. Bulbar palsy. Brain, vessels, embolism. Brain, vessels, thrombosis. Brain, vessels, thrombosis. Brain, vessels, hemorrhage. Myelitis. Poliomyelitis, anterior. Hematomyelia. Syphilis, cerebrospinal. Syphilis, meningovascular. Tabes dorsalis. Amyotrophic lateral sclerosis. Multiple sclerosis. Multiple sclerosis. Meningitis, cerebrospinal, epidemic. Brain, abscess.  Spinal Cord, New Growths  Malignant. Benign. Progressive muscular atrophy. Syringomyelia.
7919	C-cell hyperplasia, thyroid.  EUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS Organic Diseases of the Central Nervous System  Encephalitis, epidemic, chronic.  Brain, New Growth of  Malignant. Benign. Paralysis agitans. Bulbar palsy. Brain, vessels, embolism. Brain, vessels, thrombosis. Brain, vessels, thrombosis. Brain, vessels, hemorrhage. Myelitis. Poliomyelitis, anterior. Hematomyelia. Syphilis, cerebrospinal. Syphilis, meningovascular. Tabes dorsalis. Amyotrophic lateral sclerosis. Multiple sclerosis. Multiple sclerosis. Meningitis, cerebrospinal, epidemic. Brain, abscess.  Spinal Cord, New Growths  Malignant. Benign. Progressive muscular atrophy. Syringomyelia. Myasthenia gravis.
7919	C-cell hyperplasia, thyroid.  EUROLOGICAL CONDITIONS AND CONVULSIVE DISORDERS Organic Diseases of the Central Nervous System  Encephalitis, epidemic, chronic.  Brain, New Growth of  Malignant. Benign. Paralysis agitans. Bulbar palsy. Brain, vessels, embolism. Brain, vessels, thrombosis. Brain, vessels, thrombosis. Brain, vessels, hemorrhage. Myelitis. Poliomyelitis, anterior. Hematomyelia. Syphilis, cerebrospinal. Syphilis, meningovascular. Tabes dorsalis. Amyotrophic lateral sclerosis. Multiple sclerosis. Multiple sclerosis. Meningitis, cerebrospinal, epidemic. Brain, abscess.  Spinal Cord, New Growths  Malignant. Benign. Progressive muscular atrophy. Syringomyelia.

	Diagnostic Code No.	
		Miscellaneous Diseases
8100		Migraine
8103		Tic, convulsive.
		Paramyoclonus multiplex.
		Chorea, Sydenham's. Chorea, Huntington's.
		Athetosis, acquired.
		Narcolepsy.
		The Cranial Nerves
8205		Fifth (trigeminal), paralysis.
		Seventh (facial), paralysis.
		Ninth (glossopharyngeal), paralysis.
		Tenth (pneumogastric, vagus), paralysis.
		Eleventh (spinal accessory, external branch), paralysis.  Twelfth (hypoglossal), paralysis.
		Neuritis, fifth cranial nerve.
		Neuritis, seventh cranial nerve.
		Neuritis, ninth cranial nerve.
8310		Neuritis, tenth cranial nerve.
		Neuritis, eleventh cranial nerve.
		Neuritis, twelfth cranial nerve.
		Neuralgia, fifth cranial nerve.
		Neuralgia, seventh cranial nerve.  Neuralgia, ninth cranial nerve.
		Neuralgia, tenth cranial nerve.
		Neuralgia, eleventh cranial nerve.
8412		Neuralgia, twelfth cranial nerve.
		Peripheral Nerves
8510		Upper radicular group, paralysis.
8511		Middle radicular group, paralysis.
		Lower radicular group, paralysis.
		All radicular groups, paralysis.
		Musculospiral nerve (radial), paralysis.
		Median nerve, paralysis. Ulnar nerve, paralysis.
		Musculocutaneous nerve, paralysis.
		Circumflex nerve, paralysis.
		Long thoracic nerve, paralysis.
		Sciatic nerve, paralysis.
		External popliteal nerve (common peroneal), paralysis.
		Musculocutaneous nerve (superficial peroneal), paralysis.  Anterior tibial nerve (deep peroneal), paralysis.
		Internal popliteal nerve (tibial), paralysis.
		Posterior tibial nerve, paralysis.
8526		Anterior crural nerve (femoral), paralysis.
		Internal saphenous nerve, paralysis.
		Obturator nerve, paralysis.
		External cutaneous nerve of thigh, paralysis. Ilio-inguinal nerve, paralysis.
		Soft-tissue sarcoma (Neurogenic origin).
		Neuritis, upper radicular group.
		Neuritis, middle radicular group.
		Neuritis, lower radicular group.
		Neuritis, all radicular group.
		Neuritis, musculospiral (radial) nerve.
		Neuritis, median nerve. Neuritis, ulnar nerve.
8617		Neuritis, musculocutaneous nerve.
8618		Neuritis, circumflex nerve.
		Neuritis, long thoracic nerve.
		Neuritis, sciatic nerve.
		Neuritis, external popliteal (common peroneal) nerve.
		Neuritis, musculocutaneous (superficial peroneal) nerve.
0023		Neuritis, anterior tibial (deep peroneal) nerve.  Neuritis, internal popliteal (tibial) nerve.
8624		
		Neuritis, posterior tibial nerve.
8625		Neuritis, posterior tibial nerve.  Neuritis, anterior crural (femoral) nerve.
8625 8626		

Diagnostic Code No.	1
Diagnostic Code No.	
8629	1,
8630 8710	
8711	
8712	
8713	Neuralgia, all radicular groups.
8714	· · · · · · · · · · · · · · · · · · ·
8715	
8716 8717	
8718	
8719	
8720	
8721	
8722 8723	
8724	
8725	
8726	Neuralgia, anterior crural nerve (femoral).
8727	
8728	
8729 8730	
	1.00a.a.g.a, no mgama norvo.
	The Epilepsies
8910	. Grand mal.
8911	
8912	
8913 8914	
8914	Fsycholitotol.
	Mental Disorders
9201	Schizophrenia.
9208	Delusional disorder.
9210	
9211	
9300 9301	
9304	
9305	
9310	
9312 9326	
9326	<ul> <li>Major or mild neurocognitive disorder due to another medical condition or substance/medica- tion-induced major or mild neurocognitive disorder.</li> </ul>
9400	
9403	
9404	
9410	
9411 9412	
9413	
9416	
9417	. Depersonalization/derealization disorder.
9421	
9422 9423	
9424	
9425	
9431	. Cyclothymic disorder.
9432	
9433	
9434 9435	
9440	
9520	
9521	
	DENTAL AND ORAL CONDITIONS
9900	Maxilla or mandible chronic
9900	
9900 9901 9902	Mandible, loss of, complete.

#### **Department of Veterans Affairs**

Diagnostic Code No.	
9903	Mandible, nonunion. Mandible, malunion. Temporomandibular articulation, limited motion. Ramus, loss of whole or part. Ramus, loss of less than one-half. Condyloid process.
9909	Coronoid process. Hard palate, loss of half or more. Hard palate, loss of less than half. Teeth, loss of. Maxilla, loss of more than half. Maxilla, loss of half or less. Maxilla, malunion or nonunion of.

 $[72\ \mathrm{FR}\ 12990,\ \mathrm{Mar}\ 20,\ 2007,\ \mathrm{as}\ \mathrm{amended}\ \mathrm{at}\ 73\ \mathrm{FR}\ 54708,\ 54711,\ \mathrm{Sept.}\ 23,\ 2008;\ 74\ \mathrm{FR}\ 18467,\ \mathrm{Apr.}\ 23,\ 2009;\ 77\ \mathrm{FR}\ 6467,\ \mathrm{Feb.}\ 8,\ 2012;\ 79\ \mathrm{FR}\ 45102,\ \mathrm{Aug.}\ 4,\ 2014]$ 

#### APPENDIX C TO PART 4—ALPHABETICAL INDEX OF DISABILITIES

	Diagnostic code No.
Abscess:	
Brain	8020
Kidney	750 <sup>-</sup>
Lung ´	6824
Acne	
Acromegaly	
Actinomycosis	
Addison's disease	
Agranulocytosis	
0 ,	
AL amyloidosis	
Alopecia areata	
Amebiasis	732
Amputation:	
Arm:	
Disarticulation	5120
Above insertion of deltoid	512
Below insertion of deltoid	5122
Digits, five of one hand	5126
Digits, four of one hand:	
Thumb, index, long and ring	512
Thumb, index, long and little	
Thumb, index, ring and little	
Thumb, lindex, fing and little	
Index, long, ring and little	513
Digits, three of one hand:	540
Thumb, index and long	
Thumb, index and ring	
Thumb, index and little	5134
Thumb, long and ring	513
Thumb, long and little	5136
Thumb, ring and little	513
Index, long and ring	
Index, long and little	
Index, ring and little	
Long, ring and little	
Digits, two of one hand:	314
• ,	54.4
Thumb and index	_
Thumb and long	
Thumb and ring	
Thumb and little	514
Index and long	514
Index and ring	
Index and little	514
Long and ring	-
Long and little	
Ring and little	
Single finger:	-1-
Thumb	
Index finger	
Long finger	
Ring finger	515

		Diagnosti code No
	Little finger	5
orearm		
	Above insertion of pronator teres	5 <sup>-</sup> 5 <sup>-</sup>
.eg:		_
	With defective stump	5
	Not improvable by prosthesis controlled by natural knee action	5 <sup>-</sup> 5 <sup>-</sup>
	At a lower level, permitting prosthesis	5
	Toes, all, without metatarsal loss	5
	Toe, great	5
	Toes, other than great, with removal of metatarsal head	5
high:	Toes, three or more, without metatarsal involvement	5
	Disarticulation	5
	Upper third	5
	Middle or lower thirds	5
	phic lateral sclerosis	8
natom	ical loss of:	
\	Both eyes	6
nie eye	e, with visual acuity of other eye: 5/200 (1.5/60)	6
	10/200 (3/60); 15/200 (4.5/60); 20/200 (6/60)	6
	20/100 (6/30); 20/70 (6/21); 20/50 (6/15)	6
	20/40 (6/12)	6
	Both feet	5
	Both hands	5
	One hand and one foot	5
	One foot and loss of use of one hand	5
	One hand and loss of use of one foot	5
inemia ineurys	om:	7
neurys	Aortic	7
	Large artery	7
	Small artery	7
Angione	eurotic edema	7
Ankylos	is:	
	Ankle	5
Digits, ii	ndividual:	5
	Thumb	5
	Long finger	5
	Ring or little finger	5
	Elbow	5
	Hand	
avorab		
	Five digits of one hand	5
	Four digits of one hand	5
	Three digits of one hand	5 5
Jnfavor	Two digits of one handable:	3
mavoi	Five digits of one hand	5
	Four digits of one hand	5
	Three digits of one hand	5
	Two digits of one hand	5
		5
		5
	humeral articulation	5
	agalar or tarsal joint	5
	ing spondylitis	5 5
	ing sportdyllus	6
	, organic	6
	anemia	7
rrhythr		•
,	Supraventricular	7
	Ventricular	7
	clerosis obliterans	7
Arterios	clerotic heart disease	7
Arterios Arteriov	enous fistula	
Arterios	enous fistula	7 7 5

	Diagnos code N
Gonorrheal	
Other types	
Pneumococcic	
Rheumatoid (atrophic)	
Streptococcic	
Syphilitic	
Typhoid	
sbestosis	
spergillosis	
sthma, bronchial	
stragalectomy	
therosclerotic renal disease	
thetosis	
trioventricular blocktioventricular block	
witaminosis	
artonellosis	
eriberi	
ladder:	
Calculus in	
Fistula in	
Injury of	
Neurogenic	
lastomycosis	
Blindness: see also Vision and Anatomical Loss	
Both eyes, only light perception	
One eye, only light perception and other eye:	
5/200 (1.5/60)	
10/200 (3/60); 15/200 (4.5/60); 20/200 (6/60)	
10/200 (3/00), 13/200 (4.3/00), 20/200 (0/00)	
20/100 (6/30); 20/70 (6/21); 20/50 (6/15)	
20/40 (6/12)	
ones:	
Caisson disease	
New growths, benign	
New growths, malignant	
Shortening of the lower extremity	
Brain:	
Abscess	
Breast surgery	
Bronchiectasis	
Bronchitis	
Brucellosis	
Buerger's disease	
Bulbar palsy	
Bullous disorders	
dursitis	
Cardiac:	
Pacemakers, implantable	
Transplantation	
Transplantation	
Cardiomyopathy	
Cardiomyopathy	
Cardiomyopathy -cell hyperplasia, thyroid -cataract:	
ardiomyopathy -cell hyperplasia, thyroid -ataract: Senile and others	
ardiomyopathy -cell hyperplasia, thyroid -cataract: Senile and others Traumatic	
Cardiomyopathy C-cell hyperplasia, thyroid Cataract: Senile and others Traumatic Cerebral arteriosclerosis	
Cardiomyopathy -Cell hyperplasia, thyroid -cataract: Senile and others Traumatic -Cerbral arteriosclerosis -Cervical strain	
ardiomyopathy -cell hyperplasia, thyroid -iataract: Senile and others Traumatic -ferebral arteriosclerosis -fervical strain -fervix disease or injury	
cardiomyopathycell hyperplasia, thyroid cataract: Senile and others Traumaticcerebral arteriosclerosiscerevical straincervical strain	
ardiomyopathy -cell hyperplasia, thyroid -tataract: Senile and others Traumatic -terebral arteriosclerosis -tervical strain -tervix disease or injury -thorea: Huntington's	
ardiomyopathy -cell hyperplasia, thyroid -ataract: Senile and others Traumatic -erebral arteriosclerosis -ervical strain -ervix disease or injury -thorea: Huntington's Sydenham's	
ardiomyopathy -cell hyperplasia, thyroid ataract: Senile and others Traumatic erebral arteriosclerosis ervical strain ervix disease or injury horea: Huntington's Sydenham's	
ardiomyopathy -cell hyperplasia, thyroid ataract: Senile and others Traumatic erebral arteriosclerosis ervical strain ervix disease or injury horea: Huntington's Sydenham's hloracne holangitis, chronic	
ardiomyopathy -cell hyperplasia, thyroid ataract: Senile and others Traumatic erebral arteriosclerosis ervical strain ervix disease or injury horea: Huntington's Sydenham's hloracne holangitis, chronic	
ardiomyopathy -cell hyperplasia, thyroid ataract: Senile and others Traumatic -erebral arteriosclerosis -ervical strain -ervix disease or injury -horea: Huntington's Sydenham's -holangitis, chronic -holelytitiss, chronic -holelytissis, chronic -holelithiasis, chronic	
ardiomyopathy -cell hyperplasia, thyroid -tataract: Senile and others Traumatic -terebral arteriosclerosis -tervical strain -tervix disease or injury -thorea: Huntington's Sydenham's -tholangitis, chronic -tholegrat, Asiatic	
ardiomyopathy -cell hyperplasia, thyroid -ataract: Senile and others Traumatic -erebral arteriosclerosis -ervical strain -ervix disease or injury -chorea: Huntington's Sydenham's -cholangitis, chronic -cholecystitis, chronic -cholecystitis, chronic -cholera, Asiatic -choroiditis	
ardiomyopathy -cell hyperplasia, thyroid -ataract: Senile and others Traumatic -cerebral arteriosclerosis -derivical strain -cervix disease or injury -chorea: Huntington's Sydenham's -cholangitis, chronic -cholecystitis, chronic -cholecystitis, chronic -cholerix, Asiatic -choroiditis	
ardiomyopathy -cell hyperplasia, thyroid -cataract: Senile and others Traumatic -cerebral arteriosclerosis -cerebral arterioscerosis -cervix disease or injury -thorea: Huntington's Sydenham's -tholangitis, chronic -tholecystitis, chronic -tholecy, Asiatic -thoroiditis -chronic Fatigue Syndrome (CFS)	
ardiomyopathy -cell hyperplasia, thyroid -traitaract: Senile and others Traumatic -terebral arteriosclerosis -tervical strain -tervix disease or injury -thorea: Huntington's Sydenham's -tholangitis, chronic -tholegystitis, chronic -tholegystitis, chronic -tholera, Asiatic -thoric at guess or single syndrome (CFS) -thronic Fatigue Syndrome (CFS) -thronic Ing abscess	
Cardiomyopathy C-cell hyperplasia, thyroid Cataract: Senile and others Traumatic Cereival arteriosclerosis Cervical strain Cervix disease or injury Chorea: Huntington's Sydenham's Cholangitis, chronic Cholecystitis, chronic Cholecystitis, chronic Choleria, Sattic Choroiditis Choroiditis Choroic Fatigue Syndrome (CFS) Chronic lung abscess Chronic lung abscess Chronic long obstructive pulmonary disease	
ardiomyopathy -cell hyperplasia, thyroid -cataract: Senile and others Traumatic -cerebral arteriosclerosis -cervical strain -cervix disease or injury -chorea: Huntington's Sydenham's -cholangitis, chronic -cholecystitis, chronic -cholecystitis, chronic -choroiditis -choroic Traigue Syndrome (CFS) -chronic Lung abscess -choroic obstructive pulmonary disease	
ardiomyopathy -cell hyperplasia, thyroid -tataract: Senile and others Traumatic -terebral arteriosclerosis -tervical strain -tervix disease or injury -thorea: Huntington's Sydenham's -tholangitis, chronic -tholeangitis, chronic -tholera, Asatic -thoroiditis -throic Tatigue Syndrome (CFS) -thronic lung abscess -thronic obstructive pulmonary disease	

	Diagnost code No
Other	6
Coronary bypass surgery	7
Cryptococcosis	
Cushing's syndrome	7
Cutaneous manifestations of collagen-vascular diseases	7
Cyclitis	6
Systitis, chronic	7
Pacryocystitis	6
Dermatitis or eczema	7
Dermatophytosis	7
Desquamative interstitial pneumonitis	6
Insipidus	7
Mellitus	7
Diaphragm:	
Paralysis or paresis	6
Rupture	5
Diplopia	6
Diplopia, limited muscle function, eye	(
Addison's	7
Buerger's	7
Chronic obstructive pulmonary disease	6
Hodgkin's	-
Leprosy (Hansen's)	6
Lyme	ě
Morton's	
Parasitic	
Disfigurement of, head, face or neck	-
Cartilage, semilunar	
Lens, crystalline	
Disseminated intravascular coagulation	
Distomiasis, intestinal or hepatic	
Diverticulitis	
Dysentery, bacillary	
Ectropion	
Embolism, brain	
mphysema, pulmonary	6
Encephalitis, epidemic, chronic	8
Endocarditis	-
ndometriosis	-
Interitis, chronic	-
Enterocolitis, chronic	
ntropion	
Eosinophilic granuloma of lung	
pididymo-orchitis	
Epilepsies:	
Diencephalic	
Grand mal	
Jacksonian and focal motor or sensory	
Petit mal	
Psychomotor	
piphora	
rythema multiforme	
rythromelalgia	
Sophagus: Diverticulum	
Spasm	
Stricture	
Exfoliative dermatitis	-
fallopian tube	
Relapsing	
Rheumatic	
Rheumatic	
Rheumatic ::ibrosis of lung, diffuse interstitial ::ibromyalgia ::ibromy	
Rheumatic  ibrosis of lung, diffuse interstitial  ibromyalgia  istula in ano	1
Rheumatic  Fibrosis of lung, diffuse interstitial  Fibromyalgia  Fistula in ano  Fistula:	
Rheumatic ibrosis of lung, diffuse interstitial iibromyalgia iistula in ano iistula: Rectovaginal	-
Rheumatic  Fibrosis of lung, diffuse interstitial  Fibromyalgia  Fistula in ano  Fistula:	- - - - -

### **Department of Veterans Affairs**

		Diagnostic code No.
Genu recurvatu	n	526
Glaucoma:		
	stive or inflammatory	601
	, primary, noncongestive	601
	itis	753 501
สอนเ Hallux:		501
	S	528
		528
		528
	acement	701
		801
Hemorrhage:		
Brain .		800
	cular	600
		733
		735
Hernia:		
	al	734
		734
		733
		532
		733
lip: Degen	prative arthritis	524
	orative arthritisnt	52
		68
	9SS	63
	Se	77
	termittent	50
		75
	ism	79
		78
	dism	79
		79
		683
Hypertensive:		
Heart of	lisease	70
Vascul	ar disease	71
Hyperthyroid he	art disease	70
		79
	lism	79
		79
mpairment of:		
	JS	52
	e or scapula	52
		52
		52
	nthor.	52
	thersion	52 60
	nd fibula	52
	nd illouia	73
	i & alius	52
	diac pacemakers	70
	skin	78
njury:		
	r	75
	nhealed	60
		52
	adder	73
		72
	esiduals	73
		72
luscle:		
Facial		53
	Function: Upward rotation of scapula	53
	Il Function: Depression of arm	53
Group	III Function: Elevation and abduction of arm	53
	IV Function: Stabilization of shoulder	53
	V Function: Elbow supination	53
Group	VI Function: Extension of elbow	53
C	VII Function: Flexion of wrist and fingers	53

	Diagnostic code No.
Group VIII Function: Extension of wrist, fingers, thumb	53
Group IX Function: Forearm muscles	53
Group X Function: Movement of forefoot and toes	53
Group XI Function: Propulsion of foot	53
Group XII Function: Dorsiflexion	53
Group XIII Function: Extension of hip and flexion of knee	50
Group XIV Function: Extension of knee	50 50
Group XV Function: Adduction of hip	50
Group XVII Function: Flexion of hip	5
Group XVIII Function: Outward rotation of thigh	5
Group XIX Function: Abdominal wall and lower thorax	5
Group XX Function: Postural support of body	5
Group XXI Function: Respiration	5
Group XXII Function: Rotary and forward movements, head	5
Group XXIII Function: Movements of head	5
arynx	6
croiliac	5
Spinal cord	6
Stomach, residuals of	7
is	6
erstitial nephritis	7
ervertebral disc syndrome	5
estine, fistula of	7
table colon syndrome	7
ratinization, diseases ofratitis	7 6
pratoconus	6
dney:	
Abscess	7
Cystic diseases	7
Removal	7
Transplant	7
Tuberculosis	7
phoscoliosis, pectus excavatum / carinatum	6
gophthalmos	6
ryngectomy	6
ryngitis:	
Tuberculous	6
Chronic	6
rynx, stenosis of	6
ishmaniasis:	_
American (New World)	7
Old World	7
prosy (Hansen's Disease)	6
ukemia	7
ritation of extension:  Forearm	5
Leg	5
Radius	5
Supination and pronation	5
Thigh	5
nitation of extension and flexion:	
Forearm	5
nitation of flexion:	
Forearm	5
Leg	5
Thigh	5
nitation of motion:	
Ankle	5
Arm	5
Index or long finger	5
Ring or little finger	5
Temporomandibular articulation	9
Thumb	5
Wrist, limitation of motion	5
er:	
Disease, chronic, without cirrhosis	7
	7
Transplant	
Transplant	7
Transplant	7

	Diagnostic code No.
Coronoid process	990
Eyebrows	602
Eyelashes	602
Eyelids	603
Mandible: One-half	990
Complete	990
Maxilla:	330
More than half	991
Less than half	991
Nose, part of, or scars	650
Palate, hard:	
Half or more	991
Less than half	991
Ramus:	
Whole or part	990
Less than one-half	990
Skull, part of	529 627
Smell, sense of	627
Testh, loss of	991
Tongue, loss of whole or part	720
Loss of use of:	720
Both feet	511
Both hands	510
Foot	516
Hand	512
One hand and one foot	511
Lumbosacral strain	523
Lupus:	
Erythematosus	635
Erythematosus, discoid	780
Lyme disease	631
Lymphatic filariasis	630
Malaria	630
Malignant melanoma	783
Malunion:  Mandible	990
Os calcis or astragalus	527
Maxilla, malunion or nonunion	991
Melioidosis	631
Meniere's syndrome	620
Meningitis, cerebrospinal, epidemic	801
Mental disorders:	
Anorexia nervosa	952
Bipolar disorder	943
Bulimia nervosa	952
Chronic adjustment disorder	944
Conversion disorder (functional neurological symptom disorder).	942
Cyclothymic disorder	943
Delirium	930
Delusional disorder	920
Depersonalization/derealization disorder	941
Dissociative amnesia; dissociative identity disorder	941
Generalized anxiety disorder	940
Illness anxiety disorder	942 943
Major or mild neurocognitive disorder due to Alzheimer's disease	943
Major or mild neurocognitive disorder due to another medical condition or substance/medication-in-	301
duced major or mild neurocognitive disorder	932
Major or mild neurocognitive disorder due to HIV or other infections	930
Major or mild neurocognitive disorder due to traumatic brain injury	930
Major or mild vascular neurocognitive disorder	930
Obsessive compulsive disorder	940
Other specified and unspecified schizophrenia spectrum and other psychotic disorders	921
Other specified anxiety disorder	941
Other specified somatic symptom and related disorder	942
Panic disorder and/or agoraphobia	941
Persistent depressive disorder (dysthymia)	943
Posttraumatic stress disorder	941
Schizoaffective disorder	921
Schizophrenia	920
Somatic symptom disorder	942

		Diagnos code No
Specific	phobia; social anxiety disorder (social phobia)	9
	ied somatic symptom and related disorder	
	ied anxiety disorder	
	ied depressive disorder	
	ied neurocognitive disorder	
	•	
	5	
Ayelitis		
Nyocardial infarc	ion	
	S	
leoplasms:		
Benign:		
- 3	Digestive system	
	Ear	
	Endocrine	
	Genitourinary	-
	Gynecological or breast	
	Muscle	
	Respiratory	
	Skin	
Maligna		
Mangria	Digestive system	
	Ear	
	Endocrine	
	Genitourinary	
	Gynecological or breast	
	Muscle	
	Respiratory	
Janhritie chronic	ONIT	
	arteriolar	
Veuralgia:	arteriola	
Cranial I	donos	
Cianai	Fifth (trigeminal)	
	Seventh (facial)	
	Ninth (glossopharyngeal)	
	Tenth (pneumogastric, vagus)	
	Eleventh (spinal accessory, external branch)	
	Twelfth (hypoglossal)	
Peripher	al Nerves	
	Upper radicular group	
	Middle radicular group	
	Lower radicular group	
	All radicular groups	
	Musculospiral (radial)	
	Median	
	Ulnar	
	Musculocutaneous	
	Circumflex	
	Long thoracic	
	Sciatic	
	External popliteal (common peroneal)	
	Musculocutaneous (superficial peroneal)	
	Anterior tibial (deep peroneal)	
	Internal popliteal (tibial)	
	Posterior tibial	
	Anterior crural (femoral)	
	Internal saphenous	
	Obturator	
	External cutaneous nerve of thigh	
louritie:	Ilio-inguinal	
Veuritis:		
	nerves	
Cianai		
Ciaillai	Fifth (trigeminal)	
Cidillal	Fifth (trigeminal) Seventh (facial) Ninth (glossopharyngeal)	

		Diagnosti code No
	Tenth (pneumogastric, vagus)	8
	Eleventh (spinal accessory, external branch)	8
	Twelfth (hypoglossal)	8
		6
Periphe	al Nerves	
	Upper radicular group	8
	Middle radicular group	8
	Lower radicular group	8
	All radicular groups	8
	Median	8
	Ulnar	8
	Musculocutaneous	8
	Circumflex	8
	Long thoracic	8
	Sciatic	8
	External popliteal (common peroneal)	8
	Musculocutaneous (superficial peroneal)	8
	Anterior tibial (deep peroneal)	8
	Internal popliteal (tibial)	8
	Posterior tibial	8
	Anterior crural (femoral)	8
	Internal saphenous	8
	Obturator	8
	External cutaneous nerve of thigh	8
	Ilio-inguinal	8
eurogenic bladd ew growths:	ler	7
Benign	<b>D</b>	_
	Bones	5
	Brain	8
	Eyeball and adnexa	6
	Spinal cord	8
Maligna	_	_
	Bones	5
	Brain	8
	Eyeball	6
ocardicaia	Spinal cord	8
	mphoma	6 7
onunion:	приона	,
	9	9
	and ulna	5
	ral	6
	IS	5
		5
		5
	xilla or mandible	Ş
	h joint manifestations	5
titis media:	,	
_		6
	ourative	ě
	tive	ě
		ě
	of both	7
vary:		
	or injury	7
	l	7
alsy, bulbar		8
ancreatitis		7
apillary necrosis	3	7
apulosquamous	disorders	7
aralysis:		
Accomn	odation	6
		8
aralysis, nerve:		
Cranial	nerves	
	Fifth (trigeminal)	8
	Seventh (facial)	8
	Ninth (glossopharyngeal)	8
	Tenth (pneumogastric, vagus)	8
	Eleventh (spinal accessory, external branch)	8
	Twelfth (hypoglossal)	8

		Diagnos code N
Peripheral Ner	ves:	
Uppe	radicular group	
	e radicular group	
Lowe	radicular group	
All ra	ficular groups	
Musc	ulospiral (radial)	
	n	
Ulnar		
Musc	ulocutaneous	
	nflex	
	thoracic	
	2	
	nal popliteal (common peroneal)	
	ulocutaneous (superficial peroneal)	
	or tibial nerve (deep peroneal)	
	al popliteal (tibial)	
	rior tibial nerve	
Anter	or crural nerve (femoral)	
Intern	al saphenous	
	ator	
	nal cutaneous nerve of thigh	
	guinal	
	X	
Pellagra		
Penis		
Deformity, with	loss of erectile power	
Removal of gla	ns	
	f or more	
Pericardial adhesions .		
Pericarditis		
Periostitis		
Peripheral vestibular dis	orders	
Peritoneum, adhesions		
	cquired	
	sis	
	)	
neumonitis & fibrosis:		
	ped	
	maa	
	mes	
	anliantiana	
	nplications	
	trophy	
Prosthetic Implants:		
	nent	
	nent	
	nt	
	ent	
Shoulder repla	cement	
Wrist replacen	ent	
'soriasis		
terygium		
Pterygium Ptosis		
terygiumtosis dulmonary:	nosis	
terygium tosis vulmonary: Alveolar protei	nosis	
Pterygium Ptosis Pulmonary: Alveolar protei Vascular disea	se	
Pterygium Ptosis Pulmonary: Alveolar protei Vascular disea Pruritus ani	se	
Pterygium Ptosis Pulmonary: Alveolar protei Vascular disea Pruritus ani Pyelonephritis, chronic	Se	
Pterygium Ptosis Pulmonary:     Alveolar protei     Vascular disea Pruritus ani Pyelonephritis, chronic Raynaud's syndrome	se	
Pterygium  Ptosis  Pulmonary:     Alveolar protei     Vascular disea  Pruritus ani  Pyelonephritis, chronic  Raynaud's syndrome  Rectum:	Se	
Pterygium	se	
Pterygium	Se	

	Diagnosti code No.
Соссух	52
Gall bladder	73
Kidney	75
Penis glans	75
Penis half or more	7
Ribs	5
Testis	7
Ovary	7
Uterus	7
Uterus and both ovaries	7
Amyloid disease	7
Disease, chronic	7
Involvement in systemic diseases	7
Tubular disorders	7
tina detachment of	6
tinitis	6
initis:	
Allergic or vasomotor	6
Bacterial	6
Granulomatous	6
section of intestine:	
Large	7
Small	7
rcoidosis	6
arring alopecia	7
ars:	
Burn scar(s) of the head, face, or neck; scar(s) of the head, face, or neck due to other causes; or other	_
disfigurement of the head, face, or neck	7
Burn scar(s) or scars(s) due to other causes, not of the head, face, or neck, that are deep and nonlinear	7
Burn scar(s) or scars(s) due to other causes, not of the head, face, or neck, that are superficial and non-	_
linear	7
Other	7
Retina	6
Unstable or painful	7
nusitis:	
Ethmoid	6
Frontal	6
Maxillary	6
Pansinusitis	6
Sphenoid	6
eep Apnea Syndrome	6
off tissue sarcoma:	_
Muscle, fat, or fibrous connected	5
Neurogenic origin	8
Vascular origin	7
inal fusion	5
inal stenosis	5
leen, injury of, healed	7
lenectomy	7
ondylolisthesis or segmental instability, spine	5
omach, stenosis of	7
mblepharon	6
ndromes:	
Chronic Fatigue Syndrome (CFS)	6
Cushing's	7
Meniere's	6
Raynaud's	7
Sleep Apnea	6
novitis	5
philis	6
philis:	
Cerebrospinal	8
Meningovascular	8
philitic heart disease	7
ringomyelia	8
bes dorsalis	8
ırsal or metatarsal bones	5
enosynovitis	5
estis:	
Atrophy, complete	7
Removal	7
nrombocytopenia	7

	Diagnostic code No.
hrombosis, brain	80
hyroid gland:	
Nontoxic adenoma	
Toxic adenoma	
ic, convulsive	
innitus, recurrent	
oxic nephropathy	
raumatic chest wall defect	
uberculosis: Adenitis	
Bones and joints	
Eye	
Kidney	
Luposa (lupus vulgaris)	
Miliary	
Pleurisy, active or inactive	
ulmonary:	
Active, far advanced	67
Active, moderately advanced	
Active, minimal	
Active, advancement unspecified	67
Active, chronic	
Inactive, chronic	
Inactive, far advanced	
Inactive, moderately advanced	
Inactive, minimal	
Inactive, advancement unspecified	67
uberculosis luposa (lupus vulgaris)	
/mpanic membrane	
/phus, scrub	60
cer:	_
Duodenal	
Gastric	
Marginal	
reter, stricture of	
reterolithiasis	75
rethra. Fistula	75
Stricture	
rticaria	
terus:	/
And both ovaries, removal	70
Disease or injury	
Displacement	
Prolapse	
Removal	
/eitis	_
agina, disease or injury	
agotomy	
alvular heart disease	
311COSE VEILIS	
asculitis, primary cutaneous	
asculitis, primary cutaneouserlebral fracture or dislocation	0
asculitis, primary cutaneous	
asculitis, primary cutaneous ritebral fracture or dislocation sceral Leishmaniasis sceral primary cutaneous	
asculitis, primary cutaneous ritebral fracture or dislocation sceral Leishmaniasis sceral primary cutaneous	7
asculitis, primary cutaneous prebral fracture or dislocation sceral Leishmaniasis sceroptosis sion: see also Blindness and Loss of One eye 5/200 (1.5/60), with visual acuity of other eye: 5/200 (1.5/60)	73
asculitis, primary cutaneous ritebral fracture or dislocation sceral Leishmaniasis sceral Leishmaniasis sceroptosis sion: see also Blindness and Loss of One eye 5/200 (1.5/60), with visual acuity of other eye: 5/200 (1.5/60) 10/200 (3/60); 15/200 (4.5/60); 20/200 (6/60)	7 6 6
asculitis, primary cutaneous	7 6 6
sculitis, primary cutaneous  ritebral fracture or dislocation  sceral Leishmaniasis  sceroptosis  sion: see also Blindness and Loss of  One eye 5/200 (1.5/60), with visual acuity of other eye:  5/200 (1.5/60)  10/200 (3/60); 15/200 (4.5/60); 20/200 (6/60)  20/100 (6/30); 20/70 (6/21); 20/50 (6/15)	7 6 6
asculitis, primary cutaneous  ritebral fracture or dislocation  sceral Leishmaniasis  sceral Leishmaniasis  sceroptosis  sion: see also Blindness and Loss of  One eye 5/200 (1.5/60), with visual acuity of other eye:  5/200 (1.5/60)  10/200 (3/60); 15/200 (4.5/60); 20/200 (6/60)  20/100 (6/30); 20/70 (6/21); 20/50 (6/15)  20/40 (6/12)  One eye 10/200 (3/60), with visual acuity of other eye:	7 6 6 6
asculitis, primary cutaneous ritebral fracture or dislocation sceral Leishmaniasis sceral Leishmaniasis sceroptosis sion: see also Blindness and Loss of One eye 5/200 (1.5/60), with visual acuity of other eye: 5/200 (1.5/60) 10/200 (3/60); 15/200 (4.5/60); 20/200 (6/60) 20/100 (6/30); 20/70 (6/21); 20/50 (6/15) 20/40 (6/12) One eye 10/200 (3/60), with visual acuity of other eye: 10/200 (3/60); 15/200 (4.5/60); 20/200 (6/60)	7 6 6 6
asculitis, primary cutaneous  prebral fracture or dislocation  sceral Leishmaniasis  sceroptosis  sion: see also Blindness and Loss of  One eye 5/200 (1.5/60), with visual acuity of other eye:  5/200 (1.5/60)  10/200 (3/60); 15/200 (4.5/60); 20/200 (6/60)  20/100 (6/30); 20/70 (6/21); 20/50 (6/15)  20/40 (6/12)  One eye 10/200 (3/60), with visual acuity of other eye:  10/200 (3/60); 15/200 (4.5/60); 20/200 (6/60)  20/100 (6/30); 20/70 (6/21); 20/50 (6/15)	7 6 6 6 6 6
asculitis, primary cutaneous priebral fracture or dislocation sceral Leishmaniasis sceroptosis sion: see also Blindness and Loss of One eye 5/200 (1.5/60), with visual acuity of other eye: 5/200 (1.5/60) 10/200 (3/60); 15/200 (4.5/60); 20/200 (6/60) 20/100 (6/30); 20/70 (6/21); 20/50 (6/15) 20/40 (6/12) One eye 10/200 (3/60), with visual acuity of other eye: 10/200 (3/60); 15/200 (4.5/60); 20/200 (6/60) 20/100 (6/30); 20/70 (6/21); 20/50 (6/15)	7: 6: 6: 6: 6: 6:
asculitis, primary cutaneous priebral fracture or dislocation sceral Leishmaniasis sceral Leishmaniasis soeroptosis sion: see also Blindness and Loss of One eye 5/200 (1.5/60), with visual acuity of other eye: 5/200 (1.5/60) 10/200 (3/60); 15/200 (4.5/60); 20/200 (6/60) 20/100 (6/30); 20/70 (6/21); 20/50 (6/15) 20/40 (6/12) One eye 10/200 (3/60), with visual acuity of other eye: 10/200 (3/60); 15/200 (4.5/60); 20/200 (6/60) 20/100 (6/30); 20/70 (6/21); 20/50 (6/15) 20/40 (6/12) One eye 15/200 (4.5/60), with visual acuity of other eye:	7: 6i 6i 6i 6i 6i
asculitis, primary cutaneous ertebral fracture or dislocation sceral Leishmaniasis sisceral Leishmaniasis sisceroptosis sion: see also Blindness and Loss of One eye 5/200 (1.5/60), with visual acuity of other eye: 5/200 (1.5/60) 10/200 (3/60); 15/200 (4.5/60); 20/200 (6/60) 20/100 (6/30); 20/70 (6/21); 20/50 (6/15) 20/40 (6/12) One eye 10/200 (3/60), with visual acuity of other eye: 10/200 (3/60), 15/200 (4.5/60); 20/200 (6/60) 20/100 (6/30); 20/70 (6/21); 20/50 (6/15) 20/40 (6/12) One eye 15/200 (4.5/60), with visual acuity of other eye: 15/200 (4.5/60), with visual acuity of other eye:	66 66 66 66 66
asculitis, primary cutaneous erfebral fracture or dislocation isceral Leishmaniasis isceral primary sand Loss of One eye 5/200 (1.5/60), with visual acuity of other eye: 5/200 (1.5/60)	60 60 60 60 60 60
5/200 (1.5/60) 10/200 (3/60); 15/200 (4.5/60); 20/200 (6/60) 20/100 (6/30); 20/70 (6/21); 20/50 (6/15) 20/40 (6/12) One eye 10/200 (3/60), with visual acuity of other eye: 10/200 (3/60); 15/200 (4.5/60); 20/200 (6/60) 20/100 (6/30); 20/70 (6/21); 20/50 (6/15) 20/40 (6/12) One eye 15/200 (4.5/60), with visual acuity of other eye: 15/200 (4.5/60) or 20/200 (6/60) 20/100 (6/30); 20/70 (6/21); 20/50 (6/15) 20/40 (6/12)	73 66 66 66 66 66 66 66 66 66
asculitis, primary cutaneous prebral fracture or dislocation sceral Leishmaniasis sceroptosis sion: see also Blindness and Loss of One eye 5/200 (1.5/60), with visual acuity of other eye: 5/200 (1.5/60) 10/200 (3/60); 15/200 (4.5/60); 20/200 (6/60) 20/100 (6/30); 20/70 (6/21); 20/50 (6/15) 20/40 (6/12) One eye 10/200 (3/60), with visual acuity of other eye: 10/200 (3/60); 15/200 (4.5/60); 20/200 (6/60) 20/100 (6/30); 20/70 (6/21); 20/50 (6/15) 20/40 (6/12) One eye 15/200 (4.5/60), with visual acuity of other eye: 15/200 (4.5/60) or 20/200 (6/60) 20/100 (6/30); 20/70 (6/21); 20/50 (6/15)	7: 60 61 66 66 66 66

	Diagnostic code No.
20/40 (6/12)	6077
One eye 20/100 (6/30), with visual acuity of other eye: and other eye:	
20/100 (6/30); 20/70 (6/21); 20/50 (6/15)	6078
20/100 (6/30); 20/70 (6/21); 20/50 (6/15)	6079
One eye 20/70 (6/21), with visual acuity of other eye:	
20/70 (6/21) or 20/50 (6/15)	6078
20/40 (6/12)	6079
One eye 20/50 (6/15), with visual acuity of other eye:	
20/50 (6/15)	6078
	6079
Each eye 20/40 (6/12)	6079
Vitiligo	7823
	7610
Weak foot	5277

[72 FR 13003, Mar. 20, 2007, as amended at 73 FR 54708, 54712, Sept. 23, 2008; 73 FR 69554, Nov. 19, 2008; 74 FR 18467, Apr. 23, 2009; 77 FR 6467, Feb. 8, 2012; 79 FR 45103, Aug. 4, 2014]

### PART 5 [RESERVED]

# PART 6—UNITED STATES GOVERNMENT LIFE INSURANCE

AGE

Sec.

6.1 Misstatement of age.

#### PREMIUMS

6.2 Premium rate.

#### POLICIES

6.3 Incontestability of United States Government life insurance.

BENEFICIARY OF UNITED STATES GOVERNMENT LIFE INSURANCE

- 6.4 Proof of age, relationship and marriage.
- 6.5 Conditional designation of beneficiary.
- 6.6 Change of beneficiary.
- 6.7 Claims of creditors, taxation.

#### OPTIONAL SETTLEMENT

- 6.8 Selection, revocation and election.
- 6.9 Election of optional settlement by beneficiary.
- 6.10 Options.

#### DIVIDENDS

- 6.11 How dividends are paid.
- 6.12 Special dividends.

#### LOANS

6.13 Policy loans.

#### CASH VALUE

- 6.14 Cash value; other than special endowment at age 96 plan policy.
- $6.15\,$  Cash value; special endowment at age  $96\,$  plan policy.

6.16 Payment of cash value in monthly installments.

#### INDEBTEDNESS

6.17 Collection of any indebtedness.

TOTAL PERMANENT DISABILITY BENEFITS

6.18 Other disabilities deemed to be total and permanent.

#### DEATH BENEFITS

6.19 Evidence to establish death of the insured.

DETERMINATION OF LIABILITY UNDER SECTIONS 302 AND 313, WORLD WAR VETERANS' ACT, 1924, SECTIONS 607 AND 602(v)(2), NATIONAL SERVICE LIFE INSURANCE ACT, 1940, AS AMENDED, AND SECTIONS 1921 AND 1957 OF TITLE 38, UNITED STATES CODE

6.20 Jurisdiction.

#### APPEALS

6.21 Guardian: definition and authority.

AUTHORITY: 38 U.S.C. 501, 1940-1963, 1981-1988, unless otherwise noted.

#### AGE

#### § 6.1 Misstatement of age.

If the age of the insured under a United States Government life insurance policy has been understated, the amount of the insurance payable under the policy shall be such exact amount as the premium paid would have purchased at the correct age; if overstated, the excess of premiums paid shall be refunded without interest. Guaranteed surrender and loan values will be modified accordingly. The age of the insured will be admitted by the Department of